vaso10q-june2015.htm

0001201800-15-000022.txt : 20150814 0001201800-15-000022.hdr.sgml : 20150814 20150814121211 ACCESSION NUMBER: 0001201800-15-000022 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20150630 FILED AS OF DATE: 20150814 DATE AS OF CHANGE: 20150814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VASOMEDICAL, INC CENTRAL INDEX KEY: 0000839087 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 112871434 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-18105 FILM NUMBER: 151053974 BUSINESS ADDRESS: STREET 1: 180 LINDEN AVENUE CITY: WESTBURY STATE: NY ZIP: 11590 BUSINESS PHONE: 516-997-4600 MAIL ADDRESS: STREET 1: 180 LINDEN AVENUE CITY: WESTBURY STATE: NY ZIP: 11590 FORMER COMPANY: FORMER CONFORMED NAME: VASOMEDICAL INC DATE OF NAME CHANGE: 19950517 FORMER COMPANY: FORMER CONFORMED NAME: FUTURE MEDICAL PRODUCTS INC /DE/ DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: FUTURE MEDICAL PRODUCTS INC /NY/ DATE OF NAME CHANGE: 19920506 10-Q 1 vaso10q-june2015.htm vaso10q-june2015.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

[X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended June 30, 2015

[ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from _______________ to ______________

Commission File Number: 0-18105

VASOMEDICAL, INC.

(Exact name of registrant as specified in its charter)

Delaware	11-2871434
(State or other jurisdiction of	(IRS Employer Identification Number)
incorporation or organization)

180 Linden Ave., Westbury, New York 11590

(Address of principal executive offices)

Registrant’s Telephone Number

(516) 997-4600

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer.

Large Accelerated Filer o

Accelerated Filer o

Non-Accelerated Filer o

Smaller Reporting Company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yeso No x

Number of Shares Outstanding of Common Stock, $.001 Par Value, at August 8, 2015 - 158,412,283

Page 1

Vasomedical, Inc. and Subsidiaries

INDEX

PART I – FINANCIAL INFORMATION	3

ITEM 1 - FINANCIAL STATEMENTS	3

CONDENSED CONSOLIDATED BALANCE SHEETS as of June 30, 2015 (unaudited) and December 31, 2014	3

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (unaudited) for the Three and Six Months Ended June 30, 2015 and 2014	4

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY for the Six Months Ended June 30, 2015 (unaudited) and the Year Ended December 31, 2014	5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) for the Six Months Ended June 30, 2015 and 2014	6

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)	7

ITEM 2 - MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	19

ITEM 4 - CONTROLS AND PROCEDURES	24

PART II - OTHER INFORMATION	26

ITEM 6 – EXHIBITS	26

Page 2

PART I – FINANCIAL INFORMATION

ITEM 1 - FINANCIAL STATEMENTS

Vasomedical, Inc. and Subsidiaries

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)

	June 30, 2015			December 31, 2014
ASSETS	(unaudited)
CURRENT ASSETS
Cash and cash equivalents	$	2,931		$	9,128
Short-term investments		109			111
Accounts and other receivables, net of an allowance for doubtful
accounts and commission adjustments of $4,178 at June 30,
2015 and $4,571 at December 31, 2014		6,320			15,273
Receivables due from related parties		20			21
Inventories, net		2,168			1,898
Deferred commission expense		2,407			2,200
Prepaid expenses and other current assets		581			363
Total current assets		14,536			28,994

PROPERTY AND EQUIPMENT, net of accumulated depreciation of
$3,123 at June 30, 2015 and $1,397 at December 31, 2014		2,668			266
GOODWILL		22,618			3,288
INTANGIBLES, net		2,561			2,826
OTHER ASSETS		3,937			5,617
	$	46,320		$	40,991

LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES
Accounts payable	$	3,571		$	462
Accrued commissions		1,202			2,247
Accrued expenses and other liabilities		5,156			5,627
Sales tax payable		626			247
Deferred revenue - current portion		11,560			9,882
Notes payable - current portion		1,523			163
Deferred tax liability, net		112			112
Notes payable due to related party		1,070			1,039
Total current liabilities		24,820			19,779

LONG-TERM LIABILITIES
Notes payable		4,817			-
Deferred revenue		8,054			12,650
Other long-term liabilities		649			811
Total long-term liabilities		13,520			13,461

COMMITMENTS AND CONTINGENCIES (NOTE O)

STOCKHOLDERS' EQUITY
Preferred stock, $.01 par value; 1,000,000 shares authorized; nil shares
issued and outstanding at June 30, 2015, and December 31, 2014		-			-
Common stock, $.001 par value; 250,000,000 shares authorized;
168,710,370 and 166,435,370 shares issued at June 30, 2015
and December 31, 2014, respectively; 158,402,283 and
156,127,283 shares outstanding at June 30, 2015 and
December 31, 2014, respectively		169			166
Additional paid-in capital		62,181			61,924
Accumulated deficit		(52,495	)		(52,433	)
Accumulated other comprehensive income		125			94
Treasury stock, at cost, 10,308,087 shares at June 30, 2015 and December 31, 2014		(2,000	)		(2,000	)
Total stockholders’ equity		7,980			7,751
	$	46,320		$	40,991

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Page 3

Vasomedical, Inc. and Subsidiaries

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

(Unaudited)

(in thousands, except per share data)

	Three months ended						Six months ended
	June 30,						June 30,
	2015			2014			2015			2014
Revenues
Professional sales services	$	7,036		$	6,684		$	13,427		$	12,926
Managed IT systems and services		2,811			-			2,811			-
Equipment sales and services		996			1,180			2,059			2,030
Total revenues		10,843			7,864			18,297			14,956

Cost of revenues
Cost of professional sales services		1,524			1,852			3,047			3,454
Cost of managed IT systems and services		1,613			-			1,613			-
Cost of equipment sales and services		378			530			741			854
Total cost of revenues		3,515			2,382			5,401			4,308
Gross profit		7,328			5,482			12,896			10,648

Operating expenses
Selling, general and administrative		6,985			5,482			12,704			11,523
Research and development		137			206			272			419
Total operating expenses		7,122			5,688			12,976			11,942
Operating income (loss)		206			(206	)		(80	)		(1,294	)

Other income (expense)
Interest and financing costs		(89	)		(2	)		(117	)		(3	)
Interest and other income, net		80			46			147			101
Total other income (expense), net		(9	)		44			30			98

Income (loss) before income taxes		197			(162	)		(50	)		(1,196	)
Income tax expense		(6	)		(14	)		(12	)		(24	)
Net income (loss)		191			(176	)		(62	)		(1,220	)

Other comprehensive income
Foreign currency translation gain (loss)		24			10			31			(30	)
Comprehensive income (loss)	$	215		$	(166	)	$	(31	)	$	(1,250	)

Income (loss) per common share
- basic	$	0.00		$	(0.00	)	$	(0.00	)	$	(0.01	)
- diluted	$	0.00		$	(0.00	)	$	(0.00	)	$	(0.02	)

Weighted average common shares outstanding
- basic		156,258			155,320			156,102			155,386
- diluted		156,566			155,320			156,102			155,386

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Page 4

Vasomedical, Inc. and Subsidiaries

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(in thousands)


		Common Stock				Treasury Stock					Additional Paid-in			Accumulated			Accumulated Other Comprehensive		Total Stockholders'
	Shares		Amount		Shares			Amount			Capital			Deficit			Income		Equity
Balance at December 31, 2013		164,705	$	165		(9,481)		$	(1,755)		$	61,508		$	(53,561	)	$	108	$	6,465
Repurchase of shares		-		-		(827	)		(245	)		-			-			-		(245	)
Share-based compensation		1,280		1		-			-			389			-			-		390
Shares not issued for employee tax liability		-		-		-			-			(9	)		-			-		(9	)
Exercise of stock options		450		-		-			-			36			-			-		36
Foreign currency translation loss		-		-		-			-			-			-			(14)		(14	)
Net income		-		-		-			-			-			1,128			-		1,128
Balance at December 31, 2014		166,435		166		(10,308	)		(2,000	)		61,924			(52,433	)		94		7,751
Share-based compensation		2,275		3		-			-			257			-			-		260
Foreign currency translation gain		-		-		-			-			-			-			31		31
Net loss		-		-		-			-			-			(62)			-		(62	)
Balance at June 30, 2015 (unaudited)		168,710	$	169		(10,308)		$	(2,000	)	$	62,181		$	(52,495	)	$	125	$	7,980

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Page 5

Vasomedical, Inc. and Subsidiaries

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(in thousands)

	Six months ended
	June 30,
	2015			2014
Cash flows from operating activities
Net loss	$	(62	)	$	(1,220	)
Adjustments to reconcile net loss to net cash
provided by operating activities
Depreciation and amortization		483			199
Provision for doubtful accounts and commission adjustments		61			4
Share-based compensation and arrangements		260			244
Changes in operating assets and liabilities:
Accounts and other receivables		10,429			6,030
Receivables due from related parties		1			-
Inventories, net		(354	)		(297	)
Deferred commission expense		(207	)		15
Other current assets		(115	)		(119	)
Other assets		1,859			(1,276	)
Accounts payable		(43	)		(117	)
Accrued commissions		(1,092	)		137
Accrued expenses and other liabilities		(1,268	)		(966	)
Sales tax payable		(32	)		(51	)
Deferred revenue		(2,918	)		(307	)
Notes payable due to related party		31			-
Other long-term liabilities		(199	)		162
Net cash provided by operating activities		6,834			2,438

Cash flows from investing activities
Purchases of equipment and software		(188	)		(205	)
Purchases of short-term investments		(38	)		(40	)
Redemption of short-term investments		40			40
Acquisition of NetWolves		(18,000	)		-
Cash acquired through purchase of NetWolves		733			-
Investment in VSK		(100	)
Net cash used in investing activities		(17,553	)		(205	)

Cash flows from financing activities
Repurchase of common stock		-			(207	)
Repayment of notes payable		(21	)		-
Proceeds from note payable		4,550			-
Net cash provided by (used in) financing activities		4,529			(207	)
Effect of exchange rate differences on cash and cash equivalents		(7	)		(1	)

NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS		(6,197	)		2,025
Cash and cash equivalents - beginning of period		9,128			7,961
Cash and cash equivalents - end of period	$	2,931		$	9,986

SUPPLEMENTAL DISCLOSURE OF CASH INFORMATION
Interest paid	$	15		$	-
Income taxes paid	$	66		$	19

SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES
Inventories transferred to property and equipment,
attributable to operating leases, net	$	3		$	5
Common shares issued for prepaid directors' fees	$	-		$	175

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Page 6

Vasomedical, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements (unaudited)

NOTE A - ORGANIZATION AND PLAN OF OPERATIONS

Vasomedical, Inc. was incorporated in Delaware in July 1987. Unless the context requires otherwise, all references to “we”, “our”, “us”, “Company”, “registrant”, “Vasomedical” or “management” refer to Vasomedical, Inc. and its subsidiaries. Until 2010, we were primarily engaged in designing, manufacturing, marketing and supporting Enhanced External Counterpulsation (EECP®) systems, based on our proprietary technology, to physicians and hospitals throughout the United States and in select international markets. Beginning in July 2010 the Company, through its wholly-owned subsidiary Vaso Diagnostics, Inc. (Vaso Diagnostics), began its sales representation business via its agreement (the “GEHC Agreement”) with GE Healthcare (“GEHC”), the healthcare business unit of General Electric Company (NYSE: GE), to be GEHC’s exclusive sales representative for the sale of select GEHC diagnostic imaging products in specific market segments in the 48 contiguous states of the United States and the District of Columbia. In June 2012, the GEHC Agreement was amended and extended through June 30, 2015 and again, in December 2014, the GEHC Agreement was further amended and extended through December 31, 2018, subject to earlier termination under certain circumstances and termination without cause on or after July 1, 2017.

In September 2011, the Company acquired Fast Growth Enterprises Limited (FGE), a British Virgin Islands company, which owns or controls two Chinese operating companies - Life Enhancement Technology Ltd. and Biox Instruments Co. Ltd. (Biox), respectively - to expand its technical and manufacturing capabilities and to enhance its distribution network, technology, and product portfolio. Also in September 2011, the Company restructured to further align its business management structure and long-term growth strategy, and started to operate through three wholly-owned subsidiaries. Vaso Diagnostics continues as the operating subsidiary for the sales representation of GE diagnostic imaging products; Vasomedical Global Corp. operates the Company’s Chinese companies; and Vasomedical Solutions, Inc. was formed to manage and coordinate our EECP® therapy business as well as other medical equipment operations.

In April 2014, the Company entered into an agreement with Chongqing PSK-Health Sci-Tech Development Co., Ltd. (PSK) of Chongqing, China, the leading manufacturer of ECP therapy systems in China, to form a joint venture company, VSK Medical Limited (VSK), for the global marketing, sale and advancement of ECP therapy technology. The Company owns 49.9% of the joint venture, which began operations in January 2015.

In June 2014, the Company entered into a Value Added Reseller Agreement (VAR Agreement) with GEHC to become a national value added reseller of GE Healthcare IT's Radiology PACS (Picture Archiving and Communication System) software solutions and related services, including implementation, management and support. This multiyear VAR Agreement focuses primarily on existing customer segments currently served by Vaso Diagnostics on behalf of GEHC. A new wholly owned subsidiary, VasoHealthcare IT Corp., was formed to conduct the healthcare IT business.

In August 2014, the Company, through its wholly owned subsidiary Wuxi Gentone Instruments Co. Ltd. (Gentone), acquired all of the outstanding shares of Genwell Instruments Co. Ltd. (Genwell), located in Wuxi, China. Genwell was formed in China in 2010 with the assistance of a government grant to develop the MobiCareTM wireless multi-parameter patient monitoring system and holds the patents and intellectual property rights for this system.

In May 2015, the Company entered into an agreement for, and completed its purchase of, all of the assets of NetWolves, LLC and its affiliates, including the membership interests in NetWolves Network Services LLC (collectively, “NetWolves”). The purchase of NetWolves was accomplished pursuant to an Asset Purchase Agreement. As a result, the Company effectively purchased all rights, titles and ownership of all assets held by NetWolves. NetWolves designs and delivers efficient and cost-effective multi-network and multi-technology solutions as a managed network provider, and provides a complete single-source solution that includes design, network redundancy, application device management, real-time network monitoring, reporting and support systems as a comprehensive solution. The Company believes there are significant operational synergies between NetWolves’ capabilities and VasoHealthcare IT’s requirements under its VAR Agreement with GEHC, as well as the opportunity to expand NetWolves’ existing services to the healthcare IT market.

Page 7

Vasomedical, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements (unaudited)

We report the operations of Vasomedical Global Corp. and Vasomedical Solutions, Inc. under our Equipment segment. Vaso Diagnostics activities are included under our Sales Representation segment. VasoHealthcare IT and NetWolves operations report under the IT segment.

NOTE B - BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES

Basis of Presentation and Use of Estimates

The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and pursuant to the accounting and disclosure rules and regulations of the Securities and Exchange Commission (the "SEC"). Certain information and disclosures normally included in the unaudited condensed consolidated financial statements prepared in accordance with U.S. GAAP have been condensd or omitted pursuant to such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in connection with:

1)		The audited consolidated financial statements and related notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2014, as filed with the SEC on March 30, 2015.

2)		The audited consolidated financial statements of NetWolves, LLC and related notes thereto included in the Form 8-K/A filed with the SEC on August 12, 2015. The operating results of NetWolves from May 29, 2015 to June 30, 2015 are included in the accompanying condensed consolidated statements of operations and comprehensive income (loss) for the three and six month periods ended June 30, 2015.

These unaudited condensed consolidated financial statements include the accounts of the companies over which we exercise control. In the opinion of management, the accompanying condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of interim results for the Company. The results of operations for any interim period are not necessarily indicative of results to be expected for any other interim period or the full year.

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the condensed consolidated financial statements, the disclosure of contingent assets and liabilities in the unaudited condensed consolidated financial statements and the accompanying notes, and the reported amounts of revenues, expenses and cash flows during the periods presented. Actual amounts and results could differ from those estimates. The estimates and assumptions the Company makes are based on historical factors, current circumstances and the experience and judgment of the Company's management. The Company evaluates its estimates and assumptions on an ongoing basis.

Significant Accounting Policies

Note B of the Notes to Consolidated Financial Statements, included in the Annual Report on Form 10-K for the year ended December 31, 2014, and Note B of the Notes to Consolidated Financial Statements for the year ended December 31, 2014, included on Form 8-K/A, include a summary of the significant accounting policies used in the preparation of the condensed consolidated financial statements.

Revenue Recognition

The Company recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred or service has been rendered, the price is fixed or determinable and collectability is reasonably assured.

Revenue and Expense Recognition for the Sales Representation Segment

The Company recognizes commission revenue in its Sales Representation segment (see Note C) when persuasive evidence of an arrangement exists, service has been rendered, the price is fixed or determinable and collectability is reasonably assured. These conditions are deemed to be met when the underlying equipment has been accepted at the customer site in accordance with the specific terms of the sales agreement. Consequently, amounts billable under the agreement with GE Healthcare in advance of the customer acceptance of the equipment are recorded as accounts receivable and deferred revenue in the condensed consolidated balance sheets. Similarly, commissions payable to our sales force related to such billings are recorded as deferred commission expense when the associated deferred revenue is recorded. Commission expense is recognized when the corresponding commission revenue is recognized.

Page 8

Vasomedical, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements (unaudited)

Variable Interest Entities

The Company follows the guidance of accounting for variable interest entities, which requires certain variable interest entities to be consolidated by the primary beneficiary of the entities. Biox is a Variable Interest Entity (VIE).

Liabilities recognized as a result of consolidating this VIE do not represent additional claims on the Company’s general assets. The financial information of Biox, which was included in the accompanying condensed consolidated financial statements, is presented as follows:

	(in thousands)
	As of June 30, 2015 (unaudited)		As of December 31, 2014
Cash and cash equivalents	$	157	$	159
Total assets	$	1,014	$	1,047
Total liabilities	$	1,065	$	878

	(in thousands)
	Three months ended June 30,					Six months ended June 30,
	2015			2014		2015			2014
	(unaudited)			(unaudited)		(unaudited)			(unaudited)
Total net revenue	$	454		$	429	$	825		$	758

Net (loss) income	$	(87	)	$	110	$	(223	)	$	(230	)

Reclassifications

Certain reclassifications have been made to prior period amounts to conform with the current period presentation.

NOTE C – SEGMENT REPORTING AND CONCENTRATIONS

The Company views its business in three segments – the Sales Representation segment, the Equipment segment, and the IT segment. The Sales Representation segment operates through the Vaso Diagnostics subsidiary and is currently engaged solely in the fulfillment of the Company’s responsibilities under our agreement with GEHC. The IT segment includes the operations of NetWolves and VasoHealthcare IT Corp. Operations in the IT segment began in the third quarter of 2014. The Equipment segment is engaged in designing, manufacturing, marketing and supporting EECP® enhanced external counterpulsation systems both domestically and internationally, as well as the development, production, marketing and supporting of other medical devices.

The chief operating decision maker is the Company’s Chief Executive Officer, who, in conjunction with upper management, evaluates segment performance based on operating income. Administrative functions such as finance, human resources, and information technology are centralized and related expenses allocated to each segment. Other costs not directly attributable to operating segments, such as audit, legal, director fees, investor relations, and others, as well as certain assets – primarily cash balances – are reported in the Corporate entity below. There are no intersegment revenues. Summary financial information for the segments is set forth below:

Page 9

Vasomedical, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements (unaudited)

	(in thousands)
	As of or for the three months ended June 30, 2015 (unaudited)
	Sales Representation Segment		IT Segment			Equipment Segment			Corporate			Consolidated

Revenues from external customers	$	7,036	$	2,811		$	996		$	-		$	10,843
Operating income (loss)	$	1,794	$	(366	)	$	(676	)	$	(546	)	$	206
Total assets	$	10,421	$	25,205		$	9,385		$	1,309		$	46,320
Accounts and other receivables, net	$	4,421	$	1,399		$	500		$	-		$	6,320
Deferred commission expense	$	2,388	$	19		$	-		$	-		$	2,407
Other assets	$	3,098	$	51		$	675		$	113		$	3,937

		As of or for the three months ended June 30, 2014 (unaudited)
	Sales Representation Segment		IT Segment			Equipment Segment			Corporate			Consolidated

Revenues from external customers	$	6,684	$	-		$	1,180		$	-		$	7,864
Operating income (loss)	$	1,021	$	-		$	(875	)	$	(352	)	$	(206	)
Total assets	$	13,144	$	-		$	8,052		$	10,036		$	31,232
Accounts and other receivables, net	$	6,585	$	-		$	941		$	-		$	7,526
Deferred commission expense	$	2,297	$	-		$	-		$	-		$	2,297
Other assets	$	4,066	$	-		$	1,164		$	13		$	5,243

		As of or for the six months ended June 30, 2015 (unaudited)
	Sales Representation Segment		IT Segment			Equipment Segment			Corporate			Consolidated

Revenues from external customers	$	13,427	$	2,811		$	2,059		$	-		$	18,297
Operating income (loss)	$	2,880	$	(721	)	$	(1,311	)	$	(928	)	$	(80	)
Total assets	$	10,421	$	25,205		$	9,385		$	1,309		$	46,320
Accounts and other receivables, net	$	4,421	$	1,399		$	500		$	-		$	6,320
Deferred commission expense	$	2,388	$	19		$	-		$	-		$	2,407
Other assets	$	3,098	$	51		$	675		$	113		$	3,937

		As of or for the six months ended June 30, 2014 (unaudited)
	Sales Representation Segment		IT Segment			Equipment Segment			Corporate			Consolidated

Revenues from external customers	$	12,926	$	-		$	2,030		$	-		$	14,956
Operating income (loss)	$	1,544	$	-		$	(1,955	)	$	(883	)	$	(1,294	)
Total assets	$	13,144	$	-		$	8,052		$	10,036		$	31,232
Accounts and other receivables, net	$	6,585	$	-		$	941		$	-		$	7,526
Deferred commission expense	$	2,297	$	-		$	-		$	-		$	2,297
Other assets	$	4,066	$	-		$	1,164		$	13		$	5,243

For the three months ended June 30, 2015 and 2014, GE Healthcare accounted for 65% and 85% of revenue, respectively. For the six months ended June 30, 2015 and 2014, GE Healthcare accounted for 73% and 86% of revenue, respectively, and $4.3 million or 68%, and $14.2 million or 93%, of accounts and other receivables at June 30, 2015 and December 31, 2014, respectively.

Page 10

Vasomedical, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements (unaudited)

NOTE D – EARNINGS (LOSS) PER COMMON SHARE

Basic earnings (loss) per common share is computed as earnings applicable to common stockholders divided by the weighted-average number of common shares outstanding for the period. Diluted earnings (loss) per common share reflects the potential dilution that could occur if securities or other contracts to issue common shares were exercised or converted to common stock.

Diluted earnings (loss) per share were computed based on the weighted average number of shares outstanding plus all potentially dilutive common shares. A reconciliation of basic to diluted shares used in the earnings per share calculation is as follows:

	(in thousands)
	Three months ended June 30,				Six months ended June 30,
	2015		2014		2015		2014
Basic weighted average shares outstanding		156,258		155,320		156,102		155,386
Dilutive effect of share-based compensation		308		-		-		-
Diluted weighted average shares outstanding		156,566		155,320		156,102		155,386

The following table represents common stock equivalents that were excluded from the computation of diluted earnings per share for the three and six months ended June 30, 2015 and 2014, because the effect of their inclusion would be anti-dilutive.

	(in thousands)
	For the three months ended				For the six months ended
	June 30, 2015		June 30, 2014		June 30, 2015		June 30, 2014
	(unaudited)		(unaudited)		(unaudited)		(unaudited)
Stock options		335		1,754		935		1,754
Common stock grants		125		775		2,873		775
		460		2,529		3,808		2,529

Page 11

Vasomedical, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements (unaudited)

NOTE E – FAIR VALUE MEASUREMENTS

The Company complies with the provisions of ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”). Under ASC 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date.

The following tables present information about the Company’s assets measured at fair value as of June 30, 2015 and December 31, 2014:

	(in thousands)
	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Balance as of June 30, 2015
Assets							(unaudited)
Cash equivalents invested in money market funds (included in cash and cash equivalents)	$	2	$	-	$	-	$	2

	Quoted Prices in Active Markets for Identical Assets (Level I)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Balance as of December 31, 2014
Assets
Cash equivalents invested in money market funds (included in cash and cash equivalents)	$	8,149	$	-	$	-	$	8,149

The fair values of the Company’s cash equivalents invested in money market funds are determined through market, observable and corroborated sources.

NOTE F – ACCOUNTS AND OTHER RECEIVABLES, NET

The following table presents information regarding the Company’s accounts and other receivables as of June 30, 2015 and December 31, 2014:

	(in thousands)
	June 30, 2015			December 31, 2014
	(unaudited)
Trade receivables	$	10,374		$	19,734
Due from employees		124			110
Allowance for doubtful accounts and
commission adjustments		(4,178	)		(4,571	)
Accounts and other receivables, net	$	6,320		$	15,273

Trade receivables include amounts due for shipped products and services rendered. Amounts currently due under the GEHC Agreement are subject to adjustment in subsequent periods should the underlying sales order amount, upon which the receivable is based, change.

Allowance for doubtful accounts and commission adjustments include estimated losses resulting from the inability of our customers to make required payments, and adjustments arising from subsequent changes in sales order amounts that may reduce the amount the Company will ultimately receive under the GEHC Agreement. Due from employees is primarily commission advances made to sales personnel.

Page 12

Vasomedical, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements (unaudited)

NOTE G – INVENTORIES, NET

Inventories, net of reserves, consist of the following:

	(in thousands)
	June 30, 2015		December 31, 2014
	(unaudited)
Raw materials	$	588	$	583
Work in process		688		679
Finished goods		892		636
	$	2,168	$	1,898

At June 30, 2015 and December 31, 2014, the Company maintained reserves for excess and obsolete inventory of $791,000 and $815,000, respectively.

NOTE H – GOODWILL AND OTHER INTANGIBLES

Goodwill aggregating $22,618,000 and $3,288,000 was recorded on the Company’s condensed consolidated balance sheets at June 30, 2015 and December 31, 2014, respectively, of which $19,303,000, allocated to the IT segment, resulted from the acquisition of NetWolves in May 2015. The remaining $3,315,000 of goodwill is allocated to the Company’s Equipment segment. The components of the change in goodwill are as follows:

	(in thousands)
	Carrying Amount

Balance at December 31, 2014	$	3,288
Foreign currency translation		27
Acquisition of NetWolves		19,303
Balance at June 30, 2015 (unaudited)	$	22,618

The Company’s other intangible assets consist of capitalized patent costs, customer lists and software costs, as follows:

Page 13

Vasomedical, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements (unaudited)

	(in thousands)
	June 30, 2015			December 31, 2014
	(unaudited)
Patents and Technology
Costs	$	2,467		$	2,489
Accumulated amortization		(678	)		(549	)
		1,789			1,940

Customer lists
Costs		800			800
Accumulated amortization		(438	)		(381	)
		362			419

Software
Costs		1,054			962
Accumulated amortization		(644	)		(495	)
		410			467

	$	2,561		$	2,826

Patents, customer lists, and software are included in other assets in the accompanying condensed consolidated balance sheets and are amortized on a straight line basis over their estimated useful lives of ten, seven, and five years, respectively. Amortization expense amounted to $164,000 and $335,000 for the three and six months ended June 30, 2015, respectively, and $50,000 and $96,000 for the three and six months ended June 30, 2014, respectively.

NOTE I – OTHER ASSETS

Other assets consist of the following at June 30, 2015 and December 31, 2014:

	(in thousands)
	June 30, 2015		December 31, 2014
	(unaudited)
Deferred commission expense - noncurrent	$	2,121	$	2,988
Trade receivables - noncurrent		1,186		2,171
Other		630		458
	$	3,937	$	5,617

Page 14

Vasomedical, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements (unaudited)

NOTE J – ACCRUED EXPENSES AND OTHER LIABILITIES

Accrued expenses and other liabilities consist of the following at June 30, 2015 and December 31, 2014:

	(in thousands)
	June 30, 2015		December 31, 2014
	(unaudited)
Accrued compensation	$	1,536	$	2,917
Accrued expenses - other		1,313		1,098
Other liabilities		2,307		1,612
	$	5,156	$	5,627

NOTE K- DEFERRED REVENUE

The changes in the Company’s deferred revenues are as follows:

	(in thousands)
	For the three months ended						For the six months ended
	June 30, 2015			June 30, 2014			June 30, 2015			June 30, 2014
	(unaudited)			(unaudited)			(unaudited)			(unaudited)
Deferred revenue at beginning of period	$	21,453		$	17,004		$	22,532		$	18,019
Additions:
Deferred extended service contracts		94			309			305			546
Deferred in-service and training		3			13			5			15
Deferred service arrangements		5			25			15			30
Deferred commission revenues		1,481			3,614			3,330			5,384
Recognized as revenue:
Deferred extended service contracts		(214	)		(220	)		(445	)		(448	)
Deferred in-service and training		(3	)		(8	)		(10	)		(15	)
Deferred service arrangements		(20	)		(23	)		(43	)		(46	)
Deferred commission revenues		(3,185	)		(3,002	)		(6,075	)		(5,773	)
Deferred revenue at end of period		19,614			17,712			19,614			17,712
Less: current portion		11,560			9,183			11,560			9,183
Long-term deferred revenue at end of period	$	8,054		$	8,529		$	8,054		$	8,529

Page 15

Vasomedical, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements (unaudited)

NOTE L – DEBT

On May 29, 2015, the Company entered into a Note Purchase Agreement with MedTechnology Investments, LLC (“MedTech”) pursuant to which it issued MedTech a secured subordinated promissory note (“Note”) for $3,800,000 for the purchase of NetWolves. MedTech was formed to acquire the Note, and $1,950,000 of the aggregate funds used to acquire the Note was provided by six of our directors. In June 2015, a second Note for $750,000 was issued to MedTech for working capital purposes, $250,000 of which was provided by a director and a director’s spouse. Subsequent to June 30, 2015, an additional $250,000 was borrowed under the Note Purchase Agreement.

The Notes bear interest at an annual rate of 9%, matures on May 29, 2019, may be prepaid without penalty, and is subordinated to any current or future Senior Debt as defined in the Subordinated Security Agreement. The Subordinated Security Agreement secures payment and performance of the Company’s obligations under the Note and as a result, MedTech was granted a subordinated security interest in the Company’s assets.

NOTE M – BUSINESS COMBINATION

On May 29, 2015, the Company entered into an agreement for, and completed its purchase of, all of the assets of NetWolves, LLC and its affiliates, including the membership interests in NetWolves Network Services LLC (collectively, “NetWolves”) for $18,000,000 (the “Purchase Price”). The purchase of NetWolves was accomplished pursuant to an Asset Purchase Agreement (the "Purchase Agreement"). As a result, the Company effectively purchased all rights, titles and ownership of all assets held by NetWolves. The Purchase Price was paid using $14,200,000 in cash on hand and $3,800,000 raised through the issuance of the Note to MedTech. The Company believes there are significant operational synergies between NetWolves’ capabilities and VasoHealthcare IT’s requirements under its VAR contract with GEHC, as well as the opportunity to expand NetWolves’ existing services to the healthcare IT market.

The operating results of NetWolves from May 29, 2015 to June 30, 2015 are included in the accompanying condensed consolidated statements of operations and comprehensive income (loss) for the three and six month periods ended June 30, 2015. The accompanying condensed consolidated balance sheet at June 30, 2015 reflects the acquisition of NetWolves effective May 29, 2015.

In accordance with Accounting Standards Codification 805, Business Combinations, the total purchase consideration is allocated to the net tangible and intangible assets acquired and liabilities assumed based on their estimated fair values at May 29, 2015 (the acquisition date). The purchase price was allocated based on the information currently available, and may be adjusted after obtaining more information regarding, among other things, asset valuations, liabilities assumed, and revisions of preliminary estimates. The following table summarizes the preliminary allocation of the assets acquired and liabilities assumed based on their preliminary estimated fair values as follows:

		(in thuosands)
Cash and cash equivalents	$	733
Accounts receivable and other current assets		1,638
Other assets		50
Property and equipment		2,359
Accounts payable and other current liabilities		(4,382	)
Long term debt		(1,701	)
Goodwill		19,303
Total	$	18,000

During the three months ended June 30, 2015, the Company expensed $100,000 of acquisition-related legal costs and incurred $60,000 in debt issue costs. The legal costs are included in the line item Selling, General & Administrative costs in the accompanying condensed consolidated statements of operations and comprehensive income (loss). The debt issue costs are recorded as a reduction to long term notes payable in the accompanying condensed consolidated balance sheet at June 30, 2015. The amounts of revenue and net income of NetWolves included in the Company’s condensed consolidated statements of operations and comprehensive income (loss) for both the three and six months ended June 30, 2015 was $2,763,000 and $150,000, respectively. The goodwill is expected to be deductible for tax purposes.

Page 16

Vasomedical, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements (unaudited)

The following unaudited supplemental pro forma information presents the financial results as if the acquisitions of Genwell and NetWolves had occurred January 1, 2013, and January 1, 2014, respectively.

	(in thousands)
	Three months ended				Six months ended
	June 30, 2015		June 30, 2014		June 30, 2015		June 30, 2014
Revenue	$	16,088	$	15,070	$	31,449	$	29,431

Net income (loss)		580		(160)		517		(1,061	)

Basic earnings (loss) per share	$	0.00	$	(0.00)	$	0.00	$	(0.01	)

Diluted earnings (loss) per share	$	0.00	$	(0.00)	$	0.00	$	(0.01	)

NOTE N – RELATED-PARTY TRANSACTIONS

One of the Company’s directors, Peter Castle, was the Chief Executive Officer and President of NetWolves, LLC. Another of the Company’s directors, David Lieberman, was a director of NetWolves Network Services, LLC. Mr. Castle and Mr. Lieberman owned of record approximately 10.4% and 5.7%, respectively of the membership interests of NetWolves LLC. Mr. Lieberman may also be deemed to have owned beneficially up to an additional 13.5% of such membership interests. The Company’s board of directors negotiated the Purchase Price on an arm’s length basis, and both Mr. Castle and Mr. Lieberman abstained from the vote approving the Purchase Agreement.

The Company obtained an opinion regarding the fairness of the Purchase Price for the NetWolves entities from a reputable, independent third-party investment banking firm. $14,200,000 of the Purchase Price was paid for by cash on hand, and the remaining $3,800,000 was raised from the sale of a Subordinated Secured Note sold to MedTech. Of the $4,550,000 borrowed from MedTech at June 30, 2015, $2,200,000 was provided by six of our directors, or members of their families.

Page 17

Vasomedical, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements (unaudited)

David Lieberman, the Vice Chairman of the Company’s Board of Directors, is a practicing attorney in the State of New York and a senior partner at the law firm of Beckman, Lieberman & Barandes, LLP, which performs certain legal services for the Company. Fees of approximately $60,000 and $120,000 were billed by the firm through the three and six month periods ended June 30, 2015, respectively, at which date $20,000 was outstanding. Fees of approximately $60,000 and $120,000 were billed by the firm through the three and six month periods ended June 30, 2014, respectively, at which date no amounts were outstanding.

In January 2015, operations began under the VSK joint venture. The Company accounts for its investment in VSK using the equity method. At June 30, 2015, the Company had contributed $100,000 to VSK, and no amounts were due from VSK for equipment the Company sold to it. VSK earned approximately $50,000 and $46,000 for the three and six months ended June 30, 2015, respectively. Under the terms of the agreement, the Company’s accrues no interest in VSK’s income in the years ending December 31, 2015, 2016 and 2017 unless certain performance targets are achieved. For the six months ended June 30, 2015 such targets had not been achieved.

NOTE O – COMMITMENTS AND CONTINGENCIES

Sales representation agreement

In June 2012, the Company concluded an amendment of the GEHC Agreement with GEHC, originally signed on May 19, 2010. The amendment, effective July 1, 2012, extended the initial term of three years commencing July 1, 2010 to five years through June 30, 2015. In December 2014, the Company concluded an additional amendment, effective January 1, 2015, extending the term through December 31, 2018, subject to earlier termination under certain circumstances and termination without cause on or after July 1, 2017. These circumstances include not materially achieving certain sales goals, not maintaining a minimum number of sales representatives, and various legal and GEHC policy requirements. Under the terms of the agreement, the Company is required to lease dedicated computer equipment from GEHC for connectivity to their network.

NOTE P - RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

In May 2014, the FASB issued ASU 2014-09 “Revenue from contracts with customers”, a comprehensive new revenue recognition standard which will supersede previous existing revenue recognition guidance. The standard creates a five-step model for revenue recognition that requires companies to exercise judgment when considering contract terms and relevant facts and circumstances. The five-step model includes (1) identifying the contract, (2) identifying the separate performance obligations in the contract, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations and (5) recognizing revenue when each performance obligation has been satisfied. The standard also requires expanded disclosures surrounding revenue recognition. The standard is effective for fiscal periods beginning after December 15, 2017 and allows for either full retrospective or modified retrospective adoption, with early adoption permitted as of January 1, 2017. The Company is currently evaluating the impact of the adoption of this standard on its Consolidated Financial Statements.

In April 2015, the FASB issued ASU 2015-03 “Simplifying the Presentation of Debt Issuance Costs”, which changes the presentation of debt issuance costs in financial statements. An entity presents such costs in the balance sheet as a direct deduction from the related debt liability rather than as an asset. Amortization of the costs is reported as interest expense. The standard is effective for fiscal periods beginning after December 31, 2015 and allows for early adoption. The Company has early adopted this statement for the six months ended June 30, 2015, resulting in $60,000 in debt issue costs initially deducted from the MedTech debt and $1,250 amortized to interest expense.

NOTE Q – SUBSEQUENT EVENTS

In July 2015, the lending institution extended the Company’s NetWolves subsidiary's $2.0 million line of credit and increased the maximum borrowings to $3.0 million. Advances under the line, which expires on August 26, 2016, bear interest at a rate of LIBOR plus 2.25% and are secured by substantially all of the assets of NetWolves Network Services, LLC and the guaranty of Vasomedical, Inc.

Page 18

Vasomedical, Inc. and Subsidiaries

ITEM 2 - MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Except for historical information contained in this report, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this report, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC Agreement and the risk factors reported from time to time in the Company’s SEC reports, including its recent report on Form 10-K. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.

General Overview

Vasomedical, Inc. was incorporated in Delaware in July 1987. Unless the context requires otherwise, all references to “we”, “our”, “us”, “Company”, “registrant”, “Vasomedical” or “management” refer to Vasomedical, Inc. and its subsidiaries. Until 2010, we were primarily engaged in designing, manufacturing, marketing and supporting Enhanced External Counterpulsation (EECP®) systems, based on our proprietary technology, to physicians and hospitals throughout the United States and in select international markets. Beginning in July 2010 the Company, through its wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare, began its sales representation business via its agreement (GEHC Agreement) with GE Healthcare (GEHC), the healthcare business unit of General Electric Company (NYSE: GE), to be GEHC’s exclusive sales representative for the sale of select GEHC diagnostic imaging products in specific market segments in the 48 contiguous states of the United States and the District of Columbia. In June 2012, the GEHC Agreement was amended and extended through June 30, 2015 and again, in December 2014, the GEHC Agreement was further amended and extended through December 31, 2018, subject to earlier termination under certain circumstances and termination without cause on or after July 1, 2017.

In September 2011, the Company acquired Fast Growth Enterprises Limited (FGE), a British Virgin Islands company, which owns or controls two Chinese operating companies - Life Enhancement Technology Ltd. and Biox Instruments Co. Ltd., respectively - to expand its technical and manufacturing capabilities and to enhance its distribution network, technology, and product portfolio. Also in September 2011, the Company restructured to further align its business management structure and long-term growth strategy, and started to operate through three wholly-owned subsidiaries. Vaso Diagnostics d/b/a VasoHealthcare continues as the operating subsidiary for the sales representation of GE diagnostic imaging products; Vasomedical Global Corp. operates the Company’s Chinese companies; and Vasomedical Solutions, Inc. was formed to manage and coordinate our EECP® therapy business as well as other medical equipment operations.

In April 2014, the Company entered into an agreement with Chongqing PSK-Health Sci-Tech Development Co., Ltd. (PSK) of Chongqing, China, the leading manufacturer of ECP therapy systems in China, to form a joint venture company, VSK Medical Limited (VSK), for the global marketing, sale and advancement of ECP therapy technology. The Company owns 49.9% of the shares of VSK. VSK began operations in January 2015. The Company contributed $100,000 in cash to VSK during the six months ended June 30, 2015.

Page 19

Vasomedical, Inc. and Subsidiaries

The Company continues to pursue acquisitions or partnership opportunities in the international and domestic markets and to seek expansion of its sales representation business.

Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations are based upon the accompanying unaudited condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). The preparation of financial statements in conformity with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Although these estimates are based on our knowledge of current events, our actual amounts and results could differ from those estimates. The estimates made are based on historical factors, current circumstances, and the experience and judgment of our management, who continually evaluate the judgments, estimates and assumptions and may employ outside experts to assist in the evaluations.

Certain of our accounting policies are deemed “critical”, as they are both most important to the financial statement presentation and require management’s most difficult, subjective or complex judgments as a result of the need to make estimates about the effect of matters that are inherently uncertain. For a discussion of our critical accounting policies, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2014 as filed with the SEC on March 30, 2015.

Results of Operations – For the Three Months Ended June 30, 2015 and 2014

Total revenue for the three months ended June 30, 2015 and 2014 was $10,843,000 and $7,864,000, respectively, representing an increase of $2,979,000, or 38% year-over-year. The revenue increase was primarily due to $2,811,000 in revenue in the IT segment, of which $2,763,000 resulted from the acquisition of NetWolves. Net income (loss) for the three months ended June 30, 2015 and 2014 was $191,000 and $(176,000), respectively, an improvement of $367,000, or 209%. Our total net income (loss) was $0.00 and $(0.00) per basic and diluted common share for the three months ended June 30, 2015 and 2014, respectively.

Revenues

Commission revenues in the Sales Representation segment were $7,036,000 in the second quarter of 2015, an increase of 5%, as compared to $6,684,000 in the second quarter of 2014. The increase in commission revenues in the second quarter of 2015 was due primarily to higher commission rates on equipment delivered by GEHC during the quarter, partially offset by a 2% decrease in such deliveries. The Company recognizes commission revenue when the underlying equipment has been accepted at the customer site in accordance with the specific terms of the sales agreement. Consequently, amounts billable under the agreement with GE Healthcare prior to customer acceptance of the equipment are recorded as deferred revenue in the condensed consolidated balance sheet. As of June 30, 2015, $18,410,000 in deferred commission revenue was recorded in the Company’s condensed consolidated balance sheet, of which $7,508,000 was long-term. At June 30, 2014, $16,277,000 in deferred commission revenue was recorded in the Company’s condensed consolidated balance sheet, of which $7,864,000 was long-term.

Page 20

Vasomedical, Inc. and Subsidiaries

Revenue in our Equipment segment decreased by $184,000, or 16%, to $996,000 for the three-month period ended June 30, 2015 compared to the same period of the prior year. Equipment segment revenue from equipment sales decreased by $116,000, or 15%, to $654,000 for the three-month period ended June 30, 2015 as compared to the same period in the prior year, resulting from decreases in EECP® revenues as a result of lower sales volume, partially offset by increases in international sales by our China operations.

Equipment segment revenue from equipment rental and services decreased 17% to $342,000 in the second quarter of 2015 from $410,000 in the second quarter of 2014. Revenue from equipment rental and services represented 34% and 35% of total Equipment segment revenue in the second quarters of fiscal 2015 and fiscal 2014, respectively. The decrease in revenue generated from equipment rentals and services is due to lower field service, accessory part, and service contract revenues.

Gross Profit

The Company had a gross profit of $7,328,000, or 68% of revenue, in the second quarter of 2015 compared to $5,482,000, or 70% of revenue, in the second quarter of the prior year, an increase of $1,846,000, or 34%. The increase is principally due to $1,198,000 in gross profit in the IT segment, of which $1,192,000 resulted from the acquisition of NetWolves, and higher revenues and gross profit margin in the Sales Representation segment.

Sales Representation segment gross profit was $5,512,000, or 78% of the segment revenue, for the three months ended June 30, 2015 as compared to $4,832,000, or 72% of the segment revenue, for the three months ended June 30, 2014. The increase in absolute dollars and margin percentage was due to higher commission rates during the second quarter of 2015 than in the same period last year, as well as lower commission expense in the second quarter of 2015. Cost of commissions of $1,524,000 and $1,852,000, for the three months ended June 30, 2015 and 2014, respectively, reflected commission expense associated with recognized commission revenues. Commission expense associated with deferred revenue is recorded as deferred commission expense until the related commission revenue is recognized.

Equipment segment gross profit decreased to $618,000, or 62% of Equipment segment revenues, for the second quarter of 2015 compared to $650,000, or 55% of Equipment segment revenues, for the same quarter of 2014. Gross profit margin in the Equipment segment improved due to higher mix of sales by Chinese operations, which have higher margins, and manufacturing cost reductions in the U.S.

Operating Income (Loss)

Operating income was $206,000 for the three months ended June 30, 2015, compared to an operating loss of $206,000 for the three months ended June 30, 2014, an improvement of $412,000. During this period, there was a $1,846,000 increase in gross profit and a $1,503,000 increase in selling, general, and administrative costs. Operating income in the Sales Representation segment increased by $773,000 to $1,794,000, compared to $1,021,000 in the second quarter of the prior year, due mainly to a higher gross margin combined with lower SG&A costs. In addition, operating loss in the Equipment segment decreased by $199,000, or 23%, to $676,000 compared to $875,000 in the same quarter of the prior year, due primarily to $248,000 lower SG&A costs in the current year quarter. Our IT segment had an operating loss of $366,000 in the second quarter of 2015. This loss was reduced by a $150,000 operating profit from the one month of NetWolves operations included in this quarter. We anticipate that the operating profit in this segment will improve with the NetWolves operations and increases in revenue in our GEHC VAR business.

SG&A expenses for the second quarter of 2015 and 2014 were $6,985,000, or 64% of revenues, and $5,482,000, or 70% of revenues, respectively, reflecting an increase of $1,503,000 or approximately 27%. The increase in SG&A expenditures in the second quarter of 2015 resulted primarily from $1,560,000 in costs attributable to the IT segment in 2015 mainly due to the inclusion of NetWolves operations during the quarter, and higher corporate expenses, primarily legal and directors’ fees, partially offset by lower costs in the Sales Representation and Equipment segments due to reduced headcounts.

Research and development (“R&D”) expenses were $137,000, or 1% of revenues (14% of Equipment segment revenues), for the second quarter of 2015, a decrease of $69,000, or 33%, from $206,000, or 3% of revenues (17% of Equipment segment revenues), for the second quarter of 2014. The decrease is primarily attributable to lower clinical grants in the second quarter of 2015.

Page 21

Vasomedical, Inc. and Subsidiaries

Interest and Other Income (Expense)

Interest and other income (expense) for the second quarter of 2015 was $(9,000) as compared to $44,000 for the second quarter of 2014. The change from income to expense was due primarily to higher interest expense associated with the Genwell and NetWolves acquisitions.

Income Tax Expense

During the second quarter of 2015 we recorded income tax expense of $6,000 as compared to income tax expense of $14,000 for the second quarter of 2014. The decrease arose from lower tax expense at our Chinese subsidiaries.

Results of Operations – For the Six Months Ended June 30, 2015 and 2014

Total revenue for the six months ended June 30, 2015 and 2014 was $18,297,000 and $14,956,000, respectively, representing an increase of $3,341,000, or 22% year-over-year. The revenue increase was primarily due to $2,811,000 in revenue in the IT segment, of which $2,763,000 resulted from the acquisition of NetWolves. Net loss for the six months ended June 30, 2015 and 2014 was $62,000 and $1,220,000, respectively, a decrease of $1,158,000, or 95%. Our total net loss was $(0.00) and $(0.01) per basic and diluted common share for the six months ended June 30, 2015 and 2014, respectively.

Revenues

Commission revenues in the Sales Representation segment were $13,427,000 in the first half of 2015, an increase of 4% from $12,926,000 in the first half of 2014. The increase in commission revenue in the first half of 2015 is due to increases in both commission rate earned and volume of equipment delivered by GEHC during the period. The Company recognizes commission revenue when the underlying equipment has been accepted at the customer site in accordance with the specific terms of the sales agreement. Consequently, amounts billable under the agreement with GE Healthcare prior to customer acceptance of the equipment are recorded as deferred revenue in the condensed consolidated balance sheet. As of June 30, 2015, $18,410,000 in deferred commission revenue was recorded in the Company’s condensed consolidated balance sheet, of which $7,508,000 is long-term. At June 30, 2014, $16,277,000 in deferred commission revenue was recorded in the Company’s condensed consolidated balance sheet, of which $7,864,000 was long-term.

Revenue in our Equipment segment increased by $29,000, or 1%, to $2,059,000 for the six-month period ended June 30, 2015 from $2,030,000 for the same period of the prior year. Equipment segment revenue from equipment sales increased by $119,000, or 9%, to $1,373,000 for the six-month period ended June 30, 2015 as compared to $1,254,000 for the same period in the prior year, resulting from increases in international sales by our China operations, partially offset by decreases in EECP® revenues as a result of lower sales volume.

Equipment segment revenue from equipment rental and services decreased 12% to $686,000 in the first two quarters of 2015 from $776,000 in the first two quarters of 2014. Revenue from equipment rental and services represented 33% and 38% of total Equipment segment revenue in the first two quarters of fiscal 2015 and fiscal 2014, respectively. The decrease in revenue generated from equipment rentals and services is due primarily to lower field service and accessory part revenues.

Gross Profit

The Company had a gross profit of $12,896,000, or 70% of revenue, in the first two quarters of 2015 compared to $10,648,000, or 71% of revenue, in the first two quarters of the prior year, an increase of $2,248,000, or 21%. The increase is principally due to $1,198,000 in gross profit in the IT segment, of which $1,192,000 resulted from the acquisition of NetWolves, and higher gross profit margin in both our Sales Representation segment and our Equipment segment.

Sales Representation segment gross profit was $10,380,000, or 77% of the segment revenue, for the six months ended June 30, 2015 as compared to $9,472,000, or 73% of the segment revenue, for the six months ended June 30, 2014. The increase in absolute dollars and margin percentage was due to higher commission rates, and higher equipment deliveries by GEHC during the first six months of 2015 than in the same period last year, coupled with lower commission expense in the first six months of 2015. Cost of commissions of $3,047,000 and $3,454,000, for the six months ended June 30, 2015 and 2014, respectively, reflected commission expense associated with recognized commission revenues. Commission expense associated with deferred revenue is recorded as deferred commission expense until the related commission revenue is recognized.

Page 22

Vasomedical, Inc. and Subsidiaries

Equipment segment gross profit increased to $1,318,000, or 64% of Equipment segment revenues, for the first two quarters of 2015 compared to $1,176,000, or 58% of Equipment segment revenues, for the same period of 2014. Gross profit margin in the Equipment segment improved due to higher mix of sales by Chinese operations, which have higher margins, and manufacturing cost reductions in the U.S.

Operating Loss

Operating loss was $80,000 for the six months ended June 30, 2015 as compared to $1,294,000 for the six months ended June 30, 2014, a decrease of $1,214,000 or 94%. Included in this loss was a $721,000 operating loss in our IT segment which began operations in the third quarter of 2014. During the six months ended June 30, 2015, there was also a $2,248,000 increase in gross profit partially offset by a $1,181,000 increase in selling, general, and administrative costs. Operating income in the Sales Representation segment increased by $1,336,000 to $2,880,000 as compared to $1,544,000 in the first half of the prior year, due mainly to higher gross margin combined with lower SG&A costs. In addition, operating loss in the Equipment segment decreased by $644,000, or 33%, to $1,311,000 compared to $1,955,000 in the same period of the prior year, due primarily to $142,000 higher gross profit and $356,000 lower SG&A costs in the current year period.

SG&A expenses for the first two quarters of 2015 and 2014 were $12,704,000, or 69% of revenues, and $11,523,000, or 77% of revenues, respectively, reflecting an increase of $1,181,000 or approximately 10%. The increase in SG&A expenditures in the first two quarters of 2015 resulted primarily from $1,918,000 in costs attributable to the IT segment in 2015, and higher corporate expenses, primarily legal fees, partially offset by lower costs in the Sales Representation and Equipment segments due to reduced headcounts.

Research and development (“R&D”) expenses were $272,000, or 1% of revenues (13% of Equipment segment revenues), for the first half of 2015, a decrease of $147,000, or 35%, from $419,000, or 3% of revenues (21% of Equipment segment revenues), for the first half of 2014. The decrease is primarily attributable to the elimination of non-recurring costs in the first half of 2014 associated with the reclassification by FDA of our EECP® therapy system, as well as lower clinical grants in the first half of 2015.

Interest and Other Income (Expense)

Interest and other income (expense) for the first two quarters of 2015 was $30,000 as compared to $98,000 for the first two quarters of 2014. The decrease was due primarily to higher interest expense associated with the Genwell and NetWolves acquisitions.

Income Tax Expense

During the first two quarters of 2015 we recorded income tax expense of $12,000 as compared to income tax expense of $24,000 for the same period of 2014. The decrease arose from lower tax expense at our Chinese subsidiaries.

Liquidity and Capital Resources

Cash and Cash Flow

We have financed our operations from working capital and the proceeds from notes issued to MedTech. At June 30, 2015, we had cash and cash equivalents of $2,931,000, short-term investments of $109,000 and negative working capital of $10,221,000 compared to cash and cash equivalents of $9,128,000, short-term investments of $111,000 and working capital of $9,215,000 at December 31, 2014. $9,153,000 of the negative working capital at June 30, 2015 is attributable to the net balance of deferred commission expense and deferred revenue. These are non-cash expense and revenue items and have no impact on future cash flows.

Page 23

Vasomedical, Inc. and Subsidiaries

Cash provided by operating activities was $6,834,000 during the first six months of 2015, which consisted of a net loss after adjustments to reconcile net loss to net cash of $742,000 and cash provided by operating assets and liabilities of $6,092,000. The changes in the account balances primarily reflect a decrease in accounts and other receivables of $10,429,000, partially offset by decreases in deferred revenue of $2,918,000, accrued commissions of $1,092,000, and accrued expenses of $1,268,000. Significantly higher commission billings and recognized revenue were generated in the fourth quarter of 2014 resulting in significant cash inflows early in 2015.

Cash used in investing activities during the six-month period ended June 30, 2015 was $17,553,000, of which $17,267,000, net of cash acquired, was used for the acquisition of NetWolves, $100,000 was invested in the VSK joint venture, and $188,000 was used for the purchase of equipment and software.

Cash provided by financing activities during the six-month period ended June 30, 2015 was $4,550,000 through the issuance of notes to MedTech, partially offset $21,000 in repayments of notes issued for equipment purchases.

Liquidity

The Company expects to be profitable for the year ended December 31, 2015 and to continue to generate positive cash flow through its existing sales representation operations, from the operations of NetWolves, and improved operating efficiency and growth in its China operations and by expanding its market presence and product portfolio. The Company has reorganized its EECP® business model, both domestically and internationally, including the start of operations of the joint venture VSK Medical, intended to reduce costs and achieve profitability in this business. The Company will continue to pursue acquisitions and partnership opportunities in the international and domestic markets and to expand its sales representation business.

ITEM 4 - CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures reporting as promulgated under the Exchange Act is defined as controls and procedures that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act are recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms. Disclosure controls and procedures include without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Our CEO and our CFO have evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of June 30, 2015 and have concluded that the Company’s disclosure controls and procedures were effective as of June 30, 2015.

Page 24

Vasomedical, Inc. and Subsidiaries

Changes in Internal Control Over Financial Reporting

There was no change in the Company’s internal control over financial reporting during the Company’s last fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

Page 25

Vasomedical, Inc. and Subsidiaries

PART II - OTHER INFORMATION

ITEM 6 – EXHIBITS

Exhibits

31	Certifications of the Chief Executive Officer and the Chief Financial Officer pursuant to Rules 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32	Certifications of the Chief Executive Officer and the Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Page 26

Vasomedical, Inc. and Subsidiaries

In accordance with the requirements of the Exchange Act, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

VASOMEDICAL, INC.

By: /s/ Jun Ma

Jun Ma

President and Chief Executive Officer

(Principal Executive Officer)

/s/ Michael J. Beecher .

Michael J. Beecher

Chief Financial Officer and Principal Accounting Officer

Date: August 14, 2015

Page 27

GRAPHIC 2 vasojune2014.jpg begin 644 vasojune2014.jpg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vaso10q-june2015ex31.htm vaso10q-june2015ex31.htm

EXHIBIT 31.1

CERTIFICATION PURSUANT TO RULE 13a/15d OF THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Jun Ma, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Vasomedical, Inc. and subsidiaries (the “registrant”);

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):

a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and

b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ Jun Ma .

Jun Ma

President and Chief Executive Officer

Date: August 14, 2015

EXHIBIT 31.2

CERTIFICATION PURSUANT TO RULE 13a/15d OF THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Michael J. Beecher, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Vasomedical, Inc. and subsidiaries (the “registrant”);

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

c.	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):

a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and

b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ Michael J. Beecher .

Michael J. Beecher

Chief Financial Officer

Date: August 14, 2015

EX-32 4 vaso10q-june2015ex32.htm vaso10q-june2015ex32.htm

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Vasomedical, Inc. and subsidiaries (the “Company”) on Form 10-Q for the period ending June 30, 2015, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jun Ma, as President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Jun Ma .

Jun Ma

President and Chief Executive Officer

Dated: August 14, 2015

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Vasomedical, Inc. and subsidiaries (the “Company”) on Form 10-Q for the period ending June 30, 2015, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael J. Beecher, as Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Michael J. Beecher .

Michael J. Beecher

Chief Financial Officer

Dated: August 14, 2015

EX-101.INS 5 vaso-20150630.xml INSTANCE DOCUMENT 0000839087 2015-01-01 2015-06-30 0000839087 2015-08-08 0000839087 2014-12-31 0000839087 2015-06-30 0000839087 2015-04-01 2015-06-30 0000839087 2014-01-01 2014-06-30 0000839087 2014-04-01 2014-06-30 0000839087 us-gaap:CommonStockMember 2013-12-31 0000839087 us-gaap:TreasuryStockMember 2014-12-31 0000839087 us-gaap:CommonStockMember 2014-12-31 0000839087 us-gaap:AdditionalPaidInCapitalMember 2013-12-31 0000839087 us-gaap:TreasuryStockMember 2013-12-31 0000839087 us-gaap:RetainedEarningsMember 2014-12-31 0000839087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-12-31 0000839087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2013-12-31 0000839087 us-gaap:AdditionalPaidInCapitalMember 2014-12-31 0000839087 us-gaap:RetainedEarningsMember 2013-12-31 0000839087 2013-12-31 0000839087 us-gaap:TreasuryStockMember 2014-01-01 2014-12-31 0000839087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-01-01 2014-12-31 0000839087 2014-01-01 2014-12-31 0000839087 us-gaap:CommonStockMember 2014-01-01 2014-12-31 0000839087 us-gaap:AdditionalPaidInCapitalMember 2014-01-01 2014-12-31 0000839087 us-gaap:RetainedEarningsMember 2014-01-01 2014-12-31 0000839087 us-gaap:AdditionalPaidInCapitalMember 2015-01-01 2015-06-30 0000839087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-01-01 2015-06-30 0000839087 us-gaap:RetainedEarningsMember 2015-01-01 2015-06-30 0000839087 us-gaap:CommonStockMember 2015-01-01 2015-06-30 0000839087 us-gaap:AdditionalPaidInCapitalMember 2015-06-30 0000839087 us-gaap:CommonStockMember 2015-06-30 0000839087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-06-30 0000839087 us-gaap:TreasuryStockMember 2015-06-30 0000839087 us-gaap:RetainedEarningsMember 2015-06-30 0000839087 2014-06-30 0000839087 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2014-12-31 0000839087 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2015-06-30 0000839087 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2014-04-01 2014-06-30 0000839087 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2014-01-01 2014-06-30 0000839087 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2015-04-01 2015-06-30 0000839087 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2015-01-01 2015-06-30 0000839087 us-gaap:OperatingSegmentsMember vaso:InformationTechnologySegmentMember 2014-04-01 2014-06-30 0000839087 us-gaap:OperatingSegmentsMember vaso:EquipmentSegmentMember 2015-04-01 2015-06-30 0000839087 vaso:SalesRepresentationSegmentMember us-gaap:OperatingSegmentsMember 2015-01-01 2015-06-30 0000839087 vaso:SalesRepresentationSegmentMember us-gaap:OperatingSegmentsMember 2014-01-01 2014-06-30 0000839087 us-gaap:CorporateNonSegmentMember 2015-04-01 2015-06-30 0000839087 us-gaap:CorporateNonSegmentMember 2015-01-01 2015-06-30 0000839087 us-gaap:OperatingSegmentsMember vaso:SalesRepresentationSegmentMember 2015-04-01 2015-06-30 0000839087 us-gaap:CorporateNonSegmentMember 2014-04-01 2014-06-30 0000839087 vaso:EquipmentSegmentMember us-gaap:OperatingSegmentsMember 2015-01-01 2015-06-30 0000839087 us-gaap:CorporateNonSegmentMember 2014-01-01 2014-06-30 0000839087 vaso:SalesRepresentationSegmentMember us-gaap:OperatingSegmentsMember 2014-04-01 2014-06-30 0000839087 vaso:EquipmentSegmentMember us-gaap:OperatingSegmentsMember 2014-01-01 2014-06-30 0000839087 us-gaap:OperatingSegmentsMember vaso:InformationTechnologySegmentMember 2015-04-01 2015-06-30 0000839087 vaso:InformationTechnologySegmentMember us-gaap:OperatingSegmentsMember 2014-01-01 2014-06-30 0000839087 vaso:InformationTechnologySegmentMember us-gaap:OperatingSegmentsMember 2015-01-01 2015-06-30 0000839087 us-gaap:OperatingSegmentsMember vaso:EquipmentSegmentMember 2014-04-01 2014-06-30 0000839087 vaso:EquipmentSegmentMember us-gaap:OperatingSegmentsMember 2014-06-30 0000839087 us-gaap:CorporateNonSegmentMember 2014-06-30 0000839087 us-gaap:OperatingSegmentsMember vaso:SalesRepresentationSegmentMember 2014-06-30 0000839087 us-gaap:OperatingSegmentsMember vaso:SalesRepresentationSegmentMember 2015-06-30 0000839087 vaso:InformationTechnologySegmentMember us-gaap:OperatingSegmentsMember 2014-06-30 0000839087 vaso:InformationTechnologySegmentMember us-gaap:OperatingSegmentsMember 2015-06-30 0000839087 vaso:EquipmentSegmentMember us-gaap:OperatingSegmentsMember 2015-06-30 0000839087 us-gaap:CorporateNonSegmentMember 2015-06-30 0000839087 us-gaap:SalesRevenueNetMember vaso:GeHealthcareMember 2015-04-01 2015-06-30 0000839087 us-gaap:SalesRevenueNetMember vaso:GeHealthcareMember 2014-04-01 2014-06-30 0000839087 vaso:GeHealthcareMember us-gaap:SalesRevenueNetMember 2015-01-01 2015-06-30 0000839087 us-gaap:SalesRevenueNetMember vaso:GeHealthcareMember 2014-01-01 2014-06-30 0000839087 us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember vaso:GeHealthcareMember 2014-12-31 0000839087 vaso:GeHealthcareMember us-gaap:CreditConcentrationRiskMember us-gaap:AccountsReceivableMember 2015-06-30 0000839087 us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember vaso:GeHealthcareMember 2014-01-01 2014-12-31 0000839087 us-gaap:CreditConcentrationRiskMember us-gaap:AccountsReceivableMember vaso:GeHealthcareMember 2015-01-01 2015-06-30 0000839087 us-gaap:EmployeeStockOptionMember 2014-04-01 2014-06-30 0000839087 us-gaap:CommonStockMember 2014-01-01 2014-06-30 0000839087 us-gaap:EmployeeStockOptionMember 2014-01-01 2014-06-30 0000839087 us-gaap:CommonStockMember 2015-04-01 2015-06-30 0000839087 us-gaap:CommonStockMember 2015-01-01 2015-06-30 0000839087 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-06-30 0000839087 us-gaap:EmployeeStockOptionMember 2015-04-01 2015-06-30 0000839087 us-gaap:CommonStockMember 2014-04-01 2014-06-30 0000839087 us-gaap:FairValueInputsLevel2Member 2014-12-31 0000839087 us-gaap:FairValueInputsLevel1Member 2014-12-31 0000839087 us-gaap:FairValueInputsLevel3Member 2014-12-31 0000839087 us-gaap:FairValueInputsLevel1Member 2015-06-30 0000839087 us-gaap:FairValueInputsLevel3Member 2015-06-30 0000839087 us-gaap:FairValueInputsLevel2Member 2015-06-30 0000839087 vaso:PatentsAndTechnologyMember 2014-12-31 0000839087 us-gaap:ComputerSoftwareIntangibleAssetMember 2014-12-31 0000839087 us-gaap:ComputerSoftwareIntangibleAssetMember 2015-06-30 0000839087 us-gaap:CustomerListsMember 2014-12-31 0000839087 vaso:PatentsAndTechnologyMember 2015-06-30 0000839087 us-gaap:CustomerListsMember 2015-06-30 0000839087 vaso:EquipmentSegmentMember 2015-06-30 0000839087 us-gaap:ComputerSoftwareIntangibleAssetMember 2015-01-01 2015-06-30 0000839087 us-gaap:PatentsMember 2015-01-01 2015-06-30 0000839087 us-gaap:CustomerListsMember 2015-01-01 2015-06-30 0000839087 2015-03-31 0000839087 2014-03-31 0000839087 vaso:CommissionRevenuesMember 2014-01-01 2014-06-30 0000839087 vaso:InServiceAndTrainingMember 2014-04-01 2014-06-30 0000839087 vaso:CommissionRevenuesMember 2015-04-01 2015-06-30 0000839087 vaso:CommissionRevenuesMember 2014-04-01 2014-06-30 0000839087 vaso:ExtendedServiceContractsMember 2014-04-01 2014-06-30 0000839087 vaso:ExtendedServiceContractsMember 2015-04-01 2015-06-30 0000839087 vaso:ExtendedServiceContractsMember 2014-01-01 2014-06-30 0000839087 vaso:InServiceAndTrainingMember 2015-01-01 2015-06-30 0000839087 vaso:ServiceArrangementsMember 2014-04-01 2014-06-30 0000839087 vaso:ServiceArrangementsMember 2015-04-01 2015-06-30 0000839087 vaso:CommissionRevenuesMember 2015-01-01 2015-06-30 0000839087 vaso:ServiceArrangementsMember 2014-01-01 2014-06-30 0000839087 vaso:InServiceAndTrainingMember 2015-04-01 2015-06-30 0000839087 vaso:InServiceAndTrainingMember 2014-01-01 2014-06-30 0000839087 vaso:ExtendedServiceContractsMember 2015-01-01 2015-06-30 0000839087 vaso:ServiceArrangementsMember 2015-01-01 2015-06-30 0000839087 vaso:MedTechnologyInvestmentsLLCMember 2015-05-29 0000839087 vaso:MedTechnologyInvestmentsLLCMember 2015-01-01 2015-06-30 0000839087 vaso:DirectorAndDirectorsSpouseMember 2015-06-30 0000839087 vaso:MedTechnologyInvestmentsLLCMember 2015-06-30 0000839087 vaso:NetWolvesLLCMember 2015-05-29 2015-05-29 0000839087 vaso:MedTechnologyInvestmentsLLCMember vaso:NetWolvesLLCMember 2015-05-29 2015-05-29 0000839087 vaso:NetWolvesLLCMember 2015-04-01 2015-06-30 0000839087 vaso:NetWolvesLLCMember 2015-01-01 2015-06-30 0000839087 vaso:NetWolvesLLCMember 2015-05-29 0000839087 vaso:GenwellAndNetwolvesMember 2014-04-01 2014-06-30 0000839087 vaso:GenwellAndNetwolvesMember 2015-04-01 2015-06-30 0000839087 vaso:GenwellAndNetwolvesMember 2015-01-01 2015-06-30 0000839087 vaso:GenwellAndNetwolvesMember 2014-01-01 2014-06-30 0000839087 vaso:NetWolvesLLCMember vaso:DirectorDavidLiebermanMember 2015-06-30 0000839087 vaso:NetWolvesLLCMember vaso:DirectorPeterCastleMember 2015-06-30 0000839087 vaso:NetWolvesLLCMember vaso:MedTechnologyInvestmentsLLCMember 2015-01-01 2015-06-30 0000839087 vaso:NetWolvesLLCMember vaso:DirectorAndOtherFamilyMember 2015-06-30 0000839087 vaso:NetWolvesLLCMember vaso:MedTechnologyInvestmentsLLCMember 2015-06-30 0000839087 vaso:DirectorAndOtherFamilyMember vaso:NetWolvesLLCMember 2015-01-01 2015-06-30 0000839087 vaso:DirectorDavidLiebermanMember 2015-04-01 2015-06-30 0000839087 vaso:DirectorDavidLiebermanMember 2014-04-01 2014-06-30 0000839087 vaso:DirectorDavidLiebermanMember 2014-01-01 2014-06-30 0000839087 vaso:DirectorDavidLiebermanMember 2015-01-01 2015-06-30 0000839087 vaso:DirectorDavidLiebermanMember 2014-06-30 0000839087 vaso:DirectorDavidLiebermanMember 2015-06-30 0000839087 us-gaap:CorporateJointVentureMember 2015-06-30 0000839087 us-gaap:CorporateJointVentureMember 2015-01-01 2015-06-30 0000839087 us-gaap:CorporateJointVentureMember 2015-04-01 2015-06-30 0000839087 us-gaap:SubsequentEventMember 2015-07-31 0000839087 us-gaap:SubsequentEventMember us-gaap:LondonInterbankOfferedRateLIBORMember 2015-07-31 2015-07-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares vaso:State vaso:Company vaso:Subsidiary xbrli:pure vaso:Segment vaso:Director false --12-31 2015-06-30 No No Yes Smaller Reporting Company VASOMEDICAL, INC 0000839087 158412283 2015 Q2 10-Q

6320000

15273000

500000

6585000

1399000

4421000

941000

7526000

14200000

4300000

462000

3571000

10374000

19734000

2171000

1186000

21000

20000

2247000

1202000

1313000

1098000

20000

3123000

1397000

125000

94000

62181000

61924000

4571000

4178000

96000

335000

50000

164000

1754000

2529000

775000

1754000

460000

125000

2873000

935000

3808000

2529000

335000

775000

46320000

40991000

8052000

10036000

13144000

31232000

10421000

25205000

9385000

1309000

14536000

28994000

0.057

0.104

18000000

-0.01

733000

15070000

16088000

31449000

29431000

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 35.4pt;">The following unaudited supplemental pro forma information presents the financial results as if the acquisitions of Genwell and NetWolves had occurred January 1, 2013, and January 1, 2014, respectively.</div><div> </div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="15" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic; text-align: center;">(in thousands)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="7" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Three months ended</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td colspan="7" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Six months ended</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">June 30, 2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">June 30, 2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">June 30, 2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">June 30, 2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Revenue</div></td><td valign="bottom" style="width: 1.27%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">16,088</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">15,070</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">31,449</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">29,431</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Net income (loss)</div></td><td valign="bottom" style="width: 1.27%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">$</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">580</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">$</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(160</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">$</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">517</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;">$</td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(1061</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Basic earnings (loss) per share</div></td><td valign="bottom" style="width: 1.27%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">0.00</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(0.00</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">0.00</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(0.01</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Diluted earnings (loss) per share</div></td><td valign="bottom" style="width: 1.27%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">0.00</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(0.00</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">0.00</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(0.01</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td></tr></table></div>

-1061000

580000

517000

-160000

50000

-1701000

100000

2359000

18000000

2000

8149000

2000

9128000

2931000

7961000

9986000

159000

157000

733000

2025000

-6197000

166000

169000

166435370

168710370

250000000

0.001

156127283

158402283

215000

-166000

-1250000

-31000

0.65

0.85

0.73

0.86

0.93

0.68

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic; text-align: left;">Variable Interest Entities</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic; text-align: left;"> </div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">The Company follows the guidance of accounting for variable interest entities, which requires certain variable interest entities to be consolidated by the primary beneficiary of the entities. Biox is a Variable Interest Entity (VIE).</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">Liabilities recognized as a result of consolidating this VIE do not represent additional claims on the Company’s general assets. The financial information of Biox, which was included in the accompanying condensed consolidated financial statements, is presented as follows:</div><div> </div><div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="7" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic; text-align: center;">(in thousands)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">As of June 30, </div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">2015 (unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">As of December 31, 2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Cash and cash equivalents</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">157</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">159</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Total assets</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1,014</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1,047</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Total liabilities</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1,065</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">878</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr></table><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="14" style="vertical-align: bottom; font-style: italic; text-align: center;">(in thousands)  </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="7" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: center;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; margin-right: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Three</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> months ended June </font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">30,</font></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: center;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; margin-right: 24pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Six</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> months ended June </font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">30,</font></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; padding-left: 16%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: right; margin-right: 8pt;"> </div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"> </td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: center; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; margin-right: 8pt;"> 2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"> </td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: center; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; margin-right: 6pt;"> 2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: right; margin-right: 32pt;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"> </td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: center; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; margin-right: 18pt;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-left: 16%;"></td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" style="vertical-align: bottom; text-align: center;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" style="vertical-align: bottom; text-align: center;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: right; margin-right: 21pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" style="vertical-align: bottom; text-align: center;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; margin-right: 7pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 35.31%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Total net revenue</div></td><td valign="bottom" style="width: 1.31%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1.31%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 12.38%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">454</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.31%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1.31%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1.31%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 12.38%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">429</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.31%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1.31%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1.31%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 12.38%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">825</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.31%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1.31%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1.31%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 12.38%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">758</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.31%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 35.31%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Net (loss) income</div></td><td valign="bottom" style="width: 1.31%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1.31%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 12.38%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(87</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.31%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="width: 1.31%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1.31%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 12.38%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(82</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.31%; vertical-align: bottom; text-align: left; background-color: #ffffff;">)</td><td valign="bottom" style="width: 1.31%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1.31%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 12.38%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(223</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.31%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="width: 1.31%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1.31%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 12.38%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(230</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.31%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td></tr></table></div>

3515000

5401000

2382000

4308000

530000

378000

854000

741000

0.0225

60000

0.09

2407000

19000

2388000

2297000

2407000

2200000

5384000

13000

1481000

3614000

309000

94000

546000

5000

25000

5000

3330000

30000

3000

15000

305000

15000

22532000

18019000

21453000

17004000

19614000

17712000

11560000

9882000

9183000

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: normal; text-align: left; margin-left: 36pt;">The changes in the Company’s deferred revenues are as follows:</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: normal; text-align: left; margin-left: 36pt;"> </div><div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="14" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic; text-align: center;">(in thousands)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">For the three months ended</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">For the six months ended</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">June 30, 2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">June 30, 2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">June 30, 2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">June 30, 2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Deferred revenue at beginning of period</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">21,453</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">17,004</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">22,532</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">18,019</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Additions:</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Deferred extended service contracts</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">94</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">309</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">305</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">546</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Deferred in-service and training</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">3</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">13</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">5</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">15</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Deferred service arrangements</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">5</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">25</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">15</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">30</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Deferred commission revenues</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1,481</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">3,614</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">3,330</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">5,384</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Recognized as revenue:</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Deferred extended service contracts</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(214</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(220</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(445</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(448</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Deferred in-service and training</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(3</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(8</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(10</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(15</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Deferred service arrangements</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(20</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(23</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(43</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(46</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Deferred commission revenues</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(3,185</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(3,002</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(6,075</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(5,773</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Deferred revenue at end of period</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">19,614</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">17,712</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">19,614</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">17,712</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Less: current portion</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">11,560</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">9,183</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">11,560</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">9,183</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Long-term deferred revenue at end of period</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">8,054</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">8,529</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">8,054</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">8,529</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td></tr></table></div><div> </div></div>

12650000

8054000

8529000

445000

220000

46000

3002000

23000

10000

3000

3185000

8000

43000

214000

6075000

448000

15000

20000

5773000

112000

199000

483000

2200000

4550000

100000

124000

110000

-0.01

-0.02

-7000

-1000

2917000

1536000

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-right: 6pt; text-indent: 36pt;">The following tables present information about the Company’s assets measured at fair value as of June 30, 2015 and December 31, 2014:</div><div> </div><div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="15" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic; text-align: center;">(in thousands) </div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="3" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Quoted Prices</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Significant</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">in Active</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Other</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Significant</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Balance</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="3" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Markets for</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Observable</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Unobservable</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">as of</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Identical Assets</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Inputs</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Inputs</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">June 30,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">(Level 1)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">(Level 2)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">(Level 3)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: left;">Assets</div></td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Cash equivalents invested in money market funds</div></td><td colspan="3" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">(included in cash and cash equivalents)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9.27%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 7px; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 95px; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="3" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Quoted Prices</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Significant</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td valign="bottom" style="width: 7px; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 95px; vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">in Active</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Other</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Significant</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Balance</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="3" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Markets for</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Observable</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Unobservable</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">as of</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Identical Assets</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Inputs</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Inputs</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">December 31,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">(Level 1)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">(Level 2)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">(Level 3)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: left;">Assets</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9.27%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Cash equivalents invested in money market funds</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 9.27%; vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td></tr><tr style="height: 16px;"><td valign="bottom" style="width: 52%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">(included in cash and cash equivalents)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">8,149</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9.27%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">8,149</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"> </td></tr></table></div></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">NOTE E – FAIR VALUE MEASUREMENTS</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div><div style="text-align: justify; text-indent: 36pt;">The Company complies with the provisions of ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”). Under ASC 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-right: 6pt; text-indent: 36pt;">The following tables present information about the Company’s assets measured at fair value as of June 30, 2015 and December 31, 2014:</div><div> </div><div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="15" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic; text-align: center;">(in thousands) </div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="3" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Quoted Prices</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Significant</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">in Active</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Other</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Significant</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Balance</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="3" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Markets for</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Observable</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Unobservable</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">as of</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Identical Assets</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Inputs</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Inputs</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">June 30,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">(Level 1)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">(Level 2)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">(Level 3)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: left;">Assets</div></td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Cash equivalents invested in money market funds</div></td><td colspan="3" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">(included in cash and cash equivalents)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9.27%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 7px; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 95px; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="3" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Quoted Prices</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Significant</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td valign="bottom" style="width: 7px; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 95px; vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">in Active</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Other</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Significant</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Balance</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="3" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Markets for</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Observable</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Unobservable</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">as of</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Identical Assets</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Inputs</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Inputs</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">December 31,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">(Level 1)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">(Level 2)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">(Level 3)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: left;">Assets</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9.27%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 52%; vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Cash equivalents invested in money market funds</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 9.27%; vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left;"> </td></tr><tr style="height: 16px;"><td valign="bottom" style="width: 52%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">(included in cash and cash equivalents)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">8,149</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9.27%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">8,149</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"> </td></tr></table></div><div> </div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; margin-right: 4pt; text-indent: 36pt;">The fair values of the Company’s cash equivalents invested in money market funds are determined through market, observable and corroborated sources.</div></div>

117000

2000

3000

89000

644000

678000

438000

381000

549000

495000

2826000

2561000

419000

410000

362000

1789000

467000

1940000

2489000

962000

1054000

800000

2467000

800000

P5Y

P10Y

P7Y

3288000

22618000

3315000

19303000

-27000

10648000

7328000

5482000

12896000

46000

48000

-50000

-1196000

197000

-162000

14000

12000

6000

24000

66000

19000

-117000

-43000

115000

119000

162000

-199000

-1268000

-966000

-15000

207000

-1859000

1276000

-6030000

-10429000

-2918000

-307000

-1092000

137000

-1000

31000

297000

354000

-32000

-51000

308000

1250

80000

147000

101000

46000

15000

815000

791000

636000

892000

1898000

2168000

583000

588000

679000

688000

60000

120000

19779000

24820000

13520000

13461000

40991000

46320000

3000000

4817000

0.499

-205000

-17553000

6834000

2438000

-1220000

-62000

-176000

191000

-62000

1128000

-223000

-82000

-87000

-230000

2763000

150000

-207000

4529000

44000

-9000

30000

98000

1523000

163000

1039000

1070000

11942000

5688000

7122000

12976000

-206000

206000

-80000

-1294000

1794000

-1955000

-546000

1544000

1021000

2880000

-883000

-352000

-875000

-1311000

-928000

-676000

-366000

-721000

31000

24000

10000

-30000

31000

-14000

5617000

3937000

113000

5243000

1164000

51000

13000

4066000

3098000

675000

458000

630000

1612000

2307000

649000

811000

250000

750000

207000

18000000

14200000

188000

205000

100000

38000

40000

0.01

1000000

581000

363000

4550000

40000

2668000

266000

21000

206000

419000

272000

137000

-52433000

-52495000

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic; text-align: left;">Revenue and Expense Recognition for the Sales Representation Segment</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">The Company recognizes commission revenue in its Sales Representation segment (see Note C) when persuasive evidence of an arrangement exists, service has been rendered, the price is fixed or determinable and collectability is reasonably assured. These conditions are deemed to be met when the underlying equipment has been accepted at the customer site in accordance with the specific terms of the sales agreement. Consequently, amounts billable under the agreement with GE Healthcare in advance of the customer acceptance of the equipment are recorded as accounts receivable and deferred revenue in the condensed consolidated balance sheets. Similarly, commissions payable to our sales force related to such billings are recorded as deferred commission expense when the associated deferred revenue is recorded. Commission expense is recognized when the corresponding commission revenue is recognized.</div></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-style: italic; text-align: left;">Revenue Recognition</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">The Company recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred or service has been rendered, the price is fixed or determinable and collectability is reasonably assured.</div><br /></div></div>

996000

13427000

12926000

7036000

18297000

2059000

6684000

14956000

2030000

2811000

7864000

10843000

2811000

1180000

14956000

18297000

10843000

7864000

429000

758000

454000

825000

626000

247000

2059000

2030000

996000

1180000

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div>The following table summarizes the preliminary allocation of the assets acquired and liabilities assumed based on their preliminary estimated fair values as follows:</div><br /><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td colspan="4" style="vertical-align: bottom; text-align: right;"> (<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">in thousands)</font></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Cash and cash equivalents</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9.27%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">733</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Accounts receivable and other current assets</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9.27%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1,638</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Other assets</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9.27%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">50</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Property and equipment</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9.27%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,359</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Accounts payable and other current liabilities</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9.27%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(4,382</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Long term debt</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9.27%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(1,701</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;">Goodwill and other intangibles</td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"></td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"></td><td valign="bottom" style="width: 9.27%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;">19,303</td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"></td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 16pt;">Total</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9.27%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">18,000</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> </div></td></tr></table></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">The following table represents common stock equivalents that were excluded from the computation of diluted earnings per share for the three and six months ended June 30, 2015 and 2014, because the effect of their inclusion would be anti-dilutive.</div><div><br /><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%; border-collapse: collapse;"><tr><td style="width: 51.99%; vertical-align: bottom;"> </td><td style="width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="14" style="width: 46.01%; vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic; text-align: center;">(in thousands)</div></td><td style="width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td></tr><tr style="height: 18px;"><td style="width: 51.99%; vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td style="width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="6" style="width: 22%; vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">For the three months ended</div></td><td style="width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td style="width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="6" style="width: 22.01%; vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">For the six months ended</div></td><td style="width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td></tr><tr style="height: 14px;"><td style="width: 51.99%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="2" style="width: 9.99%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">June 30, 2015</div></td><td style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="2" style="width: 10%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">June 30, 2014</div></td><td style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="2" style="width: 10%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">June 30, 2015</div></td><td style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"> </td><td style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"> </td><td colspan="2" style="width: 10%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">June 30, 2014</div></td><td style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td></tr><tr><td style="width: 51.99%; vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td style="width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="2" style="width: 9.99%; vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">(unaudited)</div></td><td style="width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td style="width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="2" style="width: 10%; vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">(unaudited)</div></td><td style="width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td style="width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="2" style="width: 10%; vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">(unaudited)</div></td><td style="width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td style="width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="2" style="width: 10%; vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">(unaudited)</div></td><td style="width: 1%; vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td></tr><tr><td style="width: 51.99%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Stock options</div></td><td style="width: 1%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td style="width: 1%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td style="width: 9%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: right;">335</div></td><td style="width: 1%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td style="width: 1%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td style="width: 1%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td style="width: 9%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: right;">1,754</div></td><td style="width: 1%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td style="width: 1%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td style="width: 1%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td style="width: 9%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: right;">935</div></td><td style="width: 1%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td style="width: 1%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td style="width: 1%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td style="width: 9%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: right;">1,754</div></td><td style="width: 1%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td></tr><tr><td style="width: 51.99%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Common stock grants</div></td><td style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: right;">125</div></td><td style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: right;">775</div></td><td style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: right;">2,873</div></td><td style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: right;">775</div></td><td style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td></tr><tr><td style="width: 51.99%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: right;">460</div></td><td style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: right;">2,529</div></td><td style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: right;">3,808</div></td><td style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: right;">2,529</div></td><td style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td></tr></table></div></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 36pt;">The Company’s other intangible assets consist of capitalized patent costs, customer lists and software costs, as follows:<br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"></td><td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: center;">(<font style="font-style: italic;">in thousands)</font></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: right; margin-right: 13.05pt;">June 30, 2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: right; margin-right: 2.05pt;">December 31, 2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: right; margin-right: 18.05pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Patents and Technology</div></td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 17pt;">Costs</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,467</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,489</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 17pt;">Accumulated amortization</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(678</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(549</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1,789</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1,940</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Customer lists</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 17pt;">Costs</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">800</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">800</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 17pt;">Accumulated amortization</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(438</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(381</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">362</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">419</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Software</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 17pt;">Costs</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1,054</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">962</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 17pt;">Accumulated amortization</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(644</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(495</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">410</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">467</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,561</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,826</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td></tr></table></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: normal; font-style: normal; text-align: left; margin-left: 36pt;">Accrued expenses and other liabilities consist of the following at June 30, 2015 and December 31, 2014:</div><div style="font-weight: normal; font-style: normal;"> </div><div style="font-weight: normal; font-style: normal;"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="7" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic; text-align: center;">(in thousands)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">June 30, 2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">December 31, 2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Accrued compensation</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1,536</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,917</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Accrued expenses - other</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1,313</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1,098</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Other liabilities</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,307</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1,612</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td></tr><tr style="height: 16px;"><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">5,156</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">5,627</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td></tr></table></div></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 36pt;">Other assets consist of the following at June 30, 2015 and December 31, 2014:<br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="6" style="vertical-align: bottom; text-align: center;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic; margin-right: 23pt;">(in thousands)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; padding-left: 20%;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: right;"> </div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: center;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> June 30, 2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: #000000 2px solid; text-align: center;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; margin-right: 3pt;">December 31, 2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-left: 20%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: right; margin-right: 1pt;"> </div></td><td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"> </td><td colspan="2" style="vertical-align: middle; text-align: center; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; margin-right: 1pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 1pt;">Deferred commission expense - noncurrent</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,121</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,988</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 1pt;">Trade receivables - noncurrent</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1,186</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,171</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 1pt;">Other</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">630</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">458</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">3,937</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">5,617</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td></tr></table></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div>A reconciliation of basic to diluted shares used in the earnings per share calculation is as follows:</div><div style="font-style: normal;"> </div><div style="font-style: normal;"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%; border-collapse: collapse;"><tr><td style="width: 59.79%; vertical-align: bottom;"> </td><td colspan="7" style="width: 40.21%; vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; font-style: italic; text-align: center;">(in thousands)</div></td></tr><tr><td style="width: 59.79%; vertical-align: bottom;"> </td><td colspan="3" style="width: 19.07%; vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: center;">Three months ended June 30,</div></td><td style="width: 1.97%; vertical-align: bottom;"> </td><td colspan="3" style="width: 19.17%; vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: center;">Six months ended June 30,</div></td></tr><tr><td style="width: 59.79%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"> </td><td style="width: 9.86%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: center;">2015</div></td><td style="width: 1.97%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"> </td><td style="width: 7.23%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: center;">2014</div></td><td style="width: 1.97%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"> </td><td style="width: 9.2%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: center;">2015</div></td><td style="width: 1.97%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"> </td><td style="width: 7.99%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: center;">2014</div></td></tr><tr style="height: 18px;"><td style="width: 59.79%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left;">Basic weighted average shares outstanding</div></td><td style="width: 9.86%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">                       156,258</div></td><td style="width: 1.97%; vertical-align: bottom; background-color: #cceeff;"> </td><td style="width: 7.23%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">                    155,320</div></td><td style="width: 1.97%; vertical-align: bottom; background-color: #cceeff;"> </td><td style="width: 9.2%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">                    156,102</div></td><td style="width: 1.97%; vertical-align: bottom; background-color: #cceeff;"> </td><td style="width: 7.99%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">                       155,386</div></td></tr><tr><td style="width: 59.79%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left;">Dilutive effect of share-based compensation</div></td><td style="width: 9.86%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">                              308</div></td><td style="width: 1.97%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"> </td><td style="width: 7.23%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">                             -</div></td><td style="width: 1.97%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"> </td><td style="width: 9.2%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">                             -</div></td><td style="width: 1.97%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"> </td><td style="width: 7.99%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">                                   -</div></td></tr><tr><td style="width: 59.79%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: left;">Diluted weighted average shares outstanding</div></td><td style="width: 9.86%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">                       156,566</div></td><td style="width: 1.97%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"> </td><td style="width: 7.23%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">                    155,320</div></td><td style="width: 1.97%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"> </td><td style="width: 9.2%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">                    156,102</div></td><td style="width: 1.97%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"> </td><td style="width: 7.99%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: right;">                       155,386</div></td></tr></table></div></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 36pt;">Inventories, net of reserves, consist of the following:</div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 36pt;"> </div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom; font-style: normal;"> </td><td valign="bottom" style="vertical-align: bottom; font-style: normal;"> </td><td colspan="6" style="vertical-align: bottom; white-space: nowrap; font-style: italic; text-align: center;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; margin-right: 30pt;">             (in thousands)  </div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; font-style: normal; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-style: normal; padding-left: 18%;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: right;"> </div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-style: normal;"> </td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-style: normal; text-align: center;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> June 30, 2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-style: normal; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-style: normal;"> </td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-style: normal; text-align: center;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; margin-right: 1pt;">December 31, 2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-style: normal; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; font-style: normal; padding-left: 18%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: right;"> </div></td><td valign="bottom" style="vertical-align: bottom; font-style: normal; background-color: #ffffff;"> </td><td colspan="2" style="vertical-align: bottom; font-style: normal; text-align: center; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; font-style: normal; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; font-style: normal; background-color: #ffffff;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; font-style: normal; background-color: #ffffff;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; font-style: normal; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; font-style: normal; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 2pt;">Raw materials</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; font-style: normal; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; font-style: normal; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; font-style: normal; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">588</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; font-style: normal; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; font-style: normal; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; font-style: normal; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; font-style: normal; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">583</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; font-style: normal; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; font-style: normal; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 2pt;">Work in process</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; font-style: normal; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; font-style: normal; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; font-style: normal; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">688</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; font-style: normal; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; font-style: normal; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; font-style: normal; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; font-style: normal; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">679</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; font-style: normal; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; font-style: normal; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 2pt;">Finished goods</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; font-style: normal; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; font-style: normal; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; font-style: normal; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">892</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; font-style: normal; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; font-style: normal; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; font-style: normal; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; font-style: normal; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">636</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; font-style: normal; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 4px; font-style: normal; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; font-style: normal; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; font-style: normal; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; font-style: normal; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,168</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; font-style: normal; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; font-style: normal; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; font-style: normal; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; font-style: normal; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1,898</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; font-style: normal; text-align: left; background-color: #ffffff;"> </td></tr></table></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div>The components of the change in goodwill are as follows:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="3" style="vertical-align: bottom; text-align: center;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">(in thousands)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="3" style="vertical-align: bottom; text-align: center;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Carrying</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"> </td><td colspan="3" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: center; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; margin-right: 0.05pt;">Amount</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Balance at December 31, 2014</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9.27%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">3,288</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 16pt;">Foreign currency translation</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9.27%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">27</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 16pt;">Acquisition of Netwolves</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9.27%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">19,303</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 88%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Balance at June 30, 2015 (unaudited)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9.27%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">22,618</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #ffffff;"> </td></tr></table></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div>Summary financial information for the segments is set forth below:</div><div><br /></div><div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic; text-align: left;">(in thousands)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="19" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">As of or for the three months ended June 30, 2015 (unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="3" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Sales</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="3" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Representation</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Equipment</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Segment</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">IT Segment</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Segment</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Corporate</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Consolidated</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 40%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Revenues from external customers</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">7,036</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,811</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">996</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">10,843</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 40%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Operating income (loss)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1,794</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(366</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(676</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(546</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">206</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 40%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Total assets</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">10,421</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">25,205</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">9,385</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1,309</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">46,320</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 40%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Accounts and other receivables, net</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">4,421</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1,399</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">500</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">6,320</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 40%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Deferred commission expense</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,388</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">19</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,407</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 40%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Other assets</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">3,098</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">51</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">675</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">113</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">3,937</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td colspan="11" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr style="height: 13px;"><td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="19" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">As of or for the three months ended June 30, 2014 (unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="3" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Sales</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Representation</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Equipment</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr style="height: 20px;"><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Segment</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">IT Segment</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Segment</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Corporate</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Consolidated</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr style="height: 14px;"><td valign="bottom" style="width: 40%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Revenues from external customers</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">6,684</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1,180</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">7,864</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 40%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Operating income (loss)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1,021</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(875</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(352</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(206</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td></tr><tr><td valign="bottom" style="width: 40%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Total assets</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">13,144</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">8,052</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">10,036</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">31,232</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 40%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Accounts and other receivables, net</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">6,585</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">941</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">7,526</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 40%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Deferred commission expense</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,297</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,297</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 40%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Other assets</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">4,066</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1,164</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">13</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">5,243</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td colspan="11" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="19" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">As of or for the six months ended June 30, 2015 (unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="3" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Sales</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Representation</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Equipment</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr style="height: 15px;"><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Segment</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">IT Segment</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Segment</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Corporate</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Consolidated</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 40%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Revenues from external customers</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">13,427</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,811</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,059</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">18,297</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 40%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Operating income (loss)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,880</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(721</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(1,311</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(928</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(80</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td></tr><tr><td valign="bottom" style="width: 40%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Total assets</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">10,421</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">25,205</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">9,385</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1,309</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">46,320</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 40%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Accounts and other receivables, net</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">4,421</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1,399</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">500</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">6,320</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 40%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Deferred commission expense</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,388</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">19</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,407</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 40%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Other assets</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">3,098</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">51</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">675</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">113</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">3,937</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td colspan="11" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="19" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">As of or for the six months ended June 30, 2014 (unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="3" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Sales</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Representation</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Equipment</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Segment</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">IT Segment</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Segment</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Corporate</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Consolidated</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 40%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Revenues from external customers</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">12,926</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,030</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">14,956</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 40%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Operating income (loss)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1,544</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(1,955</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(883</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(1,294</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td></tr><tr><td valign="bottom" style="width: 40%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Total assets</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">13,144</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">8,052</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">10,036</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">31,232</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 40%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Accounts and other receivables, net</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">6,585</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">941</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">7,526</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 40%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Deferred commission expense</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,297</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,297</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 40%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Other assets</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">4,066</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1,164</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">13</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">5,243</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr></table></div></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div>The financial information of Biox, which was included in the accompanying condensed consolidated financial statements, is presented as follows:</div><div> </div><div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="7" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic; text-align: center;">(in thousands)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">As of June 30, </div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">2015 (unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">As of December 31, 2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Cash and cash equivalents</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">157</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">159</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Total assets</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1,014</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1,047</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Total liabilities</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1,065</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">878</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr></table><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="14" style="vertical-align: bottom; font-style: italic; text-align: center;">(in thousands)  </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="7" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: center;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; margin-right: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Three</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> months ended June </font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">30,</font></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"> </td><td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: center;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; margin-right: 24pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Six</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> months ended June </font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">30,</font></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; padding-left: 16%; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: right; margin-right: 8pt;"> </div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"> </td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: center; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; margin-right: 8pt;"> 2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"> </td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: center; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; margin-right: 6pt;"> 2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: right; margin-right: 32pt;">2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"> </td><td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: center; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; margin-right: 18pt;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-left: 16%;"></td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" style="vertical-align: bottom; text-align: center;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" style="vertical-align: bottom; text-align: center;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: right; margin-right: 21pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" style="vertical-align: bottom; text-align: center;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; margin-right: 7pt;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 35.31%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Total net revenue</div></td><td valign="bottom" style="width: 1.31%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1.31%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 12.38%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">454</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.31%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1.31%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1.31%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 12.38%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">429</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.31%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1.31%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1.31%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 12.38%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">825</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.31%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1.31%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1.31%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 12.38%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">758</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.31%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 35.31%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Net (loss) income</div></td><td valign="bottom" style="width: 1.31%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1.31%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 12.38%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(87</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.31%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="width: 1.31%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1.31%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 12.38%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(82</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.31%; vertical-align: bottom; text-align: left; background-color: #ffffff;">)</td><td valign="bottom" style="width: 1.31%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1.31%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 12.38%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(223</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.31%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="width: 1.31%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1.31%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 12.38%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(230</div></td><td nowrap="nowrap" valign="bottom" style="width: 1.31%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td></tr></table></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-right: 22pt; text-indent: 36pt;">The following table presents information regarding the Company’s accounts and other receivables as of June 30, 2015 and December 31, 2014:</div><div> </div><div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="7" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic; text-align: center;">(in thousands)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">June 30, 2015</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">December 31, 2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">(unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Trade receivables</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">10,374</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">19,734</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Due from employees</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">124</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">110</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Allowance for doubtful accounts and</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">commission adjustments</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(4,178</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(4,571</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td></tr><tr><td valign="bottom" style="width: 76%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Accounts and other receivables, net</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">6,320</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">15,273</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; padding-bottom: 4px; text-align: left; background-color: #cceeff;"> </td></tr></table></div></div>

3800000

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">NOTE C – SEGMENT REPORTING AND CONCENTRATIONS</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The Company views its business in three segments – the Sales Representation segment, the Equipment segment, and the IT segment. The Sales Representation segment operates through the Vaso Diagnostics subsidiary and is currently engaged solely in the fulfillment of the Company’s responsibilities under our agreement with GEHC. The IT segment includes the operations of NetWolves and VasoHealthcare IT Corp. Operations in the IT segment began in the third quarter of 2014. The Equipment segment is engaged in designing, manufacturing, marketing and supporting EECP</font><font style="font-size: 70%; font-family: 'Times New Roman', Times, serif; font-variant: normal; font-weight: normal; font-style: normal;"><sup>®</sup></font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> enhanced external counterpulsation systems both domestically and internationally, as well as the development, production, marketing and supporting of other medical devices.</font></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">The chief operating decision maker is the Company’s Chief Executive Officer, who in conjunction with upper management, evaluates segment performance based on operating income. Administrative functions such as finance, human resources, and information technology are centralized and related expenses allocated to each segment. Other costs not directly attributable to operating segments, such as audit, legal, director fees, investor relations, and others, as well as certain assets – primarily cash balances – are reported in the Corporate entity below. There are no intersegment revenues. Summary financial information for the segments is set forth below:</div><div><br /></div><div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic; text-align: left;">(in thousands)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="19" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">As of or for the three months ended June 30, 2015 (unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="3" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Sales</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="3" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Representation</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Equipment</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Segment</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">IT Segment</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Segment</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Corporate</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Consolidated</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 40%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Revenues from external customers</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">7,036</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,811</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">996</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">10,843</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 40%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Operating income (loss)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1,794</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(366</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(676</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(546</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">206</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 40%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Total assets</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">10,421</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">25,205</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">9,385</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1,309</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">46,320</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 40%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Accounts and other receivables, net</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">4,421</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1,399</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">500</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">6,320</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 40%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Deferred commission expense</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,388</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">19</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,407</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 40%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Other assets</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">3,098</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">51</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">675</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">113</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">3,937</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td colspan="11" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr style="height: 13px;"><td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="19" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">As of or for the three months ended June 30, 2014 (unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="3" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Sales</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Representation</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Equipment</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr style="height: 20px;"><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Segment</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">IT Segment</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Segment</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Corporate</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Consolidated</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr style="height: 14px;"><td valign="bottom" style="width: 40%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Revenues from external customers</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">6,684</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1,180</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">7,864</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 40%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Operating income (loss)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1,021</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(875</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(352</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(206</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td></tr><tr><td valign="bottom" style="width: 40%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Total assets</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">13,144</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">8,052</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">10,036</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">31,232</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 40%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Accounts and other receivables, net</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">6,585</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">941</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">7,526</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 40%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Deferred commission expense</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,297</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,297</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 40%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Other assets</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">4,066</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1,164</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">13</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">5,243</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td colspan="11" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="19" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">As of or for the six months ended June 30, 2015 (unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="3" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Sales</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Representation</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Equipment</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr style="height: 15px;"><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Segment</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">IT Segment</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Segment</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Corporate</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Consolidated</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 40%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Revenues from external customers</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">13,427</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,811</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,059</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">18,297</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 40%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Operating income (loss)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,880</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(721</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(1,311</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(928</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(80</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td></tr><tr><td valign="bottom" style="width: 40%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Total assets</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">10,421</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">25,205</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">9,385</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1,309</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">46,320</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 40%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Accounts and other receivables, net</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">4,421</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1,399</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">500</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">6,320</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 40%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Deferred commission expense</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,388</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">19</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,407</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 40%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Other assets</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">3,098</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">51</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">675</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">113</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">3,937</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td colspan="11" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="19" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">As of or for the six months ended June 30, 2014 (unaudited)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="3" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Sales</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Representation</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Equipment</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;"> </div></td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Segment</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">IT Segment</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Segment</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Corporate</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td><td colspan="3" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: center;">Consolidated</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"> </td></tr><tr><td valign="bottom" style="width: 40%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Revenues from external customers</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">12,926</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,030</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">14,956</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 40%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Operating income (loss)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1,544</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(1,955</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(883</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(1,294</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">)</div></td></tr><tr><td valign="bottom" style="width: 40%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Total assets</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">13,144</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">8,052</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">10,036</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">31,232</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 40%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Accounts and other receivables, net</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">6,585</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">941</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">7,526</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr><tr><td valign="bottom" style="width: 40%; vertical-align: bottom; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Deferred commission expense</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,297</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #cceeff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #cceeff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2,297</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #cceeff;"> </td></tr><tr><td valign="bottom" style="width: 40%; vertical-align: bottom; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left;">Other assets</div></td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">4,066</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1,164</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">13</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: right; background-color: #ffffff;"> </td><td valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</div></td><td valign="bottom" style="width: 9%; vertical-align: bottom; text-align: right; background-color: #ffffff;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">5,243</div></td><td nowrap="nowrap" valign="bottom" style="width: 1%; vertical-align: bottom; text-align: left; background-color: #ffffff;"> </td></tr></table></div><div> </div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; text-indent: 36pt;">For the three months ended June 30, 2015 and 2014, GE Healthcare accounted for 65% and 85% of revenue, respectively. For the six months ended June 30, 2015 and 2014, GE Healthcare accounted for 73% and 86% of revenue, respectively, and $4.3 million or 68%, and $14.2 million or 93%, of accounts and other receivables at June 30, 2015 and December 31, 2014, respectively.</div></div>

12704000

5482000

6985000

11523000

-9481000

-10308000

166435000

164705000

168710000

-10308000

109000

111000

257000

260000

3000

1000

390000

389000

36000

245000

450000

175000

2275000

1280000

827000

7980000

7751000

165000

-2000000

166000

61508000

-1755000

-52433000

94000

108000

61924000

-53561000

6465000

62181000

169000

125000

-2000000

-52495000

2811000

1613000

10308087

2000000

1047000

1014000

878000

1065000

155320000

156102000

156258000

155386000

156566000

155386000

155320000

156102000

-4382000 1638000 1950000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: left;">Basis of Presentation and Use of Estimates</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and pursuant to the accounting and disclosure rules and regulations of the Securities and Exchange Commission (the "SEC"). Certain information and disclosures normally included in the unaudited condensed consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in connection with:</div><div><br /></div><div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 54pt; vertical-align: top; align: right;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 36pt;">1)</div></td><td style="width: auto; vertical-align: top;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify;">The audited consolidated financial statements and related notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2014, as filed with the SEC on March 30, 2015.</div></td></tr></table></div><div><br /></div><div><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 54pt; vertical-align: top; align: right;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: left; margin-left: 36pt;">2)</div></td><td style="width: auto; vertical-align: top;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify;">The audited consolidated financial statements of NetWolves, LLC and related notes thereto included in the Form 8-K/A filed with the SEC on August 12, 2015.  The operating results of NetWolves from May 29, 2015 to June 30, 2015 are included in the accompanying condensed consolidated statements of operations and comprehensive income (loss) for the three and six month periods ended June 30, 2015.</div></td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">These unaudited condensed consolidated financial statements include the accounts of the companies over which we exercise control. In the opinion of management, the accompanying condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of interim results for the Company. The results of operations for any interim period are not necessarily indicative of results to be expected for any other interim period or the full year.</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; text-align: justify; text-indent: 36pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the condensed consolidated financial statements, the disclosure of contingent assets and liabilities in the unaudited condensed consolidated financial statements and the accompanying notes, and the reported amounts of revenues, expenses and cash flows during the periods presented. Actual amounts and results could differ from those estimates. The estimates and assumptions the Company makes are based on historical factors, current circumstances and the experience and judgment of the Company's management. The Company evaluates its estimates and assumptions on an ongoing basis.</div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; text-align: left;">Significant Accounting Policies</div><div><br /></div><div style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000; text-align: justify; text-indent: 36pt;">Note B of the Notes to Consolidated Financial Statements, included in the Annual Report on Form 10-K for the year ended December 31, 2014, and Note B of the Notes to Consolidated Financial Statements for the year ended December 31, 2014, included on Form 8-K/A, include a summary of the significant accounting policies used in the preparation of the condensed consolidated financial statements.</div></div> P5Y P3Y 2000000 6 6 0.135 3800000 3800000 4000 61000 244000 260000 5000 3000 5627000 5156000 2988000 2121000 9000 0 0 9000 0 3 7036000 12926000 13427000 6684000 1852000 3454000 1524000 3047000

EX-101.SCH 6 vaso-20150630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 010000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 010100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 020000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 030000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) link:presentationLink link:calculationLink link:definitionLink 040000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 060100 - Disclosure - ORGANIZATION AND PLAN OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 060200 - Disclosure - BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 060300 - Disclosure - SEGMENT REPORTING AND CONCENTRATIONS link:presentationLink link:calculationLink link:definitionLink 060400 - Disclosure - EARNINGS (LOSS) PER COMMON SHARE link:presentationLink link:calculationLink link:definitionLink 060500 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 060600 - Disclosure - ACCOUNTS AND OTHER RECEIVABLES, NET link:presentationLink link:calculationLink link:definitionLink 060700 - Disclosure - INVENTORIES, NET link:presentationLink link:calculationLink link:definitionLink 060800 - Disclosure - GOODWILL AND OTHER INTANGIBLES link:presentationLink link:calculationLink link:definitionLink 060900 - Disclosure - OTHER ASSETS link:presentationLink link:calculationLink link:definitionLink 061000 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES link:presentationLink link:calculationLink link:definitionLink 061100 - Disclosure - DEFERRED REVENUE link:presentationLink link:calculationLink link:definitionLink 061200 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 061300 - Disclosure - BUSINESS COMBINATION link:presentationLink link:calculationLink link:definitionLink 061400 - Disclosure - RELATED-PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 061500 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 061600 - Disclosure - RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS link:presentationLink link:calculationLink link:definitionLink 061700 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 070200 - Disclosure - BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 080200 - Disclosure - BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 080300 - Disclosure - SEGMENT REPORTING AND CONCENTRATIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 080400 - Disclosure - EARNINGS (LOSS) PER COMMON SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 080500 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 080600 - Disclosure - ACCOUNTS AND OTHER RECEIVABLES, NET (Tables) link:presentationLink link:calculationLink link:definitionLink 080700 - Disclosure - INVENTORIES, NET (Tables) link:presentationLink link:calculationLink link:definitionLink 080800 - Disclosure - GOODWILL AND OTHER INTANGIBLES (Tables) link:presentationLink link:calculationLink link:definitionLink 080900 - Disclosure - OTHER ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 081000 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 081100 - Disclosure - DEFERRED REVENUE (Tables) link:presentationLink link:calculationLink link:definitionLink 081300 - Disclosure - BUSINESS COMBINATION (Tables) link:presentationLink link:calculationLink link:definitionLink 090100 - Disclosure - ORGANIZATION AND PLAN OF OPERATIONS (Details) link:presentationLink link:calculationLink link:definitionLink 090202 - Disclosure - BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES (Details) link:presentationLink link:calculationLink link:definitionLink 090300 - Disclosure - SEGMENT REPORTING AND CONCENTRATIONS (Details) link:presentationLink link:calculationLink link:definitionLink 090302 - Disclosure - SEGMENT REPORTING AND CONCENTRATIONS, Concentration Risk (Details) link:presentationLink link:calculationLink link:definitionLink 090400 - Disclosure - EARNINGS (LOSS) PER COMMON SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 090500 - Disclosure - FAIR VALUE MEASUREMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 090600 - Disclosure - ACCOUNTS AND OTHER RECEIVABLES, NET (Details) link:presentationLink link:calculationLink link:definitionLink 090700 - Disclosure - INVENTORIES, NET (Details) link:presentationLink link:calculationLink link:definitionLink 090800 - Disclosure - GOODWILL AND OTHER INTANGIBLES (Details) link:presentationLink link:calculationLink link:definitionLink 090900 - Disclosure - OTHER ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 091000 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 091100 - Disclosure - DEFERRED REVENUE (Details) link:presentationLink link:calculationLink link:definitionLink 091200 - Disclosure - DEBT (Details) link:presentationLink link:calculationLink link:definitionLink 091300 - Disclosure - BUSINESS COMBINATION (Details) link:presentationLink link:calculationLink link:definitionLink 091400 - Disclosure - RELATED-PARTY TRANSACTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 091500 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 091600 - Disclosure - RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 091700 - Disclosure - SUBSEQUENT EVENTS (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 vaso-20150630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 vaso-20150630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 vaso-20150630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Amendment Flag Current Fiscal Year End Date Document Period End Date Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Filer Category Entity Registrant Name Entity Central Index Key Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Document Type BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES [Abstract] Accounts and other receivables, net Accounts and other receivables, net of an allowance for doubtful accounts and commission adjustments of $4,178 at June 30, 2015 and $4,571 at December 31, 2014 Accounts and other receivables, net Accounts and other receivables Accounts and Other Receivables [Member] Accounts payable Accounts Payable, Current Trade receivables Accounts Receivable, Net, Current Trade receivables - noncurrent ACCRUED EXPENSES AND OTHER LIABILITIES Accounts Payable and Accrued Liabilities Disclosure [Text Block] Receivables due from related parties Accounts Receivable, Related Parties Accrued commissions Accrued Sales Commission, Current Accrued expenses - other Outstanding legal fees amount Accrued Professional Fees, Current PROPERTY AND EQUIPMENT, accumulated depreciation Accumulated Other Comprehensive Income [Member] Accumulated other comprehensive income Additional paid-in capital Additional Paid-in Capital [Member] Adjustments to reconcile net loss to net cash provided by operating activities Allowance for doubtful accounts and commission adjustments Accounts and other receivables, allowance for doubtful accounts and commission adjustments Amortization expense Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities, Name [Domain] Antidilutive Securities [Axis] Antidilutive securities excluded from computation of diluted earnings per share (in shares) ASSETS Assets [Abstract] Total assets Total Assets Total current assets Assets, Current CURRENT ASSETS BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES Basis of Presentation and Significant Accounting Policies [Text Block] Related party transaction, ownership interest (in hundredths) Business Acquisition, Percentage of Voting Interests Acquired Consideration for acquisition Diluted earnings (loss) per share (in dollars per share) Business Acquisition, Pro Forma Earnings Per Share, Diluted Estimated fair values of the net assets acquired [Abstract] Basic earnings (loss) per share (in dollars per share) Business Acquisition, Pro Forma Earnings Per Share, Basic Business acquisition proforma information [Abstract] Cash and cash equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Revenue Business Acquisition, Acquiree [Domain] Business Acquisition Proforma Information Net income (loss) Business Acquisition, Pro Forma Net Income (Loss) Other assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other Business Acquisition [Axis] Long term debt Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt BUSINESS COMBINATION [Abstract] Business Acquisition [Line Items] BUSINESS COMBINATION Business Combination Disclosure [Text Block] Acquisition-related legal costs Business Combination, Acquisition Related Costs Property and equipment Total Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Cash equivalents invested in money market funds (included in cash and cash equivalents) Cash and cash equivalents - end of period Cash and cash equivalents - beginning of period Cash and cash equivalents Cash acquired through purchase of Netwolves NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS Cash and Cash Equivalents, Period Increase (Decrease) Variable Interest Entity, Classification [Domain] COMMITMENTS AND CONTINGENCIES (NOTE O) COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] COMMITMENTS AND CONTINGENCIES [Abstract] Common stock, $.001 par value; 250,000,000 shares authorized; 168,710,370 and 166,435,370 shares issued at June 30, 2015 and December 31, 2014, respectively; 158,402,283 and 156,127,283 shares outstanding at June 30, 2015 and December 31, 2014, respectively Common Stock, Value, Issued Common stock, shares issued (in shares) Common stock, shares authorized (in shares) Common stock, par value (in dollars per share) Common Stock [Member] Common Stock Grants [Member] Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Software [Member] Concentration Risk Type [Domain] Concentration Risk Type [Axis] Concentration Risk [Line Items] Concentration Risk Benchmark [Domain] Concentration Risk [Table] Percentage of revenue (in hundredths) Percentage of accounts and other receivables (in hundredths) Concentration Risk Benchmark [Axis] Variable Interest Entity Consolidation, Variable Interest Entity, Policy [Policy Text Block] Consolidation Items [Domain] Consolidation Items [Axis] VSK Medical Limited [Member] Corporate [Member] Total cost of revenues Cost of Goods and Services Sold Cost of revenues Cost of equipment sales and services Credit Concentration Risk [Member] Customer Lists [Member] DEBT [Abstract] Interest rate percentage (in hundredths) Debt Instrument [Axis] DEBT Debt Disclosure [Text Block] Debt issuance costs Debt Issuance Cost Debt Instrument, Name [Domain] Debt instrument, interest rate (in hundredths) Debt Instrument, Interest Rate, Stated Percentage Deferred commission expense DEFERRED REVENUE [Abstract] Deferred commission expense Deferred Costs, Current Deferred Revenue Arrangement, by Type [Table] Deferred Revenue Arrangement Type [Axis] Additions: Deferred Revenue [Domain] DEFERRED REVENUE Deferred Revenue Disclosure [Text Block] Deferred revenue at end of period Deferred revenue at beginning of period Deferred Revenue Less: current portion Deferred revenue - current portion Deferred Revenue Arrangement [Line Items] Changes in Deferred Revenues Long-term deferred revenue at end of period Deferred revenue Deferred Revenue, Noncurrent Recognized as revenue: Deferred Revenue, Revenue Recognized Deferred tax liability, net Deferred Tax Liabilities, Net, Current Depreciation and amortization Depreciation, Depletion and Amortization RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS Description of New Accounting Pronouncements Not yet Adopted [Text Block] Related party transaction, amount borrowed Due to Related Parties, Current Receivables due from related parties Contribution to related parties Due from employees Weighted average common shares outstanding EARNINGS (LOSS) PER COMMON SHARE basic (in dollars per share) diluted (in dollars per share) Earnings Per Share, Diluted Income (loss) per common share EARNINGS (LOSS) PER COMMON SHARE [Abstract] Effect of exchange rate differences on cash and cash equivalents Stock Options [Member] Accrued compensation Employee-related Liabilities, Current Revenue, Major Customer [Line Items] Investment, Name [Domain] Equity Component [Domain] Assets Measured at Fair Value Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] FAIR VALUE MEASUREMENTS [Abstract] Fair Value, Hierarchy [Axis] FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Fair Value, Measurements, Fair Value Hierarchy [Domain] Significant Unobservable Inputs (Level 3) [Member] Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] Significant Other Observable Inputs (Level 2) [Member] Interest and financing costs Financing Interest Expense Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization INTANGIBLES, net Intangible assets, net Finite-Lived Intangible Assets, Net Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets, Major Class Name [Domain] Costs Finite-Lived Intangible Assets by Major Class [Axis] Other intangible assets, net [Abstract] Useful life of intangible assets Finite-Lived Intangible Asset, Useful Life Goodwill and other intangibles GOODWILL Goodwill Goodwill, Beginning Balance Goodwill, Ending Balance Acquisition of Netwolves GOODWILL AND OTHER INTANGIBLES Goodwill and Intangible Assets Disclosure [Text Block] Foreign currency translation Goodwill, Translation Adjustments Change in carrying amount of goodwill [Roll Forward] Goodwill [Roll Forward] GOODWILL AND OTHER INTANGIBLES [Abstract] EX-101.PRE 10 vaso-20150630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R39.htm IDEA: XBRL DOCUMENT

SEGMENT REPORTING AND CONCENTRATIONS, Concentration Risk (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014	Jun. 30, 2014
Concentration Risk [Line Items]
Accounts and other receivables	$ 6,320	$ 15,273	$ 7,526
Accounts and Other Receivables [Member] \| Credit Concentration Risk [Member] \| GE Healthcare [Member]
Concentration Risk [Line Items]
Accounts and other receivables	$ 4,300	$ 14,200
Percentage of accounts and other receivables (in hundredths)	68.00%	93.00%

XML 12 R48.htm IDEA: XBRL DOCUMENT

DEBT (Details)	6 Months Ended
DEBT (Details)	Jun. 30, 2015 USD ($) Director	May. 29, 2015 USD ($)
Short-term Debt [Line Items]
Debt instrument, interest rate (in hundredths)	9.00%
Director and Director's Spouse [Member]
Short-term Debt [Line Items]
Additional amount borrowed for working capital	$ 250,000
MedTechnology Investments, LLC [Member]
Short-term Debt [Line Items]
Subordinated promissory note		$ 3,800,000
Aggregate amount used to acquire note		$ 1,950,000
Number of directors \| Director	6
Additional amount borrowed for working capital	$ 750,000

EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0````(`+MA#D<71Q9N\@$``+8@```3````6T-O;G1E;G1?5'EP97-= M+GAM;,W:S4[C,!`'\%>IG[_Y"G.=G88X[+J4_+?&(MM3U;'VGD:SRWV@Y%Y6VOO!M#H9-[+M MV!UDG;O5RK34N?;!YBUURJ7I4XY7LSL=THVV.07;#6P*[#]Y7>+L8PI&'TAW ML2=*=JAC>AHH'JN_C[Q4OJ*5?AC2NPH_W[LZT#"MB;WQSZ6N=SE+S+\MJQR- M;ZIPN/%OG1E;AN;']6\[ROD_7LO!3=S:X2KH1W-08'NR,95C;;49CXWJT87- M#^5):%^A-!8Z??_3T*=@9-/AA$B\JP\!TH<$Z4.!]-&`]'$&TL=G MD#Z^@/3Q%:0/OD!I!$54CD(J1S&5HZ#*453E**QR%%QW8OG*\M"_V/Z'D4X$G1H>)%]2-F`Q+M*;V" M^GH`A3&^.R6:E((C-Z."N[_8_`)02P,$%`````@`NV$.1UWP<_ON`0``;"`` M`!H```!X;"]?K M'^G8E$/?Y?8PY,6?T['+J^G^NFI+&58AY$V;3DV^Z8?434]W_7AJRG0Y[L/0 M;%Z;?0I:U\LP7LZI'A\^SEX\;]?5^+R5:O&S&?>IK*O?_?B:VY1*#N>3W$P+ M3(_?AO2=Y?O=[K!)3_WFUREUY8N*\&^!*LP'Z7R04H)L/L@H03X?Y)2@.!\4 M*4'+^:`E)>AV/NB6$G0W'W1'";J?#[JG!$D-9*PY20AKCM8"N!:.UP+`%H[8 M`L@6CMD"T!:.V@+8%H[;`N`6CMP"Z!:.W0+P%H[>"O16CMX*]%;2MS;ZV.;H MK4!OY>BM0&_EZ*U`;^7HK4!OY>BM0&_EZ*U`;^7HK4!OY>AM0&_CZ&U`;^/H M;4!O(^V5H,T2CMX&]#:.W@;T-H[>!O0VCMX&]#:.W@;T-H[>!O0VCMX.]':. MW@[T=H[>#O1VCMX.]';27C?:[.;H[4!OY^CM0&_GZ.U`;^?H[4!OY^CM0&_G MZ!V!WI&C=P1Z1X[>$>@=.7I'H'?DZ!TO],YM,Z;M2QD/W3Y?N^:_X;#H`N]< MWH[I^BGGJ;#A0NLRK93"^7CU%_D\]6](^/1CP>,[4$L#!!0````(`+MA#D=1 MR*XM7P,``&P-```0````9&]C4')O<',O87!P+GAM;+U7T8[:.!3]%8NGJ;1M M6&#:W1&-9!(/8RDX6=NA[;ZYP0Q10X)B=S33KU\[&6B8,=G"0WG!<> MF<@I7F[KNJMT.:Q MOO>J]3K/9%AEW[>RU-YH.'SOR4B4+)%_=QL,$&U MW8GRR6N?HKS\IM(=KT*A99=U_**-OA&U7)FD1]$/FPWF[LG465ANL!'EO5QU ML:]?[GNQE+6RE?XY>C7F?B+Q6_O1!WSS(3%?ULTP/^E*5 M5E5F15=+;LZG!N"K4-(N/PX>1)V+4@^`RG^8Q]&@3=ON-NMBIW3M?ZKJ;VHC MI593[[#9++O8[CJ?^-?C!F%6QTCO4)G_W+:CNNT.SW4A5;Q.1*U_4RN:FO:- MN!X/.M7O0P!1K@`JM;$CP&6;RHC7;9C"")$#@ M`L[X'`[CYFN!R`6TP9TXL#((X-2^;H\3\SH2G*$!X"6<1 M8G\X.9@L3;R88@,`!+D;-(_C\!..HDY@;-I$YM@&=NO0H"!CZ/1A:6K41)\3 MJW'WT!&&,R(4D.BR)PZ12=`LQ,RIPP3Q)CM^0R31F4GD*+(&NUM`BG_ M`HR:A,'`HMV56`DQ;V39F\`:`I$`GVB.587PZ`O`C-D>/`MG7930$X=BZ8RA M?U+K.5O\B:[V6GDTN8#C'LU>^X_7XW_NH#C MUKO7BY/A>5X,I19Y<;X7)Z-?]&*;X!(S3MPC?VS&WO"];IRXE7_MQMX4]L;^ M'XC;L;V4T[=X0SS_*@=7YU_FUVZ)7UWF[EI>_6I]\1O5._YOY?\'4$L#!!0` M```(`+MA#D?FLP/@/P$``&D#```1````9&]C4')O<',O8V]R92YX;6S-DTU/ MPS`,AO\*ZKU+LS&$HJX'0)R8A,00B%N6>%M8\Z'$4]=_3Y9U+0,NNW&K:[^/ M7\=)*1P3UL.SMPX\*@A7>UV;P(2;91M$QP@)8@.:AU&L,#&YLEYSC*%?$\?% MEJ^!C(OBAFA`+CER<@#FKB=F52D%$QXX6M_AI>CQ;N?K!)."0`T:#`9"1Y1D MU:O9&MN8D@SZJHR.:QYP;J5:*9!W[5#V.Q4[(W@=CG*0??OT]T\/*4.RKG(? M5%_5-,VHF:2Z.#`E[_.GEW0VN3(!N1$054$Q;!W,LE/GM\G]P^(QJ\8%G>;% M;4ZO%W3,Z(1-BX_#9&?^!L.Z&^+?.CX93-M%A3597)PC$`8``)PG```3````>&PO=&AE;64O=&AE;64Q M+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?A1%8C6QY9)&$ M?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@V2_;UKNW+][@ M5S(D$4$P&:>O\,`*I4Q>M5II`,,X?+&A`T%116F]?(+3E'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1TDB`@LE]E`6Z M2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP'`3@4;N>PIWT M;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG`J-6T_3:W?=TXZ)QJW0>`V^ M\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@`%AP=M;,T@.67BGZ M=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9`%#@`WQ-%,4'RO0;:*X,*2 MTER0UL\IM5`:")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']IJP&G[;N;SY/\ M<^CDGZ>3UTU"SG"\+`GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZY!$XM4D-,A,_ M")V&F&I0'`*D"3&6H8;XM,:L$>`3?;>^",C?C8CWJV^:/5>A6$G:A/@01AKB MG'/F<]%L^P>E1M'V5;SOX%^9PU"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:CFED)O816:I^J MAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[`?_1VC?"J_B"P#E_+GW/I>^Y]#VA MTK\>WZ MV22$KYI9+2,6D$N!LT$DN/R+RO`JQ`GH9%LE"0AMNZ5/U2I77 MY:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KTL@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K34I!OP_GIQ7@: MXCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'>7M?F&>5QE`T M%&ULK"0L1K=@N-?Q+!3@9&`MH`>#KU$"\E)58#%;Q@,KD*)\3(Q%Z'#GEUQ? MX]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^:CVT%4[/_EFM MR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?!8/+]<,E'#^4[ MYU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4 MU#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83+$.D?L%]BHJ` M$:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'?!^2!F.,6_0T M7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5`Y3_;U`UH]@TT M')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%`````@`NV$.1YM;I/-& M`@``X`D```T```!X;"]S='EL97,N>&ULS59M:]LP$/XK0AVCA1';*4W9:AM& M(3#8RJ#YT&]%MF5'H!=/EC.GOWXGR;&30)8VZTK]1:='=\\].LEGQXU9W.SCYV[A M`B//\:U(<#2[PL'S22?A85Y8VZ.>O9#ZK]S[Y->6/.@+E,:EDF.=IM@#:=P\ MH17AX!]9]UQQI9&!@P`5#I%$4.]Q2SC+-+-@203C:P]/+>#.KO<33"KM#W1[C?'=[`*1Q38RA6LYA@GI[L:YAE2;K:'JU%>`&R)LI75`]9([P!DIC3DL#`9I52SL:55OIRA@EP"@8J90D MW%)N(GH#:'/*^;U]4Q[*'>ZN1-['GG&(D56Q,:$0O3E>`U?48)O-OVJC6K@"KYU>4Y.[J"[5F14SUUK?+FD MR^OC1^;>3KPG\VUOS0D27J$X]L/V;J7-WJ^T?[U30=]^MWK\3H,_7?H'4$L#!!0````(`+MA#D&PO=V]R:V)O;VLN>&ULE9==DZ(X%(;_2HJKGJK=50/8'S5.%6K: M3I6"2[!G9^]HC6-J$"S`Z=GY]9M@N_W2G7'U2D#RY"1YQDKO];%^4VK?5M^;53K-=J*=VAW6Z_4\HLK5615QNUJYP76G4.K=J5,EU5&RGK;7:`;5.5.Y\^5G=KEE/O=<*\R<^-W?:=C8,>A MSDNR+%;R`$LVJOK\\H=#5G*=[K,ZT<$>^QTX/>I1VC\PS&N/2CY7"#0/2+JL MU7>9I$\#I^N0=%\7]RJK93E.:SDIB_U.Y5\URR%K55:U,,-MWMRJ7&W53Q.W MOJLVQ?-#4:J?15ZGF5B6198UKG)(=$^B.8N#!$#7`+I^#QH&@@O3<(!=`.@F_<@P29Z3A,2 MLWD4)SR<'""17K(PB0,`W0+H]CV(!7&HFPMR-8V$^$#T@#1F-M-AB8<@1B&[ M:&3W/>H^X#%Y#*8+1F8L$(O8+'LB$-&2VF)U,!I%"]VF&4V4/.A@8C9B_#$8 M3IGX#5&H=<_B-0\?=>]1S'4[$C)*%=97_-C<$X(5,>#!&%[O8L\H[9/8MCS8J9 MGI$%P[:H:\_BZY@-6Q.'5O8L6@X7@H=,"*/0D(>-WM@>9>Q9;(S9U&S1W^=! MG'PA6N10!",#PF$R_$"Z$ M68T7/MD=%6EK7H*!9#P?YHA"(:E%R-,H M3*X4':461T_F((KIE:*CU.+HR2Q$KQ&%RE*+LK_(0N1*?^8S62$*;:86FT]F M(WJ+*!2;6L1^FXV.X7S`[RMZ[5J\/IV6\)OOHMFNQ6S,2]98T&?7XO/)!.6V MRH96W6"Q^VV"LL:#7KLVKRV9QPI"JUV+U2>_]2Y:[:+5KL7JDWO-1:M=M-JU M6'URK[DWB$*KW4M+!Q>M=M%J]]+BP>MBR8=N>^<7#^1J+.M498A"M[U+BPB/ M(@HM]\XH(H[AM)3R4'#OTG+"P_3MM4KC_ZDG[,&@W]ZEE86'?GOHMW=&96$/ M"-7V?E%CV%NBR=Z9U8:=A")[%]4=#0^/'"BR?VGQ0:X0A2+[EY8?/HKLH\C^ M.>6'=9Y\--EW7XZUKR=9?9A7N5R9&PO=V]R:W-H965T&ULC9;;CILP$(9?!?$` M"S:'D!5!2E)5[46EU5ZTUT[B!+0&4]L)V[>O3[!DY76X"=C\_WR>,*.A'"A[ MXS7&(GAO2<>V%52:^"-!U^80&_MBUB_W:8T&$3@G#<>&TNM5`;455&D^_4M+CC M#>T"AL^;<`N>]R!7$JWXW>"!S^X#=?@#I6]J\?.T"6-U!DSP4:@02%YN>(\) M49$D^:\-^L%4QOG]&/V[3E<>_X`XWE/RISF)6IXV#H,3/J,K$:]T^(%M#ID* M>*2$Z]_@>.6"MJ,E#%KT;JY-IZ^#>9(FUN8V0&N`DP'F7D-B#3*7&]N56[MRHNHYL*8Q5PIM@9!9@4 MD8SM!,#098?:#K\&[(TB>0Q(1D`RSR#1]O2Q/1WMZ=R>:GMV?[ZY8F<4^6-` MY@1DVKZZ!V1:T1F`413).BY6CRFYDY*;&)XTC&+]&+!R`E:F#&(/P4H6E$KA M1!3&#SV(8C%B[42LC3_Q(*QD04&!V,G0VS*"KZ9&S8*J`L!-L7WI*:S]J,F* M%$!8+&@Q`-TPTZ.@\%2QU<_.ZO2RQG`<7=\L!T-`2^ M%V0U<`'%W??`M#7TU=JH65)L[KX'IJVAM]BLYG.Q1;.!T6)VT8.4!T=Z[829 M%]/N-*RW4`^<#WE5]NB"?R%V:3H>'*B08TO/F#.E`DM\_"3+I):?$]."X+-0 MMRMYS\R`-0M!^_%[8?IHJ?X#4$L#!!0````(`+MA#D>/5,O\600``.06```8 M````>&PO=V]R:W-H965T&ULC9A-CZ,X$(;_"LI]!ERV^6BE M(TU8C68/*XWFL'NF.TXG&@A9H#NS_WX-5622J%+QI0/T8_,:S(.+Y:GM?O8[ MYX;H5U,?^N?%;AB.3W'VF9LLHJ;ZA;_[P_1[PO_D"37C M&P`U@',#9<0&FAKHFP8Q)IO&]4;P;._$]1_W4FQ]2 M/QW\,A[]6$&VC#_&?@B!"V1-R'VB)"(_([$_/QL"YA#Z,@1@^^)Q>SVW-Y?M M]=1>)]<1LPDYX"`TG4*K^U")4*%"1F+8)`:3W)S$7B9!1"7%?:8D1JG'.2R; MPV(.$'(@DFI(A"`(*0N9?APE9:.D&$4+41`1@Q`2<$$R-D6&*8R0(J-3I+F0 M`R&5%P%3)&>3Y)C$"DD0`9-D0A*"O)P?)RG8)`4F284DB-AQ>=!H6EA(JR)@52<+K^I@##`AT$[:L$7 M:V(`4B6FH:X@#YB]BG>M0DD:X6%=$P,VE>;-3.40.LJU*61M#LS#\0[8TE1!#A/G=5[]5Y5:$T3\F3RVE3H.R-YDQAM M,_%N4T\I!(3AS:E0>492)S$*$N$FE&J6IPFYV;P]54$#DM*0/Y45G454"@%I M@%,I%!B4I#"$!1T98#7)Z#TC*1/8I2_,M)C0%B1YP'3!GB!`EK/2`(E MQB]TA'5*.5,AKSK@]0DH/2OIDQBEI"G,0/>S\/($4IXD3YB7JYEXFV9*!ZSA M@97D"*L]*\B3&Y$IZ.1$5L-(# M7IV`PK.2.HG)$REP";-@4QL2AW4BEIWIP:A6=OKO]U M]4B+3VUOY]UU_3AC)@W)P]M3*UIS!_3`E],:-65#ZND[!37*Y5;-U]=$W\Q) MYGK<(O=S\(;2Z!5I&;DF1J72/#E#`4M-S?M)4\$L^>G,*+%BFC%50$"1HOFZ M6J=4P$MYD/EDP13"HU]><#K`=YKWG<[HB94240$-8AR$0BHXS?M.HZ52R7?$ M?/(5M/0R8;'[>7CA:9*9)#QBLB(7XQ"5V0#%&%YYAA:"DO*(8>J4JT=\QI@Z M);[X'GFLWMQ?5?>V/_312SL,;3-]A]RV[>!\-\EG/\:=JS;GG=IMAW$S\]L= M?H3%G:$]SM^4SQ^V5_\#4$L#!!0````(`+MA#D<&PO=V]R:W-H965T&ULC9;-CILP$(!?!?$`P38_AE42:9>J M:@^55GMHST[B)&@!I]A)MF]?VP-9@FRR.00PWXR_,6CP\BJZ=WGD7`4?3=W* M57A4ZO0417)[Y`V3"W'BK;ZS%UW#E+[L#I$\=9SM;%!31P2A+&I8U8;KI1U[ M[=9+<59UU?+7+I#GIF'=OQ=>B^LJQ.$P\%8=CLH,1.ME=(O;50UO927:H./[ M5?B,GTJ<&,02ORM^E:/SP,AOA'@W%S]WJQ`9!U[SK3(IF#Y<>,GKVF32,__M MDW[.:0+'YT/V[[9B_E/MU%';HC#8\3T[U^I-7'_POH;4)-R*6MK_ M8'N62C1#2!@T[`..56N/5[B3HS[,'4#Z`'(+@)7P!L1]0#P)B,#,UO6-*;9> M=N(:R!,S3QL_:;PS273F0-ILNB1I!Y_-Z&6=Y2 M2,_OE""#1#R6(!!?/(Z/A_AD'!]#$<6](K5("T4`DF":^Z&RAU**'YLD3I/$ M9J!HQ@20&)-XQ@0@'!?TL4GJ7-/49DB_L*:9LY(,*L'WDOFX$D#0`LU`I0/R MFE"G"063R0N8CDT`P0.9,IX74HG`X%."0S#L5# MARGA=<#(*6&'M45Z/T[?:`/T6QF57J&I.CAR^)% M_5[$[07]C=(Y+V!PEE.,XFD#N?<:T"R)TS'J]W*W30S];MH2[[V`P6F>($+R MF9>^O*$9)G2,^KW<313W7;28\^H[)(I1CO*9E2U])%A%HX_FB1WX+]8=JE8& M&Z'T]]=^+/="**XSH87.>]3[HMM%S??*G%)]WL%.`2Z4.`T;G]ON:_T?4$L# M!!0````(`+MA#D>Z8P=-&04``#$;```8````>&PO=V]R:W-H965T&ULC9G;:Q$KL&C!>(/'L MVR^@%C$>N:V;V%:^;NG7Z9=@J=[[55?'[FFU[_O3H^]WKWM5E]U# M[4ZO*W1145SX$0>C7Y>&XVFZFLF_M=M-\]-7AJ+ZU M7O=1UV7[7ZJJYORT8BM3\/WPON_'`G^[\>>XW:%6Q^[0'+U6O3VMGMECP<6( M3,0_!W7N+KY[8^-?FN;G^..OW=,J&-N@*O7:CRG*X>-39:JJQDQ#S?]BTJ\Z MQ\#+[R;['Y/RIOIQV/7[H;7!RMNIM_*CZK\WYS\5:I!CPM>FZJ:_ MWNM'US>U"5EY=?E+?QZ.T^=9_R<.,,P>`!@`<\!\F*7Y+(R7NAXL6QB-"%'W1,:B0(>WH8R#84AE2G7$.,"HMM4@10D M$-Y7):VJI%8EE[7(2U4:@9BQVU"FH>`VD;ND*:[3W%036M6$6DU(J-%(DA!, MIAG&KA?60H^&()`)H<=`W$%29)44:4D1(4DC+(@%)T1I*HI#08C"5#$D1(4% M4B*1#O,NMJ[&6,N*[\$6/4I,CR**4D:DIP4 MI:%(4)L,0K'32(%=E7:CA)@U*3)<,F)WS9`"?FV/2UV:DB(@A6E*\,!A73%N M5Z9],B$F18I,Q($<,(YMII5Q-+&8VI(+@P6A<-$FK)L.TX:9N(R[W2Z9-JB$ M\DMDPH1RU0RI>[TCL7>B@-C%"H,-FYW#^8;9S9.A-5+NB0SCQ$Z8,>-Z1*;< M0!$AOT!(L,1!E=T_F38KRL]29"(&1&,RI&08$[,^1VHXE$7D?$:,)<+A1,MB MNS;MH@G1GA09M:/,Z94X%T M46:W3L`;;>#@G=SNG1R]\WJ@%IW#K3?,1=?<1W([$E_V"B+KX,'%8[C=.#G: MU/7#IZ4D=E_2722W(TM););D\C@3K`/-T3:92PJ[37%T(.H)0&H@&8*DKGLS M)SE0*_PK'^GXQ46^V&'SXG:_XNA7E,VD!I*AO%[%2XG"4:)PE"AN2_0OW@?4 MJGV?WL1TWFOS<>SU(^ZY='[;\PSC^X2K\I0]9LQ2GK/'0K_+^4J_W9S*=_5W MV;X?CIWWTO1]4T^O'-Z:IE=#DX.'0E;OY1Z7>^O%K-`Z#?J.C?_3-R;R@ MFM^2;?\'4$L#!!0````(`+MA#D=S8O9O[`,``%84```8````>&PO=V]R:W-H M965T&ULC9A;_"N-W%R2$!!G',[4-G//0F4X?VF<2 MRS%3+CY`XIYO7RXK0B;2BA=S\6__>Q%H)7;WNOG=7J7LG#]E4;6/FVO7W1Y< MMWV^RC)KO]0W6?7_7.JFS+K^LGEQVULCL_-H5!8N]3SNEEE>;?:[\=[W9K^K M7[LBK^3WQFE?RS)K_C_(HKX_;LA&W?B1OUR[X8:[W[FSW3DO9=7F=>4T\O*X M^4H>4DH'9"1^YO+>+LZ=(?BGNOX]7/Q[?MQX0PRRD,_=()'UAS=YE$4Q*/6> M_P/1=Y^#X?)/<0H08<#/ALP$+40("!F`U&!^Y4W'%H3EF7[7=-?7?:6S8\ ML.2AIYM!HQ=VVE&L'Y5VO/EUN/NV)R38N6^#$#!TP1P4P\W,43'"S)P4$YJ9 M6#&1F4F`H9Z9215#9L;M:Z(M#%6%8R*VE"'IGK0R2R*V$HF5 M2#6A&$O"M27A4!*.C#"WQ7&Y6 M(@4_D6=/-]2F&T*Z(5+VF5GA)=)ZB4`A0HH:V9(]1?#F(C6UBB16(OWDQI@L M\;39CK?[='WDY3T`A.4+B(^\$K%=)K$CZ6=/YIR)/F?H@3[R5AP`8L&*!XGH M.R51_09[/P%":VM%8CN2$-5P&5;CC M,3%"!"O6(T2_GB"PH,"".2B(<^9C"R3@ML3SO35#-_?S#VLDHAKZFJ=>WXK) MFEX,$)+X"1`:"&Q([>W8CJ3*%5\SP^D[,EG3D@&B5*Q8"H+M1:CJ^YIYU%U\/KEE+_);UKSD5>L\U5U7E^-GDTM==[+7\;[T MJE>9G>>+0EZZX53TY\WTV6NZZ.J;^HHW?TK<_P502P,$%`````@`NV$.1Q8R M1M[&!```EAD``!@```!X;"]W;W)KTXEST'#(`NG,OOT"+M-)IE+Q30?@G#;G,P5=%]:4ZF'OZS:]JJZ(?;=A]V MI]84VZE2588\BG18%<=ZL5Y-9=_;]:HY]^6Q-M_;H#M75='^EYFRN;PNV,(5 M_#CN#_U8$*Y7X5QO>ZQ,W1V;.FC-[G7QQEYRJ4?)I/C[:"[=U74PFG]OFI_C MS9_;UT4T>C"EV?1CB&+X^3"Y*B#&@-NFK*;_@:;<]BF:$.7NJGP;2S]6#.A5^''&`@T_$J3@696A$-TM`F^P*KSJ3I_W$!N M%0E_WH)P+8CK3@CH1/P\@'0!Y'4`"0&26Y/QI*EM-ZQFJ?EC30X:QGGTW(I" M^Z+`2OH\@$;[HFT`&=WZ5-=]L1J9B,>:'.*D'D9BU$@,1AAAQ&HT(1%)W8%(R(YP%8A'9E*AY#2*(O3A1)GA+=`9F. MA,=*90SW8\$@B%64L7MX(%:LQ,<'QWU8?@AR6*QF*12ARIV*IQXH80)W8VDD M%.5&0#M13+D!KBD/+SC7&(!-DF8B1R1`B>><-DB13P0D8.+Y*:/ MO>!YIP#<*6+?9R!:<&8*8";UH)F! M2"KR^0U4GK.$4U,`-:G'[PQ$2^I!Q6D\U2/N MLQ]Q;@K@IJ:X":*4<>IX`U6<:H_AD3@[);!34^P$$4_)-`]4:9IXH$;.^+RA ME01\:H\!EGBR*%V*1V6+3D0]EX+&8U-*G)L2N*DI;H*(TK51?GWDIX];J[ M,NU^^@S0!9OF7/?V5?1<.G]J>./CZ_*[\HR]Y/:#P6>8]>I4[,U?1;L_UEWP MWO1]4TUOSG=-TYO!5_1E&*Z#*;;S36EV_7@9#]>M_6Q@;_KFY+Z"S)]BUO\# M4$L#!!0````(`+MA#D=P_[W"H0$``+$#```8````>&PO=V]R:W-H965T&ULC5/;;MP@$/T5Q`<$V^MDJY77TFZJJGFH%.6A?6;ML8T"C`MX MG?Y]`5]B12LE+V9F?,Z9`P/%B.;5=@".O"FI[9%VSO4'QFS5@>+V#GO0_D^# M1G'G4],RVQO@=20IR;(D>6"*"TW+(M:>35G@X*30\&R('93BYM\9)(Y'FM*E M\"+:SH4"*PNV\FJA0%N!FAAHCO24'LYY0$3`;P&CW<0D>+\@OH;DJ3[2)%@` M"94+"MPO5W@$*8.0;_QWUGQO&8C;>%'_$7?KW5^XA4>4?T3M.F\VH:2&A@_2 MO>#X$^8MW`?!"J6-7U(-UJ%:*)0H_C:M0L=UG/[D^YEVFY#-A&PE?$NB\:E1 MM/F=.UX6!D=B>QYFEQX\W`01KTQL5/,.;2R>0O5:IONT8-<@-&.R#>8\8U8$ M\^HW6V3T%CV+].QS^FZA[[8.=[/#+PCDBT"^%Z5M?;>&PO=V]R:W-H965T&ULA5/;;N,@$/T5Q`<4QW'2 M*G(L)5U5[<-*51]VGXD]ME&!<0''W;\OX$NM5:2^F)GQ.6<.#.0#FG?;`CCR MJ:2V1]HZUQT8LV4+BML[[$#[/S4:Q9U/3<-L9X!7D:0D2Y-DSQ07FA9YK+V: M(L?>2:'AU1#;*\7-OS-('(YT0^?"FVA:%PJLR-G"JX0";05J8J`^TM/F<,X" M(@+^"!CL*B;!^P7Q/20OU9$FP0)(*%U0X'ZYPB-(&81\XX])\[ME(*[C6?TI M[M:[OW`+CRC_BLJUWFQ"204U[Z5[P^$9IBWL@F")TL8O*7OK4,T42A3_'%>A MXSJ,?_;[B7:;D$Z$="$\)-'XV"C:_,4=+W*#`[$=#[/;'#S*7&Q&$W/Y#EE19?4$L# M!!0````(`+MA#D<,'H,%H@$``+$#```8````>&PO=V]R:W-H965T&ULA5/;;N,@$/T5Q`<4QW$WV19*2+$V2'TQQH6F1Q]JS*7+LG10:G@VQO5+<_#^#Q.%(-W0NO(BF M=:'`BIPMO$HHT%:@)@;J(SUM#N.E0SA1+%W\=5Z+@.XY]L/]%N$]*)D"Z$?1*-CXVBS5_< M\2(W.!#;\3"[S<'#31#QRL1&->_0QN(I5*_%9K?+V34(39ATA3E/F`7!O/K- M%BF]14\C/?V>OIWIV[7#[>1P_[U`-@MD:X'L]A;7F/.,^?FE"5N=J0+3Q*MC M28F]=N.1+M7E=I[2.)-/>)%WO($_W#1"6W)!YR<;QU`C.O#MD[M[2EK_?I9$ M0NU"N/.Q&:_4F#CLY@>RO-+B`U!+`P04````"`"[80Y'[%LD5*`!``"Q`P`` M&0```'AL+W=ON M2FI[H*USW9XQ6[:@N+W##K3_4Z-1W/G4-,QV!G@524JR-$E^,,6%ID4>:R^F MR+%W4FAX,<3V2G'S<0*)PX%NZ%QX%4WK0H$5.5MXE5"@K4!-#-0'>MSL3UE` M1,`?`8-=Q21X/R.^A>1W=:!)L``22A<4N%\N\`A2!B'?^'W2_&H9B.MX5O\9 M=^O=G[F%1Y1_1>5:;S:AI(*:]]*]XO`+IBWL@F")TL8O*7OK4,T42A2_CJO0 M<1W&/UDVT6X3THF0+H2')!H?&T6;3]SQ(C%_],]F M@6PMD-W>XAISFC'?7;+5F2HP3;PZEI38:S<>Z5)=;N:>=#+MS\.X/$\4AW="D\B[9S MH<#*@JV\6BC05J`F!IHC/>T.YSP@(N!%P&@W,0G>+XAO(?E3'VD2+("$R@4% M[IU'_%W7KW%V[A`>6KJ%WGS2:4U-#P0;IG''_# MO(5]$*Q0VO@EU6`=JH5"B>(?TRIT7,?I3[;0;A/2F9"NA/LD&I\:19N/W/&R M,#@2V_,PN]W!PTT0\X^*]@U",V8=(,YSY@5P;SZS18I MO45/(SW]GIXM]&SK,)L=YM\+Y(M`OA7(;V]QBSDOF/V7)FQSI@I,&Z^.)14. MVDU'NE;7VWE*XTP^X671\Q;^/S72EIL1AOSR0]966_P%02P,$%`````@`NV$.1W+6:2BB`0``L0,``!D` M``!X;"]W;W)K&ULA5/;;N,@$/T5Q`<4QW&;*'(L M)5U5W8>5JCZTS\0>VZC`>`''W;]?P)=:5:2^F)GQ.6<.#.0#F@_;`CCRJ:2V M1]HZUQT8LV4+BML[[$#[/S4:Q9U/3<-L9X!7D:0D2Y/D@2DN-"WR6'LQ18Z] MDT+#BR&V5XJ;?V>0.!SIALZ%5]&T+A18D;.%5PD%V@K4Q$!]I*?-X9P%1`2\ M"1CL*B;!^P7Q(R2_JR--@@604+J@P/URA4>0,@CYQG\GS:^6@;B.9_6GN%OO M_L(M/*)\%Y5KO=F$D@IJWDOWBL,S3%NX#X(E2AN_I.RM0S53*%'\*7&Q&$W/Y#EE1;_`5!+`P04 M````"`"[80Y'5[IUMZ,!``"Q`P``&0```'AL+W=O+7&]UL+^NX#"X40W="Z\R*;U ML<"*G"V\2FHP3J(A%NH3/6^.EUU$),!O"8-;Q21ZOR*^QN1G=:)9M``*2A\5 M1%AN\`1*1:'0^.^D^=XR$M?QK/X]31O<7X6#)U1_9.7;8#:CI():],J_X/`# MIA$>HV")RJ4O*7OG4<\42K1X&U=ITCJ,?_A^HMTG$G`%\(^2\;'1LGF-^%% MD5L:+SS^G;F;Y=.]R.W0_9YP*[66"W%MC='W&-N4R8P\SY(H MJ'T,OX;8CE=J3#QV\P-97FGQ'U!+`P04````"`"[80Y'/*F ME7%'VGG?'QAS50=:N#OLP80_#5HM?$AMRUQO0=2)I!7C6?:%:2$-+8M4>[)E M@8-7TL"3)6[06MA_9U`X'NF.+H5GV78^%EA9L)572PW&233$0G.DI]WAG$=$ M`OR1,+I-3*+W"^)+3'[51YI%"Z"@\E%!A.4*#Z!4%`J-7V?-]Y:1N(T7]1]I MM\']13AX0/57UKX+9C-*:FC$H/PSCC]AWL)]%*Q0N?0EU>`\ZH5"B19OTRI- M6L?I3\YGVFT"GPE$7S+DO&I4;+Y*+PH"XLC<;V(L]L=`MQ&D:!,7%(+#ETJ MGF+U6NZ^\X)=H]",X1O,><:L"!;4;[;@]!:=)SK_G+Y?Z/NMP_WL^^6!K*^T_`]02P,$ M%`````@`NV$.1_#].[>C`0``KP,``!D```!X;"]W;W)K&ULA5/;;N,@$/T5Q`<4ASC=W8:]DZV&%T-LKY0PGR>0.!SHALZ%U[9N M7"BP/&,+KVP5:-NB)@:J`SUN]J#\COH7DN3S0)%@`"84+ M"L(O%W@`*8.0;_P^:5Y;!N(ZGM4?XVZ]^[.P$#R7UNZQIM-*"FA$KUTKS@\ MP;2%71`L4-KX)45O':J90HD2'^/:ZK@.XQ^>3K3;!#X1^$+XF43C8Z-H\[=P M(L\,#L1V(LQNL_=P$T2\,K%1S3NTL7@,U4N>;C)V"3H3A*\@IQ%R13`O?K,# MI[?H/-+Y]_3M3-^N#6['[K]VWPNDLT"Z%DAO[G`-.:53C_O_>K#5B2HP=;PX MEA38:S<>Z%)=[N:1QXERQO-OP!02P,$%`````@`NV$.1UT?:F>A`0``L0,` M`!D```!X;"]W;W)K&ULA5/;;N,@$/T5Q`<4QTEZ MB1Q+25=5^U"IZL/N,[''-BHP+N"X_?L"OM1:1)"TSR+M3>3 M9]@Y*32\&6([I;CY/H+$?D]7="J\B[IQH<#RC,V\4BC05J`F!JH]/:QVQTU` M1,!?`;U=Q"1X/R%^A.2EW-,D6``)A0L*W"]G>`0I@Y!O_#EJ_K8,Q&4\J3_% MW7KW)V[A$>4_4;K&FTTH*:'BG73OV#_#N(5M$"Q0VO@E16<=JHE"B>)?PRIT M7/OASS89:9<)Z4A(9$])+"A4;3YASN>9P9[8EL>9K?:>;@)(EZ9V*CF'=I8 M/(3J.5\]W&7L'(1&3+K`'$?,C&!>_6*+E%ZBIY&>7J>O)_IZZ7`].KR_+K"9 M!#9+@2`COMAB.=J_/M/*1Q)K_P/&MY#:_< MU$);&PO=V]R:W-H965T[7K+I-MG5&'TP,3[H,]M.6R(P%>A6_UZ@ M%QNSB;Z4F>DY9PX,9#V:=]L`./*II+8[VCC7;AFS10.*VPML0?L_%1K%G4]- MS6QK@)>1I"1+D^2**2XTS;-8>S9YAIV30L.S(;93BINO`TCL=W1%I\*+J!L7 M"BS/V,PKA0)M!6IBH-K1_6I[V`1$!+P*Z.TB)L'[$?$])(_ECB;!`D@H7%#@ M?CG!+4@9A'SCCU'SIV4@+N-)_3[NUKL_<@NW*-]$Z1IO-J&DA(IWTKU@_P#C M%BZ#8('2QB\I.NM0311*%/\<5J'CV@]_TIN1=IZ0CH1T)MPDT?C0*-J\XX[G MF<&>V):'V:VV'FZ"B%?HZ=#B;_IZHJ^7#M>CPW_TWTP"FZ7`YOP6EYC#A/GMDBW.5(&IX]6QI,!. MN^%(Y^I\._=IG,D//,]:7L,3-[70EAS1^ M:>M<=V#,EBTH;A^P`^W_U&@4=SXU#;.=`5Y%DI(L39(]4UQH6N2Q]F**''LG MA8870VRO%#?_SB!Q.-(-G0NOHFE=*+`B9PNO$@JT%:B)@?I(3YO#.0N("/@C M8+"KF`3O5\2WD#Q51YH$"R"A=$&!^^4&%Y`R"/G&[Y/F9\M`7,>S^J^X6^_^ MRBU<4/X5E6N]V822"FK>2_>*PV^8MK`+@B5*&[^D[*U#-5,H4?QC7(6.ZS#] MV4^T^X1T(J0+X6<2C8^-HLU'[GB1&QR([7B8W>;@X2:(>&5BHYIW:&/Q%*JW M(DVV.;L%H0F3KC#G$;-9$,RKWVV1TGOT=&SQ/7T[T[=KA]O)8?:]0#8+9&N! M[/X6UYCSC-E]:<)69ZK`-/'J6%)BK]UXI$MUN9VG-,[D$U[D'6_@F9M&:$NN MZ/QDXQAJ1`>^??*PHZ3U[V=))-0NA#]\;,8K-28.N_F!+*^T^`]02P,$%``` M``@`NV$.1ZQAPAZ@`0``L0,``!D```!X;"]W;W)K&ULA5/+;L,@$/P5Q`<4QTD?BAQ+2:NJ/52J>FC/Q%[;J,"Z@./V[POX4:N* ME(O97<_,#BQD/9I/VP`X\JVDMCO:.-=N&;-%`XK;*VQ!^S\5&L6=3TW-;&N` MEY&D)$N3Y(8I+C3-LUA[-7F&G9-"PZLAME.*FY\#2.QW=$6GPINH&Q<*+,_8 MS"N%`FT%:F*@VM']:GO8!$0$O`OH[2(FP?L1\3,DS^6.)L$"2"A<4.!^.<$] M2!F$?..O4?.O92`NXTG],>[6NS]R"_/:#W_6Z4@[3TA'0CH3[I)H?&@4;3YPQ_/,8$]L MR\/L5EL/-T'$*Q,;U;Q#&XO[4#WE:7*3L5,0&C'I`G,8,*L9P;SZV18I/4=/ MAQ:7Z>N)OEXZ7(\.;R\+;":!S5)@:_P)02P,$%`````@`NV$.1VE%&=:C`0``L0,``!D```!X M;"]W;W)K&ULA5/;;IPP$/T5RQ\0`[MITQ6+M)LJ M:A\J17EHG[TP@!7;0VRSI']?7X"@:J6\X)GAG#-G?"DG-*^V!W#D74EMC[1W M;C@P9NL>%+=W.(#V?UHTBCN?FH[9P0!O(DE)5F39%Z:XT+0J8^W95"6.3@H- MSX;842EN_IY!XG2D.5T*+Z+K72BPJF0KKQ$*M!6HB8'V2$_YX;P/B`CX+6"R MFY@$[Q?$UY#\;(XT"Q9`0NV"`O?+%1Y!RB#D&[_-FA\M`W$;+^I/<5KO_L(M M/*+\(QK7>[,9)0VT?)3N!:UJ%CNN4_NP> M9MIM0C$3BI7PD$7CJ5&T^9T[7I4&)V(''LXN/WBX"2)>F=BHYAW:6#R%ZK4J MLF\ENP:A&5-L,.>$R5<$\^HW6Q3T%KU(+3ZG[Q;Z;NMPE^AY]KG`?A'8;P7V MMT?<8LXS)O]_2+;94P6FBU?'DAI'[=*6KM7U=IZ*>"8?\*H<>`>_N.F$MN2" MSI]L/(86T8%OG]W=4]+[][,F$EH7PJ\^-NE*I<3AL#R0]956_P!02P,$%``` M``@`NV$.1X[Q&,NA`0``L0,``!D```!X;"]W;W)K&ULA5/;;MP@$/T5Q`<$FW7::N6UM)NJ:A\J17EHGUE[;*,`XP)>IW]?P)=8 MU4IY,3/C<\X<&"@GM*^N!_#D32OC3K3W?C@RYNH>M'`/.(`)?UJT6OB0VHZY MP8)H$DDKQK/L$]-"&EJ5J?9LJQ)'KZ2!9TO"DB(@%^29C<+B;1^Q7Q-28_FA/-H@504/NH(,)R M@R=0*@J%QG\6S?>6D;B/5_5O:;?!_54X>$+U6S:^#V8S2AIHQ:C\"T[?8=G" M8Q2L4;GT)?7H/.J50HD6;_,J35JG^4^1+[3[!+X0^$;XDB7C+^%O>8RXHI_FO"=F>JP7;IZCA2XVC\ M?*1;=;N=9YYF\@ZORD%T\%/83AI'KNC#9-,86D0/H7WV\$A)'][/EBAH?0P_ MA]C.5VI./`[K`]E>:?4/4$L#!!0````(`+MA#D>N[;4_H@$``+$#```9```` M>&PO=V]R:W-H965T39%C[Z30 M\&R([97BYO,$$H<#3>E<>!%-ZT*!%3E;>)50H*U`30S4!WI,]Z=M0$3`JX#! MKF(2O)\1WT/RKSK0)%@`":4+"MPO%W@`*8.0;_Q_TOQN&8CK>%;_$W?KW9^Y MA0>4;Z)RK3>;4%)!S7OI7G#X"],6=D&P1&GCEY2]=:AF"B6*?XRKT'$=QC^[ MS42[3L@F0K80[I-H?&P4;3YRQXO_VB*CU^C9V.)W^F:F;]8.-Y/#V]\%MK/`=BVP MO;[%->8T8^Y^-&&K,U5@FGAU+"FQUVX\TJ6ZW,YC%F?R#2_RCC?PQ$TCM"5G M='ZR<0PUH@/?/KG94=+Z][,D$FH7PCL?F_%*C8G#;GX@RRLMO@!02P,$%``` M``@`NV$.1Q:@!MFC`0``L0,``!D```!X;"]W;W)K&ULA5/;;MP@$/T5Q`<$F]VTR6C@@C+ M%9Y`J2@4&O^=-=];1N(V7M2_I]T&]Q?AX`G5'UG[+IC-**FA$8/R+SC^@'D+ M]U&P0N72EU2#\Z@7"B5:O$VK-&D=IS_\<:;=)O"9P%?"0Y:,3XV2S6_"B[*P M.!+7BSB[_!#@-HH$9>*26G#H4O$4J]>2YP\%NT:A&<,WF/.$R5<$"^HW6W!Z MB\ZG%I_3=PM]MW6XFQT^?BZP7P3V6X'][2UN,><9P[,/3=CF3#78-ET=1RH< MC)^.=*VNM_/$TTS>X671BQ9^"=M*X\@%?9AL&D.#Z"&TS^[N*>G"^UD3!8V/ MX=<0V^E*38G'?GD@ZRLM_P-02P,$%`````@`NV$.1Y#D-V'G`0``J@4``!D` M``!X;"]W;W)K&ULC53-CILP$'X5BP=8"`1((H*4 M[*IJ#Y56>VC/#@P_6ANSM@G;MZ]M,*$5@KU@>_S]S,C,)#WC[Z("D.B3DD:< MG4K*]N2Z(JN`8O'$6FC43<$XQ5(=>>F*E@/.#8D2U_>\R*6X;IPT,;%7GB:L MDZ1NX)4CT5&*^9\K$-:?G9UC`V]U64D=<-/$G7AY3:$1-6L0A^+L7':GZU$C M#.!7#;V8[9'._<;8NS[\R,^.IU,``IG4"E@M=W@&0K20,OX8-1^6FCC?6_5O MIEJ5_0T+>&;D=YW+2B7K.2B'`G=$OK'^.XPEA%HP8T28+\HZ(1FU%`=1_#FL M=6/6?KB)CB-MF>"/!'\B'#R3^&!DTGS!$J<)9ST2+=9OMSLI.-8_Q_>G343!5Z:F2%0 MQKI&#KTT1:>Q=/%-,S[@:=+B$GYB7M:-0#5.R M,T?:6ML?&#-E"XJ;.^RA)XI!LZ%UY$TUI?8$7.%EXE%'1&8$8\XS9?S%AJSU5H)MP=0PI<>ALW-*ENMS.4QK.Y`->Y#UO MX#?7C>@,N:!U)QN.H4:TX.R3NQTEK7L_2R*AMCZ\=[&.5RHF%OOY@2ROM'@' M4$L#!!0````(`+MA#D<$P+>VI@$``+$#```9````>&PO=V]R:W-H965TZ2M<]V!,5NVH+B]PPZT_U.C M4=SYU#3,=@9X%4E*LC1)OC'%A:9%'FO/ILBQ=U)H>#;$]DIQ\_<,$H%;_&:?UW5^XA0>4OT7E6M]L0DD%->^E M>\'A$:81[H-@B=+&+RE[ZU#-%$H4?Q]7H>,ZC'^R_42[34@G0KH0]DEL?#2* M;?[@CA>YP8'8CH>SVQP\W`01KTQL5/,=VE@\A>JU2+>[G%V#T(1)5YCSB-DL M".;5;UJD]!8]'2V^IF]G^G;=X79TW^V_%LAF@6PMD$TC[O\=<8TYSYCO_YFP MU9XJ,$V\.I:4V&LW;NE276[G*8UG\@DO\HXW\(N;1FA++NC\R<9CJ!$=>/OD M[IZ2UK^?)9%0NQ#N?&S&*S4F#KOY@2ROM/@`4$L#!!0````(`+MA#D&PO=V]R:W-H965T/?L^:K MI2=NYXOZUW!:E_["#3R@_"5JV[FP"24U-'R4]@FG;S`?(22L4)KP)=5H+*J% M0HGB+W$4?1BGN'.?S+3;A&PF9.\(+!J%F%^XY66A<2)FX+YWZ<'!M1=QRL0$ M-9?0A.+)5Z]EEB<%NWJA&9-M,.>(25<$<^HW+3)ZBYY%B__3=PM]MTVXB^[W M'_#/%X%\*Y#/1TS?'G&+.2^8#Z3&ULA5/;;J,P$/T5RQ]0$T+:*B)( M2:O5[L-*51_:9P<&L&I[J&U"^_>US:7L*E)?\,QP+C.^Y`.:-]L"./*AI+8' MVCK7[1FS90N*VQOL0/L_-1K%G4]-PVQG@%>1I"1+D^26*2XT+?)8>S)%CKV3 M0L.3(;97BIO/$T@<#G1#Y\*S:%H7"JS(V<*KA`)M!6IBH#[0XV9_R@(B`EX$ M#'85D]#[&?$M)'^J`TU""R"A=$&!^^4"#R!E$/+&[Y/FMV4@KN-9_5>4+Z*RK6^V822"FK>2_>,PV^81M@%P1*EC5]2]M:AFBF4*/XQKD+'=1C_ M;&?:=4(Z$=*%<)_$QD>CV.8C=[S(#0[$=CR&5BHYKOT,;B,50O M19KM/OOB&O,:<;<_6?"5GNJP#3QZEA28J_=N*5+=;F=QS2>R3>\R#O>P%]N M&J$M.:/S)QN/H49TX.V3FQTEK7\_2R*A=B&\\[$9K]28..SF![*\TN(+4$L# M!!0````(`+MA#D&PO=V]R:W-H965TZ*M<]V1,5NVH+A]P`ZT_U.C4=SY MU#3,=@9X%4E*LC1)OC#%A:9%'FO/ILBQ=U)H>#;$]DIQ\^<"$H<3W="Y\"*: MUH4"*W*V\"JA0%N!FABH3_2\.5ZR@(B`7P(&NXI)Z/V*^!J2']6))J$%D%"Z MH,#]>.W2?/#,A#7\:S^+4[KN[]R"X\H?XO*M;[9A)(*:MY+]X+# M=YA&V`7!$J6-7U+VUJ&:*90H_CZN0L=U&/]D^XEVGY!.A'0A')+8^&@4VWSB MCA>YP8'8CH>SVQP]W`01KTQL5/,=VE@\A^JM2+-#SFY!:,*D*\QEQ&P6!//J M=RU2>H^>CA:?T[2$GOMQBU=JLOM/*?Q3#[@1=[Q!GYRTPAMR16=/]EX##6B`V^?/.PH M:?W[61()M0OAWL=FO%)CXK";'\CR2HN_4$L#!!0````(`+MA#D<&(K7\I`$` M`+$#```9````>&PO=V]R:W-H965T*M(^V)FQN%;_EJ8-W5^$@R=4OV7EV]!L1DD%M>B5?\'A.TPC[*-@B!M7:=(ZC'_XXT2[3^`3@2^$+UEJ?#1*;7X57A2YQ8&X3L2SVQP"W$:1H$Q< M4@L=NE0\Q>JUX/M-SJY1:,+P%>8\8FX(%M3O6G!ZC\Y'BX_IVYF^77>X'=T? MLX\%=K/`;BVPFT;D[T=<8\XS9ON?"5OMJ0;;I*OC2(F]\>.6+M7E=IYX.I,; MO,@[T;CJ%&]!#LLX<])6UX/TNBH/8Q_!QB.UZI,?'8S0]D M>:7%/U!+`P04````"`"[80Y')3L"$;$!```6!```&0```'AL+W=O/.VGY'B*DZ$-3-#NCOF'A$`OQB,9C5'/OM)J7>_>*GW M./$1@$-EO0)UPQD>@',OY(P_)LTO2T]3K3+A&PB9`OA/@G! MHU&(^4@M+0NM1F1ZZGN7[AQ<>Q&GC$Q0F;=<)-=/^QN2ZPG06V:X'M=,3\WR.N,<<9Z+#@TUD_OW%S'>QL75O7S*UQ^!>5?4$L# M!!0````(`+MA#D=_/^5*I`$``+$#```9````>&PO=V]R:W-H965T0,H@Y(W?+YI?EH&XC"?UISBM[_XD+#R@_--5KO7-9I144(M!NE<< MG^$RPC8(EBAM_))RL`[51*%$B8^T=CJN8_K#)]IU`K\0^$RXRV+CR2BV^2B< M*'*#([&]"&>WVGFX"2)>F=BHYCNTL7@(U7/!M_A"X8O,,>$6)'WHH%?PC2=MN2$SI]L/(8:T8&WSVZVE+3^ M_/3;I2*7'83P]D?J7%)U!+`P04````"`"[80Y'`Y7]K*0!``"Q M`P``&0```'AL+W=OY!^3^--I(YGYJ6V-X`JR-)"D*S[)9(QA4NBUA[ M-F6A!R>X@F>#["`E,W]/(/1XP!L\%UYXV[E0(&5!%E[-)2C+M4(&F@,^;O:G M/"`BX)7#:%Q;.;K/WRK!M/'J6%3I0;FTI4MUN9U'&L_D"UX6 M/6OA-S,M5Q:=M?,G&X^AT=J!M\]N=AAU_OTLB8#&A?"'CTVZ4BEQNI\?R/)* MRT]02P,$%`````@`NV$.1Z@89C*E`0``L0,``!D```!X;"]W;W)K&ULC5/;CML@$/T5Q`,Q'4\JW].TX;NK\+!$ZH?LO)M:#:CI(): M],J_X/`%IA'V4;!$Y=*7E+WSJ&<*)5J\C:LT:1W&/_SC1+M/X!.!+X0/66I\ M-$IM?A)>%+G%@;A.Q+/;'`/<1I&@3%Q2"QVZ5#S'ZJW@AWW.;E%HPO`5YC)B M-@N"!?6[%IS>H_/1XM_T[4S?KCO(::K!-NCJ.E-@;/V[I4EUNYYFG,WF'%WDG&O@F;".-(U?TX633,=2('H)] M]K"GI`WO9TD4U#Z&CR&VXY4:$X_=_$"65UK\!E!+`P04````"`"[80Y':5A2 MY;(!```6!```&0```'AL+W=O]Q:V^T(,64+@IH;U8%T;VJE!;5NJ1MB.@VT"B3!298DMT10 M)G&1A]J++G+56\XDO&AD>B&H_G<$KH8]3O%4>&5-:WV!%#F9>143(`U3$FFH M]_B0[HX;CPB`/PP&LY@CG_VDU)M?_*KV./$1@$-IO0)UPQD>@',OY(S?1\U/ M2T]?]WB$G,<,=ODNLGFHLEF%$A_,)DPWS\%631.@&[" M^32H5+VTL6]S=;X"ARPT_A->Y!UMX#?5#9,&G91UQR?TNE;*@K-/;C88M>Z2 MS@L.M?73K9OK>&[CPJINNH7SKZ#X#U!+`P04````"`"[80Y'Y3@7^+4!``!C M!```&0```'AL+W=O-S%4(JO\>@:OAD&R2J?#"+IWU!5Q7>.YKF`!IF))(0WM( M'C?[8^D50?"+P6`6<^2SGY1Z]8L?S2%)?03@<+;>@;KA!D_`N3=RX#_1\S_2 M-R[GD_NWL%N7_D0-/"G^FS6V_"B$3)%M"2##8;,E]@VPR MR)<&64Q0O$]9!(T<4XZ:?'>?D:\R\L@H/V%$S7U$L8HH(F+["6+49/<1Y2JB MC(C=>\12Z#``` M&0```'AL+W=O[%Y3C]PU)66/W<$AIPZ5NSZHJ1WHNJ'3E%5K M9VG?]M9E*3[3NFK16V>1<].4W;\5JO%E:0-;-;Q7AR/E#4Z6.D/%+F1T;_'B/S#^Y`\_=TO;Y36@&FTIERC9Y0OEJ*ZY M$LO\5XI><_+`\;U2W_1V6?D?)4$YKO]4.WIDU;JVM4/[\ES3=WSY@:2'@`MN M<4WZ7VM[)A0W*L2VFO);7*NVOU[$/[$KP_0!4`;`(6#(HP_P9(!W#?"-`;X, M\.=F"&1`,#=#*`/":T!H#(AD0'27P1&]VX]-4=(R2SM\L<1&F M;)%>C0T+Z1M?>.M7!F,W=;ZXD&3@B%D))@;32"$0`[%1B:Z,PXK45@IM7150 M"$RGR`41&Y#BH8P%?"?AC`;\7\.[& M->J15O2H0&#B@6DH%U"2Q.$T5,Q16L]1VD@(W/?N&'H54)2$,R93H.V=0':O M?YLE&'>/8(`;^]XTE0LJBD.#5"&E8IA$T]1:4GX2A(]]A5I?H?05&'P)!B3` MX$HP3R`*#:XD%$*#)R4$H3M-;61)XU&?-!YIC4?2^(R>B[4++IZ_X!)M!8EV MP=WTO$!`8)@$Q0QFHYCD<:W`U1;;-W.[AC0K"0$7F.;V+&HS4'XTHVB@+UKM M(;&I:+D5N:%A#123U,W+2%)Q-&-:`JBO&6H>C]0OD1ZN[]A58Y$#37H#%6ARBH/Z%?9':J66!^8 ML@-=?_K:8TP1*]A]9L-R9!\+PT.-]I3?1NR^$\=G\4#Q27T-#)\DV7]02P,$ M%`````@`NV$.1UK-X1NC!0``LB(``!D```!X;"]W;W)K&ULC9I;)+J^F7V":?#CI"]$'`^K-N?K9O5=4M?A_VQ_9N^=9U[[>K5?OT5AW* M]EO]7AW[_[S4S:'L^I_-ZZI];ZKR>6QTV*]D%,6K0[D[+C?K<=OW9K.N/[K] M[EA];Q;MQ^%0-O]MJWW]>;<42[_AQ^[UK1LVK#;KU=3N>7>HCNVN/BZ:ZN5N M>2]N'W0\("/Q]Z[Z;$^^+X;./];US^''G\]WRVCH0[6OGKI!HNP_?E5YM=\/ M2OV>_P71KWT.#4^_>_6'T6[?_<>RK?)Z_\_NN7OK>QLM%\_52_FQ[W[4GW]4 MX,$,@D_UOAW_+IX^VJX^^";+Q:'\[3YWQ_'ST_TG3J$9WD!"`SDUD()LH*"! MXC;0T$!_-:"[9*"!X>XAA@;Q18.5&ZQQJ(NR*S?KIOYD(HP4#ODB5GT'T%[();8'Z7J1 M1>%=Y)ZANN$9&68L0^?!,VK>D/*&U.FP*C<>23HOH+V`/A70T`-]WDLS,D?G MUC&,/AJTCP9V8>8%8K2/,0C$YWU,3OJX=8R(4JW"5.ZH)(UU&"I`*I59$J8L M4#HS\;RO!/65C!)9&A[ZK4-D%(>9W#$W)%0`E$9AQ@(C3F=#T%**6DKA-$\( M3X[1L9)$9W)'*2&5)&RQM&Q0Z_2(/H!6E&6,^I*A]C.8J91]Q\RX=U!B)'5, M.4J6H_3@(&%DPCC+181Z'S?WHVP([\!('1$CE'N*',>"I64QK;`S@3N#U-'$ M$&X!4IDBK3G*R,LR=6Z-HV6#6F>SVE.QX`R`Q`?`YQ0C9@0>5$+Q4T#@425\ M5I&'P4'4N36/%/.(O4+"=@QNQ\R7?V!N##7U MUR)FI`!`0D499J2H2L@2LZA8V!P>VB)AU'B`R%DXBQ3SB+U"PG;PP!8I MHVJG\VYFD6(>L5=(V`V>OR+C5&J`!%&"RVC&=?C$@]-J1FU&"`1::K7N<>4T.2!8ZE9 M5"UL#P]1Z1>7I#T'Z1EWCHI-2M3"@J5E,:VP-3Q%93Q?F8&1*B5F;NXI^GJ: MI64QK;`S/$)EPJC2`/6)3EI+8-$64Y<'+"V+:86MX7$J(4XC1H;)*9I?"84]X:&J)*,Z>\C(B*@%.6"D*Y:2O5(*V\+C5/G%'FD+TDUEU`(`*-(5 M1\A>"85-X4FJ]'P]!D:0CN:7GPP9>R43]H-'IS*,*@R0(4N$F3`"KEU%X'9124`R0$=9%8^/U%AIPMGE*< M\<475RIC%&#'W,0)Z0RH-*$NM3S57R&2\\9CF6$<-8TGIO891E4L@#)%72'F M0*41>3>&I64QK;`U/#>U7_N1UN`N840M\@'*-+6TX2A91"EL"X].+>?+L9Z- MQ'P>*>81>X6$W>")J15>C,^><0$47YXU9X^XO)(@GW%QI"PF%386>+X(J1EQ M)C#^_%`;D&#<0M%X-&@?#1=C<@IM)\B$H7R"XC!43%`2ANP$7=Y47YT\7S]4 MS>OX*D2[>*H_CIU[#CQMG5ZWN)?#\_F+[5MQFPMD>R%NK7N>_R6_6;^7K]5? M9?.Z.[:+Q[KKZL/X"/^EKKNJ[V_TK9_Q;U7Y//W85R_=\#7IOS?NE0KWHZO? M_1LBTVLJF_\!4$L#!!0````(`+MA#D&PO=V]R M:W-H965TJ682BK MFC`L7WA'6OWDR`7#2A_%*92=(/A@28R&",(T9+AI@[*PL5=1%ORL:-.25P'D MF3$L_FT(Y?TJ6`1#X*TYU5@%T%@@E%3**&"]7,B64&J$=.*_7O.:TA"G^T']NZU6N]]C M2;:<_FD.JM9F80`.Y(C/5+WQ_@?Q)21&L.)4VE]0G:7B;*`$@.$/MS:M77OW M)(>>-D]`GH!&PIAGGA!Y0G0EI'<)L2?$5T)L6^-*L8W8887+0O`>R`Z;MV.Q MU'!A1+0RD%9-]T#:X-I$+V4$OQ7AQ0AY#)I@-@ZSN(W8.@3*KYA0.YBU@8*Y M%,@)W$GA$?EMR,Y!!NT]4()RJ+;J)U#90E*'QM.9@TGON(G_K=TMF7I\RW+9AUD3[3,8>(( MWFO9((3@$U[R62^Y+^;+:SC%;`9,=!NS'3#Q%R/AY((R(DYVTDE0\7.KW/T< MH^,P72-[P:_PLNCPB?S"XM2T$NRYTF/"WNDCYXKH]/`E"4"MQ_UXH.2HS#;3 M>^$FH#LHW@WS?/RHE/\!4$L#!!0````(`+MA#D>5>J3&PO=V]R:W-H965TC,SEZTUU&C,@O$DJC;MV_^0+L;LNR-D,]S3KYS8,*7WVCWRDZ$<.^MJ5NV M\$^I:*HF=_QC1 M^YZ2^'C?JW]3=D7[6\S(FM:_JST_B6Y#W]N3`[[4_(7>OA/C`4G!':V9^O5V M%\9ITU-\K\%O^EJUZGK3_V2AH=D)T!#@0!CVL1,B0XCNA-A)B`TAGKH#,@3T M;H=`>U?)E9CC(N_HS6-G+-\G,!?P3HH(98\I-1$:4\6EK%Z+"*`\N$HA@X$/ MF)7&9&`<4FK('1&(!JQ=0-^V`U1T.+[!6B,R!Z3\5&3S062TS:AO,WH,*S)A M)9\+Q+U`_"@0&X'T_R:1PK0Z"XT!*($H&X>M>QB*8#@.*PT'TA7CMIR^(I\1KCD+HC%>#TM0!*@T(9FGDBO>CE/85/'S.&](= MU2#%O!V]M%Q_H(;J,*PMH1P'WM578+X&EGHIASLU/MSEB_R,C^0G[HY5R[PM MY6((41/#@5).1+_AD^C^),;/85&3`Y>WJ#V1ZP>FYGR^'(;?X!U!+`P04 M````"`"[80Y'H,EP]@("``#/!@``&0```'AL+W=O5G(`9.<&6:.@I0$"2@PVWO%[FI/?,B9Q=)VYX\2?UO3/,W7C>CR[?S;+5?A'+$C)Z(^VDHVB#7RO M(C6^4/G"QB_$KB'6AB=&A?GU3AW^%Z'WZ9KVYOK.-W)`MOF;D"V`2T- M,+K9$-J&\%T#F,C,NCYAB8NP)XZ:6)$SQ45>O18BB M'%RUD=6@E>9ITJ"/%:559(L$*``G!9HIPC4%LA3Q?8-P-HC6!J$U2/Z&3(VF MGY81NI:Q5I23(H/1[CY'Y.2(+$=ZWR!V)A%O3R)Q$B3N).)U$HDKB;6B3/XC MB=3)D5J.#?^)S)E$MCV)G9-@MR&)21/<2.*]XD,(&#@I3%EC;$@20F<2$&Z/ M`B(W!=KP@5A1<.,+^4)9,-\?"QG6/$;4$L#!!0````(`+MA#D=M3-JI_`$` M`,X%```9````>&PO=V]R:W-H965TFH?+/,^.B7\4P'@IO];'2M@#*`EQT^[IAK:I% M&TEV6,5/<+G)+>&`7S7KU:@?V>Q;(=[MX,=^%2"_Z[VN3-@DCO;L0$]AEP=M"V2TQ?^OO&#[3HAMOS&ULC93=;ILP&(9O!7$!-6!^(X+4,DW;P:2J!]NQ$TQ`M3&S MG=#=_?Q'1CM" MU).6<8JD6O(3$"/'J#$F2D`4!"F@J!_\JC2U9UZ5["Q)/^!G[HDSI8C_><*$ M37L_].?"2W_JI"Z`J@177]-3/(B>#1['[=Y_#'=UIA5&\+/'DUC,/S_0")C@H]0)2`T77&-"=)#:^+?+_+>E-B[G<_I7TZVB/R"!:T9^]8WL M%&S@>PUNT9G(%S9]PZZ%1`<>&1'FUSN>A61TMO@>16]V[`*PF*\+MC\?*\C#Y'P(3O@'XJ=^$-Z!2772S;%L&9-8Q00/JLE. M7<#7!<&MU--,S;F]D^Q"LG&^8:_7?/474$L#!!0````(`+MA#D>QMXQEW@,` M`*<3```9````>&PO=V]R:W-H965TW#W6>BHU(+C`L8=__]\M$0T`8F+Q$FIT^?;GJ..,N; MSG[F9Z4*ZW<2I_F+?2Z*R\)Q\OU9)6'^K"\J+?]SU%D2%N5M=G+R2Z;"0QV4 MQ`YU7>DD893:JV6]]BU;+?6UB*-4?[&)W2Y\CT[GHEIP M5DNGBSM$B4KS2*=6IHXO]BM9[)BL(#7B_TC=\MZU58E_U_IG=?/OX<5V*PTJ M5ONBH@C+CP^U47%<,969?P'I9\XJL'_=LN_J`"#`/89P"<#.`1PTPP"`H1I!@D!\B[`:9I5MWH;%N%JF>F;E5_":@#) MHH1G%4G);.4U6]GEO%Y\K58_5HP%2^>C(@(,[6'6#<8GXY!M`_E$.*4`5`6U ML0RT#J?C"38-PI^`;&=)WN9)=D#BSU?"VDI8OY^LZ2=WYPEX2\#[!!P([KKM MU9BTJ10PU/==UR"10!,)2'37#=%/U&"H9Y1&HFED,QEB*@U@`N8RHTP>FLF# M@MAXY]8-AE))!JU[E#0"')7DH]/@@R0^3Q"@-05`(,:EKAL,%9(\E-2O?0I\!]@S+S(:*X;U#8Z>+.-_J@;0K?Q"M?C&I9[!E@%0-9K3U`TB`/[A4,O$)X!A04'51&S0>5,5P% M,QA4`!%7/+XV#9X``(/ADQK7A%L%XP:3"J`GR>XJ39[R^&O[(P:3*I+>C^K='I'2HD*CO5YS^YM=?7M&A^`W>K MW1G3*ZT.)>[6UV2Q(FA.D3_K5\A*>U']A=HK2W'K71:&3^MSBJ'6A M2KWN<_GPSBH\=#>Q.A;5I5=>9\TY4G-3Z$M[+-:=S:W^`E!+`P04````"`"[ M80Y'T?5R`/0B"`U1%5G,5+5QV?BUEOP%`'&O28O'$>M*I-Q7C+99JR$]`])S@ MTHA:"E`0)*#%3>?GF9E[XWG&SI(V'7GCGCBW+>9_=X2R8>M#?YQX;TZUU!,@ MS\!55S8MZ43#.H^3:NL_P\T^T80!?C5D$).^I[,?&/O0@Q_EU@]T!$+)46H' MK)H+*0BEVD@M_,=Y?BVIA=/^Z/YBJE7I#UB0@M'?32EK%3;PO9)4^$SE.QM> MB2LAUH9'1H5Y>L>SD*P=);[7XD_;-IUI!_LF2IUL7H"<`%T%,%H4A$X0?E<0 M.4%T(P"V%+,1>RQQGG$V>*+'^N^`&X5S;:*1_862;]<@,HX&Q2-0<-I4&3TKA<]CH3B!"]#>02@*;_*" MR2'J\8G\Q/S4=,([,*G.HSD\%6.2*)/@2>U`K>[5ZX"22NKN2O6YO6KL0+)^ MO#BOMW?^#U!+`P04````"`"[80Y')%J4Q.,!``!1!0``&0```'AL+W=O_HL`GGI M.B+^'BCCXSZ$X33QTIX;929`D8/95[4=[67+^T#0>A\^P%V9&H45_&KI*!?] MP+`?.7\U@Q_5/HP,`F7TI$P"TDB%>\F2QATY,VU;6_;T;W) M8F];-R!O0+,!;ANP-^`/!N#(;%W?B2)%+O@8R(&8S88[+1!"4YOBTHG0O(T$$-\6U1Z4?25 MKY*LHB0>)=U`<1J$HVP#Q8E@"M'G*.DJ2FH3XHU/?W"2!"9;^^-%*?JX/V#Q M]P_D3'\2<6Y[&1RYT@?)_O4UYXKJD.A.%]?H^VT>,%HKT\UT7[@C[P:*#],% M-M^BQ3]02P,$%`````@`NV$.1W^E2FB7`P``9A$``!D```!X;"]W;W)K&ULE9A=DV-"F)]%]58?.&^LCR(OZX5]:)KCS''J MS8$7:?THCKQL?]F)JDB;]K;:._6QXNFV#RIRA[BN[Q1I5MK+>=_V4BWGXM3D M6>_Z#HI<^ MN\#KZT']N;?;#O\UK7DL\M_9MCFTHW5M:\MWZ2EO?HKS-XX>6">X$7G=?UJ; M4]V(8@BQK2+]D-]9V7^?Y2^,8)@Z@&``&0/&?M0!%`/H)<#3!G@8X)GVP#"` MF?;@8X#_*<"1R>I3G:1-NIQ7XFS5Q[0K0)BU>-6)M,I6W:NU6:[[QJ>N]7U) M_6#NO'="R)`K9B69$*:11"(7PFD'H!P%L54]D#Z<3'<02R+4(,E=D?5]D6<4 M">\[H8,3>IU/BODT$/`&`>]:P$.!Z':00<^4,EV2(>`Q.DW%DH+`=;UI*D$M MPBB9IM:H%;H0W3?&E,:8-!:XM]VP:V.2@<@';YJ*D0H"(--48J2U5FE-&O.5 MQGPT!AICD@%@OL9^+*D(0JKQ922UGI*ZGM5GA,+0P'N@]!Z@=\U$K"03NDPW MIP@Q$FFLFRBMIY1NG$L(B,_<^]9#I?40K=/[`I%RJ8C,EPIPE4/HF[LQ:/*Q M0BC297\0Y)@::?%4(/1+M2C!31_%>2@?(\K;.1 M,IDPHK9&T)I)=M0;#'QAAP'U%@.>2=D@I,LN[@JZU0H9;6)1AAD84F\MP$PJ M1D(/6D?(A#I'R(!N^1TA$U/J;06&?24PD`C4M1)\H5;4JQR$)K42WIOD&!&B M81)D0%LL.!Z#91LBM:/(I%@B7#ATV_4(:?\`"'D::#U"!NL"4>\%9-@+#.:: M@+)<")B7"U$O<(08E`M"X'T^4MQD=Y#2/K\E`T6I[N^(%*.A9V"-JJU1==W< M/)DC]$`AU&#QB+FNYJD[&3#?U76Z'C`6_/[?OC>VUMQ*ELY!%F M;!U?$3SU!^E/[2N8Q:!H3V"VEB\`+O++^3'=\Q]IM<_*VGH537N2[8^=.R$: MWH[8?6QGY\#3[7B3\UW370;M=25?`\B;1AR'MQKCJY7E/U!+`P04````"`"[ M80Y'F'9#`20"```>!P``&0```'AL+W=OK%=NTD3D"U,;.=T+W]?(+0RFW(17S@ M._Q?B'^7`^.OHL%8@C=*.K$-&BG[31B*8X,I$D^LQYUZB.L MRG#BG5J*.]&R#G!\W@:[>%/'B888Q.\6#V(V![KX`V.O>O'SM`TB70,F^"BU M!%+##=>8$*VDG/\ZT;NG)L[GH_IW$U>5?T`"UXS\:4^R4=5&`3CA,[H2^<*& M']AER+3@D1%AOL'Q*B2C(R4`%+W9L>W,.-@G:>YH?@)T!#@18/$E(7&$Y$ZP M26UE)M$*%2]UK`P$>'UF(=?6Y1CY@%)LEHDLQS)$X`/A9(1X%T+I`Z@>1]E7/, M?L2DCTTRKTGF!++'`BMOS-7RF+FW@MP)K-['S`VFLS$M!F:1^CSV67M]ULXG M?RQ0>),6RY/&D;<$LZTEUI]GK2=0M"QM'/N]W#E:%U]YN8-4+/QE8^CWE M^'"@LOD[=*#5`I?$[Y(L^*WU6I_:7@Z[*K&DOJS>_/E%C$$B_S/+38K7L[WVM M5DO]WA3Y27VMO/J]++/J]UH5^O*X@,5PXUO^=FRZ&_YJZ5_M]GFI3G6N3UZE M#H^+3_#P++!#>N+?7%WJFW.O"_Y%ZQ_=Q9?]XR+H8E"%>FTZB:P]?*B-*HI. MJ?7\DT3_]]D9WIX/ZKL^W3;\EZQ6&UU\S_?-L8TV6'A[=B^:;OGQ6E$/4 M";[JHN[_>Z_O=:/+P63AE=DO<\Q/_?%B?I&#&6^`9(!7`PBM!H(,A*M!2`:A MJT%$!I&K@20#Z6H0DT'\AX%OJML_FVW69*MEI2]>?Z&?*3S`Q*D.DAT[DLHMYP5BMI`Q"<33*6T,@R@AL9?(!HYR)Z^8N.6>L*$G M%+K#Q$O9XJ7N$P\"-H3^=B>13B>[)NBON3?M#'AGP,_S:.3,0!`B,]%'#VN* MG`X+^;!,_PIMSC8$@:LKOM&!F.\N&X(,[!@X['LNBLR8(4A&X#43D>P;2S@=M`Q$GMD?3SOBV@2&5,7*0X&M-C^!<9C`J:6O M$P0R2.P;GNU`1D$\5T7:;$`8IE9R1R2FH7";98+O'R)PV",3%"7VS>J6N#N0 M=O!I$(1XYC5C$`RD8Y9\XQ+4N,#B;$.0-<%9Y(E'DE%6U"&#^YMU;SHEOCT* MVE`!V%+"^91FD2<>&:>$DRGY-^__Y^Q-_9-5;_FI]EYTT^BR?^\_:-VH5B:X M;\?X467[ZT6A#DUW&K?GE?EP8RX:?1Z^0UT_AJW^`U!+`P04````"`"[80Y' M"4/+"E4#```#$0``&0```'AL+W=OP=K[]\?+8J%N(/I!(#[[ MY-G=[)*X.,OB71V$**W/+,W5TCZ4Y?'><=3F(+)8WJ`ZP9.%B>YO5HT8R_%:B%/99KDXJ6PU"G+XN+?HTCE>6DSNQMX M3?:'LAYP5@OG8K=-,I&K1.96(79+^X'=KSFO(0WB=R+.JG=OU>+?I'RO'WYN ME[9;:Q"IV)0U15Q=/D0DTK1FJF;^BZ1?<]:&_?N.?=VX6\E_BY6(9/HGV9:' M2JUK6UNQBT]I^2K//P3ZX->$&YFJYMO:G%0IL\[$MK+XL[TF>7,]M[^$+IK1 M!H`&<#$`-FK`T8";&GAHX)D:^&C@?QG,1PT"-`B^S>"TP6I"_127\6I1R+.E MCG&]`-E]!2]JDHK94@U;%675##[4HQ\KC\'"^:B)$`,]S&.+X2'38Z(6`W-7 MCWGJ,",\S]U<(SSK:QZG\I=T&CJG>=]I0*?Y-`'O"+P^`4<";ZARUF#RUI,6 MPT*W^>B!ZQ;H3FOQ2"T>:O&G"7PR&KYY-`)20=#F['ON_7XT6DPP/<6,G&*& M&@T(0M+)T-S).:E@C@0S?2:C%L,F$OY,PK1RF$OJ:8:KJ'-]T"/$C.7E"J+7 MP6@=70<)QX0@*+P*S%`,P@*SP``M"'`YA@84G%PLC)NO%D97)?.F6\0C@I@' MQ)(91D:#U,OR:5E=L<\-*`(Z.,$-P:&KF6$YPXC+$8*`BLV@G#1`O:B0%A4: MM#$$&;0A1K<1AGW$-6C7X)()`-<\`4`7+6"A`1M9G7!Y%T\D0`/4BZ(+%\!@ M570@WY^H&`U0+XI^TP.V`@`#"H_.EW=#ONBR!2Q;&.OV"`K&L_6DAPWCU\(8 MC./6-$[O(+V%`&PJ,-(N(P01BH8.!M1;;[ABC9C65TQZM^A&!UVC,ZEV>N," M-^Q<@.XY@#T'@J&O?5!T`'E*Q*^O;675?M&?T]J&4Q^XOA\O_'JO_4$L#!!0` M```(`+MA#D&PO=V]R:W-H965TP*(/P:4YX-[:84^(J7L0U-RI`:3;:946U+JE[H@9 M--`FD`0G:9+<$T&9Q%49:J^Z*M5H.9/PJI$9A:#ZSPFXF@YXAY?"&^MZZPND M*LG*:Y@`:9B22$-[P,?=_E1X1`#\9#"9S1SY[&>EWOWBI3G@Q$<`#K7U"M0- M%W@"SKV0,_X]:WY9>N)VOJA_#Z=UZ<_4P)/BOUAC>Q8C MA(2UXB9\43T:J\1"P4C0CS@R&<8I[N0/,^TZ(9T)Z4J(/B0:A9C?J*55J=6$ MS$!][W9[!]=>Q"DC$]1<0A.*1U^]5'F6EN3BA69,NL&<(F:W(HA3OVJ1XFOT M--#3V_1LH6?;A-F<,+LMD"\"^58@GP7ROX^XQ9P63'';I+AJ4LP"]_\QB9BL M>/S'A&P:)T!WX7X:5*M1VMBWM;H^@6,:&O\%K\J!=O"#ZHY)@\[*NNL3>MTJ M9<'9)W<%1KU[I.N"0VO]],'-=;RW<6'5L+S"]5=0?0)02P,$%`````@`NV$. M1WSM_3.[`0``&P0``!D```!X;"]W;W)K&ULA53; M;ILP&'X5RP]0@PG)&A&DI%.U74RJ>K%=.^'GH/I`;1.ZMY\/0-D4+5S$]L]W M,K^=8E3ZS;0`%GT(+LT!M];V>T+,I07!S(/J0;HWM=*"6;?4#3&]!E8%DN"$ M)LF6"-9)7!:A]J++0@V6=Q)>-#*#$$S_/@%7XP&G>"Z\=DUK?8&4!5EX52=` MFDY)I*$^X&.Z/^4>$0`_.QC-:HY\]K-2;W[QO3K@Q$<`#A?K%9@;KO`$G'LA M9_P^:7Y:>N)Z/JL_A]VZ]&=FX$GQ7UUE6QY?N M'5Q[$:>,3%!S"4TH'GWU6FZR74&N7FC"T!7F%#'I@B!._:8%Q;?H--#I8W)? M()L%LG7&+`JDV_L"FUE@LQ;8!('L,?][D[N`D3%EQ&P3]]RWR6_:Y-.W_/(? MFXA):?ZO"UEU3X!NPB$UZ*(&:6/SENIR#XXT=/\37A8]:^`'TTTG#3HKZ\Y0 M:'BME`7GGSSD&+7NIBX+#K7UTYV;ZWAXX\*J?KZ*R_]!^0=02P,$%`````@` MNV$.1\Y;*?^W`0``@`0``!D```!X;"]W;W)K&UL MC93?;ILP%,9?Q>(!:C`0MH@@-:VF[6)2U8OMV@F'8-7&U'9"]_;S/U(ZH:4W MV#Y\Y_=]!D,]2?6B>P"#W@0?]"[IC1FW&.MC#X+J.SG"8.]T4@EJ[%*=L!X5 MT-8W"8Y)FFZPH&Q(FMK7GE13R[/A;(`GA?19"*K^[('+:9=DR5QX9J?>N`)N M:GSM:YF`03,Y(`7=+KG/MOO**;S@%X-)+^;(93](^>(6/]I=DKH(P.%H'(': MX0(/P+D#6>/7R'RW=(W+^4S_YG=KTQ^HA@?)?[/6]#9LFJ`6.GKFYEE.WR%N MH73`H^3:7]'QK(T4??X[5:H(J`HJ/FUQJ]K.F_,<$+X[72$_PDZH3&S0Z2&,/JC]6 MG90&+".]*Q/4V]_!=<&A,VY:V;D*7TA8&#G.W_OUI]/\!5!+`P04````"`"[ M80Y':`_4I_(U``"=`@$`%````'AL+W-H87)E9%-T&UL[7W;#SF:]`N>2)5-6D>;\XB:NX*>YMQKJ9E+;'QS4/+1(B.R;93'=3VDKE(?]P MGD[5F5^8CYA/R9?,N@!H=*.;I.0D]G%496^1;``-+"RL.];Z71PGXM-ZM8E_ M_]DR2;9??O%%/%O*M1]7PZW?=&HU3I? MK/U@\YG8;8(_[>0PW&V2WW_6:G4^^^IWX+[,/].N(RW"3+&/K,Y3S_]`^[354T:YYH MU.KM_,/!;E$5M5[QPT/S^6%P'R>1/TO^=[ZG:CR1BP!;P!!7_EKF6WT<3*\O M1^?CX>#"$^.K8^A&"0IS[ MB?/.2J7>J#3K):_Z3JY6E1\WX=-&3*4?AQLY%^,XWLDHW^$J+!GB8[B"C?6C M9YC.2D;.9NE%J3E/Y#:,DF"S$-/$3W9.\^_=[58CT/!B"&MAGD^X7L.63I-P]J,GIH1GXGJ7Q`EL/G0OQ0T;Z._A1V>Z^98W M,@K">7';;QNEO6^?M\YFUFN5;QV,AM9S?M_*=Z;]X*]B9QCS#C6U,MS1)^E_ M_-N_%1V7X?75^>AJ.CH7\&EZ?3$^']S"EW>#B\'5<"2F7X]&MU-Q>K?Q=_,@ MD?,S.-!WTW-Q>G(F3D2P$;?+=WAA_DGW;!H[^"M3KOF"X!3RJ)C-8PE4<9)^NB5H/9#.E63$.&R1(P M+)(S"8/>KV3LB8U,1/@`3P6@7_CD;V92`,$0\W!WGSSL5L*W!Y@!T@5QC+3$ MG_]QI]Z)`YRTO'JW)_Q$`-"E(5_4"YZUNW5\!G"1ZWN80QEL)NGQ;B*Y]8.Y?FQ# M;:;.OQ_'T@7S;9C`2=G?YF9R?3.:W'XO!E?G8O3MW?CF$M`@W8(9(/6.5SJ7 MP(MF`5-MA&[3JS>:)="M>\U^]RCH?KB^/O]N?''A0/#J=G#U8?SN8C0MA.#U M[=>C20F^\LH'A2O6F'XQ'KP;7XQOQR.GN\'/K?^,VU[P/-IE]JX(Q:E)P::M M`O\^6`5%6#/U$<<2_U/9FPW:1!+P"W"Q8O:7*'2X<5E,(LU"#CH"D=*"#AM^.K#Z.K(/M]`1%0"XJ9N9Y4:W6$L@!*O)._%76O5JOA_TJ\$_XN`6(<_%G. M?RLVP4K_'*`@,F=T3!FS@>BH=@66-0OCQ!,(:9#2:[VNV8RC5EQ$&CT9;B: M@WCZ&Y()R@Z\=6#H!B0,/)Z$>187EO&9`_2 M`'/2Q"FL+5ES8]?!R"[L=N=:2P[OW=<5'97H+?Y@57;\7B'F#VS$T4(SI\F8R^AJZ MC3^.4&L&%5J<7EQ/IVO762O`,GJWFT1:%`Y":N[1ZA*'R0=-"0`I&T M%,OH,9BY32_]C;]`S?M6Q,]Q(M>*^)0T'P$9VI+^QL/N:\MD+2J9XQ#W"^3C M0\^WQZ]%=UF_;$VZFWSQVF8'UO`A"N.85N!RK6LXBSX9"[3PZP@\I"SN@@12S^:L18ZAUFM0EI1\?3#@U-()\E,5)RN8$7. MV6(Q43=1@SFMQAL0#$'9ICX/9D8QD'JQVB:+\AUM_!PM=8G/_$3!M M(3/3R+"#\CF5$'Q[(C^%)Q3I'7\_ZF_;`L4/ER12.B9>P^[V-[.DZALE50]9 MJB[O8@E5YRQ>']66D3F+<`JG2A<1%HCW[_P5"8UL`C&&MV99.VLS#_:!^2#< MH!,THT]GN!73C%P](KE:_#`!5!5P$[\:.Y,?2*W.Z"J.!90^V+'0%&;?;A' M9M\*8#%;2)"F%(JS9>T.CAV+39AH.0R%KL)G*;-&"X?#?Y+1+%"K('0+ MMTF1[::TX;Z9E>RW(]D2+);8`7_%SV2J!@GE M,0#A4]P_'_76<]O&25+)&NUD?R[1QV!P4OI^JF98>A1H"A$PR84L[#ANV6Y)&'_0K[^]PH@A5GI5^2>\.' MY*E`$LATB8]R8TSD'"B/-HX$4'D*5X\EJ_:Q,1ECEU&X6P#L M+$)E6[!#?H,TQ(,UO0RKFEO?)/1I.1H/IZ`SU;OH$'YC$DFJ.'U`8^SBX0/I;C!D%+P-R?"\7 MP6:#:T+]DOR0+^DND1"4=9S>W=Q<$$L87(CS\71X<3V]FXP,>QA?O;^>7)*- MH53G09-HN0)"F^XVR+QX.OQZ='YW0:^]NKZJJ%=_'$W1T$X`?#^^&EP-Z=OP M=ORQT'=@N>=8!]%>CQ"Q!0``DA,"R=`.M,0D47"_2\C;`>U2VK5"":S8S3?, M"/V6R+)53KTYG.\93`0$M@=90'4G'P97XW\GJ-+B;BX&5UE[SBNZ[(FY(!?% M`'#AF&$^^C%LW1SMK1X*R57QY,>DGD7;,")Q&JC+N5SY2''Q\Q]VJV=1[_>Z M57&W`2X#T%^B:@0(\BD!]D/T+F9N]`0B&)E?!9D/^;0!X/_VU_]ZDG_[Z__Q M\%.XB_3'7:P_J2`%_34R`23Z%VOB\).`_8`?V;B"FXV_T3OQ=>XB$3$".##Q M[CX.YH&/6(3K28(5BE@@:#U)^`]6O(V"-3R&-C3W"24`VBP!\9;7Q_(S(.8$P-L<9',&7W>!>$G6!-@Y8Y% MV6%8Y:>G^.@LZV2"46&7Y*>MQCS:/\1(&BR#1>ANRKI;L"M/A_K.\2P@(4.L MV:`0$?WH93`".P&VS''3>`&D0"/Z"$EB,0G1& M\2R+\\!?;$*0=V8Q[6N`!DZ06FDAZ9Y:R(<$&Q^R]31"'2&&>9M(B`\C@*H> M5,"17^``"H3Q;VT2(CZLPGLZO]&VJA<0VS#\VU__,S8H9A#KM[1V>Z!IN*(] MC"W2BU%U#!J&KE)!PF@.P@X`"NF`IA.X+_[V.=T0Z/\D@=KZBOX*_:94@%;0 M@9=6\40.X'"ME%/4Q@))_!ZI`\P$HW@6L"\TP%,`^SEP0DG]\,+)@\*^E1@/E#:URK7JBV MF*/Q2/4,"6)`#?X8PEP%R@2(A88(@/`L+A44#`6!'^%\:IQ8\'X:TNT1EBB+ M]J,A`KFYI,>M"FIS"CFB-ZU^M?\Y]L#Q,S/39`GD/']C[0815U@Z(BLJ^;0[ MY-D]M#F`4NA*&\Q1/D8C.\7[#P84\6;P7`*&QPP"1B`Q@#BN&*"*$#MD-31 M69O2%IX9)0X^J$-`C77PB?9M>"B+K':$&<%ZNZ(UT$B>37XL9HN[$0!MVJV2 MX!F#$3/+ATV?[9";I'R=PK8"5I[@60+PB.#]"Z;J2EV&=C@EUD`<&@1#W,NE MOWI@0'T]!%(+A/E)$3*1YX4>#9$!)Y,3+T<#@+@1#-0X"4-'T,-DMU9<\&D#+GL,K_ M':G\0!0OAD8.]1\>@-\C'[$1'KNNB4_'RV#+\AEP9Z(59B"V(D0_`E/G(T,# MG\Y@K[7P00*SZ0"B\1F3K)PM0HV'\$8#&"P,I"L,!-M%\4[!$*!`,7E"&UO2 MHP4X#QV19L#1RP&2E'`6A/1+&8,B=+'`HI,@T6Y-Q$]>,.XD<3."WE*NZ/29 MF5:M2;-$'BO?X@I>%<7X6I")-7U`7U[%S(0)1$5)3RR$T2\I7;=)$ZY,NVYU M'V64B(RXA=^PH48*`4=TL9*5&)CV+*5T`!H_4=MLINZ980'C=ILYH#)*2UO8 M!$4Y`7UA>RVJAQ*FOZHDP5J:SJ"J!J@4(Q>+3,BW11Y3K[.>:>HDT1.LBN^D MZFU+5`@(V))24>B0>`.K0E:"`DSJS68Z6R#7I28=P9HG@6MNC<*AEI.L+)<9 M,$MA<7XIQEB+4DOED7'!Z)Q7XS@&^L%T3`;UF\EHB@8-HUT/)^-;O,(@!L/A M]1U%#8J;ZXOQL,!X\;I1#BG][T#+>.7([WR@G[B[-S8P$6)W3!]&L"MK$G21 MJZL#C@H3C^[JTZ!E0P&-Y^= M\3&UB%FB5J)>1;0CB&>K,$8I)MIIBA3)Q6Z5'@#L-I4@&*0*VDC;%H>IL^`4 MVWTV'0T_`W([E%'BDYTVO3:3?1^ZQ*(U+<_@NEK>3OMK7@3J?0`V4+$V)!T; MY.(0).4D1_OC';4:19IZ>G0-;[TEPZJO04WAS+A;5)MQJ+L>0CNRR+4JM1:Z2 M2!*S26Q&(+87?$*F",MEFWBL]BXS45IO_-J#IE9HDQ-#)U*S$@JD2O=[DJ!Q M*`>U,DN1&,^\-M@HFX3-Z8^%7.$$(_E`!CX2IBSGZREV59H/.6V0_J`'$70> M(HAIVS-Z#4H[)`"!F!EKLXHO'OR`S.$9BPI)J\':X([>&G78&,4LQ+)VF4;= M/)LA>.<(FS!L0+\^(%(Y)_GH47*L&P]'BBT%0\T29:TGU5P%865&5=-ZV`%P M\&PKT9B(IUE,R;XC4)">8Y1&CJX:0[BEI9)1YT>8F.&E9&.(X]U:12>09.BS MRRI9:B%,DA-;HU6Q;YAL/HQS<[(3:?P[&DT8R2P&2`X_8HVIO]AY[4]B463; MS&,VD3+//"L"@8YI]+*7*KL>,OX;R%$1!/Y=A`@ZC&&# MQ4[1T0%J%,H`@U16NH&-G>'^XQ4>$#S59/A"#^#YT-[[]V;OIQ:VY1G#3^>] M*-^_%Q[G3$B5QB3(><5.)*JPVHFSLN!6VD<&V*>WZ&21' M0)D9X2Y1466RH]])H(P0C/#04ZO#AP'*1Y^XPURBBP"65K:/!,F!KAX=7+9+F;CG]FR7HG"]7#*:MU97"Q8GTTB`)V>NQ3-L5I+!G9 MQ/#L-3#]9X'NU@CF@9*G@#3-T7PS5SQS+1->`!-UF,2*B'+J0#!S-$J8S[PJ MM9T"'RA2.N@\`$O&\R!P_H9CJ9CVU)*$YQ5>2897S]!I6-R*5IQJZCF_1-9( MC7-@`[XY3WJ./'G[D15CA,J?Q+GCXN)4IDMCJY2=*7>34YWCDD-[KT+[*!,$ M4=9UL/(C7*!U"]7P(L0X M.5FTDMB,5[5U6CV(>DZG9IX."3W0Z1FR*;CH,-G]T$83!;18$UY"60@"9670 M!_0A7!%3)V?-+I@;,V]*4/'0/^K1M*$4#;@TFG:Z&*%LIM3Q\B[J/&1W\%D? M1R+Q]W)#4]J^P>#F)RSQ0N\EFK;R@S6Q];QOTES:()F.I864I]@V"G@SKD0#4`6' MO%BA*Y8W`TLH(\V9]_E+BGY-="CJ&=J581Y9U?)TEP:Q\G.'78OR0*D346]W MZ=^^X`L:2KP]P5NXT)7^MKK"O?Y(3SIM^-OK]O(SO26]<\UWIG**YE1KHH4J M*,\X_62O[YC//%&,FM5G[42TVKB05J./DVW@E+OM'FKP6EU6RO.)..UUQ1G] M;?#?1J.I/C1K\`'XZPI=+`_*&!T;@U;D/$DM2FM_+CD>*\!X*:7%*6+.WBUR MWAKN8&ZV&UU=#^+4DL.J8/H>,K$/QM[_^ MASAJ))N&/0;R*2QLMVB.BP*#KLDA5RKTP_`G0H4%2)`S"7BP)RJU*KO<'3TIMYF MUI7Z3ESO1&J?TNZ(`C>KN,[XW;-04ZYY]3M0VF@N_K3#B!7R@^/IY`DY>X"` M^8E18BJR0^IH,:FCQ6;Y:#'MQ[D/`4IS.,8QW9I>J2VR8[E(ADI#0TC-3T,T M/!WFHISJ)5-#$TTFIH3]48I[S):!?+`LAG,0\XCSHPH<(6`*XF.@Q^B3G.W( M?'.-SCITICTM0V5:^>-NDUJ`!4P%WVX9Q5+%5F\`M"#>A0)"&CJ7NR@(^G_F MHB(@*[\G9K&*;+C(KZ0GECL8#-&57'C*+&$S2,M=B!@VDY2CBCFX99]-[10K M[>_&H"X?7F<.J[Z$AQY>9.H<6(H;6AJWJBF'9V9.#,$3*\#AE6=B4RDRU5-1 MXF'$TV+7G+DZ$&>01$M(BB\B94I#)HB?*GF6G[$$JBPUQJRN8DA9+$*!"=@[ MX0O&B9$UCQ%5;Y^VZX!PK-3H8JG$1'-IPAD@"I!;/EGR:TJ$"`1%QD:\AR/; M[+60B*8$0*N50$7T1_TWA4+&"*&O1[.-*3WF2D%!.:/KU9H=^-OP>O6ZZ/?Q M3\I\U.!YCW::?;86;>;O&'1JWCB#TUK]6HX[.V MUZBU1=]K]MHT5K.&\D.KXS4;-7$HU0(*(-!8C84IA/JB7:NIF?,8>Q(GT6J; MO1[V[5.7"OW4JG6%?34%?FQZM3ZV:]=%ITLSK3?IYWZS^^+-;OWLF]WQ.KT6 MK;?NU7L:8%VOUVGMW>D:`;J"$ER;-[G9UC)<#7<[O\]-K][B%_6\&C2EK6=$ M`\&YT6PI+MQBZ$#J<=F&GX3##F:K7 M>8/[C9Z2VFL%&_WK/M![=_SG/\[UAM=O,/[";CSVEC<$!!Y>@#*1<-^TF_"D]365;)_ MKTI\Y:C4H\'D"E39J4XCMSDB#V.P(M-:M2#=+D"96;,^H@D[-:1\.3EMY[%EKVH8) M"M"H<@5V!"&[*LD%(X('$(!-2!(&\"AE8D/P)W,+W5W+S9;N..E@A+FZ)P,K M3'3\<0J8_=/G>=-P!N!&`[,!*%P`%D!NN]J1KI0N'M0.7OYC;@T8:ZWOD*>I M+3D%!T;]JDFKE]@.-[..=`&@V,Y45!-9;\N-DG\_4Q^CL@.?`JA@]KM&NP=_ MV\1X*1M>K<'?>QW>(/(YF5NO<=F]]&:M1^2Z8K;UV!FT@8:7S8`LR00Q,E/3 M`3/&Z3B#3QF#+"&T0D9E7E;.=XU/9F?G>2Q,=V]/^,\ANGXO9S[@!N.%@1Y\ M"R(V-Q''>])A:C[@9$7C8S6/&WM8V9$,)RO-['OV4D/Q-),.H]ELH[K8;@&C MT9_LY&<C`=XVOBRZ$5W2[)`M=D2\HJRS;7[E<'8D>-K6O-6I'SA@=#H4/<#GO_WU MO]YC-!/?J;FDU#96L,IY&JZ)-TQ/H;GJR5'U=V3&5#]Y'!C%%VH"\LH%&^9# MJ5>7$3^-?D26KEQ\9(E1%ABDS'3;&,-6U6UGX:>94@`#J[+*MF&8E/P4)/P" MG!FK[XTK3&)`FJ41S$L]_ M*=#*;.M!B+7T(/\X*/5`E>I;D.+OA/(&2>,BGX;C9#PP)8Z]X#@.F28(X38@ M\UN`I`"/*`KOU95\98UV!'@5V<\)(CF[]F0T'(T_#C@']]7H]A5=#E'A]T2% MCQFH2#HPLH%-."*Y\"-S!RI#/`[H0:^F'MD^KC,YXVR-T+-IOY<4[F:75-J^ MUVVVQ+E.,Z]36R$3;8EZO28&KT^)?\KY\,_P`R:_/SM:L4=I#1W>7@,8N+L` M$\&FW+.4)1^CNI;!=BO-;?)LYDD3IP0RN.J7.@9QA#10ARZ;G[OZ/ M%.@:6DND?`2[>Q7]8X(WU06!7%02!\<07U,3]\1NBW(:12MP^*B)V0$63'*P M)_BR1O6G;(2&EPZGG%/F*@()AFR0]J<%6(S38BZ--JQ=9%F*=$BPBDS!K.O/ MRJ/#]X_3-_I1$)MA+1#-T@12+CR49+WVG^E>V4Q%J=.S3*CJ4P#2!DX<%[-Z MUI)(Z0Y6BQ`\L._59@#WR*XB'1'`$\4@.;SFL7((&::#N;J]GHQ+J%;^^2$2 M]8%(E-,K7^)!Q9"C-0+#'\OP(M1(<:WBPX\Z73[&*[*]S`7(9Z$7K\A.LHO5.^08=7K]7MB<*0%*!N? M'&S0RR?G9MF\3S8`HRCTZ]BF@CV%%2'S2[5.V>K99]8"J8([X_=8E727" M8A!6@8B7M3ZTWU_3?A\8XP/`D]#>7RR0X="A/6DTO$Z]ERZNZ35Z_!6#GTR4 M74%4U5%Q?Z^RU)$%D&G:";"79JW)\,XXD[-1#)XB1+8B[3N9RU2H1)#>@-;W M,A`U"!Y-K\G;BUT6&F1![+[S.^P MGUAIURUQ;UZM%DE.?72KM$`0T\MI M=^KL:6MT-`SRR@,_?;`MM1\<+`B/SQ&'#UYS4O)G.^)0^!VUS,)6-Y)L9 M?)^,[5.I#+*+)0HP&*'/)TQN,+K\$?_XE-GZD:\XQ'E'R,"&E';LL)S`)_RD MWFE95+')-.&E%K="9PB7&.'/_:JXA-N-%AE20RL$_8ZP-1=+6`3',,1.A@%]`S>+&=)IR9=L]X9=%U MUZEW':L?Z(*3N]&Y&/VO&TQ,:^N$^VHV'=7K5=OW!ZVB'O."XPH__:Q;;I6O M2BWZY#U6DF&_WG7745&KP!"")E),$!NOG74U@.%UX6FGWJ`-KK<[O-$-=Z// M1^]'DPF`=#("T?K.\1#FG[]J\[ZI"&><6R,Z&')K,]S\A8;XD%#Q2[;8.Q7# M_*0H32CN>]UKM=&C7N\"%6VQ0-)N-CC.I`9<4Z=A!PB883&`@1:DKR&E7L-^ M2V"T2+/6%A@[9KH$FXIN3&''D9(6F^C0;PO"7UTO1K>S* M<1BG)(W4J7N];7_+?"TY40<2TJF)/KR]F?UR87+Z M.;>%G/>>4!A*B_ZV^?I!YKM+)MXY*C[^=DC-NR"R3BVO-YE! M$?N&+N7<$GW33,PJZ0*Z?%03Y"ZMC3+R^$KET?BJE M`$MEFB8G>4%_&M[.Q8PT4=FT3!K<3.8ZK$*'JP_UW5Q:5U>]GJX3,:S@;7H- MV`23&:E4F%0C`M:]#2E%[TDCG7MZ*E)^&/9,\;;X2:XBW0/0E1A@;"UH^ M;X5';K?T(I5Y);[I'@WQ3W)N6<9*$E57KZ#?(_7BLTE,[SDCRXYNO`OZ M_<\Q^CZA5#!A!IO['AGP[J7).8R8BJXU8.S^*E%R=!!G\8O2=3V;(X[!5&[R0L8+S"_PGX?TJ M6*A+&3G8\DUU*[F8C>[DH49&D%U]K"=EH%X@)Z@+<$YZIKOI^&HTG6+(T;OQ M56%&[*(VA^C5)=&KPIXOH%^_ID1T3`_8WD9'[%1YL,UQNM%>[']$SCJ5I,E] M@#F;_NGI['!]V74S;<,3OR/;_PEHN@T%*>W(Q*02=$#86JDY!H@LL>56)#]$ MC#!)3Q^=K93P9K-&W,M5(!]U4B%VV%B.8'/K"N]T/L,2%P&1.0XGL/;X/]UT MQLZM+'4GC)@-"TU,`!`C,7VGEM[2*V'.A::0+BKM-GCBTTS+F7F8+)_&?:4, ME]G,FNR`_9=,@?1RDY6K[&9"%TLMSFD>1AM$#KDTP9864>F&(;F1W,T'<[- ME5/1JP&]?*>O50("WP<;?;V)0!$J$8)/ELYDE$;YY2W9Z`I*;;5\G2YGNDWS MH#IY>.+=.A?\F+'1V6$$`+T,^ISF@88@SU.^K:$,Z<0SH9:V)SWUQ_J/?D#I M$YAA*(F"/8RXC@>ZX'B?*%5GS67G"GSRE)`!-4\R'21+#,+S5)@2W\ACT!=` MQ5.7XJS(*T#D58"I+$`,SB79R8<*<&X52M3!`51I3P4)*W7**_>I:#JY/=MC M;-]WX[S;;*;.^EPJB:):\&B":?:R9L9V#?A"47$+M-JT^^GX.HN$.[@-@],6 M:-.H7*)R)Y1R!T+A:=WKUM#8GKK(S#CI43#.$;Z-P#8&X#SG:>ZE0['\.;[* MABK44&I&QK=.0T7?IJ3;C>JF)!]/E8;FI&-X(RU$ASS'.LM!IFP"4 M5Y@*EQ]4LH3_Z:^WO\U?'>61_@ETG:>?7Y2;JX3=_!PD'E(B?M[73$6>5WLH M''*OV(:3FHN6LTG+3N;M+PNIUFZIFHJTKH M.<<)KM]VBYJLC]#C4W8 M5)+)W:'%%%2L'_(L.).6.R,>@00Y3Y,YZ3STJG8A$^WLCWF'RQ'1\0>"XH^W MGTY,@HMZQZOQW;*V5^O6^+93B\+W@*6VFG7A5#ZE8`NZ3U?OU.A25;O>I:^U M#E*\\GLE'&)^(FI5NOYV2G_/LC_@"(=O21P%*2>^^46Z`HDE4G4B%^Q!D/+YEH2`, M5'P1)IPG*G$55$X:Z$=KZ@ZRS@)OX*.'FLD&T=Z]\/4!+3D&R02J/)+19TM& M/25)E)G73-F->S4(5=7@'*K9*%*4X4A!4+N26XC6FRP=1:>"HGDA9]UR#@8T MCK^A28Q.J^`2&5,*%2"*ZI3BI;++#7>4;_O^:9G;2\MK)X&FLGJ[K:H)WD MQ3A@E@UK-H=LQ!Y:(Q5&IO=L'OQUL*+L6]U*0"T69.-%+=U@\2*HR57_A-M M*.7%DK,?:6XI*K.(^,Z/8`PF+C\DA'%ERHP5< MED@:"N)HH,%D<-)<5Z1)VK:?%YH#G#B-1*V#DLN>--*MMFZ'_ MA$9.I7=G)C[.5M_Q;!&3\P&E)FDL*92IZ9.E1"9Z&+RIB'8TDN M\;R6(#MA%+5SL&S]"(4T,H5A,AA;3<(:=]-OF$KDESG78;KX8@KN-#JC/;:F M!0&63H"6*+W(/+/+1.JT7A6IT\X+CG<&KIF4D,;$[3G'W*>XAMADCU&V?9@U M/5;BGCK?%.R$\T"(YX,JVO1O1U\#[,(F4T5#?49MCT7B1PNI-"X?TQT]8MC[ MD<$!Q('U"+B-F-]'9=%40[E5G2\OQ[=\DTWE%L,\8Z.KHGH2>QL?DORN2?+; M/\2TJ&Y:ZH:P/'Z-+,[BO5Q6]I#50^.YG1,L=RO`,N^&4;`(*'<5F9W91(.V MLCK;RFI:\U0C>I9)D4M4>FHV)A:`36,!W:0FG9@F@5C+2()^>,GU9*T1Z'2E M<7.&/N74X/$FQ2XWT#H+A51$*YY^1M-JZQ48FXJTJ&0>HWN>?:T")@S\-!(J M62QM&M,QC>$%*:>MMMK-R%=C.2$!VPDM`'5-7MG,6/J"!&*Z#GBGTAV([V1O M4%/@NP"+$(1=3[7FJ'1BUP+-+>O=VKXN[N#BH\[,A?D\00=5S!5_(0RC=,O/ M&0_#"PD/9R[5M9Q#+AB+RGW`]E=UY]VFKD1TZ?4/?*V>ZED\*@<%2SRJ;(]S M^/'FU-7MQ?=B/)UBQ)I=LF5R?06?A\47:8_N>(@HW(B*.'ZPM(260OSW@^D[ M[=H?3._H2:761\^>5M\)/FE<#IU]`"T MQ,0[O%TBYV0F?B2D,/Z?HC%T7EDF*V;$620Y5SJ1@$J_#U_:O,2=/I6[/3 M,RD23^MG@E3LX.%9DQ#]%D^<-MRG,:6=3_,:Q!I#)^.'0"7'3O>= M-&^SB^Q-E-ER/?`OT&"FRP6(D!LPL'U>B#L/,!1:]Y0XFP;T,8$UA%T)*5W6 M2S@1,HEQ`1E'J&Y%)),HU$(5J5;D'J,0+?N)/^=[_QZ?-F0/S^9'G(JJ^J-N M46;X4#QOY./8WQOS@?_V"C M$Q\:8RW)@1F?0SY`6"O'.*L'_U/=_J_9&9\*W>WUN] MO[=Z?[^F8+>W>G]O]?[>ZOV]U?M[J_=GU?MS])+]Y?]>V/RM6N`OIEJ@8SAV MBP<>T>176%^P;-4L]K^NW.`_8LRW$H9O)0S?2AC^W"4,\R>[K-C?D>W>*A_* MS$U/)9.^53Y\JWSX\U0^=#EWKMSAP08_?Z7$UYJ=;RDGD`."Z6PIYSN.+BTG M8_E>;P?M[:"]Y*`=56"S%$656I7J;N-<]3@E1.?1M#@+T5LQNK=B=&_%Z-Z* MT;T5HWLK1O=6C.Y?HAC=BTN=E8DB$ZG8L2 M1\FMI'.]%>/Z!:?V_$44XRJE7:K6SJ55J"DMCO5:#'RK%/56*>K77"GJ-066 M2@^@+2IG/1J'O!61$><%V/)6@T/\M!H<1VV++B1A^>N/VIVW0AJO+J11NB\6MS(XITV` MQ_.HM\H9;Y4SWBIG_`HJ9Q3FDB^C'2.3SS8UXQ@I%34+I3(/5,[<5RN8;XEZ M_ULDZG602:?0ME4%6`9G'[5"*`J#>][RF+[E,3V0Q_1Z\F%P-?[W-`#MYF)P MA9%IUS(Z%BF)<27:;FLKIS6=ZD#:*[38L=9H*) M^>)PH`M%YPH2I/'AVRWF>2.V2%Z'1\N!XIML"-F0[?/`7VQ`L0+PC]?^@B\U MJ^+9?^%+).63'"[Q!-IW,=,;A89"_D5+;.7C/"WA.#Y7.%.HN6R(MOCA`M,:C!.YCIV<"T[LFP/'?,B;`QL, MB_[ADG21DN'](L7W*R<^\'6A<@;&^R&;.7)J,_:U:1W11H]3F_?XF>[^&G/FE:/RT4?%N[]^;`\ZF0UO6*P)XOW!S#H?T6.!6X2#JSSZ0 MNP$_?X=PG/)D0,<'T"#H^&<';"^(G2GL>F0`S9X99()EK&0K>\-C"B*E]F*W M_8XX?4P=YUQUG\A13?SH/@ZQR"*A,;K4'0WLD#_Z M\*J&QEL\TUY@WWBCC0/YAPDH;&A@?_*CN2MFJ6:>>&>LWX?-@1 M$_22,:^+?;8"B[:]4GIKCQ5A'*"EVYY93\MC%Z3)O:MF[ MR@:_BR6>JE7P(%6BG2R8'.6XQJFJG4EJ2?F"7,AEK^L6]S9.X[)^[>)^62?P MBZG4L8[5@]1M;VO"V-=Z4%^\IB*G8UF;O,^Q^*SML0ZXGL67:Q&IN]#Q8.PG M1$W2#-,78>77XEW_;2?ZZ:['$E M[&^ZA,WC7:(TO?ND2VJ`:4VC'6=-,]9+,K`6>"IL*[FE^^Q'M1I]3HEE:#^HLHV]UB M5^1A@2>#%4>YI/;AA.DP2\O`>JQ!8'6E8A3*)'0N]YK:SD7EO-S(Q'%@EDLX M^[UT!29E._UC^5FVR]E2[KL45BY;V5M-L]0@=(0;U!%K"OV?I6\XRA%:1-)3 M=^B1``0<+CUQ>R%=C%N<29KR*18DVLVY*57(Y<$WV#6`M]H#:_M-RY%L4NR@ M..001&HY!UZ.-4[,K\66HKU.P>/&V5-GL)353!2^WE"IM5NK[$%JRA=S>+%>7!6J7D?]6@Q]?J*07'.%?%P`&74VP@&ZNQJJ;U'BI8=E+EOQ.C MQXS',*=V7G)!`-?@X`RPA\I?9"L2//@SRB+HN94(4`B'IPEF,7L(*>O<=N7/ M"H'ZFE&+R0.7)2CUSV;TEFWJ$#MPVJC"0?KC%W&7!E&UL4$L!`A0#%`````@`NV$.1TAU!>[%````*P(```L````````` M`````(`!(P(``%]R96QS+RYR96QS4$L!`A0#%`````@`NV$.1UWP<_ON`0`` M;"```!H``````````````(`!$0,``'AL+U]R96QS+W=O&PO=&AE M;64O=&AE;64Q+GAM;%!+`0(4`Q0````(`+MA#D>;6Z3S1@(``.`)```-```` M``````````"``7,0``!X;"]S='EL97,N>&UL4$L!`A0#%`````@`NV$.1RS# M=D65!```-Q$```\``````````````(`!Y!(``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`NV$.1QR8+MB(`@``B0D``!@``````````````(`! MTAX``'AL+W=OZ M8P=-&04``#$;```8``````````````"``9`A``!X;"]W;W)K&PO=V]R:W-H965T&UL4$L!`A0#%`````@` MNV$.1Q8R1M[&!```EAD``!@``````````````(`!`2L``'AL+W=O&PO=V]R M:W-H965T&UL4$L!`A0#%`````@`NV$.1PP>@P6B`0``L0,` M`!@``````````````(`!JS,``'AL+W=O&UL4$L!`A0#%`````@`NV$.1[)LB26A M`0``L0,``!D``````````````(`!6C<``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`NV$.1W-^>0VA`0``L0,``!D````` M`````````(`!Y3P``'AL+W=O&PO=V]R M:W-H965T&UL M4$L!`A0#%`````@`NV$.1T'8CN>>`0``L0,``!D``````````````(`!;T(` M`'AL+W=O&PO=V]R:W-H965TL8<(>H`$``+$#```9```````````` M``"``1Q&``!X;"]W;W)K&UL4$L!`A0#%`````@` MNV$.1VE%&=:C`0``L0,``!D``````````````(`!\T<``'AL+W=O&PO=V]R:W-H965TN[;4_H@$``+$#```9``````````````"``:5+``!X;"]W M;W)K&UL4$L!`A0#%`````@`NV$.1Q:@!MFC`0`` ML0,``!D``````````````(`!?DT``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`NV$.1P3`M[:F`0``L0,``!D````````` M`````(`!4E,``'AL+W=O&PO=V]R:W-H M965T?\A0&I`$``+$#```9 M``````````````"``117``!X;"]W;W)K&UL4$L! M`A0#%`````@`NV$.1R,$6V^F`0``L0,``!D``````````````(`![U@``'AL M+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`NV$. M1W\_Y4JD`0``L0,``!D``````````````(`!CUX``'AL+W=O&PO=V]R:W-H965TH&&8RI0$``+$#```9``````````````"``45B``!X;"]W;W)K M&UL4$L!`A0#%`````@`NV$.1VE84N6R`0``%@0` M`!D``````````````(`!(60``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`NV$.1UK-X1NC!0``LB(``!D````````````` M`(`!-FL``'AL+W=O&PO=V]R:W-H965T M5>J3&UL4$L!`A0# M%`````@`NV$.1Z#)```>&PO=V]R:W-H965T&UL4$L!`A0#%`````@`NV$.1[&W MC&7>`P``IQ,``!D``````````````(`!YGP``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`NV$.1W^E2FB7`P``9A$``!D` M`````````````(`!0X4``'AL+W=O!P``&0``````````````@`$1B0``>&PO M=V]R:W-H965T&UL4$L!`A0#%`````@`NV$.1PE#RPI5`P```Q$``!D``````````````(`! M8H\``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%``` M``@`NV$.1\Y;*?^W`0``@`0``!D``````````````(`!R)8``'AL+W=O&PO XML 14 R46.htm IDEA: XBRL DOCUMENT

ACCRUED EXPENSES AND OTHER LIABILITIES (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
ACCRUED EXPENSES AND OTHER LIABILITIES [Abstract]
Accrued compensation	$ 1,536	$ 2,917
Accrued expenses - other	1,313	1,098
Other liabilities	2,307	1,612
Accrued expenses and other liabilities	$ 5,156	$ 5,627

XML 15 R33.htm IDEA: XBRL DOCUMENT

ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)

6 Months Ended

Jun. 30, 2015

ACCRUED EXPENSES AND OTHER LIABILITIES [Abstract]

Schedule of Accrued Liabilities

Accrued expenses and other liabilities consist of the following at June 30, 2015 and December 31, 2014:

	(in thousands)
	June 30, 2015			December 31, 2014
	(unaudited)
Accrued compensation		$	1,536		$	2,917
Accrued expenses - other			1,313			1,098
Other liabilities			2,307			1,612
		$	5,156		$	5,627

BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES (Tables)

6 Months Ended

Jun. 30, 2015

BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES [Abstract]

Schedule of Variable Interest Entities

The financial information of Biox, which was included in the accompanying condensed consolidated financial statements, is presented as follows:

	(in thousands)
	As of June 30, 2015 (unaudited)			As of December 31, 2014
Cash and cash equivalents		$	157		$	159
Total assets		$	1,014		$	1,047
Total liabilities		$	1,065		$	878

		(in thousands)
	Three months ended June 30,							Six months ended June 30,
		2015			2014			2015			2014
		(unaudited)			(unaudited)			(unaudited)			(unaudited)
Total net revenue		$	454		$	429		$	825		$	758
Net (loss) income		$	(87	)	$	(82	)	$	(223	)	$	(230	)

- Definition

Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.

+ References + Details

XML 18 R50.htm IDEA: XBRL DOCUMENT

RELATED-PARTY TRANSACTIONS (Details)		3 Months Ended		6 Months Ended
RELATED-PARTY TRANSACTIONS (Details)	May. 29, 2015 USD ($)	Jun. 30, 2015 USD ($)	Jun. 30, 2014 USD ($)	Jun. 30, 2015 USD ($) Director	Jun. 30, 2014 USD ($)
Related Party Transaction [Line Items]
Related party transaction, amount of purchase price				$ 18,000,000	$ 0
MedTechnology Investments LLC [Member]
Related Party Transaction [Line Items]
Number of directors \| Director				6
VSK Medical Limited [Member]
Related Party Transaction [Line Items]
Contribution to related parties		$ 100,000		$ 100,000
Receivables due from related parties		0		0
Gain from joint venture		48,000		46,000
NetWolves, LLC [Member]
Related Party Transaction [Line Items]
Related party transaction, amount of purchase price	$ 14,200,000			14,200,000
NetWolves, LLC [Member] \| Director and Other Family [Member]
Related Party Transaction [Line Items]
Related party transaction, amount borrowed		2,200,000		$ 2,200,000
Number of directors \| Director				6
NetWolves, LLC [Member] \| MedTechnology Investments LLC [Member]
Related Party Transaction [Line Items]
Related party transaction, amount raised from sale of subordinated secured note	$ 3,800,000			$ 3,800,000
Related party transaction, amount borrowed		4,550,000		4,550,000
Director - David Lieberman [Member]
Related Party Transaction [Line Items]
Fees for legal services		60,000	$ 60,000	120,000	120,000
Outstanding legal fees amount		$ 20,000	$ 0	$ 20,000	$ 0
Director - David Lieberman [Member] \| NetWolves, LLC [Member]
Related Party Transaction [Line Items]
Related party transaction, ownership interest (in hundredths)		5.70%		5.70%
Related party transaction, additional ownership interest (in hundredths)		13.50%		13.50%
Director - Peter Castle [Member] \| NetWolves, LLC [Member]
Related Party Transaction [Line Items]
Related party transaction, ownership interest (in hundredths)		10.40%		10.40%

XML 19 R42.htm IDEA: XBRL DOCUMENT

ACCOUNTS AND OTHER RECEIVABLES, NET (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014	Jun. 30, 2014
ACCOUNTS AND OTHER RECEIVABLES, NET [Abstract]
Trade receivables	$ 10,374	$ 19,734
Due from employees	124	110
Allowance for doubtful accounts and commission adjustments	(4,178)	(4,571)
Accounts and other receivables, net	$ 6,320	$ 15,273	$ 7,526

XML 20 R37.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Variable Interest Entity [Line Items]
Cash and cash equivalents	$ 2,931	$ 9,986	$ 2,931	$ 9,986	$ 9,128	$ 7,961
Total net revenue	10,843	7,864	18,297	14,956
Net (loss) income	191	(176)	(62)	(1,220)	1,128
Biox [Member]
Variable Interest Entity [Line Items]
Cash and cash equivalents	157		157		159
Total assets	1,014		1,014		1,047
Total liabilities	1,065		1,065		$ 878
Total net revenue	454	429	825	758
Net (loss) income	$ (87)	$ (82)	$ (223)	$ (230)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

ZIP 21 0001201800-15-000022-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001201800-15-000022-xbrl.zip M4$L#!!0````(`(YA#D9=&!"NG>GMFYU.;8`3?Q@)#L)^^E7DFTPM@'SL)%! M75,UQ'J=<_33T3G'\M'[?[R9!GB!F"#;^E!23BLE`"W-UI$U_%!R25DE&D*E M?WS\W_]Y_Y=R^3.T(%8=J(.G"6C??KY^&""#5B6@]]"E/R&HG39.*Z<5T++' M$XR&(P"L" M,"00OT#]M%QF@[\]80-06BURQ7ZB#Z61XXROSLY>7U]/V9-3&P_/JI5*[0Q9 MQ*'=PY)?GQ+XO*0Z*WY2R;3Z6ZS^:XW7IHPTSWCIM"I!215IM\K9O[[<];41 M--5RE!XVO#YK&*;F_,PK#*HB8M>KRL4R9KT:TP;6"R3.?-\$:J=#^^7,*Z/- ME%JYHI1K2M"(3O-051!:P*K7(R,X>"$/S3-: M&E2T7#.YHN[@,VT!L1(FS:PK11M;*L<::?9KN7@23(3?F&"J#078[H^ M%K7S2Q,D8*E((\FM>!%KHLPW(4A+;D`+DJH[8[R@/BU):`#?M%%R`U:2,.DO M*K&G#=@?)M21IAJGFFWRZI7S6L6OG&9]TG4-P'NVH*X(7RH/<`#X`KMBT_:A M1)`Y-MBZX<]&&`X^E-BXY6"PTS>BE\"9UQ'7"W1B+0>^.0#I'TH:KZ=4%,>> MDL?K3FM#JGVO1\:E\L'-+]>S'8!(J2M#+K"S2"%IZJ,EYN5:9#:R'&@1/ M0T,'CWS9+1?G9>6R$$+T8.;X\KBD_TT[]TMV(8^Z4J4+I&#RJ)>5*EW76=0+KW[JXJB?^E2;UXLISOKZVKR>I3CKA1?GNNC,4)PUMAE\ M[SNT/Y,RU/[3I3RU;'-L6_1/C4!'M)[G(_I.P=52-DL?@VHQ?M^?)0XQ(^TLB;:M]'LM MN_VNGF+*'S%4B8LGQS/I"1SO8=HS-'/23+M7WJ(%6&,"I#G"F7-JR@ M-JPX$)'O\XYRVJ7OL<_3#1E.?G$^)IL[ZI.=/'C`^9N*D?ID4%WO0`R)TV94 M(DAN)BU#)80RHJG,5.P.>,F$KY'$1I,>1J:*)S?0@K05HC^+O78V$, M3+$RIT1?[4AD'C4R!7J%%+4S6[9%;`/I7,8=!YI>M*@[9JDGD37L>Z+P(R>S M&-.-2Y`%"0G*>:N.-;"QR;MZA-K(L@U[./%K%!NER6*:X7"!O%8!;J.05Y+H M2Q]9JKZKU1,@#=J8V;#3)<#BD6/VIX1]?K!/%KJT0V)VR$ZAWE<-2![@F"4/ MMAS>Y4&`/@WB5O&^RQ60T2(\"F-'R<[8D?"7\"]6?&0!_%LV'MLLT?S]@2!X M%6(6,BPMAK06@\3,OC$CT#:;J4-UJ-ML05RK;7?Z(U"9*4-J4F7*&%0^COEA MQ:"R"P`)H*Z/P#I(Z81+];AO]2B0YYKI6ZI#M2AEX.90K(-,XY;2.CAZJ`ND MZ3.-'12[0(;A$+D$Y!(H0I@D0Y?WL&S^ M@A@_`IU*$\V]E0"73NT.O\O,\FMR&;,6*68MP*3+H',!]V)1CC'D@U]Y#$?B M-W/\9IW21@8!9!!`ZF")88GA/>>5DXZZ=-0+CE7IJ!^FH9AP>D"C-&(NE@=$ MGF]8$@AM9*KX.>S&O$#+A??09_[[%_4/&[=7BBHN9U]'QJ4MSP4DO1&2X);@/HQW0`EO_"6XLT.40&OJ*-[E MQTYT27!+S7T89[6\_-HK(7VM:;9+?^0/-,."[7VL$:5GM<5-DKG&+%DJ)7%LM5 M)W>X8][AMC=!<[LA6B[5[)?J0>]4A[1410N%S`>QKRE3.C)@_FMM9<4"O&]=""1>9R1*O4M0>A:P5";_0L MA]2UHJ!6#%TKUN&,J`LJT2K1*JX7EB=:I650?,M`-/3F9QE(]!X$>@6R%/*, M@$E+H7B6@F`1+_[N\Y.*\#?5<*D@IS]_IE.L8FTTN8,OT.!PFY9U+#H7A!=4 MBPV\=)S/,+1$!(=U%&5K8"@2&(H$1H)4:A(8M4,$AF>L2XU13(V1^:>:4F,4 M4V.(#`QI?.[1^,SR;*9G8R`+.?".>G1ZQZ)]#]&3`:\)@0ZYF7C'H0L>_P+7V6+*+@X$C/O7\@:;$,#LO06!\=7O``XKX]<%Y5#",-C@@HH5C( M:HD<%FS\W4;"Y@!A(]1>%!P6O4,DR+UR7"")\W_LFD2:)X*9)]E[-5)A%$QA M9`X)F2E-I(3Y>C/DI]`F:S5'G;]-'B*XYSB6*MM-=TJ39ETDC M-*)J-64/.-C6.JAE%O3HN@1S!0PZEA]B%^0!EEX`JN('2\\$B`M M9GU?4!+H?&3T++K42`712&(?"I71BQ2`WL*$" M:1<6DZ;6$X22&(`22Q[:8/-308'1`@.B+:QK6UV2WTDACX2S=A> M>V.3QK9`QK9`6]L&.DE"210HB::5UK:29%1)M*B26!;3!I"2%I,8%I-H0&I4 MFQ0^3T['(@YV&9\<+E]@Z&.7CO4"B<,E=W?7*CILHKSZ,%G)<5YPF3_!URA7 MFU.)9'B^7V)`)`P(K3(87!Z18\#NH&/IZ`7IKNJENKA%&&J.C:D9&/PD_;'M MDH)?,Y/(K8^953SO1VUD^T&85!8B*8N\9IZ:"OZ&P8R&X/NX:^U/%Q'$\EMR M(-Q#YY^V0:51^)E?P*$__7$^][4YA$V$E)M#N,G.[ MCS!+)2@*2`2*'4==*PD244`BE!LEC:A]0B.?*$OTS-:B^?X,K5=H&-2'I!)Y MY1(YY&E?R.Z^7A<)?#I+0D9`R!33X)"0D>;'@O,-$C("0D:T MC`AM&ZU<[(UF=1F?A3".]5 M,\@=A,1V;6] M=+I]E;/VQ'__IF*D/AGP@:*/5[NS+=VV.G0,_*1:S]W!`+(\*K3XKG/3?9!X MV>[%3E3>LZ%3"7Y?ZBT,WI3J+=QD&_7F6L@#^]=*)7JKF`E50E7_1Y^PD8HA M";H*RL+=L[X6]5U=T#+Y<2[BF43?MN+NL[B'.DZ_PO MY?(U)45GY(!/ACHLE[T"':*K:0DK`+XV>8"#1`^Q]'&@&H3**]9R.E++Q9B/ M@XBF&N!WJ&+0MG3`M%EX7+^>5XW5:GL:;S4)Y;)2Y9IR63=3>FYMC1]A`3VN M.Q-I">IX55(3$C9*%W8S):3-MQ+P3V@8Y6?+?K5`G\Z:;4$==`AQ(0Y3Y%5F M=7]E58.:7L75E-W;'D5+NXE2]LTV7(ON5!,Z=P;$)$[/M(9785TZ(LVCXP?( M>8#457&0-01,8[D)=/@UIQ6]>JO)^9VIXU7=1,GBQ((6GG:%:!E:\FZ=MUO_NE?=MI7=^= M@,Y]*TS)?%^Q*8,LE:0!.I8.W\"O,$$\?A5>@U9834W8LEW838P0VS1MNJ(< M6WL^`7V^\X*NZS"G0:="3J"+M^`-O.JAV@E$7E)E#YA*Y<^X805TJ"$ZF^1# MB9*M-"[K2K5Z69NC>LD@<0T55IF?Z$.2I*-FFHY72:>EYO53I(N%A/@:4*F4?YL?DK6;[8N:9E.=1`"=$V"S\VF` M[JP0O3"/@YP`"SK!V('7$30)#K0]S.K?0R=08G'"&#ES"*J&$52F%N]YK3Q]Y0V+$&-C8]\,W.IA=GX8?HGY&_CN256K-94"0N7=9"(C&=SEN& M5U%QN*4^K->K2L8H7+*K9R[P##:@C7;\9CUK*:?5IT44^=:ZM@#F>0I7XZ)1 M/<\817-U>)\@U.D,*2T,=>10#][2N(_/8?>`R/.LRN%VIL MOSNJL_S.0GW-NF(=\7Y6AV]_,)QW.GH!Q)D8\$-I0.N7!_P+XBOP]T=D4A+O MX2MXL$W5^OL)X$].`($8#=X!7IN@_\`KH%3&SKO2#T/G75*/H3I@O2$8]675 M0$/K"AAPX(]QWWUL@U_`#ZHY?O?7RZJBO`/7K=;#U_8M:/^KU[[OM_O@^OX6 M=!]_;C^`N\[U3>>N\]AI]QEQ9Y2Z$*'!SR<,SH+?D2H[XH77?H5H.'*N*)"I ME6P$,F3]SY[%F`9T=QTBJ\S^N`*U\T#6`:+@VQA:!(:M#",$,HH"@H@#[`&@ M971(P[!?F5NA.N`7UX*@5CD!#!.\_2W%-C\K5%/XT_K5*I&DX,F#!I\OY;RR M4LBI>Z1M';[`-&@88U5G+W[8ZR+^-QFK6O#W;J;P%>G.B#6M_"U$`)[^TL$+ MG[;*=-P7B!VDJ48PK5YQHE@WU>@.G[+3P$N7DD+X%-;6ZI/-M8AGK+W5VX^5QB;@$<+LF8V#*8Y M)94IEI)F=5V`'8[<8UN!\++?T>)^4K7G(:8FEUZF4VEC.@\#_N^PEOB^N)S; M*%Q+=:GS#_6<=XF5[&>TOE<+75"^UUQ;OJUT-)6+X@$YGVTI;_,O%MHI>X&='+>FM,90QB#8#1G;+[[, M$.#O(C6E)M3BRW[Z)>;VC;E*\[)XF,M`X2>&'@1P3KK16'Y6ZG\C`62C%%;% MO_*T@9>MX/4(W9]15ZOD9M2EB^#M!U<2X0>*<.7D7*D>",+GMK:`K)'_,E0Y M#[]BVNV&5U^P&D2->N]N!E-QGJ<>H`0!W7:?#+B)T52:[._+2&Z<*(W< MPGN)X!3$6Y,+1RZ<]1;.>75OEN>.%TYH7S[CYXVF?X5Y\W\O/`V;]MC>\E.G M?FI6P'*STO:KST&&"#[_3,,##L-Y':2S= M`"(L?=:R<[^L`:\_J[[-P=]JM7X1)7[Q$'E1GNKX;+42.\&^!N71T/<"@D-K M:2MB:TKL>_KD[C,D--5!\$KS]@>0"YSU0"?(%/8`1B"C$>`IW8&T]S. MRSXB87V&NV0]+O_4;%?YMA=+J!+]@FP)D2+)9[?YR)?*)ZX+T\BH]]#MM1\> M?^<'J]N_?>WTOK3O'T^`JFFNZ7H:76??MFJ(GZ%(D$=0[S94C?XV(+],BFZ. M)LO8\Q_^G)(SIGO]I&>HED/+9E^F;O2="EU74:9W0HWXXDFE4FK-V!:S6_&$ M.O0/J+/S-AB.6#;*%PB01?^&2X3"(^&M<)L.;W)G$_:]5G?PJ+YMN$G%DDRL M,^:>.4PSN\W89T.;,4@M;,=3C6,5Z65D`4T=LW/@,::F-7NT8L=J>=4VR]E3 M52XCQF=R[QG2F4;(YTJS6E^/SA6?AJKL*PW5TM@'&YA[=L[`-9A"F373ID84 M4/4_7/^JR!B?04^?Z';A]Q.W@+?Z5#'V'>`Z0Q9.)&F`6UUAHCYFX1`)\'AF[_8:[FQT(Q\`+=TJ"RICGZZMI3J6JTA"-F1 M2_J6D]VH"$)UY-*`Y50KY_6-R+8%;L]&[@[8_9@]BGFR0\NDF>CKSUS)N.T%3K MX^*B4=`)W:_FRV]&I>;+9@Z7[OPQ:=;/*P45YAX57_1&)I$47RP:(B%Z1/O5 M.OE9!IMJG5AHK3`SNU=?-[^8D%B^[J/-WJBH//07D_6BX&.*Z'K\+H?YZ.(& MXZ9ZT5%I-I74X^XHG?*BR+(8^9(O*XUJ:HFD2'.^`;>;YC&G,UD[3TW[[B]J MR&UBM\P\KM24>GW7JRWEL8WTV,IK?L3+#*]48JGAE\@IB_3CN2%YI_G%A1"2 MB!=>4/N]TA!CFQ/E(J!F+7H;31;;7"87QRBU2G,9Z=Z?BP\&\^*MSM;6&XG[ M;.RPPS:$I#I+?=F,GH9*).1&)8@PUZ(7WB_8\9(^&EIH@#1V.Z!_>H.ANV>S MNX]9SO4E67QYK]U!N,]K2P_U..LPZ.\X4OG>@#*XN>YW^J#["?0>VOWV_>/U M8Z=[ST]3MAXZC^SN1);CM_OU_K%S_QGTNG>=EE`)?9]L(^G+7<[D8CA])9`] M;Q.'HM2)?]^?*S]AXMG)*328^`^1Q2X_#Z<>?AQ!?NZ*7ZWI7^FHLY,G.D\W M[&DOYJ\C2[4T1%4C"70R`2.5>O=/$%J`6CQCZC3J@/KIK#NL\^-=K\@9!<>Z M6.=CC&@G8V;##:%%=;YA3%@Y'#M>6Y;7^*O%L@CR2TTAE_:U2?G25/!CZ>MI M_Q1\OK[NE7[B8A^[F+AL"3LV;QH:BA7KLZS_OFQFUD7_C_4W6^`\Y4MJZG MBG9$ZCW9I,KC\23>G1G/'3O9.L_6K11-018W%*GEBSW:3_]T`R1%291$2GP! M*9PZFY$E$NAN_+K1`!K=.E!K)IR+]?Z\,+TQL`<<\RV/D+TX3V(N4>\3<"R5 MQ("LVG9^CWL M8_/2F^\L?B1KM_NJ,->[DI"K!_)VKG.D![Z3SE')/$0&;66]5MIT`)<@U,7/Z=Q:[BPTNL0TMM M?'TKT:X"GB008\%O3%69M;F]P88^Z2YH8)0-^6J/\#/=6I0J5+\*::U7(9@P M/U/_'X[U@FU__'B30ZF8YHPN__[]]0Z-N`Z>@3*B:I%*Q-=X"5+IQ&M0F%\# M:X,:?J+P25\2;1Q600`:-LHBN'2+JBS.S[H`0CK0?P@#U;>NAY`+<`.\M[&) M\&?N4O_'9BX+EBA#<4WU_\$`4:K1F8A8,H-YN&QM3_3`4[3*:+* M9^.(;@B(6I_'\.=;5>S59+$8/=8-1.Q*3S+#F2M#8@D%3:`6`6*1^!W=GK3( MP<:V-)!-*DK\6YH(7/I"[0"?6JN@8^C>C$PMY]4CDX!I&C80V=U0D>@$USL^ M.GE1BWQ*XQ`WV%)F8L(8N'R*\6>.EQ@SKF#[AC#613;:'M.O)YTMS6PR`[O@ MX.K6`O7&>\#`1%SJRG2-8`[R@97>2CC(HFM27/WA5_\*)GRO-ASAE>NZ0AJG M,:*"ONA6P&@U@<'=E+-%+?SWV4'1/>'>1[U*FWF?YL#F7F,L3[$]1YE2>)Z9 M?)1\!B4D[R*,?>9^GD-NDBK](5;IAX01V?2W3E]0`4R/)2=C%S'-$7G,:XV_ MAZD8M&2.$W-(@9<`7'*[*]I-#KR5`#:FDIQ6.4T#!?-.=K/\E?O]F)7,@0DXK>2/L+Y=TB-W M.?W_H5ZTE"&O,SQ5HWA>P_:5Z(LY83X_KOC`,7==/*%BCC_]!FL((&)"+7@2 MG)(9KOT,MHI@ZVZ@[L6$5_%[=CCDHN<#/RJA0X(_FKA/_8V_,*&`G3EX'U') M6Q@BW-G@R[PE/NM2W7/P@25;,T!C6YY)10N"7$CAQWMLC9A$3>P7[HLO:SJT M$ADU(I3A&29XQ:E<>V$,T(5'N8M-;MX>`\N*T$<>XW-*,]R(QX>K/+@W7XKA*@2[A,QZO1IL.P)S%.&:$\6V0Z!W>Q2^WY%>J6_[,X/O8 M1)^\Z*'LUVCDQ"=_6G&(KR(F7%S>`+?Q1NHJ00L_RJ93RNQ'`BI[EBI/NL7Z M\V:4PB*%/)B`:]U%!E>P\\@B+*,-X^$$;B@:T#V#QF<(T=$TRH-=`MBD.*8L M@>=PVVJ$W!!IF)W8GH M[2ORSG2^(4YULF/.`C'9+C"(`-@D M$X<==+C1Q$?T5RJQI7JAS_&$4SA3CC?8UUMV21C@X`"E'PT MX*^Z=]0Q9/HNO9G8RF;1!AR7.V-L]JE4OO``68M=UF+?.I0NNA9[DZI9E%DN M7(PJS]?,K8V#%:J9`Y($L#B.JFI-'U\EIHH"U$U"C(@5Z$4J7"=`C;H;/"V/ MC\W1)P5^T,78/U2R^+`P!46$J.+5;V#I80EC">--&(^;!^-V5M!.7LBL<"H2 ML8)QVW2X]++(!?F98I6CED`^/R#WQ/*JSGB9Q*>C"DIY2[^RC7ZETAGTA5)E MN4"20#Z"N=%PU#P8[[P[M^M,L]7G8&4=JZF]@QNT)YQZ[0I?;.?I5Z[#S),/ M#'8-0;%^57AYVN7!^>MI:G:%M!YII1[QWBT36I:XV2,[X?=YUR[REMUEMZ-L M=5'S:4K!YN9$;1@T5!NT7HG:\&!^D[I0ORZ4&2P1?38_E$`LP[0D! M2C7^72W.E"3MC+0SN]>$HP1.&FU>"O;U5F[=FW1IE+6G8) MO4W]Z&;F41L,T7',:>P>?[:YO]^F'V^JVE5W)/@19Z]?;/18T2-:%K8DIEN, M::W8N&:):8GINC$]THJ-J)*8EIBN&]/#?K'A555ANK)%1=6W4#[#[J"@HB+\`&`@-"RB%*5WA^[`@T"I';%3; M)7PTF7%WN^I7^'E5Y?B4RL.KHLAA+6UR;?P[,#V6\%`A7ZB+)Z/Z,TMB^;O# M,B5&R2'#9UTZN=PH_Q;7Q7X/OV+]&O)>?S$GY*-)X6N0_\[*V1$9"2I6--Q/ M.04Q`5'_.RIMIS3&2FW'U`*M84WQKSS1[!?=]9>/6#="9X5)O7?+Y"_L[8@G MQE+,45JM[F&R0C56I[_J](>)<3N*UZI&[`LF7"8WNN=;NPN=-VBX&#^4OU'ZE6%T/:P!1_Y57?LP#6==AO42=0!^LB["#[6+TG5Y8G;VW%[@A86", M8[+21-K=$&F*++,3VTR);M2[EQ(M`*-J:1C5WOQ\"7.9>GY2[<>:WS*4%D*Z2_MD&7":U6B8D!8.^`.:PS`>IKE M_KCF96[C]0S*,5ESX!H+IF(MFSA][NTJ<^X)[OZ*GB0YG)J(&)!>@I20$J0# M?DA0D;Y`*&99<`GKIV&W>VA54"`W\3B&)9U.1[@7X28J$E4RJ+<$"`,R3%]8 M[:&R!CD4;"BWY3#HC$:-D$.AD^^6'+IJKS=N@!P*=NJVY*"->UWU:#FDS9DX M9;*R+.1N59XEQR28>"O>5ST$CS<_I^U?Y]QF7^UVEQSQM*/>3O\J3DS"RMRP M&C.XW[@J].X%BX7%BM+H%EF`:\(%G:R#$^YV\YI)JVHV4:UU+(LS#:OAK,87 M-S)WK]RYZ"72VHX9LOU%KN+'*T\_"D MU>G`5OF[^@)<>#LA0U@1YX=-R0Q60>1C[N(WNNX MNTI]3>SL!U^+R'F@#64^]_/*YZX.E,ZH@2G=964"B>3-TFU*9UAL%+E$LD1R M#1UYK2QTNNJS4-R-4N$.G(9\"0&84J#:A<+!=W6*_)> MUW?5*URYU\KZ([$\H/+'7`*MGAN;(%)QD58XNZ>92@E?T>#;5QM86%4"K7E` MNU`[`[$<8"'NM;=HXYT'Q-,H$C],%K:@+O$P"%UNR,LE%F9->K-':`.F5G4*F/\J> M2*=YLBLW[4Q?';96=F6G<+J$^;PHX16S%1?(3%7CF/@1QLZQGR]]ZL[)>_KDUSBJB1^0ID<@"2DJ>X0OP62E M3Y;E\[9WP,E[TS,LQPM<2OZ)[@UA_DV6H5B]V=(44XE`]/O'6_*)\!712%/5 M'\F[WQ[N/M\^/)";^T_O[CY?/][=?]YT16LK%[$C.=:@?)D=ZOG>)I_T)='& M_!*]PK)H`:@6NKTD[/(VV!;3]ATP,$1_=BE+U(4INGBB+)B-%A;%_7T3K-$B M<(V9[F%=`?@9IFW7.U-F; MF0LD(RQ18-J);%YLPG7_)`_4?3$-^`(:7JV5R06L>ZPH=9<28T;K_!@W$7^G M_OB69=[_3ATI8!WP?^0"J4B\]27B\8L+O25?O2*8XBPA@P21KSHP:3!IF=X, MQ`6/>8$.HN2B95:%Q&U?QY)FW;_9_N'-VZL$D]?0>I@.;6,(I].(]YBR"1L: MMB`&P9'WFA4],#^5DT`A+GQV? M54[Y1">/U)AMDA(Q_D0MDZ+D<8X%!,+_/#,N=T*<15AJ0+>(MP2VGW'2?`(H M8766+62HPQ^![L5J>D6Z?]<]YU>J6_[,P.;O'A-/>S`:;(:8L[QUL/X&MP61 M_OOU5V:57=WP>7677VY_O5$PAQUW:'F2.V>Q<%P?Y[`E,DN_+=92V"7IHC`# MLA(>7J0`\`*V,4O2AL5J_J3^SMQUE=C$:`N"9ZC(9ZD>F538J`&O4>J_-26; MNLY\S9RA)-:2A#`<<`/#[%J8--#@H,&&86R@9X\G=F?I,W26I-"'?_A80IKS8"+IT!J^!HJW?D&+F!#OQ67HP?-J+C;1 M=6>3GKWZDQM9/>G)6PE/7N=.)0POCKC#,&NZ!"9"<&BQCZD.?[[H5H`/^^L* M<+$YV`B5MYM&,^9D$=OO%0O)?M>RO*!AL,SVE>V48";#W'J>^82TE6N=AD**]()V_X8*Q&B"(?=8NOD M"IPC(*].5QWN%SI7N/XQ*.ASY/#P&3VJ8LGGS3,/"#F:C$(TLMQC8%49=,7* M"I9)].V<9_FA2>4Z)^+46J_.E3L+]L4*F#KC2?"+BSM$_I+-?.C7+G#K2$YW MK9WN-*7;%ROAVAE/=[$+NM"7._S/Q!Z-G!!;.R%>])3N2!-*+9MVNTSTF18# M*P@+9)G0)SG#MG>&O5"5H0RD+D^7LU:221JP7QQG\FJ&49A\@EV=:WE%ZL(Q MU!5J``Z66#C*^A>HH_DHS#8CJV.EV^F6J6?'5VK8(\H*M*-7?YTE#.AX-NU+ M_`.:7,5)X-ET61/A47(HY[)4.MZ!(#)Q`K`_0ACQ,@]>!&X5P^EN5$=&S3=VH8 M%(C!B*L(EDN76BQ4A-6-'UNT$<:XB+`A9!2/F#/$1S[/_R/5D;MJFYV/4STO8?!4199R%3<88 M'R[%0"<,0^'AH)/`8,$JOD.L>)UD.SY=;8WD('A_>-E6P-J<[\$`;VY8!AH9 MLURRPC.; MQ(0*OLH7C'302Y,5GFN/Z)(5GG<^O^6=0U ME55HFS1:C:Y">W:C)76K2:/5:-UJ9Z$)6>%9S&U^P:-H9(5GB>26(%E6>)9( M;@62985GB>1V(%E6>!8IG%96>&Y]04E9X5D"359X+I[=,R]OT#KXR@K/$FBR MPG/%AK*=&^^RPK-<,A?(G'"E<>36C\1Q*PJ@R0K/C1)HJ[5#;.605E[BN*D% MT)J6@T/T0P-9X;EI%XL%WQ$1;NJ3>V\2QZU8X,@CD$8)M-7:(;9R2"LO<=S4 M!8X0YS=9*SSOKV!XH#IFHA`D^1KF!;G!?!@GE+1,M!DVR5H\NB1QKN*4G3<_ MJYV#Y4=WD!@+*SW_Z?L&0ATX`[>Q%`5QP'+1-JA93]_PT<;(25YV19JJZC&G_8 MF,>R#G']`9\C,D?A8*A"#H:::3!&:F_<`'7XS79VJ4)72.EWFZL*Q0JQN?@3 MSB1P+[ITD]"$Z;%J>W"RZ!ML#^IV2TZ6?55N29KXLHGAVK_171=S2[(.CK*D M8U4;9=#AG&8#P>#4KAX)WI?,MI'#)I MQ1^_ZRY;T=YAFA6P=[/J]=WRQM(]+ZY9?3]EORR9F4A]:0E3/5C(Y3MJ M4WC+A(_9EN']+"Z,$"+CME0$D0U/%EE44MJ?N4[P/%O5Z.9YO1RR>.D];1^AFPE]ZW0%SG&]G+@3K.HG*' MV+[_].GN\=/MY\<',MN=_FTYG/39]E MH,8>@1%0:6H;N%V;S5'XYID_V*;UTQO?#>@;\GV%!*7[7KL)6C7-\;'6>,+- M_2<>X1!VAK-MW'?3EW($=!`:/Z>=<>5,)[PZ$:ONKCT;/!*G.%=_)'N'>_/8 MK=)$X(>2+J_8>@!-P^K/849OGMY;?W8I3:N!*5HV\[B,RIW-\[X#RK3U`@4` MQW!AJ0-CP-2$G6_WI#KB%WR:OHS]IU"'-=\-FW=LI;$`Q+@?1#, M)WU)U#'+F-?AF?WC%A5"IU.>D1Q(L:)4Y4`-4,PSTV.')F@NIDIGR?T9$9BE M>$EU%Y5]/D>]LI^3+70PZ_P4F^5/1;/S1CY_D``82.;NA"G2=TMA,F&S)I"1 M3OY:LO5^Q$%<(`))CZB(^^SRITOPCLD&4S=F)GUAA1-"$CRF`L\.3$]*^#36Q3(Q.I;H!.M&S(,YL0/& M)XR9MZ4S[$P/B7\!O]0)O+!F!7[#$+9P0`67\`KS7I@IO2*_,4%$$O4B2,;* MMSZ"IA>]SLH06&P:A@%%[YCRR@D!"B8^/R93\)%X][@Y"`BPV?B"GXP-0-NF MBP4>7AWWSZT,^ML!`/EF@;49",;MP8,W'M3! MQHIQH]%2",OB\ZB#<2["/$X8B\CV>.V0">Z2A=^D>A%A>P_L"Y0Y MZ@]4;:B-NGNPE>BB(L*SF*3^J-?1CB(\407I+DSP]1%OZ;!`(O04'O5O"KGV M?==\"G@U&YC382PQ<&R;K55SO#5HY'X*31R*DCNT>Z'V-U5^5T\B,->+FC:=+E9OLQK"70V[L"S]JEJN"VL= MDYTTLO-*,H.E#+CC_@S/)=F:(,S9S641;Y;__/%3WJP6C6K9??X2ZX,<,S5K9ASN@+R0/B.`U_?-+_Y;@WL+8&>;@> M>_`7NJ(U;?=\F!2UAC/+H)^4\VXF&BGH#9M1JZ!'E0IZAS#WR?\T1*O"('K8 M;36B57$0/:A2T-?)QWGPR-?$X[%T;^`%TR=K!!&DJ*IQ84?)!\4O<1YVWJBR$$=5ZH]&08KZ[B7,D_GM&JB#NI@E'-0;^*BK^PN171@ M3Z(3>\*/[!7RA>^-_C/\=^]!5*+)'1$`O)'>%E/\#9(5B3>B(<+PE2Z3H^ M)WI,[*CSVK>\ANUS`+#",A(6/'@%?HZC5Z(C@>CM*\*B<$RL%[U+HW;X6O0QR/ M2/*VE+NZBTILEL+/4Y%XUOJJ"K>!PAN1SOD-<_K!K M"/>I5'R+]2P*'.>ND5J#I3[[^L8BY#R2Y4\C"%ZS<^8X=J":.2!)`/I@Y"*N M-E^N%L@RD44A9C/.XPP+1@X'8N>MWAF[76&>'YD`LND)(-6^6(449!Y3">.C M8-S`>GO5S$M5.]^/CA\OLF7*N5;I<+G,J4I1?J;,.2>!7"^0>V)Y56>\3.+3 MD;7:=I;+HU:I<>JTHV$-+:TZ_\ M'LN$AN^6U`GFH_)G'N&W=-G96-E==CO*5AM"F<$2T9=(!H@4U]*U;>&&KNDZP$>+G#$558209+$H6CD6I=KA.3@6 M&%XA@`*5L(\I`7,Z8`:I@&ET+(=8@&E/"%"J\>]J$8"DG9%V9L^:<)3`2:/- M2\&^WLJM>Y,NC;+V=`Z#K)+5$M\0JBCZL^PEKI1^8Z1?^S6!@U.KID8F\RP' M2`3UV!B1H>`#FZ,3WL%QM>516F*UM45'T+!=-J75B8J1!3-SCSBA<5!07Q%P`#@>/XBU'L MDNO'CXJ-Y!=^1`_L>4A%D8JR0U$TD17EK82RA')6*&M:5V0L2Z/?$+&>@:9T M.U)34A93Z]=5TLKK9,QMF4BPZ;'4>+\XSH2G-GV@[@LK#_[@6"E%;#S_?LH> MOK8GT:/XY(E%`+K]K2H`NWJJA/8\:>+[F'17&-KSU2?0NB--)-KS5!_H=3NC M8VE?%;CB=;B0"R]\80\#!4B\W]VLF+#6>JF4YM3)X4[Q5B#3/$@8@0K6)]-< MY6A[.TW%&J5Q/E97]RG6^HER6V_E?0^>/&`'>;E]P?_&&:<_WKV[_[HS`?5[ M^N3?V9[O!BB'=[IG>@\+E^J3^WCB^`I=IR6C'G8C?N'3'RL"6/]Q.NF-[\,T MTLFVV6,?'7OBV(S=)]W^\WXZ!;XG^#.C_V!>Z:@PD:8EZAID92X6-[Z0M9(I M/GMN)4L_KI4L?7_[[G'382[OD-T M\MD!5?L2E:O>J.?YB4X>J3&SP1U\7I([^P64,TR]^_'C#;F(Y*-U?@P?C;]1 M?WR+5;"]0+=9/4N>_M?TH])VX?-`@4>-``GR`@S6Q?J5\,?"=>;PI.,N,4TQ M7>L*25[K!W--?]=5P'`K&-R+?[*TT.M%N/_!BG"3J[CK5Y8QV)WSLI!A#6_V M)O;`JU)^IRKC/F\V+C(),GI&`S4%B^21P$M_GS4/;+R8$YZIVC._81M.X)() M/&CXCNM=K:!#$H588P("5+HJPO\&HQ M2F#A>(BB[[05%ZM,S$GR])@JQOCJSU@),/&SMW"`X239"5L,U*R55E4V2J;& M1&#?,-BN\PI]!W$QSQU8;$Y&[L>0">".ZNXJA[GN,TG8=@!28),;#,/X+PI6 M5PTP_;FSIK%C_`'3F6-VZX5N3N)JK@L*N,PA"+%@;N"ZKT^L" M0K%Y\%1M$_YB]AXD/Z%3TUZEWWY(MO&`RHBYT%?29\F]#SP4*C$@2E^ROY$^ MF,!9'O`P.?RN7.+.$PB7+=Z\32PP(*[2F2MKJOOLZCSO][H4O(BX6/KF[CSF M8?[RK87HUB)SQ_RW/I=BD4S&+3HXE[')X<9RKT\2OHCOI9527Z]8]2[P8/P\ M[QHMCL>4BWD5<8?079H+H6T4V1NL^^1;A.QC[@@FLGJ,^2F+G1YEE=(?71V% M\.J,9%5E8[]'&+V-+_-7$P56,I0Q3'72QKM?EC;2?ESJ=S7O(D[N:S8S_0YWGLV!YP M^]=&,)6.3%S>@QWAQ0O"SA-U9V[C-4WX6[F2B$F)*`D=_(>H)D&DFM'O[*V8 MR!J$=XH4#NVB]#K##34]GLZ[1,F(A,NY-:K[P'`DK[WB1SS!S8H9P50GJ\3% MT:.3I:J."\-K5'EN5<@>Z^56@-82Y!I6J4NRDD>J6G]6ZYBEM MS[35#`/7P"DMT\&`-BYN2MLWDMG,ASCC?:J).%JNS-U7R`U?T^Z2"'LJ?*98 M7R;9ZZW##Q?OA,@&2L`KI86L2/ABW2S=H_DO9>PWMR+*&WNU-U+%XOV(<3^2]^Y`/1[WM]]\GH$L0C], M!+ZK&QD^WGW^[K37F M)%DCP,8S#RLM8#_,N<03XZT'H1@SQ)FW+_1A$D'%C1P#'4"ROXBZ".SM#;:+ M;TO(XA7'%:^H/=O;">4QBK@\(U19C,J,8#D)R7.5+!!*,DF0?0BC27VLI[&6 MXU\DP)WYX&!LK:A#4WJ)G,8:B!,+G920-+Q"Z*Y%2I>*UR86L6G/V(J0PUN. MK=1;.;9MTUNYR&AT+O.UE:R8>;+E:,C1D*,A1T/\T3@N^69?$SN=__N-/7J\ M2/I$GTV;G68Z4[QB:3H'=CMD]?)*O]B<;(*DC)9(/B\DJT.E MTRFV3H5$LD1R'3994_K=8G.^2B1+)-=ADT=*1RVVSHK`R?OSKA^JSMR_"H6K M<(E04$;:0G.7'DW&Z?J6E8Z*M:+\49+0D-"0T)#0D-"0T#B3;5H:W;L(\^JR MH'EVU>',MVAK5)=RUSMCN?\D`5(:C;AB:XR*(76).'$1U^\- MFH>X=NX@QJZM:5]ZB2O5?GB36>XK"K$,+-[H"Z6``DX*H$G%@^ MK<1;V_%6T%TAN5M;G$L;^[.)K"QRG[:E2TJAM$]N8;0=;YH$G`1"S0/<"W?HTT4H8B2NLG]V98N)Y7>2!5*`>461MLQUU4&!67%$$ON$G,B M8ZXKF*,A,==VS/65[JB!=JZ=N[5?J>$\V]`HJP0=NK557F>2B\JCZ!!Q^2>A M(:$AH2&A(:$AH2'W$QMRG4DN?2I<^EQH(N_P%,[N@11V$L?-Q;$F\*Z1Q+'$ M<48<]WIBG>M+'$L<'X?CD<1QB[=I!;HG)M?7%48!78AU;Z=<9JNJ M)8NRDY"/T/J.+Q1U5-EV0[:BSV+M04B]D7J3JC>=3F4%RZ3>2+UIB=X,E,Y0 MSC=2;Z3>Y-.;OC(<5K9GT42]:?E94:(`.K4GM90^EUL[5>:W&%;1P+@58$N(MA?A844=-VQJ2")<(ET9<0EQ"O(5&O()%2F\' M[JO>G__H`%$^=>=D4M=._5&BJ=(D`$%DX@1/%A4BC/"[4P;B"$.SB_VZMCY& M2J=?V79;*C@%V8.3BB,5)Y_B]+6Q5!RI.%)QY(PC%4PL]__3[P+I]U??%#%`#UE:^JWIN>83E>X-)'H.R=Y1A__OS?_T7(7__G M\C*.E0J?O;SD/^UHBB7SA4:^TNE/;PRMH_94K:N^(8%M\N]^ZW2T-["N,\RY M;GD_O;GLOOE9T_I=#:"RD\#"J.EFH$8===1Q)=3T.]W#LE%[_6XEU/0R4*,. M.YU>1;(9=#N'J!D/U&JHZ66A9CA4V5:';$91#M61WM5=9/8FQEF*/&(:9--@'H'R'RWO%[E-TFQ MWRG04#NJ[\0@^3EM8LV\;[P-'/&V>^T.TEGTI'FCK\T=O:7O2([E*L"#1U+,MY];8J`@G" MWH8_L$Y@[,>@/T`,:EFA$_+3&P`P_NTM="/ZNQAN(D^HT_G+"@M9MJEW^$W' M.NG'-@=.%P@%VE-[.[V]O6V7A@W3A^Z,=6P8H//4#>\P,'@[@:?;$^_`%9B, M;FWF@*M"#RRJ$V\F/O*NCTY&WD``X.T"V0?'93;4G[F4DCFT.?,(*^(A$N#. M?'`\\YNP0U.,+4@]8FVX@=C#4Q9@:KE'[N#)?870_5M@4]+M*`3=TE+QFNUP MOF#[(L3CKMQW.F+E>9!(ED@^QB9K2K\K5O((B62)Y&-L\DCIJ)5%F`I] MPU"`RX37$UBIF8Z]'W)P2\6A.#$.2^HA#+P.*-OE`**+<=VHXW50). M`JY*P(GETTJ\M1UO!=T5DKNUQ;FTL3^[RB8B]VG;NJ042OOD%D;;\:9)P$G` M51IX)P$G`5?ML4#S`-?R/5K#F<]-SS,=.T[J)O=G6[J<5'HC52@%E%L8;<=< M5Y;5E9BK''-=P1P-B;FV8ZZO=$<-M'/MW*W]2@WGV89&)YB;.'1KJ[S.)!>5 M1]$AXO)/0D-"0T)#0D-"0T)#[BX2F!=(XECB>.,..[UQ#K7ESB6.#X.QR.)XQ9OTPIT3TRNKRN,`KH0Z]Y.N)8K$F)XEBB>)C4*R*M>:5,)8P/@K&8BUYZX-QRX\7:KY_)S<`*MV0 M%6MNDOM8$L9'P5BL]:Z$L83Q4=NQ$L82QBV`L5AYXEIUJ)!:H5:DDX8*;SL> M)8MRX@D/54L692B/U)E5O.IW*"I9)O9%Z MTQ*]&2B=H9QOI-Y(OM/RLZ)$`71J3VHI?2ZW=JK,;S.6 MR48DZ*H&W5`9JF*589:@:SWHI*63H).6KK8<-Z*>#MQ7O3__T0&B?.K.R:2NG?JC1%.E20""R,0)GBPJ1!CA=Z<,Q!&& M9A?[=6U]C)1.O[+MME1P"K(')Q5'*DX^Q>EK8ZDX4G&DXL@91RJ.5!PYXQQW M;VZ3?_>]`S+ M\0*7/@(?[RS'^//G__XO0O[Z/Y>7<615^*)"/CMV>-IT>RJKQQ>1LE@GX(4S;<1(F@R3\_ MT?D3=?_?`<;B?^)J'MN#H794WXF&Y8^-!A*P?EPNZ/4WT_LC(BND*B:*DW1` M5KU>?Y^HM@@63V*]3B^46*\2B6G:7K4]46*1H!)D%RHK-:^L0H*2]&0#UJ!$ M*=VL+CV&O]8+J!4]$3F99-2%[QJ,I=QB.A9+6K=$*=W9L77"5)V/8:K.6DWZ MG1V)RIY$!&62E%JF;:I`4KW*)%4FI$HU3T<(Z5CSI([*=`Y*A],1%NIH.(T: M:\>/,$]'^P1E*ETUWGENW3O-UU3WKKK$-E.Y876DF1ITALU?P^3VRT]<]95I MKRHP[+G%=;Q'52:VRK;LN:W5T1YZF7YGR:N]W%@ZTD[UA\-3Y[]'_1OY:.I/ MIF7Z)FX3?Z:^0F[V;ZK!2XEW;D[9LU33EZNI/51*?98]S&.I7[C0C([W#A0" M?UD4/S++=CW'^PC_8;]MT[]Z+WX+C$_RG4-@/,30>'.;\W"7]?"UX0PB+Z]CPV0A-[6?')TOJD^N)L_`!H?_$ M$P+"C@A2+$O<\/T4FEVUNMXHM/F_U(]:/"2)G]/.BS*'HVV>+E46\?;Y_O&6 M?"&7Y.OMS>WGQX__2^X>'GZ[?4^N;V[N?_O\>/?Y%_+EZ_UG^'QS^PF>>-AU MR`,?GUSR_8YSH!*8^%?@^>9T&7YI@@]E^S^0[B`2'W@OG_0E01U4B#^CY,/U MPSL"]CZ`X;Q^^(W] M_5$A.B9N`UC/J.V9+Y380+L;MN+R&8!!V/-!(75W0EYGIC&#%BV+>,$"FJ,3 M2J"!%],)/$)A7F(`3VOC.3`G.L#SBCP".W&+ADMU'\2FDRE0<.GY=$'FSH1: M(%PWM2%_IOOPQ;\#TX7WD`'=!I-)?`<(H*YA>A3$.WE&/0""*3,$GCF!00#2 M(KD0C)3TF*%QJ45?='AXRN2%7QFF:P1S)-*@'J=XDSS3-JQ@`OU>J&^)B>,' MXXD]X&A%O2CD0MO^U:,+W06N,1H3N)QC+\1Y`F0P*^)!VYNM=-^">4*2N1.+ MO\)/M@>_HDP6+OA+\%CO+=$M,!RZO_,IE%,F(E`.%_VWD>S_DQQ8)E:J`Q;2 MWR8SW2-/%![RX&]O:M+)QKB#G756HTB_P2#B\F82'Y-Z@#"7'>[N0-1&@R:T M,IU2X!2`C-B90E.Z%4:\(C7/ILV$IT]!D##9&,Q?(FI?06T:,H91>J\>>Y^" MWL#/TP#`[E+?=;Q%V#K\"!@PD:N-7W0TN&PN8UI'===:QE\B*7/31X,,TH%I MX6^Z'>CNDJB<`,[0#0/T$OD)SP>A"<"G%:P&U81'`,+0!/X5M\_^AO=BFTR>?W$$3#,8WCN>OVTEN]HP9.N$>:V&QT<($6S"C%@QL M`;5X&@O;6PF;7(/N@$'PEU$SB'7L('H->WC2+=:6-Z/@&^AH(2>@*S#LH"M2_6O.M(AB%O7O0&-YPY2@U MP7$`&GW44)@D-JWWT4K7Y9CO;RG=FL:L:P3:E,3O0&"$=BY9U@`S;>8W4%#; MGWF$;YK\+;`IZ7:4$#7`4&`Q90)9?S?H*!AP`Q_C05R-(%@:H&X9RAR:BD7^ M"7QV"H/&7D(NOE,5K=\A.ABC$_83=K-W7?3'N\`S M;>IYUP88?8^9<+:0C4D"@GA??SR:OD7OIW=@^U_,2:!;[,&(1G"Z&86ZQ"::)UN[,]WPV0#O;4&I$) M&N.7]LNSU]^,&CHLSZ^@^N8+1EMY9!)YJ9'=6O!W+G]_^#LJ%L:$P2(=)DM< M#NT6V0=H(X_0'HP9Z#%"ZQ:DY@-V_)DS6?&__2VEG_5YM.'B@EV$OO[F@%K_ M#H^#EY)%6NMRVDES+"FVBVH^!=S;=4X5TJ-S/9W"?`!MB"@=-4TU-RE>TTJ& M'`HSNK.D((YT6-Q&OY^T6:/U-FE+:[L$ZK)MA&U);B]UM]=?/\.2^(%'A+OMQ^)3?WGS[=?R8/OUY_O=VD]59W<>KVOE#W8:8G`A=;O9_P/G8<5?5' M6_156/IVW&9CZ/,%A[@<06A!Q@_ MKR_`AS;0@*-1BE[Q`0\SQX+5-9AUG*WAK:*<8JT\FE_D)=_9D2.V"^ M'_B;R0YA*13XS*-$CRSRX;@'>47>FQ:CY"#9+IU:%-?O[&W'1P\;#.0$WX^W M#<"5LF!99,#*BIA3D"-\8!NNN*9SF-NSVCA!_RUT!I/4OH)'%^\T3/!%>`4C MF;G+EQ1,O>LJ_CHV]0.Q<8UNY5MK[1,]ESD310R6)YW)PUX;?+(]^"FCOK`" M#Y9D13SL6(` MIE`CL'@K@'L=%R%L,?+#P6%9DVM:O'G.ES&&GBF702TK#(#'"9+][<%Z/_J[ M&'!$4?B=SE_B.P@&\*XO/&@Q^I2@+7E[>N.V]/AJN.>&P\&K(]`9\&?_]&:X M>4>@U[G2]MP3*&%BB.X1\%L8ZSID^M"]L:Y#!L457I@8E^',"3P`M7=,?MB2 MQ-K=NGHQONH,:Q7K+A$^SEQ*T]?N^^^>;#!X-3[(W[&24\64W,.N/8^R<9@Y M#TC6FV0;5Z>N1H.3,FI4FIDAZVBAIUP@N&5UFWE$!RX""K0$(RO]B8' M;^P(-$D)QJ=E]A%U"/8IP=H$$9$V8YX]T#4"`;\Y>MJH-*WG/GFLUO]\@;RU MK^1![:$)3!0Q\(O%FUK1XD]J?Z!H_5&!%NB$G&+Y9ER)F1)1T5>ZAPID MUX.*`TZ`!$6IID(]5&.M+E.QWR^1J*C3D(SV%<6M93MU.D"R=W4B18"_]TV1B`MF:?2>*SE?AL MSRZ.RT734=YNQ),U9FF8O=Y8&]\8XR_&6Z_&HVR]3RRN*] MG[!MW[R,`HJSAF4W-1Y7W6N*8.STFQ1%D0+0JCS1VBI`8--A5(V^,KE\Q&4E,^K$T9R:FBK4/27,KW@:EJ M:WP(3YN.1RO'9+\-[IUB@P6(0ZA(S1K/::R6VE:=FD8=K^Q2Z;4E@QST<^-T M-[S53KO`G>_^2HN'_'PX/1]PUVNYB]@>*;SG\QE\:=FVW'6Y.5([Y<QT90?9[\E>B1Z)'K$&(/F4B[1TP9GKMH8D71N'U@P`$_0 MZQ7EIPO`5_&;#8UE2D@$)J*2NMW"=@<:.T:2J:8P);HVJQG)TD4XUA2G1M.LO9J9C%HJB''S?)J/)G5[?]PM:1HK(L3[)/L$+B MGE\F[90F8XTDIV?":?/5=3B4ZBHY/1-.FZ^NFC(:=N7@2D[/@]/F*ZR<7\M< MR5>?8J@N/9:<-H/3)N6^V&&R>H-\J6O.9FPEI^WCM`7ZJBE];2Q'5W)Z'IRV M0&.[RBAGMNZS&5W):?LX;8'&RCDV92&_.P-<]'E5E'UG$?6X+#LO78P9H":8 MYZ@D.Z]8MEV.O;=6CGVMC'PW64:^\^;GSFY:6>NETJDV@LY>3&?O M`)W:FY\O.U<=M4Y:>QEIS2/3Z%<"/Q/VNQ)59C]$9I1U^F2A:KN)#?LHD]RB ML%H!J45!H!*I%F.IMDB-,T+2;\9,MY\I<76?DHD)/[C4-C#=N4T,W9NQG)+L M0R*_Y18_K+W[Z6W8VE=H[-Z^@;>N[0G^KQ%_8#?PN&.-%RU,2]_94:T`OH/SSPV;'=Z$^=HV3.6;([LO>!@\N2\Q[2DF)F9I>O4G M)_!9'KP;9[[0[25WB4>:.OS1(SH?PWEB#*T^.'36\Y^K@O)W*\T*@I%V\\HFNG=R]L0'YZPU\'_S+_ M!@[.6%]<$UP-D4#1%`$^P#?F%&BP_?:)3W)0OUUK3`#-20,F1F8SF".O#2P\ M4*TJ%Y)JKJ$BOP=?UI7B;OUT=!%+>4MYME7=T[-,0B174R/UQF1@!Q-W&YQ9Y^#0L+/CG69!?76=8C MY?I(@GHJDF_)MZ#*?7(&?V&$WK`SB9N-,%UBVB_4PT`;T\;BM72)L8%_4I], M012E654AHB`D!Y*#RK>RHVPM>TJA"WO)[<*T#2N8<&.Q,_+_@.7>+Y?"[_[M M`=[QE&2X>9EIABEM`%F+WYTR$"=>/-V^"UH]_UHA+L2QP,P/@%*@*I5&*DT> M_B^ETDBEJ59IKK2AU!NI-U)OSFZR:8N'5M'^NMSPE'Q7CJS]2C=$1:J3X\@8 M]K,2LMO69:5$XD!P+ELZW`T[:FC5]0=Y&[FIU[L*-BZ5SI<53XJ5FT)!QJ8N M>L4?@B8&#IWW/0UY4;QRD-N%+B^*-WINJA`I\J*XO"A>F_3D17%Y M45RH.?3\%B#RHKB\N"SE+>5=O+R3V8`;(G5Y63P;O`2ZT"DOB\O+XF8<)YLV>6F)%>+W/@O'C_Y* M\A9^_NOW@7?YK.N+'S[HION[;@64GUI?VY./IOYD6J9O4N\3U;W`I9-[^RLU M`M<%\N&!SX[M1G^^TSW3>\3N'H&3=Y9C_/GS?_\7(7_]G\M+;)JPMLE[TS,L M!]ORR#_Q2<(>_7^7E_SI+6H2+\0-$P,&&/[X2J<_O3&P#D!'[:B^PSX-NITW M/ZDR;,^T,33]!](=1.)\G%%RX\P7NKV$T9PO M+``9>37]&?'AEX7KO)B>Z=AX*8)D=^`2#?J3"%3[.*%=6%Z9$*GIDTG1/="`DV#PB?=)Z]. M8$W($R6@"M1\@6=\!X1I64`,/`ZZ1!P7=-YD/_BN;GM3Z$2W)A7M$K MA36<())^,WW>49).W/6`AIE9M9:\/=WP059`@_]*J1T=A"QT-#\FB!@%X[/F MYRMAD8GNTZN4X8P^/KGD^S3342+6D/1GT[YT^786HF4?@*:.93FO8'P(LW,> M2(MZR)II3QUWKC.IZ$].P)D/\1:KU_!'CP^0%\EE@G)*##R[E$.B,ED$[0N' M6"(>&K_M_;!+COOT)IY&G-YTW[&]OH1O1W\6(/)J>.IV_)#8* M3[VIF25F4^T+C+IC4QZ(]0<>GX+$)GT1B9AD?*6\BY>WM&Q3T,D+A/>9(.6>(E` M9,*;ZF4N$]Y4+_-F)+QIBPP-:# MB>G32;ESF&C+@-BJ*_[;4WI9* M(Y5&7FN52M-6I9'7P:7>2+TYQ\FF+1Y:1?OK2F7N\JV+A4.E]6/"E6;@H%&9NZZ!5_ M")H8.'3>]S3D1?'*12XOBLN+XFT7NKPHWNBYJ4*DR(OB\J)X;=*3%\7E17&A MYM#S6X#(B^+RXK*4MY1W\?).9@-NB-3E9?%L\!+H0J>\+"XOBY^1S)MQ6;P< M.5?8H0`\[SQM*A)N/*ROH_:$1U4)][::>S_^A$!;6S<#-"'22/)V0J')D*1UZT/NC1R[K;,D.!5!SA%$>F]9!* M(]/A2+V1>B.\WC1?:=KDI256B-_[+!P_^BO!6_1Q9X19.;TZ7/^)F M[;-I7[I\W=K#5MESIHU!S#^0[F`1KO<>9Y1,==-%@0<4H^2)#U_=./.%;B\Y M`R--'?[H;2T"#VP2$]VE9$)]ZLY-&Q[R9R#MYUGXC$)6%QKX$M-Q70?PK&.# MGA.X!O6NMC`3?O[K]X%W^:SKBQ\^`.V_(^GO3<^P'"]PJ?<(K+ZS'.//G__[ MOPCYZ_]<7GXP;=TV`!7D#@.%@&IR^VU!;8]>7O*'XO:B)Z,'P^>`/AM%^)5. M?WIC8'&$CMI1?8=]&G0[;TA@F_S7WSH=[0UP;IASW?)^>G/9??.SJ@Y!,1-D M[^BF3(I[G5Y(<2\#Q9H`]*HYZ.W63F\_EF\61(S&N0DV?7KYT7P!_8"'=/O9 M1-WA43`*N3:,8!Y83'VNYP[8QO_HONG8EP_.U']%7?SG)Q9E_/]2&(266<.K M=GFSB4:3;::P#@S_L:>A=\M/^K\<]\;2/>_ZF^G]@08F`$XCZC9>X*0>$.&@ MU]N484Y&3I?N%_@*;2&:L$=JS&R82YZ78LDZI/':GJPHS";@X:AV`=_`G.;, MJ4L^FA[(62C!1K0QTC))M-<])XGV5*VKEBS1[DBM7:+5&X'\DCW:"/1[6S-5 MY0*N8@X[`JP%S&&]<;\JZ7ZF?@ZQP=/I(CKD-XZT05:.H(\*J<_BE6G]069S MDI?ZT^WNSC$I>]92,YN`O$(Y1;-W#G+U6HR@:1)JJO!UNH.M-6110BENPBU& M.$=/KNIP>QTHJFK5-$$.MG9.FH&B"ETT==P[RO[<.*#+!8KA%]?QO#H%H?6R MJQ,C=D,4IZA,4G@042F=)3K`5O!ELY=+Y2@NWX M^4O_?[-(9D7D,=*)%$D8X80$Q4)0.Q5(X60=*@LI*1KU\Y?AL1+YY?[^_3_N M/G[`#.K&!=X%GVM3SPO;X:,7=A-\>-($=D%Y7[6?D`ESC?SC6"QZN M?_QXB9NT3'BX]:A[8Q>?;?3W4]ZH@\\N8?B5WGQ^O/_]R]^[C[<.N.+)@8DWHPA*W2=_"VQ*NAV%(&98;\GD7?AM3X$>O05ENHH[IWJLCZ4H+H2U3L"C.A1V88_V`7Q4-=_^"X%)XB1N"ZU#:6Q'=UV[-8 MX$Z%NMZN+$.%YZ`J7"VUH5`Z6==DF]5SJW`&WJ6HNW;2RE+2HT13Y16Z?2E> MRR/TN$NB>W/!5C\I\WV>NNZ[9??!ZYJJLUX?K7#^WG3,U_?Y+@);#R:F3R>U M)SZI($EA05=JRYUA&W$5O60G@VU[BW^M-J_WL7ZM-B&SO&4<*G,CUJ_3IFVA M.UA*DYBKAR&/J";;/^ATY`V'A&#[]Z&*MH1(?G%CL\QU,' M+XJY"!_9V%AOXP[ZGF(AQ26;WUN09,-J0((67:6M<95T`@GL?7=9+6;V$Y>/ M6JZ>'*&0&R858:%@E6J[0([;@QL.A#T'W]B%'T;FGUVXJ/!<3)Z!EU_2HUSF M-*4W$.NPK8(3&PGD5@)Y5%F.Q+J/A_9.34?%^]4S7R43UNB)G"Q5G1*=&@I9 M^ZEQ^76GBCHR+O!K"Q[U.2Q!>S=YDU:&`-VLA-Q7N2+8K M4O^LZP%+:$AHR`,=>:!3HXZ47-:G4YD3(XA'+A$G$2>"ARR/2.1FKWB+YI(W M>WM=>40BM49J33ZMZ8Y4J37RB$1N(+=I`[D[T,17:HEOB>\C\=U3VW(`V,[C MD2BQNCP8D;O?\F!$0D,>C,B#$4$<'!'<%U7I](NY+2V6W"7FQ,7 ML3P:D9N\XBV72][D'?0JFVZ:N,DKM49J3=J!XKB8/$8MU1IY-"*WCINX==R6 MR'J);XGO%'Q7E^ZB>42<\CGW()DSDI_4%N@3L&YG*7B2,6I4'%& MVJ`EBM.<).B'"K6&21`WI@:W;3#RJ<&SZ>. MA4PSUFF%/ECS?$^5EW[500JNCB`%4FP*[WBF1QP8:>S&=`D%CN:LN8`7+K=, M++"*!4VIC4)XP7^P[2G\0)94=[WU6J]7Y#JQBTOHMP72BF0$=EAB]3MUT$L4 MJNWRHJQ3AQ$!_W,IY2(ROY$YC,[,(]1&Z:QE7]XL,*OX,"%N5PR+7$T05J_:]J\YSXO'$TR=6L+[4AIVT^M7I MG:V81A7V5=LGT]+O]'((:MC5 MRB.E%Y.212S]WD@K42JY"J!KH_'@("UW-I@Q2BX^PD]O>5UG+*OL+\DGZL\< MK($.UB9$_^\/?X>O)S@#D8_F'-,A[ZQ&SQO&9C]`H[Q-WF2BQ4,L_O%@S.@D ML.C]-+V%[6\I_:S/*:ML?^.X"\<%T_DWQ[3]W^%QT/J#)>X[;W[NK@FWWV!^!9_1M'5W M2>Y\.HE$IS7/Q2`X#P*GF9FJZ4W MW]2@'84('_%/%KHYV4DE];[`SR<._V"'.'GCQ5&5IQ<1"^\ MQ0VR>[9A=L.*B_N$;[P<9H^]%;YT'=F8-_UQ]>ZI+&W[#9F[KIRUG%JFCC,-UW[> M0!/=@$ZB#5R^H''V[-D=K9V&)#W=$IA MB"?D9J:[SUGXBMX(7SAYVCID%#?ZJYZA?.C3.H>FX9P,<1NRTL5\5G[U7B%S MV*4ZZN>T'7DFLM*XS&G[M>$A33N*R=C'0I/".?Y*#6J^H"N3S:2P]Z_M"7L[ M\?*I:CCH=+>V\++W+A+C>0'=Z6F'$'T"Y[$Y^HHGHT$&MSIZ(WSAY&.[L7IH M,MSHL7J6VPCIN;GH>[/1DMS.U\83E+2K]2=A.I2&^E,\[D M:>ZFH%KVO-J^XV9B,/'PJ9NDVZ

^+=Y7LZ=%AW[W#-L,FDRWF0X)ZR*:>1$N+9+CGJ&I+AMU. MR@I`"O*@!DLP9I3AGI/IRF081@O@!L-[^N1'QZS;_/,'P<3B8]%A[/'350>W MB_IK7*7UD$XIWU8VV;FB0FR:XK7'C;$9(3P`/>WH>K2YTY/61]D$YSHYZVVZ M9=53G#<@>7.NKX/B/!$C6U&FV0A./X3G/Q9P`I]"T49`P+%TY$3@YBE%"BU? MJ4==O`R!%PKH-X-ZX=G1D^=8U,=+'-SO7FX3&O[PNVX%+`@I;FM+?*K65?>; MH]$6L;M:KY;T#)9T.-Y4FX.DQX\HY(-IF]X,)D*\FX#!:Y1-D=$K.TF/WF.O MP4OWTZ/%SV)9NINJ=+"?FKC)-%EL[4X>P0U9W7,A_\2;+H1==4D)*@]?2+D7 MFQ+_%6U=2Q+.?5M)]_ M$(#RW1<`N8]M4,L*;R^B/6)_>PO=B/XNAMSH"F6G\Y<5S+)<[M]UX9+3@\_\ M0&S'!>4]^L9OD5T8#@H/^A@<;/YU9OKT$D7-VL<;J.M]FK!(,(WUH38H3L-E M:&H('W9;%_#32<%/I9_(!;OGZ00>S,K>V]2'B[C M]&"83G#TE[(M.K_:?<#,G*2#67G/KIC:P3X/IWLYA(W2M'2#S;6[OZ5J0V8, MYE01B8AB[;8:F>WWU&"W`DE7Y5>X&PF/@BQH-F-97S+8\NUHF@1.R)V20W.'W0(;0*AR)$A+9U`"%"BAIUNB4D,DLH]!JJV2@13/05_V5 M8-H4U]2MT@H:'".-4G)"'8VCX`A#B$3P?@0/*ZOPV;BU7^9M-B$7A/'I_C,>GYQ4FHYIRWM>\JC@M M#[ZH[N]H7&]9;(&7BE)?I+YL3\+=VC)G5Z`O5=67$,8-%9NZ#/GDB_'4FK.- M5(!(ZDN[KPXJ6X-F!K8@"U.IB%(1JY*)JHS&;5;$]M3$N/;7JSB$-[HV`G@4 M%EM\PVM>P!+;M'WX'RRGW/KRO>F"X8#OW^LOYH1\-"E8+3").\LH?,3W66N' M2B4D$F@L6=$5W>#IJI?)7UAAA(@*1D1,0Y;*"(/UJZ$Q=54ROG%O\9P85ZMG MG"7>KIOSS4(K@G">2$.U,Z]2XIF=*:.RS-_CX88%W6ZX:+HR3>F\A-`1=*V2 M(^XA+9'P\1CJU&Y_-W6KMLLA,-.P=GL#]3@"F4_*B]'LH>_:GCSXX&?.'`O6 M9EY8V^<84GN=\7@GJ:G=E$UU%@3T!MW="#A$-2PS8!%@N'1B^F2J&_@:N,9S M_9LY#^:XWG79U45BZ'@)$$CD5>HN'X(GC_X[0%3)T$YJ>V#/KM5_6(&N.-9:29O/<[@-_6+L/?'US<__;Y\<'W-[]_OUNX^)*\(;B_?H8XTWA\.+.!H>>^]:\#\F+PD3?@]W@":M\Z,+\C$58GI-K_UA,PQ\]5@4S3C/+TVBX"33JK$YEAMV%M*O* M!_=*XJVD!M\DSG[!89CW/#\NF=DDF&J^:IK_6FE+Y"[`/".S*5+PN+MUK-C06D+8VGS=2818-;6C=(?%3(NEC&8YH1H2 MR2U$\E@9=AN(Y&IFI:J]O[CX=BX^KG$;7K<-RL[[,:C3GP;6VK[ZF2]':M3"K'2(Z!5):$AHU'PU M6``O>E67C^@3#(1F12S*LJA'2:&FBXN"N$/Y"*W+8;KH*>JPMML,Z<<@U4OA MP/:\U!NI-]MZTQ^J4F]V"Z"JR\`B+'7VQ@JQN@95&9A,(JGKDF.;][ESLE]; M`@*EJU6V19(*3D$6@E)QI.+DVEGL*]JPLER/)6O.SBN^>0-5R[S4NQ[WV]L7 M]KL9YX`5[ZP`0\GG?&*>!'P;TIN9BP6=X/7`26"$,W9T"PE:@*9=.KDBU^%[ MX9T*:\E:"/!G%C'\R^VO-^3ZV:6L=B3174J\X.E?6$C3=Q(+CAL<_U/E/"_`]-%B/`2H<`B=I[L47=-+VXV,;I\'#PV MYEM#"3W,=!_Z6$(7@#W*".*_K5U`?S4MBR#AR(RU#(=\-_BNR/:!*H)CX4(+ M+HS>NN!>4,H>T#%A96`YH8!+S[%M:F6XH7[4!8OXO@O]N)L\(W6]RF=:RP72E.5.5'9J;&S>=2P+069&52DQZGP&(`#T^#/O[2:= MGTS;<0'943G)^U<;!A7,W1?J8DRB_DS?+=?;YH]D$?`PR0SR\V'OW`_33S>YCL\U^22W'_]Y?KSW?]W_7AW_YG= MWOGR\?HSN?]`[K_RP]]@SMEZ@@_:[[H$EGZ`WI9`[V[@BKSJ; M'1QWX;AL8@`->D\M_16G:_C\MP",HSH>#:_(;[:%V3W0NH8PBB8"CR_H7TV/ MPDP`IMFE4P`Y,Z)@/Z,[0UKGQU<:_Z'^J"1_@9EFUT^!M^N7C4M)FS^[]-GT M?%>W_5U/)`22>`0FI>1#($V=%\!./L-X1/:VA8J3H0FS&L";G]!N;%9I7-`[0TB\#R^'6NB]O;FR\,V8B;`P#SP(Q9AQ`6 M_OX"#.@(W2C-#OOVE7*/9NW+]7P\,QQ!8R^S4CRT?MSQ%MZ/IW# MM[RL.\@*W1YP?V%TJ*^[2]!08V;#XN%YJ>"(+V9+SS2`:>YTS1QO@?>A4#=@ MH?$,CBMW5WZS,:Z=//BZ'][41;>'6N@"LSG+9D,#H\4'%D#R#B!KVWQ2X\J' M@$DZ/TK4"X/8ZPSFBN6E\XK)>&*\+'5N#%U-E3>NS?7R"-":U9]\`2FO,6W#=_!AX: M^97JEC\ST-1<;+R9?)XG'YJM'HZIP/D7)\1?*,R4(,9;%*UK&K&C>/'Y?Q]N M?X"^WK*!>^*.X=HE1OH-?&,/O<=MCE^XKXW=XX_853A\C+M)+#H":OR,HQ8O MFG"D%^`/3.%'/KKPZG/DCK,F>R-F2,WGP`E`WAPE81G7;>C@M^_1G)D&X_G& ML8+YDZE?P6#R2Y:`%$U)6WJAD=?GN'";L*;`=/,_(B1MW]'4GW735OAL$%X" M6N6!2FE^&KAL3W=O-YOWB49*H.ZF&Z*&*9K!',0 M%)M9F%`2SR*J4/,,/?`HTV(@9PI/A),8ZW(HX!*PNOD?D/)`%WX\GNIZ7B_= M"-=U'W1PIG]QG5?0TULVC2C/^%S[#O3^0;H!YT(N&+=.%?\UPO\Z>UZ9C%H%5'V;1%-S\RJX[3- M&EN;:ED&@K4<"_@J)X>].V&:^!0PY-D4&'+_5-;F"7PIM`8$I^FI8YE`WK4% M-M?`#6%.V1$KXQ7@5GHN(2SG< M87'P4CP*#+V$R*EJH!]5IE.%0^'JB^4*J"#/5PI+`SU<+)!(\KB$6#``._$Z M]6J;V"98;#"OUV`IK924B>S&(W/O<>_33OA-S!FZF8&Z_AOQ_N7A[Y?<+R(/ MAGF)9@_F3;!?#A<2F#@EM''PZ%OF"40O*PSI.N_9HCI+WK"R:R!T>!H`&X]. MZ/FB/8K>=!CLP;3_RP%:":8Z09,26_3?'_Y./H5#%T\'\"48VTC!G[ERQHL5 MA3M/?(OP);;H&[2L;.<5>4Q(CDT>O?'5^"^1;[1&633'<,=U!2'F/P/K:'G0 MJVG.O)]PY_:"".R7%5!R/4$7"S/F61:,\,HMN_C]^NOJS]CK!M>-><(PHC`F M)%Z"O+#6=-::&[7&S7+"3[][_#\>^0K(XE/QE^N;!P"BR>>=:]>8F2_1\A2H MG@(&HN@WF,;9=!_N<:]\]-6I!DM%."%/ MR^V)#U=$=*9;4RZH7V]@?@=OX#6&10FX/G8GN.SO#X$6A^^QP\PT/;NI6VJMX:/O*/X)N)BTW?`?U,=SS#7]$[ MCKQIW!$+31>L3W#YPF#MS727+_C@'38W[FP1?X46+<>(]NB0DM#<7ZU.'^.6 M$FB*;#M^8'L)S`ZP@Q7/,_EB"HG0R;/S0EV;:S!N@ M^9"_@Q65C]@XSN;_;(Y_!G_H\=-./PB$`9:'.=)H-RX7N@LK6%PS+L#8H"3F M#JS$';8FX+-EN.5C3;B_"<_1Z/0-]W0LW!X(P)[B_A&L6Y?\--X+9T>P4+R9 M-/TMT`$3TPP4[&46V^0FM"*3\4GG'D16APX&6HD.8Q>8`YNO-A MN"'\A"M36&V&Q_?0<,)<7`#+5K0^7ML8CYM(;L1QQRS!2*(GML=D,)9YH2UX MS`M"*P+RN48VR9?HW=71;(*<:V@B/)+>$/9T&J_BH^ZY7>7*!4^;OA6NU)WH M9(U9-;;D8!*>48O-XC'-R:Y7C/#==][4A%K0J>LA`:9A1AZ'`=/_94Q3:#K" M30"^E\"^67FT26<'>>0>S"3:.$!;\6).J!OO&N!?^&`$(8*'Z1:]]&#-::Q\ M)WY>'I[N1Z0K<;-XB&Y/P,#CHG\!`Q/Z8F#4`0P)/PHW2G3KT@=UB%]>&3[\ M-3IH2#A<\>I!CRAUZ8S:?"LU)#`IXC7#F_3PGT#*](6OWW'W`IU#/``!D>O) M92$FPUW"V#[CGLP3D$EI`NN)%?_V[LV6V[6V/Q`>8_&)EV\YHN*M.Y"Q^ZPD MU[)\MP/%@7O1R\0.4RIAL<,9Q]/`"]M.'E\Z;:^"=UGT+QU;M,O45 MA$.=X@?^@X:(3FY6H7*"P=BYRW1HQXCCANT)Q3L:X6HBJ05;:PA,M?P2(I6= MN3)EGB3:>V`;9E_7-\QV-+V^MEC#89+1D/U5O`P\'+=X,+QE.[!@%:0`1OY& M]V;D"S=BS.)>_.:QF?(MP9SO7`&N8[;!C>7[A_CUJLFM:`;J8\-1N^^6V.B= M';>X:G#5W)[(AXWDWP<"4RZU3G\M6.8T:IHGKLU`D0/B4H?]?K<&@=W'&\]% M"2QNL52!#4;=7A9Q9:2F>>+*IXY:KSLJ2UP8#0-NT`5&2&Y%D,$#=^SWC_#K MJ39%U392::^U7A11.35WH)5/TD;%B)F*&9) MWYG$/-=X_L%"!'#BYNG6T:EV;/1D6=9RWB'K[W#&\O4(S*P\74\F9NB>?]'- MR25N..DL(*82#E?=8^]W=MAW:=P:1@#+.[8/QQ.PWZRM?'@CU7"^(H51LD8( M[Z4L*7RE8?VO6]W%:"6O$H:C7J-.,W%WK$4K'-:)V0%#H<6"=5$#FH_)HP94 M5;6MR;^,.6J-D;)H*F!"R"?R*B:$,DUD3BVJST2RX*1BK.+O>#+R9-'H[L`M MN+#HR[Y;WEAXB#,--_;NI^P77J@I]:7E%W;\N7Q';8H[FO`QFQ'5M*WE7-E2 MV*Q+)H`41L=-)2=!H2<:%$;#ZI&@BH8$I@Y'2&'CC*<84+P+8P*N\<398VX# M8SGN#+K*4J%-&PZ.T_*"N%)+X4KM9QVJ/3LE'TQ;MXTB=TKB%LO>N-Q2UQ.H M:9ZX\FU_]/K:N!1Q.?8J)C;T?RYNORW`$:';CFGB8?YL^.2)&RF]C2W&7=V4 M376^K9;+L2A4YP'2YO10%]7YK,5&3>LL5&/<=7@]=V=MS.0=WE.*8ZK]32]T MN^$22,NT`-R<.0]2%MZE9DD3?"<.@%Q@I=5]5"8JLJ+5"1T>.CF)^DYW4\LR M=U@36YGPPN:^4]D*V"T-+%RY=5G+C/).;!R]SG0,4*`V1EU@L#*=)*Z9I5PP M6X^Q79T.D[N-6Q!;$F3$W4_Y/;$[^Q](#?=L[Z-;$1DDUTM*[N[S!\P.D)#: MX4Y2I!5%TNXB.3Z;>8A#;O-8W-$6R=UMBK?Z2*$S/1D_F MH[F_1;.V3?-V)S'1J^.ZT`YO"3=^(GK@Q`E!5<>]]37O5@\%4Y?'H>EOEI0O ME[A\?LN0'^]51UP>]T35QAN':EFHV[N=>K_N*11Q\*=U=M"8LGXKD,I\XUP; MD;F.=4>=.HC,?2`^[IU,YNK[>&*)]R-2(ZG"QW;N6AP!F3]@,<@2L;(>[C!* MDFU=;,U'O,O5)G9D_*/?>>5II'J=Z/#W;.`E^JXWS]9@C=1CI4J@!9W]CD?5B[[O=.M638M:Q)L3M7`?N]T#;Q+E.9. M7(9OM%P3/*U8RB/99B*U)RY2.YI:Z@R<%<6BR?4LD;IY(B,24K51`2YM,7-R M1A-Y])P\&G6%X323BAW-:;>_8\EI<_5+MRY&N M?E<]?0(LRM7/))VCE6VL[=@\$U+92EUA'X>5P:XM-/%]I5*E>;*O=-D=G"[9 MFM9+I=JTTR4[S.'??W!"H48TDPE:IG<9%B?L!=.X,[(BVQ\;#-F[#) M1VP1;T`Z]K4]>5RU?QWG$O],_?OIH_[MU`/Y#;Y+H;$YHLNUP]V3HCOR"$/M M2-$=>QK0%5-V)T:WUV,<*PJ3%]3(WF2Y9"'DP-PA]IDX0W3@I2JF`]B,F;B>"VNBCIE(4W%E%R=%$;YP M-K^"V\("#H.X'E$M5]1+'I;[QU]OOY+KAX?;QX=4L;+,A!Z6WCHA@KX_V*BF MEMIT@41EVO,:=X\FJHSMTVS2%G#;]#@19C@&RC[411__J&JW4KQFBN?6>D<3 M5="I95T0/>H$2E4'*5Y>-GF52CS%\2I>?+A178IU M8I@14#0H0\6.BT2O2\%.%&*WLW&QM"`AYH@PJ$MR1]GUP684SWYQL:T/_C-9 MU17>6QHVT6)*)>)6EXF]B].2G#M8(1V71_92B?IOU]WH_[./-YV6'-]WYG&_+]3U,1US)#K^ZT:(NF#U*)W`P]I];[?2 M/Z\Q:CNOKK[XZ0W_]TU..>[0RYV2_3X!@>/!0$+\7O*_@?7%M]677+^T)/#* MT6HF]T,)TD]!:2J?V:&K'6S_R7$GU(V;#W.O8S>$S9@5@7N#I34[5RIZ4W&4 M$]+BC>KKS/3I)=IT5D(')2/,4&_8K-AD;PZ@3VY MC(HB3-G_56/0-H9(/5P$XB1M.,3M:3HQ-R<3BZ:"NUHY[Q#J16#KP02++E8\ M3Y\B]WI&N.!>Q95P3LL2NMK#`9B.',(P#$K+-RDI*Q]U9?.GU.4Y5^9ST_-, M5L"1I[VZA.&(%L9'F9MH`7*"4/)K0(9.,\&DM+%A+7YWBD#'&7D+YY+*F=,4 M55,+,:6E#&8IF))`;B60QZ-1\X!15C3^\;_)Z=/4)IGXSJ/F"^VI>75/6 MB4Y;4>`HAHS3E;(T9+`6544=#812RO*'7V*N7LR!1S,4RZ.I:Q63NFTCY-*& MG>F4-0D<)89R3$.N3<62/>1]>IR/T+I9]L!K0=5$M\MQ7>O7]F" MIF1\5S"Y]7:@OGS?2QQ*=L`:""(3)WC:W-C/YK`T9QLB)_MU.:A=9=P=UJ78 MO^/55P/@]P3YWC4M1YP079% M8A[?<::"X&G9+](Z)I:I/YD6*T&42L3'U>^G%3A1M6V*MALOGKI,*6JZG92; M3@>I2SR@D%5H[2%*3[R6->B-]]*Z,\:W>'*SC/QH,R->5G(?9H[K7_K4G9-W MCNNRP%3O\KWI4L-W7!Z1&O[AD8>%$W@';E&P!A^AO55S.V*X'TW?HO?3.QNL MB3D)=(L%8T>]7=N3N&/>;Z;J>/T4E4PA*9,4/M%)XF;-G?U"^?5%;V\!O9Q2 M>$^?_#O;\]T`FV8B6.LWT6W&6GK#O#+XHB\Y6UCFYBM=!*XQTV&QDFR=7]JE/U M>;2?QYT=B\%MWJFE7P:W4=UB+#KW-RPJ1WZ'1V`I=)#1Z,T[F[T7OE:B44OO ML%[NP6+"$4PX7@?YB[VKI)-X8B[4`^J8UF5MK.6#9>_`N.UGS8U" M3#WTD12L6HE;*`$E>$=JXEB6#DL54%[BS71WNRYKW`#SL;[H[KW+KH=.?L=& MOJ"KK*=B M/6H)W]E%+VNR1.*R+-AS$Q=B@HV\1TQ&',,%_^8`&-AX>)RE+/2J&S[03G*3 M#5=+=0H$RJ%:#WPP2.9_\E-^O7KS")FK6PNLO5W4PT>&42B:#R?P/1_<2+Q" MG9.1^\2KQ>,IT7I=3)RNRCN86.CF)*I\RGSX9$:#G96[PQ?#]\"-3FR1G[*5 MW!^IFX@ZU$\]S&29"KH;9XYH+E-VE\6HFT6_7I]T"WA+=Y;B=F%#^&@RB\S5UG'FUO%?7I0E ME-$Q*)UX9.HZSE'[%3VDIMGZWMG"MB2E#EJQ[85/'O< MH>U@,-ID8695;5-G*"9:+[*^69JF%%ZR])(I-IYJ1-80NL@>3[YY;! MZ?-:!J>OMQ^O'V_?7WZY_OKXO^3QZ_7GA^N;Q[O[S^+D<\)9RIPNTV[U\^=, M>P)H6/3*+C:]`"ZF/F<]WS+:J05]WC+\U,.@4_ ME!J!C[G0[Z\A;0,3`,/X8J$U!HJ9N04_!`G^%U_159F>U>]7_ M"_;C!<8LE8@K\KA#P$^.[C*F8TD3FSX[OLD,"#+U)3IT!N_(`)ILUKL[7VO& MHO8SN&!/NF=Z_'#D"<9VO[SU)R_,$SK!9T1)O<77!:N=7_][%*6_&[+ MD:M?V79H5D+HQ'D*F46D+4P;%RDN?0;I1YQ.==/%T[<(31N"QQ``_'H%)NB- M1<5P^>G0W")@`6X*05I@W<4TSY^9[N1RP>8",YZ>8:SL/['KJ>G.K\AW:D_1 M.AT%@Q'3^T=U8RM.).1I20S=FR$:9C"R?,CQ)9?.@4UL][NN,@H;Q%==W?22 M0^V%7HY.'@(,BC1MAK@'L"*XS8!N(%X08,H01I)<@6EA[W[74\"%9$T_L3B0 MJ.'PP:V4=`KY3HO98XP@PB:H7$OBF=^0$"=PD^8&F`PU*92'Z1(&$A#X3@3N MS$-3#_ZV3"8*[W<4>-/1N/*0#!J\'_D MG0X^R(2;\2\*II&"008_"!=_X-N&*TD+U,E".3&3'RM,R!L;-)1U00,1Q:#R M;<'-&%3R@5*&G/59Y+L!QR!*Y3M5"P$)1IH\F9;%\CN,AQ-AV>$10_^"5!NPZ)A0CF\ M?W_X._D7.\9^X2?#R6%,SD"Z87"AH6*8\&]B,@#MP78P_H-/1I1580`3Z,^< M2;+%ZRW3FM`QF`SXWKIK/@5HSK]30Z,+5APZX//$YOA-`LK--Y*`Q-$X/"+9 M=C0;F/X5>Y+J+IM/UQ':3R"T-V"?(T.0`L(,RI-D_K=8ZK@LCV=J/7)-E)W& M%(3O!H`7X-U,Q!\`'VN/A75E0VNZI'A22OD>^68>NC[[[X#Q`Q^&``D+O8?( M&H;F4;?!W/NP&,#P<#PWU0WPUU_HVJ!^""6T7R[C\M<,]JHY;MKEY*I?CH+<$,U'H`-72< M`$P3&$C+20ULBI[#J.;54]$1Q&GU2[7.8$/$>_HJG?)9Y"P>I&N9ELE"?+N$W8HCJ%Z/7*3XE7WO,WCMK'N\2"(]T-D@_U5#+=6>2, M=(_[Q]+]%8;"#OB<&XW[5VHXSS;;NXAGYGTE"K8996TFFHDV>6[B9'V'][N% MWY3,<_YWNI`;N:7BX0.CDIG+MA34<+CQP"-E6P\U;6&%0 MYC5Y@^D,?](!?=)I=.N".X M8!LGL&:>FM]P:]$%Y4+'T;39_(X#!JL$"SQ-?L-IB<^Z5/<$2QH`5W"9[9L"[U\7!PRCE>K MEO@=WL4OM^17JEO^S$#.D(;)BQ[*?HU&3GSRIQ6'^"K?NT7FO-6"9Y4++9RR MPEB6!%18)P["S>/A06%=#ES3ZA;KSYM1BENI#R;@6G>102-A<<(S5!P/W$KB MH@'=,Y`H;KKA)^9"HSS87:I-BB=[\H[&HPNH<`PSF@LV./'B]J[(S78CX>], M:R:K)N$-7/(X433.MC(EW\ODY&\LRK6! M]TW%"D\(X&?JXH%19$V],DJSQ7T>6`X*5I>MLR7?+?MTG!BS5X[:*;F-I9$` M9:/&X\W%>EZ1%5[V;8_TU/*D=V*Y,K7;TS87LN)*KK!X MJHH>6UZQ/K8RZ4XM;!5>\[`>^WLB[H>=[JFP/Q(,!V_B:N-33=L)R,WH;=2" MW&(*"-:50R#1MU0*%*B?O$MWO$XW88##J563$\AWMJ+UQ M_U3S6K*VE^J4':GM&QG%BIW;BUZ7ECJ[G[PNU39S8I6I&GG.:X>C054ZF_-H ML#/J;9ZTY:4L*\:$5^!Z]T6J%&.I7H\(:ESR)E.I_L%1\XC*DW,=EEGJ59S0 M)6$/I-Z^.=$1V&B_$)I.76&50]-IQK<,FDZ3]DO2Z8TJ2\MO[C`FKM\%]T*<9>9E*FGC2N7@2J8 M#(8;*7;+E\&F;UF_#'K]JG5APRPH1\ MT$V7I^&*`Z:0F#!5>Y@E;BLUUX,QHY,`+]5_C2-N[C`<`@PCG?"7HW=!@Q+9 ML>&W8$XGCZA(HL2^8-S&U+$LEJN9L-N)!*@$J\WB-WA`!;5,#)]P\2(LT,S7 MB]'="BXM/>28C7TBTSL+IYBS*"T,W'+L\*I>LE$:CPA>L>2YZ/#%D##OAWVA M&)QD@UI66*8`LP^QO[V%;D1_%Q,0$]5*Z'3^LA+D6A6?N.IX+U?5;UY&8N.* MVD7!%^)2`I%8CRRZS@D\&#GO[?;]K%(KG9=1*VDT$K:<.4^L@Q=S61@2?L#P M2.`'5^)E5?V319Z/*1)SI0T%K_,\[':K*@%3=_VSO#I=895GUL?UCE!FGD`C MRGK%Y\H*U;Q=U7:+T,BRBSP/NF)57B^QX*[H\RS/MEBYSHDXM=:K<^7.@OW* M*M_*27"_PD6YS]C,%U_[D=-=:Z<[3>GVQT)IWQE/=[$+&EUTV_8_$_LR&WG3/O1P M'6G]"]31?!1FFY'5L=+M=,O4L]1Q/564%6A'IJKTY4Y_Z]4*U-7]<\?7K;(F MPJ/D4,KLF+,\?4U&O,R#EYP2J&TG>(2I#:N:N%,!*@`0=B?<33=K.*PPG8QJ.$:6IN8%L^5SM(=\T"&VV^&%4RB3,:8ZR+PXTB(*-<6 M^<+*?.LL?3];A>_)B[+B)MGGJLNH1RSCD.CO?AKU%E7`$R&8I*:<(YNQ*VYT MQXWGG,)<4JR>=N*8G?@SS%>+F4WIVICR3#MKX\H&!7ZGT?C&91%S9RV-$H'V M%/)$#1TKW+/T2-,I-?Q5#FO3!I)8;I]7)[`PNSR\Z)N7$3RR9E>O*RXF,M"8 M8T5?>-!B]&E'R,RZE>NK5^/Q;DMW<&K-;#,K6ZMGLH')T"&UMVGZ>X.K3K6L M'$I:9%",\PW7J-L!1#N9;.CPK/G6$3F@KKQVQPAFVS>G(5H41IL[1$D-&FPJ MD*;5QD924SZL31G)J:*M0])!J6IK?`A/FXY'*\=DOPWNG6*#,V^T5;W/ M7[B:-9[36"VU[7V#O4-\>*>P-BDD57IMR2`'_=PXW0UOM=,N@L6,DF6H*4Z)KDZH,^X5MN#1VE"1336%*='T:R]E),M48ID37IK.< MG8I9+(IZ^'&3C"I_=O6#>=O.Y+SGC#EM:-A1TDYI,M9(KP1V\K=7%4RA$D MXYD>2TEGZ`N6_>L_,#`+W>?593T?B(C*WA,+'@TK?CI3_Q4SXX6/;!1P3":G M2\).K`*..0L:IFWOI:EEEORG^?O8:CDE:5$QF9/7+KM@9RCW]4'!S[45ELR6 M43E-:CG3)HL)A(SW[G/V=Q`BE4SED5ESPTQ/W:M./S)M.7(N5`@P.>*%CKB6 M&/#WU&`%Y$E7S9)K08!!+\B^%)]MO(2>3D%>O<=^FT9FE,!K*%HE?F._.W?1':LQLX/5YN1_-Q[!2"DPJPD+!*M5V@1Q7;F0X$/:" MPT9ED6%D_F]P-7N4JK2G7%Z1DFZ[FZ8@@] M+0I6A!)6%X/A@?-N$2KBE2N#`RM^J352:S:UIM^K;,ILHM;4.#F7[Y"*0TD9 MI5N%UNIR/6%5&5;G"1=4'E8B7"(\#\+'O=KJE1:,\&KV)JN^LG6S%G)3X8YD M^3ZH(![F$?[C'CHJWAJI8*4@H=%B:,@#G3/:!Z]11\IU8T;5%5T7Q".7B).( M$\%#ED0V[2!W!UHXBNU MQ+?$]Y'X[JEM.0!LY_'(0WC]6!Z,R-UO>3`BH2$/1N3!B"`.C@CNBZIT#I6B M$7&C6F*NP9@;5[3 MQZBE6B./1N36<1.WCML262_Q+?&=@N_JTETT[V@D:^+@\GTU<2C)D$!:`$>D MM-P>.=FORQG5E/Z@MD"=WG'>J%0_J5\F2EMN/.=2OJ%]M??9WLO7^L*D4FR+)P%,: M7(MH$?6RP:GH#TXZ<;[)X='Y)@L&<#@*8 M`1W0I!WPZ38NJW@23(W+&-\2N[E"%Y3OUH74 MK?G0AC-')[K4N(F&A#8U9VM!A'UT5>EW*]LW$.102`*YA4#6E+':P`SH[;P8 ML[6U<\DW=BJTV+I#T6VI(75\ M]<X.EQ@71"3:JKS/3IY=HTUD0,DI&F*'>L%FQR3K;`+YMJU7?[D;H@*\/D;HH MU\85$=RV6R?FYF2RN*!3DQE$!N)9#' M([%B7LXSR'''Y/7HZA-*7%BVF"^XK^;5-67)0+1*`]'4D5@A]#+XL>V8`X]F M*)9'(X,?#\T.]V5&P,L`L98&B`VZ,I&?Q'=[\=WK-Z"%_J5&&_V#7"^B$7`./^C,EGP,6 M,@`_/UOV4MR1,,")^O,9M1LV0!0F*_$\"%@>57L!73([H71AAZ!U/GA:%G MQV7)2WO9JB\@,;(/`'!+7WC08O1I1ZSBNI;UQU?#/=8G^Z'V<%-_>YTK;8\. ME["A$>DXMY#I888G9\[;Y2V7)-;NEED<7W6&M8IUEP@?9RZE9`YMSSQ"[0DH M;Q3]MG]>V&#P:GR0OV,EIXHIN0?S6VZY%8+#PJOC;+@U5Z.]9V$'%_J5GI9E M':W#D9QY`%WR$`ROM&XKA^!`4*5`0S"^TEHY`DU2@O%I&XZB#L$^)=A_JWFT M<:LYW[11Z3G5/GFL8IO?L47$:[2LTL-E5;B4<`+?\\&U`XSE0>VA"4P4,:3? MWFCQ)[4_4+1#._"Y+-`)1QWY9ER)F1)1T5>ZVH%SQWI0<<`)D*`HU52HG0.Y M2NHR%?O]$HF*.@W)WN"X&I??-3A7[W%CUGRA!,!'#7:CFSE6ET^ZERN+^=EHNF MH[Q=":;J3%.Q>ZYEFZ9C7%.))A$^Y=JK/2Z/:([PVCC8]\Y^H;;ON":.VV?* M]DR_4AC`%^KM#N2-WEK>\+OWPL3N5G/G=)5(=$U\-A>?&XI/V9E9]'#D;_F4 M;UB=EN0LS5I>_)3<6L=TD2.W:6HJP3PQPL4":B-Y8"<%/Y5^(ALAT&D/[YW/ M3\PYEC+Z(F5D32-O/=^A.FIIEM;3%+.(S*V'L'$FV5P+4!&)B)*27PJ0]%4< M"YK-6-:='+9,.YHF@7*SPV:=1^O(&,NO6%64'C:3&E28,K9$*%1`2;-&IX1< M%AF%5EN>)BV:@;[JK_`+Z+:I6Z65K#Q&&OE5Z4A"VIS&\Q"_=>7!Z5>7V+.8 M(:\,C<(0(M6B#K6HK*YXN6I1WXQ:S5)@WXSZ#\?]$Q-0+%S'H%[=#AN!X*K2M+;F`7A!],VO1F=D&?'F90V M>Q4FHU(,PND[R4)G0A75_1V-ZRT.+_!24>J+U)>4;-FU53NO0%^JRC`LC!LJ M-G49PAF+\=2:LXU4@$AJ+*DQJ"T5^4Y@"[(PE8HH%;&Z>DJC<9L5\:BLR/L# MFE-3(_\"J]57T[)R94".7A(A5AH_/LXH2XOAV,"T%P4J&S/=?J:XI?P<,8F9 MC/>G+HX^/KGD^TV1,UPU.*PX>[1#]U!3%85_I00,\^B6K`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`L![<%00ONLH2VG@ESZTN]) M?9'Z(O4EZZ%!1V!U.:^S[T?'URVB>Q[UY3FWW-([=4NOI\G#P/KID.`N8<[J M*UJGF(KV$MP"BT-T'(Z5[DC"L'XZI(TMX[B@VZFLU)[$ML1VA)Y:4DMB6V,U1ID<"NG8XS M/P46:WT@(2AMJ\2UQ+7$]6Y_N-<1J[3C&1_^WK/S7A%BGN6&5M,WM+I*9RS6 M0E=NUDIL%W2\)L,7ZJ?CS(]X!T.Q@ITE"*5U+6@;414K^Y%$MD1V43[QN"O6 M8K>,0]X=!%6VBMW@(R^6L@/H6$W,/&)E=I"1A?K*Z*AJ(\O&2&")"*PU$Q:U M/:-(*IB>;K(F3W[N!=BYRVKSC%/*N-;%YBGU6WN5U6^5\VU6[(E<74[$*JYR M/A%N/I&C(D>EN2S(41&1A4:6MVRB[WM$73017-\ZBQ^7L!]9ZV9H^QD7"0%- MU[R:2DXW%GMGR[A$@$2`(`C8N^.I=4[;\91%S2OA>` M#HGMMOME$M=GF`3@8B1R%H#"V97NB#39I^E+MZ])?9'Z(O4EH[X(79"\4GUI M9Z9[6>5<[N<5MM;O*FJO@1MZ$MP2W`U;[$M-ALH_9'`YS+R=%!BNR4+ M88GK,SSU'O=D2%']=$CC*HVKQ+7$=;90[[XFUNY.)DRU\\Q75C>7.UTE,:(O=7//?/;[MKG_K-B'GZ!V`E07113/@+6!!CHJ(+,A1 M$9$%.2HBLM!(+[J)#G-#RS++@NC5=MYLQD5"0-,U3Q9$ETK7.*63"#AK!.RO M9MJ7!=%/VA^M=A8;D`Y"ES^4MJ)+S MPO>T!EZ#DN"6X,YPQ6^DBI6-3&+[##,#:$JG/Y8PK)T.:6*+9TZL"VD2UQ+7 M!?G%(YD>H.Y#35D`7=Z**I4Y6!^,.D+IN+SQ)[%=#',70TVLI6^Y[,JYX'PR M$%RH2E>P?1T);CD9B*PQ8VTD]47JB]27C/HB\K*@4G5IYZFZK*PN=PH+VRGL M*#W!EEIR&UR"NZ`=LKZB=<2JEBC!?89'Z&.E*UC13@E#:6,+&A]1/ MA\1V\.>L)MQB61^H2VX4Y:F.Q'#6)[3,\ M_NYWQ'*H)`BE@6UC,+G$M<1U,/+N2*PX*[F3 M*[%=T.)7K)6O!/89G@*+M3Z0$)2V5>):XEKB>K<_W.O(.]2"'/[*$NMR0ZLH MYKI*9RS60E=NUDIL%W2\)L,7ZJ?CS(]X!T.Q@ITE"*5U+6@;4998%X`.B>PR M?.)Q5ZS%;AF'O#L(JFP5N\%'7BQE!]"QFIAYQ,KL0,@:?KXLL2Z!509+LL3Z MAG+)$NNLQ'I/EE@7>HXV9(EU40UX"UB0HR(B"W)41&1!CHJ(+#32BVZBP]S0 M0L^RQ'JUG3>;<9$0T'3-DR76I=(U3NDD`LX:`27NDK;*LQ.H_JZL,BV+J9^! MT*7$93'U\]5_64Q=WGK,90/QW2N$KC*G$M<9V%N:'2%^P*9"9,M?/, M5]8ZESM=I=W%T\9BE;N0N[@2VVWTS22NS_`$6$*P?CJD:96XEKB6N&ZQ.]S. MC\- M$]5_I0O'Q21:=_;4<>>L^M:[9?CC(Y#[SG*,/W_^[_\BY*__8&)QZ/KFU?=,W0>3_?&0_X/N$-?#_+B]Y&]N$1,U$K42-Q)T3`P85 M_OA*IS^],;2.VN^H'=5WV*=!M_/FYS149%YV;V(HB3/\^#BC9&K:NFV8ND7, ME9A0!N],YYM"7F>F,2.ONH>9R*P`:_>:-JOIJQN&,U_H]A+3E`$?$SRNQB/L M5?[T1..>#U^@X($ZTR-A131X!%J>.I;EO'H_;(YQ]'%G-9'$1P848E#+"O.J M__2F\X;][2UT(_J[F-V,2!LZG;^L1'IRQ=\LJ?6'`E3@Y:]C4S\0TX?NC-W) M]"\85IS`T^W)H?1UC2RCV)IBY"44;:A/#MNUR.-ZXRDFI&0"T):WI<+Y&2'F M/37H_(FZI*OR*O5-'K?CS@^&`['#YFYT;\;NC!GX@?X[,($?=#'*.DR01X(M M/!)4^PT\$)0PEC#>A/&X>3"N9EZJVOFN(H67W+!KX8:=JA3E9S9G,UH"N9U` M[HGE59WQ,HE/1Y:I/YD6VWZ6RZ-6J7+)?J72&8B5.4,ND"20CTG6-QPU#\8[ MST*?7/)]_,NYG(.5=:RF]@YNT)YPZK6B8`\MK3G]RG68>?*!P:XA*-:OFNON MLVE?,LNU>92.+15HI1YG+N67OO'=DCHA:E8%]OY=:]29=&67LZAT%6R6J);PA5%/U9]A)72K\Q MTJ_]FL#!J553(Y-YE@,D@GILC,A0\`$Y[GB^V[_JGG+85YI6;)[0V]0G+GVA M=G!:UL_3V#W^;'-_OTT_WE2UJ^Y(\"/.7K_8Z+&B1[0L;$E,MQC36K%QS1+3 M$M-U8WJD%1M1)3$M,5TWIH?]8L.KJL)T98N*JF^A?(;EQ(7E>-Y;3-W@S"M> M5!04Q%\`#`2.XR]&LNJ^M'1]![/DQ2GZU@J%\^SQ7U>% MPG?GX8O>^^SXU/OHZ+9W;4\^\-QT]O.J"1'R\I6U)MP\?<7`)OZ4B:G[,-8I M#I9C>0%94C[,[<>O%(49^[RU-($N?=;="7L(7KGA^0"Y/1MIZO!'CV4)W%W; M';/_);-SL5Q9^.16]B69'%`F!Q3UH#G_A9`*MG]$R`!8,K-),*V9D%*Q5-#E MHI;(7<0T>94HMP`[O%6HN`@)&6L+1ZHK3^9AH0O*=TL3J+CZA";=UI,6M3+O MQ'GEG5`[2G!2&YGELGW`253UYD3.E]8SI)6.BT5 MM'\M1GI"X;/I:6(I7?F#+Q%7,^+48@\U9/;&H\W\-6[#Z[:!._(NF3C!DS\- MK+5]]3-?CM2HA5GI$-$KDM"0T*C.DHI:*,EPYG/3\_`P4Y_\*_#\>9D%1(I. MJ7""`N?*L%"C.Y2/T-K"0'J*6EU^T8)20!0NA=."J*3>G*7>](>JU)O=`JA@ M+N[MT*;*ESI[8X44O"!?E8')))(J#0P0Q!9_%FWW/G=.]NO:"A\H7:VR+9)4 M<`JR$)2*(Q4G7YDR11M65I2\9,TYN5)Y[L#D5;5R:@0NQ4#9)__R$YT\4F-F M`^W/2W)GO]!P'4L^?KPA__S$(K2VZY3S)K"%E'CGOC;^`W^ZLSW?#;"UZV^F M]\=:5XF>H"/>S1L2V"9OZ+=.1WM#)M0PY[KE88SMS]T1@V5"%BLB$KRQ$NTD M+N!.WIN>83D>/$G^B;+857E]H_#[ZK4V1W;SV[[WC[?DAL2QU^J/Y.'VET^W MGQ_)U]LO]U\?[S[_0JX_ORX/.H:P M`]IX:#P/B0^?5M@3M_\.S`7#3S0&'$6U-7!1"!%3O`\ M8RW\KGL.:(;^;#L@.\,C7O#DF1-3=Y>L%],CH%LNO&\M";6?]6>P%[#VH_`G M8XZ2:6!-32'*EYY/YQ[.VC-P5J`)-IE;(8QM]AX^B=\I>&?DE5I88),-^82^ M4,M9<.U:N,XD,/#9/<,&L."KRSF=8$?8A&E0[VI+&(TPC0AN8V;2::1;P"). MNFQ3>Z[_"8R:WD[=OF%OWGZ#>=@W7RBYGTY!%JY"7F<.J@7,E_\*;"92KN(@ M1Q2=;H/B<*%3<-`"9IXBS8(GV"4A/+9\TCT8?7A[11W/1W%%KB=STS;!O]!9 MU].P'[1DQ@S'=\I<(:J060"-H1T"FV.@G#@R5C>1_)7_@Z8#PX==D-]_H&M\ MU*46$(@@7%#;0W-C@3?`OO(=0G7H+K;&_&*9`4;5`UWRR<1TJ8$V5/=]UWP* M^&TB>&W%4#1%*#'E+&!9@0GZ6;>4L`G')5.*Q)O,;W)<3A9RK*SV/+PUA,-0 M^#H,`Z\FNS8%+5SPJUS`$Z]__J1;**OU9U`6+G.'N)'C*'#A"^`==-,W_258 M4,MY9482GL8W;(=K732<859"[XH\!/,YSB]\8$S0G>0@X`DU]A#/F"9"PL?O M`3BLFYWWN/:K5;PZ.(N;7+E#QBN*"Y<-OJ=WS99;Z(&$M MXT#.^M+&BF%CU[>%I;$5CX/R,1#O7\OAEW9>>#O?L-5=LY.PA.?>PB_3VB/Q MNT+AI/!B/RXZO=<1^\[MU_"\,\RO$`[-0)E(1-9'*4.ET!X7HMEBW9B6V);8U9:16=J%+8KLN<8@.P_%8 M&MCZZ9`&MGCF+B6N:Z=#XKIXYM2.,NI5=C.L[F0I>9?`5>=%N=\(U@Y+"=:[ M\A4Q!US;E+SDQ'+*<'QNR0PEML\#VQ?=@5AKCH8F^VFNOK0V'^C%8"BA?=;0 MEE-!+GWI]Z2^2'V1^I+UT*`CL+JL(MAN79M\1V88[:6"Q'36+[#,^I^QVQ'"H) M0FE@VQCU+7$M<5T,<^(M@L_X[/<]G5(7JXHDJF*&&;/E4;#<[3KM6FAW5%E] M3+F3*[%=Y2F%6"M?">PS/`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`NAKFNJFC=!EKN=IYTRPKG(FRUM'K; M;*#T1P*?R\C308GMEBR$):[/\-1[W),A1?73(8VK-*X2UQ+7V4*]^YI8NSN9 M,-7.,U]9W5SN=)7$G*9H8[$*7,A=7(GM-OIF$M=G>`(L(5@_'=*T2EQ+7$M< MM]@=;N>YKRQN+O>SBF*NIW0&#=S/DMB6V&Z8,R9Q?88'O*JB"I891L)0FM>B M;DE)8-=.AP1V\;,9%PD!3=<\ M61!=*EWCE$XBX*P1L+^::5\61#]I?[3*'2E9*5H61&^_T*7$94'T@2LX+W],:>`U*@EN".\,5OY$J5C8RB>TSS`R@*9W^6,*P M=CJDB2V>.;$NI$E<2UP7Y!>/9'J`N@\U90%T>2NJ5.9@?3#J"*7C\L:?Q'8Q MS%T,-;&6ON6R*^>"\\E`<*$J7<'V=22XY60@LL:,M9'4%ZDO4E\RZHO(RX)* MU:6=I^JRLKK<*2QLI["C]`1;:LEM<`GN@G;(^HK6$:M:H@3W&1ZACY6N8$4[ M)0REC2W(@5"Z'1D>4C\=$MO%,]<;*%U-K+7T&1^CR^KJ(FRWM'KGK"?<8E@> MJ4ML%^:HC<5RU"2VS_#XN]\1RZ&2()0&MHW!Y!+7$M?%,"?>(C@3IMIY]BLK MK,O=KM+BR;LCL>*LY$ZNQ'9!BU^Q5KX2V&=X"BS6^D!"4-I6B6N):XGKW?YP MKR/O4`MR^"M+K,L-K:*8ZRJ=L5@+7;E9*[%=T/&:#%^HGXXS/^(=#,4*=I8@ ME-:UH&U$66)=`#HDLLOPB<==L1:[91SR[B"HLE7L!A]YL90=0,=J8N81*[,# M(6OX^;+$N@16&2S)$NL;RB5+K+,2ZSU98EWH.=J0)=9%->`M8$&.BH@LR%$1 MD04Y*B*RT$@ONHD.:RF'K-5_]E,75YWZG4.]*:,M8&A2BW MO,PGP2T6N.4EU?KI.//[_YK2Z8J51TG"4)I7:5XEKB6N=_K$/67<;Z!/W-(D M`+*0NKS[5(*2*_U>3R@=E_?Z)+;;Z)A)7)]A.H`+%7PH@3,"%,ZP=$BDT3ZQ M@/-(X#P#4E\:*.-VZXNJ:&.!/?A*-::=A]^RYKGLS/.@>*9V^)F%8.QW2O);@.W243K>!!X(2W!+M<[G25=A=/&XM5[D+NXDILM]$WD[@^PQ-@"<'Z MZ9"F5>):XEKBNL7N<#O/?66I<[F?511S/:4S:.!^EL2VQ';#G#&)ZS,\X%45 M=2#611()0VE>B[HE)8%=.QT2V,4SUU>T7@.QG5CL?N]C"'#\5X*-Z./.2A,E M+E[Y-Z8]H;;_`^D.%N%Z]D-8[=:?N93NKG?;9W'.6/A6(;_^*[WE67@``M/*M&8D=_"7]0>U=:\I=Q%WZ!QO2]4=Y$]U,H?@\/S)_@ MR:ZJA.2O<;\%[O#S7[\/O,MG75_\$!8M^$H7CHL)U=Z;GF$Y7N#21QC$=Y9C M_/GS?_\7(7_]G\O+!PI$V\\*>:8V=?$6-I"@3^:F;7H^YF-[H9>7_.E5\^R5 M7_@+U_;D>NWQ6WZ(3PP8&.CN*YW^],9`[CIJ1_4=]FG0[;PA@6WR7W_K=+0W M9$(-D`H9ZR7@;%^;Z0U@Z]^S%>6 M`1N,1_UF\-6+@9AEO%2UKW5/8FP&-@SXPA?4/'EVJ@SXNR8,/RDC^ M^8EI_/_;8I"]FGAQBY>NJG75/QY\W:>H\EC\S5_>./.%8\.?WO4WT_LCZHSU MQ7M:YUG=Y/ERW!NIZSQO4E(->[URV%,[W<[H!/Z``IAV*N&.=Y6=-W4PZ'7[ M]?.6!9CY>>L-.P+PQLQAX;R-AJAR]>M<%NY*USEP7"Y]ZLZ):;]0ST="O&U6 MX*E'>.AN]4PZ-X=,?&>\0=AVPV70QO3_X/2S:8CWT<:&_L[S`O!MWPY?5D8N*/ M,!M_T&>' M!*:!L,(YH&%%9D(/S/$5UPZ@[?`R2!W/$>R.,.PHI>1 MNT8M)S;3D(@Y&E^IKYLV/'FKNS8TYHDC^(BTB+(&2[ET41XR!X..J.8@F^=2 M-?8..#E;`NZ>NW@32\_3_>,4/T90\98NR$.X&PNKV/6X6/EP>(J+U1V-A15] M[2Y6SF&0+E8]@J_1Q;K]1EW#]"A*RV,2=Q;X0!%3%OYVSUN+NIE4/&-E%5(: MJ1ED5+1Q+4%B)]G607;3>J0$"]+*$@17JE(>B[<29Y0RL%?QA'*D5,N64E5: MQDWU5[H(7&/&)L6T:3/S1B[^FFALBY@3P7%PBW=[^=SK;TMJ'X5Y)5.$>I4H ML;+4J4@1%BV2NB&1W0LJ<>!/]7H*U9$C79XR]>($%Z=,4>7T;4J44"&^3#;1 M[%B2D6O7U>UG1B)Y6JXMW;[H2_;U]:ON@O#"^4TAT0SG$0`9[^RD50D_#ZQA M6;)U6,FLUN$Y?P_!JWLPAYST3#6SG=2^'M5"RJC!,,IRVW M3`I8YA0BE?RA+",M)6H@AW!FCC6AKO=_"*='P76+%;!8G"\8L(NSL>^[YE/` M(L&)[Y#/CHU:ID.L0V^8)EK6- MFB-R[FS58Z..VO2Z[&N];DH8F;AC4<2A13T#5-1YQK@GQZN2>::@\5*;->.( MXPR4?1@R4,=:HW2I]GDHB]H<.0]U^X-&+=LK%/@A&/>:M>(6Q\"4?1]JH*F; M]W[%'IHZU^%E7)!0!RG1TN**7TQ?J_PWX_ZZ[:N%HEZ"+7DQ?=-J#O`&CD2:NP!X6\SDQCA@6/3#S" M1NL1/`>@J]J`)7V"_SY1W86^0QW6X?^)"QJ+Q'V\>W?_E2RLP"/:E1:FS,+, M5AXU`JRI]+1DS/JZ[9NZ!3*$_^"+V#_//8U_K20#GUX=]T_R0-T7T\#!^_CQ MAK6*;SP'N@LM+?&=WW4/YL8)9D-C-C!+.JI=*AEK]2?=UI^![+M'XBT]L$H\ M89874K.IXX_4F-F`JN=E1.]7GK3KQ.BEA-G:V47Y-.=+NZ2--A)$U$AYOD18 M8M"<\X9X?FG?.!Z+I9J?R@$VM#?8Y529LPZJH[LPK%1*=S[M5`=J]P!>*J8^ M5PZ^O-3'RPMV@4?!2R;1MKJ*VVRV=;#AJEK?*V]QQ2)#:F$F]=\L;"QPT#5N3I5/PQ05INNMAC,?QURC9\X6O"+)7>T7*_M'!S6@+FC`MQDJQTORX:EA8 M.(^&HY,DFN!1!+&*@]2-LYHBY/I.]TR#O%),$0X^COY"77!VPIF7.(GAYN@S^9-K]>]Y4:SK-M_@_`Q"WC:WM"DAX)_![,\6)@X+IX^W?MMZBLP1=]R1K#O8GP`'C[ M\E8B0;FS$JKI^?7?J,9T_PR-`=UQ,196LR:Y#[NR"KO6H M.TG\OP(@:;K<>;K]...%B-B!=>A&3+!P"$MV$:^FR11TWH8%NP4TA@$;'IG! M*H(\46J3A4L7.EI?\&>P.7>"Y\WDU?1G4?4A;'SAFM#(`FUN6%\%#X4-@RY\ M_BZ>\_X&&@)_L<`0)NWK.?!EZ.3BS6]7#U?DE^OK+V_>,K$O`M<+=#`%8`7\ M&4UVA3]/XHI#Q`U8I2/X$G0*(ZXP3T9T%OV`Y]5\ML`G;K\9,\Q"@M//W/0\ M'.0+?.[-P^W-F[=7Y(:Z&)8"!$\==[Y"P:H_C]CX"[)GLD"3%7N!K0<3QF$> M4>\3<"R5Q("LVG9S`FL M"=`!K>J,8GC'QLI1(">D^(?CU",NGL;F?8-:UD*?()EH/-G?WD(WXK]Q;^JG M-^\?OGSX:'K^([[TIB`-BXJR=3I_61FDM?+@Z]7;^CWL8[-^F^\L?B1KA>JJ M"-T--O1)=T$#HYIKVP$L1U;EDRI4GPIIK5>A9+C6*CHKFU(Q MS1E=_OW[ZQT:$<:>J5JD$JL`-J3265`L;09S.\RO@;49/#9UG3DHU9)HX[", M(="P4=<0'(%-JK(X/^L"".E`_P&9-]9BS4T>:WX!;H#W-C81O"PE"YV(:D62 M!PGM@?]<<\0*W#" M,I>YJJMGW[)NS`E%5P]<)EAPZ^Z2X4@G4]UTT1%<+3V@-1:::',E2&QA,)P9(M,B)(GW7-)!-*DK\6YH(PF*Y\!3E M52]#RZQ[,S*UG%>/3'CR+VP@LKNA(M$)KG=\=/*B%OF4QB%NL*7,Q(0QNZ0AJG,:*"ONA6P&@U@<'=E+-%+?SW MV4'1/>'>QYXPZV.WCU9W*D`962@!;K^NUO'L<3/#UE7B_=7KT=OGNV=U0*S" MWLDX9)79QNR["/6?N>?IK$5YD0^QD7E(F+5-#_#T)1XHSK'D9.PBICDBC_G1 M\??@'(#>8F1-1(&7&/;D!ERD36SO/!3`QN269&8PX^AG>0;O@=I`^Z@9/\4H%%%K][]"ZZ>X07T>%7 M\'K>4<`S138MW>"[=$';Q)OT,!CN[G_*NHI["?N)NHEYX)XD^4N0PQ(0+ MZS=^'I<+RDYI-KX_?!C63\3_GDYM+&!^HD[NI^0]N(9L\C_F^&IU,!\V]F-/B6.[C^PV6/%:I8SV/PBR'Y*^L>CZ5LP MVG>P!'HQ)S!5L`>CKJ(S2TYV4;+Z&NZH?-%=T*I'5[<]G>^?)])`W+_:U/5F MYF)UJ7>7L&(YO]>!!_+1I/`U3,GIX@Q[9YTG^EYU'?=\X')O#BGOZ--[MTS^ MLB9ZQDO,2IKHATG1XP6>*[7;#X6?G\G]\0F)@;D)U_#\!]8X+!_`6F15[R/C M#E8DK%&0("#]*#O4BWS1`R6P3IWX>*^,K@JR!]N=2[X M?KJ^D8QD=89C82X#,+$VW5S\Q)TD3,:C\R7L`8B[C=I?S]EQ'[7]D36-Q2-. M&__^2E!%4M4B>>:#7K=D>8+)<;'.R&UR$Y@O*A(QB$H4Y+F^:\#?C5Z-O/K$ M>U%HZ#&W1_N#L%A#OKYJYBS+F/;5_N`4SM[3$/1\?R01<84I>%+8B5Y@SZ\> M7SU]W/7>\2@1ZWJPCRK)SV3454T]AOSP!CF>]IF\1@^Z(72^L)PE!0.C?XL/ M=Y9Y$A"N)A?OL^/SLC;@&]R_JWR)(+&NLZC;>F`@/TGJ6 M>"M=2'M3*%8GG[R9$JL03?%"$$,OCDS;6*%M*:Z2ZC'"7.V7_F/F8"0Q;DC! M3!.E#S.IE[H)RI]F#R>?S3*Q#+:V*KL;6Y4[&D]DCHFF&SSLX,F./F^XI(EG MPD?2?HDF2<1TV`PZF6G MT?-1B5)HW:#3\^^GVVV=2*HZZFM)4M,[*9/:/!#M]OJ].JG-F=>JK]5,;;[E M;V^8B=J_?O_MR;7@P_\/4$L#!!0````(`(YA#D?V__YBN!$``%OW```5`!P` M=F%S;RTR,#$U,#8S,%]C86PN>&UL550)``-K$\Y5:Q/.575X"P`!!"4.```$ M.0$``.5=67/C-A)^WZK]#UKG=679,SM)9BJS*8V/E+>#):8L)/'GD_/3LY,! MC@,R">.7SR5X.KRY_&#],PXJ1L MG9X-+LAB1<.763(X__CQPV`X>'=V_F'PF,[G83*X#F,4 M!R&*!OHV$8LX2WAD\& MG/X3RWZ\)0%*,HM+[&_/-)("WH\V;6DIQ/^&DFPH?AJ>OQN^/S]]8Y.37$7Q M&-"()']KT.V\P6/N/D@@_X.E`_/W+P\V&>XD8 MF>-)&*#H-"#SD7@^&@A)A=X@2%$>,: M9=*3U0)_/F'A?!%A^=N,XNGG$R%_*`!P]NW[,^&>;QR$C]H:D$D<,X:3;315 M26FMTD^$3%[#*)+VWL0\1B_A<[25,R%26ZM\$R]QG!#*0_(5)UMHJ1'46C$. M(9+&R08[#SC`X1()J[=3%"BXM>)7B,8B9]X2QNXQO2#S.8D?9XCB+90&"&VM M\`6))^(UG?!_,!*%$]$#/";\SSF/*+N;7B`VNX[(*_LE1NDDY$_;F-"JF=T9 M=;<071WO)`00N#\7%,\X0[C$-[R#G&/AZ=W:ZZA!MZ[X@B+1?3S.,,]\W=NI M$U\V@BL9I%'F@5O^_TK3^"W!7.Q&(6%(=U9F2D@U(A)4FH[$X('0JMEYRUD? M/$7L.>N(^?CI!:'%2+ACA*.$R5\R!PW/SO/1PC?YS[^O^QDI.4+/./I\4OTQ M"1-AJ?QQU)>JLM.I*5O_.5>W^+FJ<"G$8UK5'=%`"N'_K,2W.=K)*4:,#S`S M:4,>Q[GDGU(R;_B1:)4M*?5IL.8:)&104!,ZP?3SR7LQ6G[%8KR:#YU[BT9I ME/*5Q$%**4\AM=`8:7+3-30^!0UBAB:"&M8\G/_P)YQK'2^4850^JV2%"W78 M]JC_/<4+%,KAO1Q(F:QRX,AM!7'T#=RZZJ2-I0HTYX0"U"!Y.<0_^`/QQQFA MR1.F]=- M)+DOU"0>QA5@BSFN:@%Y7+_W)ZYR5ES,AA]P)(;0]XB*]9IZ+P4DEQV7E=S# MV#O::,:!79A_PQ0Q(1=34_[7U9\IUSH266F<7"!*5V'\\BN*4EP#AA-/[CD@ MCX<0:6.M&2=`B3E8SOT!BWE933/6=>&II1(+CX=@:6,M+*E8)/HWGY6+Q2NN M9@T3JD>Y,ZJ//(RP07=S(*N,>;R^M<2KWWFZXXPF@ZMRTN)1#KL.8V[Z;;C$ MD^(C2[Z@T``JC#CWB(W8I\@Z&:8)M4V&?Q/6>TH6F":K^PC%"4^HHO==B&E8 M,_(0TLTJAHG4IZ@[&*6)N5F"?U/9TM=HKNUC0H(_9B3B6C*A>;*J11U*GCO) M3NZ#X>IQF9Z@:5S_JY%?28+9/5HU)U47$6(LG(9\^JVTLP5G[@`GSOY>:E+351;[*H3^0H+D%$`!.CD M`(>W/640>Z:P9P3O0VPWQ_$-KP?WHS_!?411U@5?O04APT_HS1AH(+7\/F&C M]A4`;F8"P&`5Z-_RILQ/7%GKB`A$6\OW&EI?(>%BHD/VUXCS]PN(,3V8B6I+ ME(>2#$!&`4*ND]/E0D^S_DS\\KN]X%@;3S>^(L10/H^CWLIT&!"@HOU;F\Z5 MSSHT46<;,K%YP@@?,VT5,CI:SV$",A$.#9TXX"I13^XQK_L0P,*)SD-*R<)? MAG?&HX7SINXW<1"E8IO1/:%9F)*$AL]I(CJ&)R+*\TB<<-]S55YNX@13S!I# M\4Z%RA%[1T+[2T^322C41-$]"BQ&B2S=Z1KWLM]+YVFV4)?UUIH="5]QQ,RKFP]!\[U3))#XY#8.PWN'`&7+?0QB.":G.#MH1."%Z^/B% M.5\2R1RA*IXS4!15\4V*8X*8W04[PI2R8?]&VD\4(Y;2E19#>H+NUNT&--,TJ'OUNT'WO'XFFW*9[+$M/JLQ]U[0@GNP[S`XPN.\;2QFFZAVNSITU#UEX'4(2!0 MBRJIIB)KO=-/(T/5Z?2\5%1H?LT=L\Z!*4^#13[Y@J>$XHU-F%V])11Q4\(8 MT=4-=RT#?>K?0TL5O.VHI?YFSFOMA2Z:O&*@D'-E%45_YX]1<=(A)6"%.1E-L@#61*.PI2'I<,M9XGX"LJ:[_ M5D5M:N`;(O90_5H4TNF!9Z0I3PF:-%[&"V*/+6`:&?ZM^#[A8!:3B+RL'C%= MAL'&D/K'/QN=_`:HI_,RV%"[;`$WR`'N3]FG0U0]';%U(147E"34$U3GN:FK M62#C\[,L>XJY>1ZE1SX];^0S&^$FJ>D)?3#3;)O9()45^T0H(`C$9DX%L'J! MZWQ=$[27OE6TV>PIE"'3DU5BIR([C"!:#72.IDKB(73`V8%^UNZW0J7M?',J MWR$`,\\!`5J!A],9@[LA4[]L$@)=%]JG+TR+"<0T0Z\X02$E.X>[S.W?IYB- MUG)WFVZAI?Z\OLQ2/.]ODH^S!:SUM3_B?I'Q9![&(4N$ADN<:UB?]CLQR84` M(),'F&[$C;2T60UV*3X;CP/%^C=,?\`,:\=D>R@)S5@0+2;BGHC MK:?P<+'0C@J+-`^+`RW]@2TE0GH%A0S56]%WS[B/#QD$LII?\>D.M:K$IJR- M?SF+&T"JFJKSE95N<^*/EJ['3W;KL!1WA0F]&E_;3$2;#V5JHAZ_RUKC0H"V M53_1ZL2N/]>JQ?DW0\TO72S>3#6X;63%>:4:,L_C#[0/C@"]0!]G9GOJ?Z`I MU$9,==GU5:^M/(RM%;E^#=: M,NWZON9Q#U_R4UN"U1-%,4-!%J9XDOTO#]KD/^GZ+AM-)=]N&REO`ME!(]YC M=2_>=0']KA2RY'??ZG$5%YWZ=<7+/:8AF?#8B"VM^!*O_ZY_\6K!:KSP1DF7($?!E]0L3Q]FO;^CB_=F8PW.Y/II)T3W69Y6=""LJ@;<2UM\9 M"&B5O01/9!SPR%.L/32^YCYW1GEB@@-CK\/!+M!!MG!4?3BXA3[9>0H.>GA8 M^]Q0'W"AH1./#IZ^77FX0V2Z7IJX`U`:KUVTKBSO]WJ2`.-)-AD395QW4P@@ MG9B**TM`3$P@[7LX*"S/[PWYS$:F6)TYOGP&=$+7P-*V M"EQS.>!18+O!Q2Y&@6!-_%L(TUBTJ8OM8A3H*,P\"@0+Z_/LF0IP;F+]A;*- M\E9WUN)T&`=6[S*N*T;(5LZ"9&&@1GG!F8,F3G*F%(4OV#5)Q`'@4$.O!6&#_C@1:';+SN'7:%[FP>^\SH/9B.%JOHC("LM9E/-`T[4!2]@#E"^:?*)HT]S:[,)GZ=073<4(5X*!] M].T*'20HSWP&Y66*Q8>#Z@*5^KKX=LSZ?M_(?)Q@=7#8[D<$1EWD\,"G70WZ M%T\>*T)5LE[G-"%NVMOZ5:IB@2N3]L?FB;([432A&P' MNOK3>CMF+73-S,>)70>'[1R\9EWDF,%6N7GH][T<)K+`QR=L#QSO3UBPKNZ/ M&<.-#XR.7-"O.)+K&$#6SD7[_G8CE9#`_.AU=UN[01*\AJD^)1I`?YQ`-+ME M;VN8]9.VWWWK?5J\<,^)2A9S0KSXO\F&)N?L)Q5>J//@]YWD04U)3V:%.&S^ MFM!+DCXGTS0J38:*P^B+8V84FZI;BRB*>%N(.`8P=N"\CL'93B/_:E`O\8+B M(,P,X_^.L*QJFHO+[O^+%)L075@VEVE#6(X!J2V+9AQR7J[2J? M=U&B#M;$O\GFU72*@^1N>O46S$25XP-*\%VL]DLM3;1AS8/@QGIXB-W"-5OA MTZU=OZZKOD(TYJ\+$\LR]]EQ@&+[EBC*O<0)"B/6VV%XOV6^P9/QDK_)+_AK M.G_&]&YZ&4:I.,%/J,CNTH0E*)YP"VJO24ON'`[.W/W.S\0P"$6EV+%QDM#P M.4VRS[>D*++.=^T92N:[$UB>VVTIL+]>K"0I1\4V,[\M%?*O+]4X MHN$!;E,8P+*$F=><(W2\!PGA;?RS+5H=V\Z!J2M.V7.W:OBDRT>S?7>M9NW4 MU3)./#D$@#S]S=+7)2.R$D]3)V2ADG-Q'55_+[Y;R`C4TLJ+#6HCFS_K9/MW MC,PXBL@KB@.L6(0J[-.\)FUXY>OBQGM`P-K&*^W@YMBBAR=5-+6UYF83:2TE MJTD/"5)PFULBR-B`91R\Y^%&:4>8!\,+J?3=8XL,G.#;<"F^ MJTFMUJ4@S3X<1EQ<76@D[O.&1IUBJD.IH>1VLWL_E!H8/^)L=.6%-;>2W^5H MD6Y9T_,+-7R^D,[3;/.1H[:;2/;%:^2OBZ=LDKU;RA?LD:/8SUZO0ZSW@)80"O\'J[?JU;NM&\XD-JT?GH@ M;[>;I3`H6&5:%G#V_UU6G%J4WT6]600N';[1OB?5]#CV)K6+^FY\!4*A?/TF M5ZL'8/8"K=OSQPS'T!&HM?5O&;!V-DE;)=^_OE=_-(X:*&!Z60AKIS\P\+AZ MH#V,`"UY.2*H'59GS+G0''L$P(%:W!XPAA;:UFSE#\0?SXAA_LO_`%!+`P04 M````"`".80Y'^B\;5A(C``#H,`(`%0`<`'9A`L``00E#@``!#D!``#M75ESW#B2?M^(_0]:S^O* MLNSMV>F.]DY(LNS11ME22.KN?9N@BBB)TRRB&B0E5?_Z!5A$%8_$2;``RGKQ M44SD@?P`)!-`\N>_/R_3@T=$\@1G']\/O#VW=O MWQVG*3I0=4J/R`H1^01Q6\/#YEP*N7WG]@?=U&.#JC26?[3GI[>/GUXB\G]T?MW[XZ/_N_K[&;^@);189+E!96&WAQ0^I_RZL<9 MGD=%97&C^?,=23F##T=;64(*]K]#3G;(?CH\?G_XX?CM(GB9!ZE;^=X><2>']V4=SGZHT19"%I\?,.X'3)4O/OKAW>LS_XB9'5DJ]PUFE-&Z?HBSTL4 MG\SGN*S@=D5P1O\Y1\N!*AL*L#;D#+.!4S$[R>(S7`FA`S5!0[37X3J@[U,V M4ZPB4JQO293ET9P-N6&]K6!IK>QIF2<9RG/:(W=T=GK>9Y1#(6BLYPGE\APM8VG-T\1&3(+*7!U%KA&W3/3+]&*TS8PKM9@ED\ M0:HE(V_][SK)?Q\26]D+&\_`,>UQ$!-$>9)?+J[8FPB=H1A7)H70Z9[2-6(] MG"8#`S%K4?:+#;F/LN1/+NHJC;++Q>4*#?>,+F>7L=IM-=LY"M4X,U=!DKUR M`D8CADCVNNKS=A$@V>L),!DC/+)74(.IH^#(7D>8STBAT2!,:O!U&QC9:RME M-T)89*^IFN=X,8.]UMJL]Q8Q#%BV+"7MS33^]SZ,V\FRAUTG]>@B?3EZWG*\ MA.4XF4K'*W`_*-MXM%=,.T@C!XU@!XG='83-`\,E\<) ME!V'R,Z"X^%A\6@!L?M0V'40["S\'27P=1ORCAGLCA+F[C$*W$?T-UX2;(3L MUZ#`*HO9^L"\F5/;8Q9UW-`.VHR4R\59E#]\3O%3_DL6E7%"G]H%7!9BQC/J MIL#SWQ]P&B.2G_]1)L5Z7.ND\L8S0:K@N5P0]T`;)([K(*!?$IIUQ#3?4 MP&U7G$8I.ZMR\X!HG+&5R14-B;CPO&2PH$L[I M7%NL+[(%)DOK%Q$YOZ::$9ES3>M_-I7='EQ*LN(H3I9'-X?JC4K;@YT(K^FXT@G!W&:!&5J4;@IJTCP-NMQG@9)1K.ME&X9NU"WXK5 MX1(M[Q!QJ6R;KP--'ZA29%[>H<-M1SC4%^3>U)J"),D2-MYF]+\MP>BY0'12 MV4Y'3-TAT\-H8JWG/E]:2-:4\55RM+;O5U%9]%4IQ=5*\;RE2\H.]&("#I]J MZ"RB_*X:/V5^>!]%JR.V0!VAM,CY+]62=?CNN#[!^Y?ZYW]N]:,=@"[H/[?O M!6ETA]*/;\0$=&RP+H$(CGR90SU.Z`LV^H0V?U]D_4Z_QFGZ&9.GB,0=6RU; MUQUAW+K=2SLLGI!V?]%9EHNJ)US+M6-!\%+J43RT#W9&_'30EW-0X`-C_IC0 M!_7A?6^XZNM([4C+N'I3)Y73BH(D=V7!DDZW^!NF4T]64%=05>XOL@+1%_ZB M-[1<,MT.1S=,@P3G*#VFQJPKL364W_N%,DOKY9=EP6Y0,!.ZJ!0]YP#K/P\3 M*PH[--S>YU![\(/_R>@:K4HR?Z`S:/RI)`R)B"0XKG+,T#RC0]^<0N3T87K< MT$[-@2_G6"/BOX)%Q`;%!I!H-]#`!&\P.5"`E@Y#!6=9P^('_[#8G(7H(;=2 M]#2J7E>6;&NVE?]JPL2*01,VA@S"A=&0GM"$E:&(&F9_#1%FFZ$P!&T[7ZY2O$;H-GKFAT36 M8(RJVZ@5N*H;A8D*&XMU0UPUV]KW?PMQGME,D.S9Y:I*`YX_(S)/=@E-QG9R4A*)LW#]V>9''UOW1S_B;^5YE79X>_H>)R0>?K#A;' M%5)[:2PA06)Z+SVJQOU8:O"QX3?53O79F=.!-/BL[K?.LR`!)--?[?=.:^XN MS^EDKFIU"4>T>=AZV-TXK!^.Z;'&$1J]Q4NBM\["U&[./56EC8OCG^8IIHO1 MQS<%81E$]@/."O1E:I]+:>J>$-",.C,+CGAU M'"QU(]:S#O0SQ)BY7C"XST#A_NDKZV MXIC:X\+G=5<`SSV%7/+!BM6F-+T*,F/>!)@$,7IO276A:"WVI(2B[@"0(E1O MJLW1\B?()HB1>1+'E?)1>A4E\45V%JV2(DI!WVK1UMVBH`W5WR8F:GE>P3"( M(Q[7K(Y0AF)^,0]TOIRH[A(14:CNUC)*R\\B3D&?]HQ\]'G:Z:T?]Z.V:NNL+H5!NC&Z%.)0^[2>M4 M%<-+R4YEZU[==BI4XS:[4WDF]_N="I;5/'`J2+OH@]O1*ZI_X=I[1A5`W%[G MDI5'<2RI6PK&[7RGJG?C5)I>W1_'"YMF,23'AIJ7C'*[>$@+:WE=,O>P=+HH M];;?M7QT#[\.K%B5SQUS[1Y>G66YY MGR]@8$%JKS,XU\A7YN77B"3,*?Q:WN:2_TQP_5F3NDXU**G];?=$^0-S"_V+ MY4`>H[2*LXJSB)`U]0YT;\RH#=\6TFOC*<>DZTUL9WPSTZ0056TIZ8D(8IL) M-J>9@N):GRS9@&_79)0.)ETFTC&F9A(^Y)QTCR$&;64&L5-FJCQ0R=02F5!- M5#MX`EF0EX11<4>-#-26X"#V]&[H_)[7H6BCSBD_1`<_YLX4GX$+/G>]+S!Q27*;I<@`;P5]7NB#5KQ4>R;JN] M'H+)+-UWLO%YM^`0Y<#V$A"U.4 M+/P>SS8$GBA:,>NHUI%//0V$X8I2ET%X>$*'A.V:#@-H? MB?5VL:CJO]^2&-5O[E^C?V%R5N8%-8;T7B[X52.S5OSJD6XKCQ=N.I\@OJ+A M+MLQNT?'W65+@W1[#4=&ZNLHKZ$+L9')K?.\>I(V%WAD$H*(=';O%SV[3M;)6B=*-(,EZ:1(VE;!F1`Q`1U M?T,$@60OAD,*:W0`G+>PELW`",D,8M[\%BVI;2WUP-=!)1W/SXOI_"4>)![' M^J8U8='G6"7HQ9Q>AK-[K[#^W0V]U5OZ6_J";NAQ!^_:@JJ/7]`_4)06#_.( MP/?M/ID;^D]=VP$D-;N515.( M@;'291_H!#4(*_T=@U#0`L43+N$B#3)<`":8+'_GX!$8JTAIX`-V7INI8,&B!ZR@ MHBN,[-/CD) MSAY2&K[@PS03\;Z.A5:+/LPWC$]N;7-\$FM.U_5#^51. MQ$_2"XA"\YR6,5)OB3@$D2G<5;:@RE?O"O`1&@G1;E<:))IR9*QEN(.06"0G MB-Q_7SG1,08IF1`F_H-EA9M!(.@<:`&8PMX.*F@>Z&_HN(I?CPN.J5BZ7'4H MQ=#IP1Q!V6X^\IV=IO)]J;>GT$QP*$I-*#HU.0O@ M`-3K1CUX3K#O0P?;\V(IYIOROJ?O[^:.MQXT+*]URQ&A=9/;^ZM96T5H"U9. M)'*^CXU42V>K=D@-W=S>^IS0Q[2_ZXM1"E0,N^L$,S>ZOA38BO%Z?>GU^M+K M]:77ZTMN7V-V0;/HJZ)2LL[+2I\LE"!4M;*E,OZNA2 MB@..'>7T8@V!E=9AQHY?$%-`7W6(D-.& M$BH`@QZ;&2I?(;;L*SS(V08Q/[S`HFOJ>,"HCIHX#)"41O-[C.BU--IK:;37 MTFBOI=%>2Z-YVN$7?\W9]T[^258D<9*61?*(;M"\)%6M_O/G>5I2"S]3_U%E M5^7FB/KE@AM"C:C4GPGV_5VSY;DG9VS])>.&F;#YKIW;WF[S=-/5G*>G*<@:1$"S.[4]T"KY#6B7S'N7H]TPW^MV_QA#:-3>'FLL MN59Z>I78!]I]NH89`-F%/4ARL[[))05RJ\;I(!N^`AIX![ZUX$>!ZNCW(X@ MUDQ80?;:!.8"=,FE8Z=)[B\-M`^,"H>"L,<)9$MTE:=6CM:+Q97;->IEL+HQ]PQGA_SV- M\B07969'X5W#P3%O?X,]RA_8)3SZ%RL/\1BE#!5;ZSXE.7MII\9T)P'3=GQR MT&_G:=(8!S78OLN:,X]3Y:II2E^I(!8G%QT`)4>=\W4X3_A(B8XV"L;JZ%%' MB4.EIY<2W1I_NM[^\Q$(A0[#^L9>D0ID-TT:]0=+(I&7G..[@&,+;O+->2W M24-=;<):$9IA;5]M,-5BU;8+5KVV_M*$AMC"P[H%!*54<@MQ>A*_+^#UVVDO'])2('-=HZ4]^+L8"!(^:"-E`_:2/GPDI`" MF^T<*1\Z2/G@*8\L+U#$$\I<,_?R+[)'VGV8)'N2]P7C^"E)4V[O159$V7W" M[/6>/6=6HEGRB.*=5ILW0&%2W*`)'\!:3?S-66+U*#Y.[O*"1//N.6*S1NJ. M:#7R-:F9N!9;]D%K6M,06,UFFH*"");X<.\`IOLSOWNR_7DB3A?88>/6':L@ M8I>3):LI^6=]2*.K>?>0C18Q/V"C()Z(ZXULM@&$2D`0-T3%QOR2HT69SI)% M;W/(H(ERJ6@VF0AP+.QWNTPTQ03Q-4J)25](_QO$NN3J.*,FGSQP0+L=QQ:U MB"`^72E1D[Y/E M9/1^]!+@U+?9_?M0^V.7`=Q%E*@KOV>HV[!WAU#=<+^'80P!9-T#-F`R$58# MZV\3.GPBMNETO:F*D$8Y=+_.HJ5Z&NNW#.3^FS;0Y/.;HF?@NVHJV8HIKR\S MB#R01..=OL)+/):MU0B$6WL\76(!)CD&-?I'C(G*\2DQ7](5ELZ^W^Y@GN/>K)JQ[1488WLN`=.+!!F9K@@&2 MQP`ADQ/$;%0K*,.&#`Z31\"(3@_J-`@O.#9+[>J$Z;"6+'HC.&HDE/9!![*3<%G?I8 MFN&TS),,Y3G_4B7P4J]%R]-)^Y8?1T(OG':>E+Y`FOERO!="=B-X MQ03)/LTK)^*50`1$GA9S>%!A36-:KFIRJJI["#AX+LM;G5S=3/3CGY@]F<]) MB>+SYQ4=.&A[4+AQ(W%\'3ZA!2($Q=?H$66E]^+#'75."*&+;S7&9X*#N@8M M:EQJM?#WN07\6.ERD77TO,9I^AD3&J;&G2XP:<(_R:#5Q-.T8^)2;&5^"4HF.V@_E%(*9YTG4:!Q+%AG4_MZG$6>_[ MG"J0[1IXW;PP@Y`4/6*^C:,@#BYL!B8';&BSOO<;FT`*`0.G$('?+[):'CLY2*@J278/^EQ- M6-LN(YR(K[5MM?&SC/DX8YO+VVD$#VLEW78?74@W$0?K6FKC7PGO@7E0@7O9 M5P.2G*UVM6J"8Y<*LL:7&&"RB?A6TTX;UXI9]_.@>]VI_X3N"M^[U33QR-&>ED)DZO2FS]V0[23:>^#JR(N]M+-._=6`% MY+.9[!KMQXE03N[O";J/BOJKJ[_D*+[%)_,_RH2@;[CHINATR7F9'B5YL+XS MM%3/H6JFX\0HWTK6!9>+3U3.G#;J3AS"Y[5UP/-@':>R1<]3`)<@]EFK8UM; MM4\Q(?B)??FLXU`56=T78K)@W:MIF9Z7Q,K1.;T073?WTDQ;;A-+NDW#!8BUM;K@<:$?1!;M[O+!BVCY)5"Q*2] MVB`0Z5XWW#0B,7V[-$,S*\M%:D8H=C<6K&' MV[=S-?@&,;IOF5FLD&^I/2U/TBH)G$>JUCG\F2+>`7Q!'[GFZ_ M)<7#-4JKZI7Y0[*ZQ><9M1G^II5E:Q%&5*W]+?UR2$"8,>J))II`42",5"+" MG%#&!%AO`0X58E#,X1ICTFC$%` MJH@HIN_$C(0H)9SK6&RPH9 MM!`#JM]B>BA26#T0.GWN-5Y^#!8OLM#.N)T&=J85$MKV@"L:7['#XA%!IU&>S/77.6ES]4HG:#X]C)GTAZ/53B"*(\YODMQ`[T]) M6A;"?*DY`W/4;1F\'-S!?3(2\K;"./;\'BQR^NX2Y0_T`:NS_1BE;/-AS-=F MH;`QWID!81/!_U[ZVMO;,J`8'U>.[_^/]I)/N2"J/6VY+>KZOU).N'F.G MI-1Z?$\C;X"'@DAAJ77FX]7OSLYH'5"9O*\QW!(V]D"MA7VOHQ'JZR"&7*T8 M'U=^]]9<6DE#ZA4BQ?HJC:BMFV5_M;DO.=KP4LH<891)9'Y'@TVWYWV-.8E^ M?.C9;HKN+P1M/IC/62V2_"I:5SS:JW6#%OQ=CV:)#$9L&TE^9CTNZ/]!>/X M*=E5*ZE'3/?GNB]W/P>.-H'^)EC8L>">"F,OV1";W`P0H]^0HZE25\JP>5$M M)7!8[J=W]S#CJ37B5SC\[ICO+M9#F_VGZ\;_Y+6FS)KWZD_I-M]K32I=U`[L M!1,XFHOB.#N>3B$KP#2@1H:"2KP]'E2=#$/$P+OCVM4S]*0)ML4#JH0%:;>9 M>>%22=KT$M1TZ/U5RE`!0(`1F;V**8A7+M!@^S+AT2OT$`Y`H#H7+A`BK6TQ M!"/CU;.@<=5O.'U$PD);8H+=M:`>03@ALV`(8PW#5,YK<:ZO"O4XCE.^_`O* MGE`5*5.93Y5,T'E*.OX.+J:;@BMUS33VJ(1Q$'6RON&,L&+Y),GN3^)_E9OR M;4#@IR;DHUE".-GP3]OZH1&@3%#`@`$7>!U2*6C\1WT:?A>B0QGSB9F+D1!4 MQ.<("[V@)P@T0"'><#A(`SQ[0(P8WH%2+Q>73QDB.2NG%9/H*4KA\,&RM10' MDM:>0@VM\2\$AFYOJ)'2""1-)8T39<)JG.*L9/O$I(Q2`]2(FTGA`C6;)$Z4 M]@\'""1BG]/*+69I?A+S;T,8H$/>5(H04=-)HD2K'X8C121FG&$PCIL-)BA M^RC]C`3OKQ8MI5@1M)PD5'1Z83A2!%+"*4_T4C_>8?Z6:_E!#_VW6\E'/OR6 M/GO]R,?K1SXT_/SZD8_7CWR\?N1#[R,?>ZV)79<^7$6D6%>%-:-YM0SY+HQ= MZW75T6O6/=!2PU67O/:?FCRDS>#=Y_TN%[_B@@:)_.5A>X!+O4-LP$12JD&' MB:=QK@T!0U=S=9+P>DA5726_(:3"0#T(I M@PE@:W"_F.+*1F`0.V+?:=JK[0J;;"@*T:U0C#MX#E7C[CN&17Q!)QN9*\I$E3,@ZC,7"T2)XM% MDB;4(,E*+*)I+L)]F@E@0,>[U";`(T%WUB"CQ+F:T"R-.X5*QG'W#P MQKRA/!T/-@SDH(X-\,09>G47P:=X#+20I.M!Z4$<_6BJ!1[Z$!,`T/)_H,?" M_5C#2(VY#!#11410AWXL/-\[#./1]]`1'U?.EQ[Z&>K^\8X!\>3=I^@QB6<) MHJ'F,LK`$T`ZI/PM2TH:0-#A MRS!]@KAN)E(17+WTB.L>5A'["VN"4C09EW8U22D_QF>8T M@TWL;,)%SI\!0LHWB,GF15^?MXR6+._0&\9`DHOT(554>+U(_WJ1_O4B_>M% M^M>+]`,NTGL8W;?,K,O%118GCTE<1BFPMDMIZGX1T$Q[A=6K46H4K7V%RS(L0*!R:@GFC`#18$P4HD( M,75R@;_VP0__+DYVB9I&OIH1(9:>=<"4SJ*92Q MG3RPD>E2]\LE-L^EP)(\UPTZP\MELHG!J'YG.&/%2U`V3]"V=!!7R[WP:\2J MIJ3KBSPO45Q_.)7*OR(XH_^<5Z>X]Z#'37F7HS]*EJ-\;$KTM@78UF&[]-7I.EN7R%!."GZA7SZ(5?5*L3]$" M$W2-5FFT\7#'+">\^"7A8;P\36M*QV*WO=0*U@6RJ\O'PV0&$5:9V#``F`-P M^&)@MP>4!;(GU$YYG$9YDM^L"(KBR^S7B%0?ZKRFK[?'TN2@NAF8*I0U"QA( MEK;K@DB??1#G(3JF@'<7)23P2N_CYJ&.ZS4LT74SS*JY$32-:X)=.Z@\Z#R7 MG$J`@BV5WZRCS.D`*&#;)+C8'8\2<0HB_@"T`Q,X2CJQM_UG_53.A/VM/L`$ MLQ4X/:ALWF"W]Y)2_AT/GD,:X'GYZ2(+WP=S9JBC(9B+D]+`/O>GE]?@:FK4AB?I]-IX6FTE@Q7;V2N"Q&Z]U>2JOX=5_\[^ MN(MR1'_Y?U!+`P04````"`".80Y'=5$N8!^+``!QQP<`%0`<`'9A`L``00E#@``!#D!``#MO6MS MXSB6-OA](_8_8/N=B*Z*4%:EG=W3TSWOZ`U95E9IQBFY+675]&9L3-`49+.+ M(M0DY4SWKU\`O).XDH`(._-#=SG%>,E?A#\[O],_^__ZW__/V_>_`0C&'LIW('[9["X M_FEVMP]"+)J`V[LU_A."=S_\\8>W/[P%EP"%+P/HB\R`^\$-S&091B`Q-P`@%N=)3\Y4L2_,?O'M/T^)(-]+Z3>NJ7^YC\/"P+L?2U]<"?*O-X78 M&_+1FXO+-^\N?OB2['Z7-Y$\5G!2B'_IR.??"?^(?_Z1/BU%L:%`8+K\VOC7 M`R#[_6(4PCNX!^2_'^^67.T__T@D?HQ@>N/=PQ"[I.KI\Q'^Q^^2X'`,8?'9 M8PSW;#MA')=FR*_S9_+K7/PK^77^5V7YQR'->R!0W*+4"\VTD]KKMK7C9GBC M5Z9^6E&35R9_99PBX!E^Y9J;X8V^A7&`=HMH9[_A;5>F&K])O?@,4.DZ&_X% M[+>:T=20?'2#_VKXA5]2&.W@KO!,;`MR)W5-DRVU7-I&?L-J2'H1%#._#C68 M0/^'!_3TXPX&V/#%'\@?;\@?;]Y>Y!W%_\(?_<_L@%N'_Y>^#[V'PAS])O_Q M.^:S-$C)%V@]^['96J+?:"_N4M$I]F'+0Z<%_Q/>AUJ_5"/06=-X1@\A=DMJ M"QB]^;CY'0AV/-EI^1$@G_WO'ZLV=[_G+&Z&QHO]HD'X3\F7R"5^]!'N+X_I MF\;WV`RP`B,2X():&$JG_[$UH M\S0*E(LMG@GPU\@_$::5734#[4*9_#MS9`;@G&G1%,A%QGD(Y^M,BT<@>^8( MM,5Q0XH__$:$0"$%,K%Q>:`6:*09CR8OA&H% M/Q1LGY4GOZ#P%.'AS?/[(,1C3"8_.#(-7G1D!O.A9=$L#]C&Q?AGZ12X+Y^! M[*$+:.>%#2G^RBQTM\2;J&;:.BN:\WKJ#AY13*9/\<`]/;%!+19M8)LG.ACB M;,-FD2[T(0:\0+7`?5'4ES(@$W(!_Y((([U(L-C`UFJ20F3YK-R@I)SC:NP! MQ<],2C`E&DQH20PF0,.>6=RS3(OAWM4H4$Z?@.*1"]AFAPHI_;8L)#>$FP!F MV#DK;N_@0Y"DL1>E*^_0AI)(I('N0!? M3L"0V@_,`G!3NHE@EJ7SEB6X`XB]$52-.BX=*# M:5Q2P;H0X"?N@!E7MR0XL_,K"N:XJV"@F7KO'!&AP.*-BGR?]L\ M>AACZU-*%M7)Y@@VMA44FD`7*@Q'O<"\80K(/4GX(#-0DH,*`BHY`9DLJ`D[ MP145'*`^D6*R2*#;HI34RYFGXJL%@??XD_8`5B+5FH[O2!F8D&_9-#TESS8O MFY1G:573\O5E)_KLV@%[UX$:W-MZ'<#GRU'.09X53R;H.3^]"/8U%3;P.S;/#/TM-LM!>_U1 M"^#9(P.8)H9,P[AF4X;<4K0"*_G(#70V?G\D_MW8&"12;=A5F@.1MO>2>_J] M3LF;!\\[$KC]\4<8IDGQ"<'='VNXRS_^GYGOHQ/=5'R+PL`/8#*[)Z-B/VTA M12Y8;+,2"/9$J;RQ)G"K[(6%9$7EZ=5LL]R`]7MP>[?8+%;;V7:Y7H'9ZAK, M[Y;;Y7QV`V;S^?KC:KM<_01NUS?+^7*Q`9\**__?R#N[Y"A`NO%J[?OBZA#V MJ%H>FT_)+-JMTT<8WT$?!D_>?0B3%4SS:7\VM=1TFBR3Z9@AG-B+!>XI.52@ MH8*=:2$*\,@.("(,XDIZ`B*8.L$Y17ATZ:<>/283Q>H,4JKX.Q]3>M]\3GQ>F`'JAA%"`]O@I\,(0?2;OL8`]BL$.G>[3_2D$7MV`CPZ'("%O M,`%O]_=3DI)*)"$&_N4/DXL__1OP4O"?IPB"=V\GV7M(1`L_^^.?+LBS:^SZ M<(_;\.Z"/O_#:V?'Q;GI<7$^?ESJ\"/MOCO4DQV7IMAQ^2U_UZ-X+H1>G@^A M[[00VGWOJB="WYE"Z#L90E\[.-^=&YSO'"C_J\9]H)TEI^+GB;6*_*Z8(?:U M#=LHY3D^5,C%5&W2B4(!U+``/F6R;@R4^1%F4$D4#39YVAHLOK"MCLZ06^^9 MM$D$F8+M=C1%C+$C:99769HC"68CE3HP5"LR'','KK!`DX<&1S@_^IL!C3E M6?AG6;0&$:WQIDKV9+OHAX[Z4#)_.BGVZKY\G$B&:7V`TAV(C5E)2.`Z, M)UJ1HR%`JB?=2F8"L)1CR=<4LB2)>"BTG$O**_S3JN?EKK0H-=>E;3"JLF]W MZ,=RI)'Z+D%,,M_))>X=;$AX\ZEIACR[5K9@=6ZCZM59?]6N' MQ@!%R_)T-I_??5Q<@\5_WRY6F\6&;IU8;W]>W(&;Y>QJ>;/<+A<;-[C?%X#\ MX4X?-`B'0ZH&!>,EO3:-QPY;0W/=-EBB!F-P3R=(5N-0K?QDF MIO55C]T)`L(C7`Y307#,)-W@M!0-PC*8'S%9'=S4%!?"+"]G`)_%B0RVLZ&X MXTUHY)+@]C4#3WEN8QCR1D[XI%?:>#BMS,N]8MR99[ELE>I%LL.IQK=N)\E+ M_4F8)M&?%I5;M6%O?%(I1!OU"$J'37RU%I5D]FW#RF3ZEGL:A*B+"E)4"%12 M[LQ$&P88/U\;0I@#F;HV?A!F:;Y<,T.SY,S0J&O9\*RST(D">3BZ)6_@ER., M$CK13/?Q.4$705R[5!&'@,F2K@J#(3R[8Y/C-D9[2$GKA>^AA"$2X29-N,)F MN,(Q;V.>5^Y.@3HB`]/Z&0LA?/!"L,W=^G9QM_T;76A<_/7C\O;#8K6=D'?J"B]@5W,S>I(Q M"VUD%U:=O&7$0RO#&6RU"ZF0OO*`!Z/XRSSBT4CP!)>1CP[<-TWT]+K)3*9G M+EN)/5E*1TI.%?.-@JUI33Q_>Z6A`#(-=UYCT80/.V&H1Y:;$<0F.)17\>LR MIV]00MYN6^^WWA=]9K.TU?G=U+;/\KJ_,W.=X7H@XSL6&[S/7@+U&[P/J)[S M=&=B2H_TO$!K4[]N2#,!=-LP7AK8[8*4#KUNO6"WC.;>,4B]L$UWL51!:Y[4 M4/JR[1JEJ="%D(X"S6GU$!SQTS=!!/SL^JP%1H4$=ETC0KL MRE9%5DP+4Q6LR/H9**)>J4KUZW2YS>E2H,>1BE0I['+V2"M/D9H"D]RH,*L# M?K;H#I*?-:!;_JM.<(OF7O*(A[U/P0[NKIX_)A!_B?61W%P>1`\S/PV>Z+(. M[UQ`BRY*]MIP,9CTYAME-E=8:Y\XQ5AR.ZU9)O2+"]OT^*L0VR6?DK]];!T< M<_/@_AF@PC3P2MMC)S&+I$'G`VD[99KWULRTMK[->`FZ.+#M/8JO\^/:NAL$ M.8O6?72+E*JG.S17ZGA33H*B^]-;N;"'?V&2T[8WG?4^F6_D3-4+9,A`[%NY M1<=,(VGH^S\WVLVMM/?Q;!3H"J=5]C^C\FMC`F]U_VQ4&'7MO[8HM]XOHQ1C M-"#O324)3#MO'2D)%WV?1'@H_87FC9;X*IZ$])8;F-9EBOV/(Q-1+=BH3TA: M3!/J-:BEX&$\*D5IL`O"$ZY]X0;ZIYA6P(LO?GC"1?)[_*.2"?)3FK=^X<41 MKI636QC3>X]N@@@N4WCHD,ZPV8*>QLP.);*AAABEO-DV"9.#25?3NC50F0.% MO>SEQ9I%@U.GA!I)0&N^+"]%87MY*V*@?VTU''EWZ::9G@I8\)O;L6?,I$G4P(#"!( MB'".<F8;F'T)#)F"MW5`%IM`(2.358%,F_VTM-VS/Z\I?9!-VT:285 M%S;'3;I9*QQ*KXT&64RD-3_-E)E4*1,V!I%^RH()7?LL6(AEP#V@P+Q@-L;BF1:5HOMF0Q M,)LI=^;ZTAYQYJW":01ZU'4TYGH9T*Z^J:C;+@FT=F^U%7( M*Q)7S@31#J\P\:C$UYDT)!P@<618:YNL=H" M=P91O,CQ0*TZI&J)37$.<6)B\,-$=$VL'FIU>SS7(#UN_![=UB M@TD^VR[7*WH,S?QNN5W.9S=@-I^O/ZZVR]5/X'9]LYR/?O6%$:PB\YAI9I0A M5NN)9WCK1J:4L=+,1$-LL@D7?M0$61"H&Z&[S6MF0&4'%(8XWO^"2*N740KQETLSJ1CNVEW_ M("-%I]_3R-#U2[I>`:X7HT2\FHJ.8@;?8[P5WH, MCB#(=>DRY>,IVF'U]''LI8X.]T%$2XHYBI)@1]\01]&6 MY.(]C'%3+SB=L8YJJPM64S642E2ZN%7)6DHFYLV'M.W2[T*FVYD`BWL M,/BO&U,VZ56LL*BN[GUT?M>S4HS>H_C@M3<+76<;PQ1*;C4#@G);9L!"\2!V M>98R6ZD)NG6#@M'I=7O+WW?D?)CO6SO_=B@,O;BV']#!REH1>9)*01T+\B)! M;$M6(*BT9!0R6*VBU=R;9P*_>HX1H,J,5RPG(+?P];)!HV:V30?':F5RZM)# M%/P3[I8[7.D'^\`KWW(O2OQ95+\-"#\['>"N6)T3[8T]FS]^56[:G_E2WFP+ M+=?_5AJK.6BPT(;I(DF#`YW!VWM!#)Z\\`3IVD+ZF)U'E^T=RL8?9-SLR@;8 M\U%,/'BQAV+IB,>L:\DPR<;W'+T_4.C!R,J-WW]DU5#7'U?EZN)?$UQJ*4$2<)W9F#IA.'-IWJ33/&N%OM7FGFW:A-V`*?D\.]R7_`&KQVXD M1)J!,.XMO&><,8'^]*<>Q,652E+UW\`E&IW:>T]#@CQZ[&N:' MC&T?EL>)''>:@T.FE6G^#S>RBTK@Q2,[462DP[FVLF0,Q_;E$M_RC,$^`UA9 MGL^UMKQYIC4]6.89TYDFRQ@V./.QA:0C)P&KPT',0'[$I/QKJDK8Q_+C$O<8 M,SS>.YAD MUC.D/WLJ?D?9C:JW<>N?1NW+U%.H@%MZ%NO@AB<;YQYH^NY;&G=M3?%'^37W M^1X"YT@MP8EBPC6%48<6?@'B9@_CF:P*Q M^MJ^812[,/-B?$_?FMR,>*X-T`UGMG<_Y\Y'^&MTHECNT-L+B.W:NK.$U] M"0,O<=//7'*)&C,EGP#\$QW`#G_F1M8[(\_LUDH*"+9>-G':8+F$$G[S%Y5J M7![.29KM3IZQ/\RK/9P`XOX-36K7WY+:&%SY^K*:"X/$VC?5."!%XVP3J\>2 MG.M$D8&'@;3.\;CZN%FN%IL-F*\_7"U7V0G[KKVN)XRV.%OT.R%#]7`+A\^E MN,$?+%-X4)AKZ8CR)UQJHN9G74KCEJ=>VGXTYU^:ZIQ)&"($J)0C'!+&6SP? MPXR+=%*FU)+,S+2LC\ZA&KVO@\0/47**H6RSI9H2OV=B*IGOHQANSC$=P7>K MV7GQ##&[,3=XIX@,<2\FB9NT/V/H2WHVKL>S@=+FP%7@T@PB.0-&4(F[=*?* M&:"J/K0RAE7'AC2U+B^__&*.$I4S#"2*_$Z%JVB>PQQ7Y^A$\(%SXI=FWV0Q*TYX'(G+^L# MEN(^GOG7A63U;LDXE!WKGGK/+=[&Z`CC]/DV)->192^-'P^P<\OV67U:6(`6 M^'1H08C;2E?/.98U^%R+0.)V3(O'="4'%L^<2Y06&65I548)L/;68[CN;2W% M2+[O2^L2?D)H]SD(0^9W74%#G8"JEV%I7^YEG$0O:YG9RHZ'K9T*"X+H"29D4BZ(P`%%\!D/^+)U[)8=_EG0X`V`^&.T!UG37:0O#RU2Z@J" MJ4+;EKJ!7N3>G%J!*FR_\"U-596K2.6K%)\I?8S1Z>$1'/'W?O022+(_'@Q_1B$>LCC` M-DG0VQR31X=!++92ATXBVXZ-'&YI_[V,_!CBF%[#[+]*`PBQJG`Q MG6FOH)"5!/TZ3>A8;1;?@^4J^PO_`>:SS<]@MKK. M_EC\]>/RE]G-8K7=.,!;75Q).TMYO%6Z3+85><\I\GYF>!M;0^CCV"2VZP,2 M^D=-:P(R/5`H8@[DJD[.@]E#M]8@Q3R\1YT1#[TD"?:!3^?XU_M?O)C.ZR^C M%&)2I8L(_R;/S%L,^J@6?9N6ZE#R:S@S6F/J^Q527]?Y]'A$*0'.EK%:0KAED4/,/(#V'[!0D&R8+1( M9;1?I(W\'MI^RG&0VWHG5#>A)4N[;LD+> M.DM7Q7<2^X=8F=225Q3[M.#LN#8W'NSEVBRDR9BP4LJ&AHTL[.1[MV-@G35RC;O.Q`7;6#1I_?8/C0$:TCLHT^Q0D MY.,)^))`D)W(Z8@K^\Q1!\.[M!)`84O%K MZ,/#/8S!NPOZZ1\F`*L*!9P;K3I9QG5!?E&B?).A MG#Z9@"5%YLN,OZ#&TP'`V'5:WIX-I7(6#W[F9DEU$WA3RAR^ZW9-UU-\%XI8 M[VBV\GHS%W\71/DG#DSDPQV>4HLZ8MMVX60R)\O\#,#211M,RQQ, M-P1,]$`G\M8BEIZ`69K&P?TII5O+\2^-A\AP[-,]S0*.GZT-(&[L7'W"(ZT- MVJ>?<=B6$>Y$'H+B'"?>5(*Z3BU_*^@8H)[4B^%I"&6',C*JV9D6(NZ,3C7` M@`;$JDL]J7J;A(K^1F0C_IVC-,Z.5PN2W[;8(_M5*[EDR3R!Y&"^<6V;99G, MC9A;8NUI0P`0"4!$7'D)2B'22#LD;3)QE9H4DMAVASA7SZ1MY-IZ&7&ZDCSB MU"5-$Z>R;94X'3=:Q&EI\XE#1%RC#2/.(MJP`R*A3:4DI$W;MCNTN>%<>RD7 MY)&F)FB:,Z5IJY1I>]%B3%.911AWKKI4B+&(,,QH2/A2Z@CITK+L#ENN8.0_ MDD-%U4HTCCBWNVF+&^]SF@[L=CQ,7WJ]#\,$BU&EG*L%'`\'PNZ('RM9G]34 M%'=,+"_N\&U+)IBD`Z&Z$'<,E`D9'_X0LW9'/C4/>H.>4I'9"]''KA&E&4KA M(*?]P\O&-\54I8I%=PAP"V/R@?<`+V0T8(CRR-`0-4V)FG$+;^I(G6EQI*T^ MK3X@<]TQ?()1OH?N\13M8KA+'\=?6%$(O(@ZG`!)"%33$M*H8]TRO@RNKL@= M#0'711M=GN^C4_'Z-4H?88P!Y\/@B22BY'6#CKN\8@9UXRZP=`;_996E-CW% M%.?/4;7$S4]4-1Q8GJUB^=*<"*J>;)196EYEO!3PQ;WO+K1V:D) M%C0PCAV^JIEH$5?'[SG1:K)FT_-J#*ITMTQ-GKP(S3MJ,8_-I_R_#IVGN1"L&DJGLWFSQD(Q5L?3$#/)W)IAPX6>R(3`$GABSQ$>'Q%/Q/%$3I+WAP=8HA9]^E5+*D@D!R,!^XMLV20N9& MS`RQ]O27S7^!#W`7^%X(;H)#0.Z)=&5#I3S*2#L<;:IPE9I\D=@>GS0K%&W@ M`SE(34P9GER;,%TY4W1I6[9"%HX3):HP=:?E8]?HP8THBQRB'Y]#C;8*DQAL MNR/2(DG7>W+G,CE6<`/CI\"'R0:%W>-M9((E,?B"@YG!,VWAK2N)*S%!A,K3 M+?$.?"Q56R0<^Q8O>7R1;B3:/.'I-(DBMFP50@;GE61N^N.'SAQET*$B=/FO M$`)$ZO4@B3OO,QQ*X\[L\%K&/0I954&:A0T>>BQS8;9@4?36CUBM,XU?2&H6 M'UBL$QY5?K&/)E;SY`+=Q)6-N)PQ7DG=5T]B!61;8`N%AV*-Q%UHV" M7\&1D`I2_6DFTMS\D&^&=6.@JQ1UU",X+2@Z,U+1X`^L05'@@"AY1_Z1;FN\(-I/-LC8;O M:WB?2F]8$0OEOP!/:"#0V69-8EWH001W@>+T>G&U=>96$TG\D,ZOW<0[6[X. M>9'%45&_C'!33J1PO?*2(-D<8^CMUN5.CSLO[;P+H:M68X::F@&NJ#@RS1X- MGS(^*9N:EMN?Z!K"L=KR[M2&=FW(H&'A[-)3Q4*;L.I>':$P8VL'7X!)2R-; M.KHF[5%-<2L'1VE*/@?5`R>V<`A"QJ6%>.M&5Y8/=0>V;#0[2][%KA(I9CUF M[JI6CEU=H"L!ZD14!')\-[D'].-QJ,/&//CU>[_^?]Q(SNOR[:Z?V[=FP`P&CJ8UK7 MCGZ1[HH'=(7CI49?D-CTPC]Z,BNKT95W8!_0*!-CCF[J8D;'.)5A>R.=C@_U M\4Y+M3WJF0`BX,B;'-+`1\R"9'=EE2]E"^D MBHHBDSQB1:-T$KFR4TGHN%;GG=187GO4F!@TYO,UX-E45EF&4*GLBCM1@KC+MFBWB1"[$'.1K3HN'>+Q:/`#PRQ%&R>C, M$@<4:?WZ;1V'!PE87 M%"TB?PXRE7/?CKJ"E*/&;M^1NS@/.S7NXE$T(N2E.Y?S:(!"B8_RJWKDNFI, M=.3BGG8#=[N`O(\C(U];C$.Y2LPPT0K#-NG5\J%#JH;JM/SG7]PB2R>(`HJP M?G`Q,0H-$1V:5ITA09.EG%5Y=16E_LC8:KWE^YT9N(E>K80NVLSO4S?-&MA\['`C0:V&TOU-S!) M_@+\?&WRB&(RF^04S!668_D_O!#S@A59ED5K*+$UG.BQ8,_2[':&;UX?8-1Z M12W$.#0`J$U3W;1ODI=.QW8TI+.Q-0UKD[$WK#ON[/-IQPZ-D&"5 MBH!*;;LV`:4U\M%?P.LZZPTJQC#HM4!';>C3`SO&)PF;YFU-%W:]]$8-8PIQ M`BJ1UX(@M2G&'@AR:-JQ_(^/'J+@G[!]V8&J.+L'9XB;I4['@7)__N>,0!%\ M(.\,:V1?GDL--K%-3*M_`R\ITK%;6P/Y\>>32A@C(;4ZF@*&<;R<`6ZVYCFY MSH8BC;%E8E+.U52BKQ-X:F7!8.2Y,$NZ];[Z2IG$550&DTWNQ$I*5W8KYI^BF6E=DMYWYM5$QB:?!C10 M_]"UF2C7;A)2U=N9$&FP%U!W:`*,%TTT3D`I3($Y^VJ`R>TC["!SW!XC\>/@ M2)JRWJ_@YYGOHU.4!M'#;8PB_*=/%XZ2%4K_!M/9#AU3Q@3/`!MEG]++QF!* M]_!JI=?IWPXQ\_O:G=XMYHO5]N9O8+G9?%Q<@]E\OOZXVBY7/X';N_4*_SU? M?,`2F[%3P1#L(8-0:.>*'N::R:-W>\8BA<&.;T`+K/"!=HVE+EDDQ=J@4@=- M?8`-@&>8@B*P+KU#-#9AN+WK6(P9M?\]P2VZ@R$]==2+!;-L4L&B)Q4(#LT, M7-/F]T#(7`EI+E:>YH_`$3][!FGL18GG9R4O'GUAS(![%,?H\^@3V/*8(]WH MM$C'U6DP2V+9*JS,]2I2-_TQ1?J'[%61`ENYC"OS:`:1Q,O?!J`T1(/S0=#G&U6BR26!^WH)GM]T$8X+8):AF>3+V,ZM`VKTP M]:9S%*5Q<'\JII='3H"^/8[0U$/SJS(V@K,/H`MLW1 M*+#P8G(00'(+X\VC%T-RY[,_BW;707C"26N=/L*X>@LAX9SX(QN9.%'(..>[6$6$H`.J5)ZD4[;']< M:@_%'S(*AF9JZ&FPGCH&M;[\'MX@[,UQ\^K%=@\_/L;N0#V>3Q%=!/X=T[KHJ(0JZ\3\>D MMDKOJM)WVND9K?=[?7NUC`SWY$]ZA^`.A:$7)^3]N*S'&ODJ07$<97V09@\C M[3\<`W[>ETF@WY+B@+^4,@S_W*[QQ1.Q'QT>U#6GN^P?+X(+[<`*V,"(@I@/ MN8*($0V;]E!C;&U$XJ,G9"YP*9$_)7=6`OI\`G*)UP`8SEK(,,2,N0K2;I;B M`%UQ!&YMB-UW#*V=2@>,E)M#X66$Q[X0?(?'6,GW-(W6Q\)N<4-G?*L_@%49 MH0J'H";!8RVCMIWT1:'C86]S6L-+@N[;W M\5)`OG*S29'_VYKN6_P`#_0FR\WE,D\RT9I*W$BY*A0=TH_!MGG M"?B4/1J[;Y1&%6D&H$4@GDJ#+6*[HU,CW^`B?05=6;Y%%8&\(H`8+!**49L=G%562R3^#D'XLP-;U2]#88; M&?#D-'L$RF=.,8,7Q`XA!+\YBP?D![ M#O)?WX:#@60UWR233+?6.E&:L.1TFID#A05RCCIQ!:BO2C', M^ZJG1UO?Y.7G5ELIU58F=2>!.IDWSYDNLRQ9I<0B4]*S.,BAP;D&70JMFP"? MJ/[(M9IYJ-M(G6?(F%82Y2O(C[S)22NV#>9)(M79-Q*DNKW/JY4??I^MKP#O\QN/B[`A\5L\_$N.[?1F5VB2@%G\5KKM5F1 M%I-U[KT`6S;MZKG\\^<`QO@W?GR^@4\X5%\";AFBI-0FED3)%,6$;JR03<6C M$NWDAAI]>"F#Z8<%7*&>&CA8)%0.'8>.0GTF,14\CD_16O:0SDN+9`4]G879 M8I9U7?HI''>LXD^WSVO-RG(Z/4?H)HRXI*O3F25EJ*K.?-!CA.X3&-,# M8$&F`+ZC*N#=]XZ\KZ,2>Q8!Q4'BT*VKQ"07S[935+I0IM*%,I4N+%+IXCQ4 MNAA$I;KV]*\G1$\#^'7)ZZKHV8A@ MS>NN+EVF4SO^$CHQ`B6GTZ4:G2[=H%,0>9$?1`_+*(48RNGB"WF?L;/;22)6 M$(DK-I1%',/*%%*_J%[B2D@CD>JT^)"N2^\+4>"C9.SS#J3117J1:'&$H]$@ MB-"J1?"8FWN3..F+&S+C5F*EA%`N\#I@PYM>&XB;42?5@BA(X0TN07>X93CN M`>XH\TT,OG\ZG.A+J(([B?L;J%*QMH'A/--T:2=]]VN$A*!]C$YK#QVZU'@` MMI"I:'>HKFFKE01ZM604N)OL<'JZ-X_TK)/"BF^H)JA4\['V!-2IX,XURF-2 M@=_MG9T+CG:5*]C9&:ERM9VM?EI>W2PV M$Q#!D4\448RV&A-;,5$F'=93)%CIP3JPM#J1%*5>.`Q9`WJ-TL*TUBEX>:?P M*A&FG]>U(=;-U^8Q=GF&0J7F:AB\+N4%R.HU8NW2/M8NW:P-;GCO'&FHR.N$ M&W-O""DX,;H@H.ZO)_5N6J_I"/GGTELW.@A18R,S@LJ4O&&^^J+LS45V9H*L M1KY.+)391C45Z57SXB*?KIXK_K/>?=/7E+.LJVF/<&U?9^(>QVU/&C*MR2KF M^^=&G^K$RW(]T*3&95&8E6G=-J+(<+9O%\F.A^2\5\:UE)0FR,V]1J[DYDS$ M[GKL/_/4?,D\VQ<7,&5D[.N*S5<=J/J"TST^S?(,0?D/N).GQUE9\,;"BQDQT[ M56Y6VFK,;'L[$R3/L*NBZ]`$'F4[)R8@QRM1>-W0U%XW&X;-,?<\_(30[G,0 MABW4MS_.?XCJXX%L*@Q9.,^@95I$C8;HM/@7W16-6B74R,FX$P\D_BV;P"V_ M60V<32V#X326`-M&52.)$]E/Z_7UK\N;FY<1-$ZZD45M^-)[W9K6(KNTEFI; M5HW=947#EQ$[SK*W+';=I>PAL7NG$[LCC`.TVZ1>G*I&\)U&!-]5$9R`*_@0 M1%%VX"'6]D>N&U2#^JY?4-\9#>H?](.ZB(0;TMO654/ZAWI(L8\7%\\_](OG M'QRHRV;^/TY!#'?7)W*,Y"T-,Z=6$XFVZC>VJ"'PLHR;G%)3\*.";*[ZE#Y) M`KJA&8_+5S#]C,(G5TI`89@9!)"%@\T)EA:+)WSKXU,GZDS65:<>\BLBG"*;FS.-32:H`2-]4-EK4^F*VNP7K[\^(.U/:..\)9/32Q6*P=8PZO ME>PPF:[1@K,#V_B@4\^U64Q?M.8BN@NRE:)#I]V-`7;)T/D<:'=A]FX;>U$2 MTI>H9KN_G[+[!]L;,-2$6UT93]@0P]GF+;R,J^10A<8"`]/W*(;!0P1\>H^O M_PS22M@-;DIBS^"B/$)LZK'U6%03>;`.,^,=A]C5,(1=U`?B-3%0DWM].)/D M>!-`+"E7:6M/Y(U:!Y-@U MWXOC9WKWR@&=HI0,Y!^*HNH3T0.YHB-5$RNX#)IPHL&F1DV8Q8>.+3N(,9YB M&?9[@*5>9;\>0$B2I1XB7$B+PD*Y2 M%$_<.+-/L1^8=$>U\EV+6F:TA[2.[&&DKSCL)Y:1CP[P!K?G/?[:BW^<@O3Y`TP?$4Z*3Y`]8Z:ED_\@ MBCH#<:WDQ<)P3<>OB!#J=J8_D?=/"53!WU&`!W)/^!'NL,8EC1XRT(#`-7FF MI%YGH(:_XS!1`I@%J*J\=HYS.P!Y(Q^]` M-JF7T@M4.$-/B52CDV!(&>%@QZ[)@:/8A9QE;,WI?+VZ7JPVBVN`_]JL;Y;7 MLRW^QV:+_Y/=D+I^#]:WB[O9=HD%Z)AQOOYP>[?X&:LM?UF`F_5F`[[[&'FG M79#"W??.#"!ED.@P3Q@_%M4Z"EUR<6PZ4H[-490&T2F('M9'&-,9^N0*[E$, M,[FM]P4FBR^XX2C>!9$7/]-39U;X1\>:.`!A[>!E81%GQ1.S]#/LR6CO;+1M MQ@?*]MNJ7@R8]UY6$"&M(.ZI,1!D'Z;$G`OIRBY?N,6&-6"**A2C3OEUC87O MYG92L%3H6VGGB!F!/:BHW(#*3Y$M8 M7,8?:N$FYW=H7,$(=E<$)%*-HHPA921W=NQ:V+HF]B1/7&S-(N?@B@-`%^YP MD86SPVOA;\^B9$>A2R>.37M8,=Q'R)TQNO:"]F8SSM)TMBZ>FD)_9,S\1U3:MA/.:1BT-P@0<\<>.8+H5'A:6 MN[\I!\*9(!.Z=1MC(C:&7@*O8?;?933S?;)K#S?NF5SLN(V]71MB>DH5OI64 MAL->P8UA-JA[E)!$U="T>()Y0Q^-3AT=0*`AX>H034&_Q3]ECP[1DAXL-Z=O M-Z39#B(I*?DJ7$JR5(P3LNO$3NFNZE:/DQPS^!=Q^$01I`Q3Y#J"KN.SBJ=JC+=&:WM)/Z[4%DOKF\4PE1 M]/`FA?$!A)6`D_P5(T?.8VE$E>C,M*)`:X%WA]B-R]7XA(L?#5;S542#LXZ* MC:%9RXGU@1G;G_:PC&5FFG]>3.HFM>,,'2:N`!RR@9H@>`K#M):V=)#&].80 M,:_A'N+LL9L_>O&#`BLY\EQ*=N2-\['EX2S#,K9//4*R;$R+#X&/#H<@2!PVPNA-V#D_4<8&A,X[J.5W7-J`U>K(_ M:CN?3$"!ELW>5CLL3>(8QJS>-9PBT;O4LQ>K4+-K1%M]!'P9/9*%* M:=POTY6NSC)UK2W2,KR=I<>1^^^WD&NW)G90KE;'5LQIKN#3S`Z MR?<8<>2ETV6EO+4YB]R#G9?^E7SVF[BHVZBFR^+L4]?8R0N_T@0%(T*J\Q.Y MJMK\1,//.?!VACFREK?!4%.8([M[W1#4GB/KBT&W$G[^>DST,/>.0>J%_/?X M-17Y,V5<1?/3$AQ79^D4),XU9RA$QO)C/A-"5U0(YI-HM,JK+73^Q37^2G$D MGJ10B+!TFH)C0S)3(?1\5BC;G&23N#6'8L%46PGI7,VEHRS.AF;U63?C<':L MQR*#J,7A&*)G".]@2.>5='?3R?7%*STB?3NSZWR/9]A<)W7>8[Y=8K/B&PV6=KAR56YW9U(U7@VX#O3/E=-=BEW#^=ZR4!B;DJ?%R\+TVX. M8[7>R3V[QGD%%`D9KQ9=&=WY5L1DEWD_,Y@M=FQRQR:1S._4,H3GBI-VU_9U MH5NY-[,#;[=Z,G*0<82]J71=#%EN7]60-<[GFO6S#+RZ_O1HV]:?UCZ8@`@Z M5U.R0BVD'"%F%MY>I,B M_[='%.YP,9T=1'_'O9>QIS8WETNTC3-1Z,_N)+N*:SVNRBWRR%O7_'UQF8-+ M-P+VQ9F0YLK!E_%>:$B<"13:X%!JN(W)7H/TN=C7F)^>1LM/:6904>8F!K&R M\;P@$J#)PC@?@]]>AEU0K3>W!,ULN)/3@2@ MIW8[D'[,@+>=DHS!AY&F!MGNI"X#+76";V:'UD::8Y]LQ2`],P0R2R`S!>JV M2-A+7BY*7FYJO,Q=@+J/;_R4PLU]@HX[YY!=LH!KH6MXG^9GAW>*")%061BP MA08G'Y99"QVXP(TX3W`5I^5%&8Z%U<:O'R<<+-O?Z`XDB7IB'%)#ZSG9TF&4#=+-H3,D:!FUNST MB,"#(@7:BDT&9&_\!_2Q$\MCPG"R:<#Y\;DLJ,ES6-"Q.#H)F-=X=!^U`&_H M`H_*F`UP*U_=T1*O@.S"G1V,6##0*KNMHY)B(=.)>SJRE;OG7[SP1&]E#))KM*DDTC#% M*;X/"^-$59]*5)-8F1;/P0,1<(17"B!@$4PM2ARF\969E)/Y.@_R#`Y`E?T9 M@-U%M5/M>0)*"%+A"<#B9&:R4'C-F.2.8FV`.K3Y>J7Q6J[OELN-IACBZTCO!)% MF44H230X1&)H,1G$M6X93.83N<#1$!S54S>H9,`G(@6HV.C;Q\PB2Y:C!T++ MB:R,^PI>%JX]:F==^L@4,;`QFUFU,J^$_D+J!-;Y=16RK_PZ,HRDR2\W$0B*O+I)7$T_A9K]%X=X.B M'8KHXOZ]%_VVWN\A.389=ZLWRZOUW0=XN(=Q"^M:.OGOIZ@SD'U*7DSR3\>A MB('J=J;T`_`I^VCDKDT/"6A`H)HT5%*O$U'#WWA4A`]>^!YV.KK.YP6EJL^' MTJ:P9)0:+:-"^#=DI^0ONMDD))\#DB@#?^P5QVX8D.07;&&V$&G@LJDW'O:J M`T?91WGR!0HT,@2&PK)C4GM7AVRNDNM"B%:VTG1+O('B8CIG;KD6A`ZI_M@M M*'=D&YCF6+*"!F,+='SS^E"XP+UT]<"1DR2'P(`SH]T'!V.NJ]5:5-UUR$]T M79ENKJO+F`-X9=5FQNMX441Z2R_/>R&*'M[@^NK@9.9CQ)*->O9/S\5][292 M-O3;]FR!Q$8B['KHA9!V.JR>OG1XR/.B)CX[N\5J"VZ6LZOES7*[7&RZ:M+. MQ3T&S:)=]^`U.9F4U+J\DJB9HYC0D26VJ?A4))[+N\WOP>*O'Y?;OSE#236XL-FI'$HN4846.)Q5\.HL?35IJTE7ZS2U.=@6 M.1S"S<80O';G%'E!,VD<*0JIO-O,[,/(_DS48:#IT3O7B8V!O-#94/0UA_<4 M>(M7##7YF-\(UL:="8C@>C^/X2Y(WWL^:>KS!^]+<#@=KE`\#;+U:TT&:_K?<0=05Z4T#M-MK&W@\5)-+6;`>7OB@ZR4>X8 MZF5C\`ZB'EXMO"`UI!WBC49][4YG\_GZXVJ;#?K6VY\7=^!N,5\L?YE=W3CQ M[NHPU"&#(&CO5NIAKKE[J7=[QJ*#N2IV2`NL,('4NT1WDEVS-0%4G]:]U`*H M7Z+JY*NXXQ.%5T2/QI11RVT4/6QA?*A?)-;I4/DBU0Y;ALCP#;4=HX;WS_+L M2[;+LM6:=SN.S3)!S)#Z;]S9^MJ1;NUTY5@;#=\?O+^C>'Y*4G3`0]S9EZ"] MPY4OD']WEL!`9'=-FL0UU[H(U1RE*?T/5,UM]0E.(?$_M_R$3:V!]J MIZ!(?SM#F=37LU'"#6R$D)>#;$^;3T!0G!CZ71"!QU.TB^$N?4R^'YG/@V&( M#".BE1WZFFPDD6'M&B_7H"=Z:<`RNH9[&),W5^`3C$[PCGLIH(Y*D4&45(8F M"P4G1O."NC]A"E`U,YT_DBL>$O*6Y"X7!7$FZ]1M?EH`0?T#V**Q@G:#L M1B,GSAWRI4+YK^52'`@_?BF39).ZD5$-8GRM/X< M5`).5,4*(4:ZP6@2B*]3IXW,LF-DN48'+XB4Z-(4%1*F$+5"F*.?CKRWGM!&)'J#]^&?5NVB7>V)2O(,+:$RC>O#XH+DA;)`Y(8:S^2 M.XN;0S#!69;L`XHQ%Q17,)U[R>-MC)Z"'=Q=/7],X&X9O0\B+_))1>.GP5/V M?A6*TB`ZD8FNLO6<=S#,&BW2K"&C0PEHI!E&RQJ3+1+2W)RC*3$$]B'ZG`#" M1;`OC`"OM#)R>+J`12EA*5H5R%1:;5P=#:9F[@PTA2[5+K(N$3K@<(,N'\&WWW,B/4]*(V! MRMH$5/9JTRC?",?%DKN,G7!*(P;N2Y8 M1CXZP!N4,+KY[K.JUZX_&YXR*FLV^M2.=0FG6_*4H0']#'P7XD]'WH3/C@Q2 M^$$[+*C$6J!NZYL.L?++,XDOB\MO)P;)=7#V[U3DL1RH!7@=UF`,P;G?'YID7XW--+O MW)MF4)PDT5ME[6G4R%*$[556S6:<896U7XOL3:F*5UE?VR)%CU76`1`R.86J MLZ%SJZ,23F]N=13&C3NW^GGF^^1$ M5-PL_!TB_*=/WU(GI_GF[_\OH[H,'K(&QQ#R1T+&+):U@@&+@Y/:X#:8'0"9 M:HXXN9GQ,B5':ZZV-W\#R\WFX^(:Y*=O+E<_@=N[]0K_/5]\6)#C.%VYY]XD MBI$U&+5SVF#CS<1FJ*UCOJ!/"M9JS!;MRK2\3.&!F\)T]:I7]U7UAK_'K^;) M\$O]6DXE;_AKV)IN/M[>WM`4,;L!F_G/B^N/-POR\N9JO7HSGVU^!LO5+XL- MS2CDW<[WR]5L-:?_FF^7OSAPLY(^IM#`<'<."U`ST3HY0,?OF$0OM_9D$\V+ M+T<8)6WZ2.4J(O/DAA.7;=G\G(+$DX2=`MW\@A9$SP=@ M!(TZ9N0UC%].JBI!-#8C"!.C:U"QCI7AJN#S%3V%K-P]3!&U#<9'U$ M,9F)&YLD_"@BY9^]382.FC[X70_#H)>`>P@AXQR,B%P3L`/SB MAZ(*8YD?\@Y+CZ5/RSSV*P4\+4-.^#KR'""5IX(/EP7L@DP/'&.U.?CKV MXK8&_%!O?+2R@%RYP7Y57Z.SOGSS:`,?Z(H2A^M-VQ;(/-/"`)[KN,$>0=P9 M]!%'B,V?K@Z+0#S+5J%E;@I!ZJ8_KB[JP*I$P.S5X8@WRV``2&/..91]0SX3 MS-LD(I7+?Q:!W$"V<"WKYF&%]]YDOD2$$>M.JZ,#\@6+D2L5>6"19@R:!.&J MU/DAL6L3.<;2K-1+;]!ZF79.S66(72CAG:-;`7D[I?,J>N]+/:VCG'A:->`[=.J/*'HLP*L<\<009@+= M\'%/'+OFNWR]HY^X:J\1$++^7PL1H]8`\8,7!?^D;W7.492@,-C1?\RBW6VY MY(FB]3Y_@\(+Z3)=]CX59XK)I,TBMYJQ.91Z)EIAM'8QV"`AN8WY4;G0SITI M$:-(1A:!U,I#)LPW,I>Y]HZ7ZL@N\SDZ'&/XB,=?P1.LTO![%,/@("/V"]%]A]G7+>VA7,%WOM]Z7=NZSZJ1(AI:<#,V.5IIE-%W:;*$P M?]IS/,WU\YWA_C-(*QWP0&Z+=:+>LDL,=$X8MI*M%7^-[&OQ&XV;CF=)`M.$ MO*_+W`XME*DGPZZ,B5S6MFI^Y"WP(DTG3+ULGMT!JG.CUF:JZ$=F$*TMWN$) MVYXM.)@;=8L\],("&7EO?U[<@=EFL]B.?([`<$SPAMR]03'\5&:N::W3F56V M,8@<]0+'9?'6I4]VIO?10J$ MNWTE4]@<'QCFC6^S5'*GR`Z>`3=3J"C2;+I(XL&E#4./PQ^N!^N@LM$'"UP- M0]1%D7@S*5")@4]$$%#)L>>]+$!-WG\/QMJH$^E5Z_@9FI^.3=+$^(Q)PZPB M_&LG.SB#90EPE1(B!Y$N#*8Y,P3%>/\6Q@':X<]CZ"7P&F;_Y:WA&#.H,&>I M:M#B_*1:$\XU%ZG5FK[SCAI.\B[+KQMRX@X0@S!5G$'4!XKZ;*&:;=6909V6 MNM!MBC(16Z+;C9K-%4V;EKI5738SM!J#%'<63P6!8W?`BNQI"G,Z9)?P?1-X M]T&8':;-G^?F2]5QSI(R@?6N7>-XY[J08IZCF7=+8?74`<0+PMA&O?@W9R"_ MJ]!!/\^F,PP0+_8(!3D\,+WLPS1MX^4TF3,=7K37@7)JH.CA30KC@[LD49CQ ME09$3!7!U*_`LE4DF9VR$KKI#Z)RJJHF,0&5S.O!D6AN:B"01I^3VCRB.-WB M%'"%XAA]#J('Y@250*R>=IEB)JC",&QGP8#O2,H4GNITMML%9).%%P+O0*X5 M`/=4`N[H44&?4?P;/9[!.P9NK,Z+HMUFC20R#,HP-#J$X5JU"":S65?@I"^2 MRHQ+GV<==R7Q.G`CRK4#@#-FGKWU4N[K<\QG^5=O/1N(_(8UX[F395T$\Z[\ M-/_(D=?@V(%!"K]G$[@-L3I:&?JF(VPLH3$M:X7WXN7'EY.9U`,\;@ZBIV>2 M.XYFOA^?O)`WH:H@6>8G@>1@+'-MFYQXDKL1HURL/9W-YW?D9K#%?]\N5IO% MAK[0DLW&WBQG5\L;>H6/,U.R*J%'VC%JTX6KU"2/Q/:83**OK;Q'\1T\8@@_ M>@E<[^?H<$#1)NUNP5)7J'@E51A.+XD+99;].6-9!!_(N;SB&D'1J81S*D:F MU@<4T4#ZANO#N,DNBWB*7DZ"P`-%C"J[H9CCY8ZF2`=WC>1 MF`F#S>M&(K=6,@_%D:LJVL(MRL_YJP[^^RGNGA&A*M[J!_CBADC(9Q*.`N2,51N^LA>\LR>]-N4LSZ8AR67<$Q#OR1=T?9`J,D^9M"X_`7=%2\ MF'Y71]7G4$!>_FY:?$JJW_L@\C(LDJM/,4:#D<_LM04^SJL^IL'7?0'(!OC> MF:Y_9@*H[.O$WKOS8.^=2Q7O;4P.[4R?;S%NTEFT M6^!/CX?N]AU]15X5+%`T34FNJW-4QC+G6EP5&YO>YF5)0FH46#P#7K0#"=JG MG[W8M5I%#A\1>94"*V$QUX:0SQ+/9T6P\>D5=;?FP'O![G(*G0F@6A.*Y5+Q MZP&S:C%N`*%)WA+-C1[W7&* MEE+1F2@J#:6KDANCF_AT/`KIJFYH6LIFFXHF9-D//!$Y\!VN`7EU:72O_SP]J+BT[^#B\G;MV_)_S(J)<`[I3B5!_^$NW\'41`6'P=)0S_;LOWN@G[\!Y<(VD0+EXV= M$JH1X7Y/*O9L@-!<^49WWX/_%W4`;C)`$@?3L"2XNDEXX)72O4"ACME$NT` MDBP\PJS+$F0FWZ:@40+43=LK>QA>U,G04>[FY&:*)25.]HE3=0TSW%R6\`(C MXDI=AT^9KF6GB#,KNT\%\G2%!02J"UL@467>-I$ZGG3)U#+`)515RKA-*@8, M),1B!TM.KDI/1K"V!Z=(MJXJ4`66,:0%-&M(6^!9S;YMHG5=Z3*M;8%+M?J8 MP&FNL<`@(1LG8G*VU11E=.OX&)-O9`=K?E/N+-K53G9C'Z&FH5'Q3JXQG'LR M'S8&[XH^)414LC+-!79>:'Y8C@MW#.C@`_4.8(>.,N46)=5\G0>4 M)H?SJOX,(/*B@F0N2A%9/W1]`N8NG&!E%Y+\F0$+F!QWYB!`<7;([1WT0YQL M@GW@MRZ]NH:)'P='\F&GX^BG7O8BNNJ#V:OGT&Q]U\NWF-4]3$[;HJ-W+CTQ MA,S$M4UQ/4M-OO=IQ8C<1SZ$N^0]#L,*I3#)CY7H<%PL5G*9)S:8LVS#9KDI M]"'FH$!U6CP%!.L@PL_!,7L^-NDD045Z`6B3B*W1)(O(JA.DV'@A7.]5=J]I M*3$((U(R2!^^&UTRJ;S+J>-8E6$20[AOV\'#L7BOW1R5>3P;3`T.K71\Q7DE:`6[DW)R MT:HK$8@.9R;7N(7Y-ZDS"1'%ZM/;N_7MXF[[-WK8W.*O'Y>W'Q:K[01$D)Y` MX?G^Z7#*CJK8P6,,_<`K>I-_>3>YN'S7V3!#9TC^Y6+R[L]_(L^]):<^;2MCGQ2N)FYAV9) M$PW-P?11]F5A@*WO7J29NA\ZE`[.EG9*O'K1MFN!3%7PBDH"*NDG/+A#D MG&0&2XF'I:8"^5I>7"-<IE) M6Q1K6%>E4DVI39GLD4.D:86,0X[NC\PG02;+`WO=DA.@KK./.WFG)B[I@PQ. MZXD=G*._T9KP4S`AF&]P:-)/$0<*78S*=*!84Z4[<6:B$@?1[+>"[:BR<1* M?O'$!O.*;=C"\4\25V(Z"52GY5.RI$DVI"5N[$B3QA;IQ:'-%;9&DR,BJQ:A M8W!>3>RD+VHN:K"AAX-1@>*VLM>!&^ZDUS#@C#N=E4#\"S[.HMTU?((AHLNA M^>L(G=2J(%OF5Z'L8*8(K)NM7.2.Q(R1Z4\+$;IVOZN$QJ:,2JQ1CY"TN2-0 M:Q)(:G]$$J5X/`)W"R^.R'W)S(N*Q4(E;=A"@_G",FM\9Y;0C9@F7,7IK+;= MZAKN`S](';D!5Q)1I//[MUG!DF_2@6_1&E@,%B$B%_V00@N0["$HGKXBH'!K MC_Y(&;?N:+:JQO*GPAV.DD75WV0.W."2( MOX!/X@B)J=75%=&,YVE$QCW!Z`3OH(\>(GJMXP;&3X$/$W(?:)`D9*ZG0SH- MG9)W2CJ#J:?@Q2S[U!V*":AJ9YJ+9IMZ\XJXID?OQDT?(7T_)"&C4/R;X9HX MVXR^@0\NC")T\(,&A+=-707U)GN5_3E$X%L4!OXS?W^DHCR7N!UYXZ1M>;`P M(E'SJ,=8EHV2K34YU\C'B[^0>((0R4C74A43CNGG'(`S.*I1]#88;1=,N$U` M)@H^Y?]U:&^B+2ARAT6FL3CN8(DVD%.=<0HP8S66C3)*HU)J%D/Y*[$X,C". MO!#XIR1%!]P-.`%P42TC+U=8%M+?.VK&#*V=P@D&RE..[5)A](]F*@-1O[34H16V-0-^ MV>S`7F*L+TW$^G+L7HD<=_#%#Q*X];[DFX_8)STK2M=[+9&T"83S[=LJ\J4> MI3206)AFL_:I]\6-O96J46]312TT#.;P%3M,DOFP#S&SHP2YKX'HNBC@E2T= M$3F`!8O=F(ZV1CF7!EC_(30+A$/--HBC-%&)6*P'"F,FIP]%-A7 M+4L::M/R`""0E'Q)\I4_!\C!"R&G7F']Y/R:I9#F%2Y-:T[`';>&N;=2*,,> M7AO:63$/CEQ&/E%NFP[)5-<4*\+-E.>$??^ M(]R=R"&5^<+4/^%NN<.I*M@'<)?=$)!?R[S#G=5-X-T'89`&N.M*DM,![K:D MS^)M#K!DO>"::>M#66JV/4;Y;:5IPLQ@P>-TD:3!@>X6?.\%<7;_)WT-B&Q0 M(ADFLUMTN`);J!_BFF; M<;D?GG9P1TX'GJ/#\93MI%OOBRV=Q<79\IQJVD$GK9IS8"RSFFJ2\3U@UIJH MEF2-.IW6K0&R-Y%L]20WS-%C7Y]P'4->ORRL9YLE:O9)1KXFZO67)+`K0'VY MDI2-TX>9EVT`EI>:3?EB9V>SW\3)C&!N`LY:\\Z?#L@T7VZ8$+N1&RK;XFS0 MS0+@$^VVW=D]^)(3`V\V\@5FAE'G/(U](\:1(7:,&Z_9C!Q/8K8Y=@;"!EMV MGIQ,4LRF`+Q!ZMT(MX^E9;:2U[*+?2BN?V7,E/>ECC9F# M>@6?EVB4C;&SB69;QB&`A0&:MG\+V&\-L3+=-U2YRP&'1TYCT$(Z]CDG+QP9 MO?A^?(+UF7+%+E15L3OJD"J:&U%(7-F66V1(;G!):R?-9L6MC#E+1K3G@MN<,N\AUN!>S#V;Y?)TU-+O10\DZ MU=Z#O-YCNS-6M';FLQ2]FJE>NYV34LWJ#,658=2K/C4Q6NM7C#HSG4/'[UK3 M-U*-#J4%&L:XS/5ALAP96@#E-):T"0JW:C^?H7!PV,*=[,G&'L/<'4B&Z'7>[HJ MH=I=]+#1Z4"T;!BCLX97BYV,?BO46*]K=THV?48^'J^4JY-77A+X!-S%'K), M&7Q,\-]!Q%J]G'NA3X[!'/TXM&$`96:/GGCAI1,-<^P$H]V>L9ACH6OLT0(K MM&EUGX4VR-5!ID\>Y=QQMT\=BR?2?O?<1'&C;[XZ)4$$DVS'?1+D5_W5_B6> MG]%3[_3(JNK&4HJ:0SLS-EJ^U=*(ALE&`BGT0%UQ`NZ?ZQ^X-HFCB35FTM"/ M/R]=J%EB9PJ=5CB0(Y;1$XRPE^?\777%DEU-K9,39&K&'6`MHL(?^GG7X,= MS%]"OGK^X/T=Q?/B=%-RI>\1Q2D>7.4'NTM68P9;[)!]@$5C>:!W&^RDB*'- M4P[PTBHGBT&AN9.5^J.0G8X&H8&;A[2MUYMUZ;1U' MI=L`U4.G].RV!K#9E914!M35\P%L_;%C8]<^6.0<*-4+&OQCHY3-\0Z'TFR/ M`\DE'QF7(^5EM$?Q@6Y3N'K.'XI3B[:%3F+1L&`LK2C[M)-4=-VKI10]JXV$ MDC^M37W5E&E.*2021:1CS5Y6^F43"V-4 M+;\6M\WU:8?!]-(:]9X.!R]^)N]>>)$?>&$]K="+>XNIV1>53]0&++T1,2BO MB,]E MY3Q7M-O3,D3-)8N.<4N5.,^/(NG9ZDUB$YDWN`L_`"+E7`7-CSB;F,+(<,G7 MT>(PC&/=`1;]XL4!:=`RPK&$24I7H,DKS-+*5EFSPS$%36.4D_JR6+6J^E9C MI9JU!DD+%5#H@$+)%9ZJ@XA)6ZWH\E@L-<(FM:+O\R+90G6I[-<@C"]4<>QP MV7@.:$O+0YO8=J,,G/D^661.5BB%R0WR(G*[5SXTCQ[NH`^#)[6-TKTML"KT8R=-J+@<6%>PQZ_2DL+].D(^JE4. MJ';YP!_K*O@LL7BB"$8)`F*GT&$,_/(3&"$!DE_TQ:B*Z$&:MNZ9N-K;C#6M:L17#*8 MRCZA4W4O*9J\\8U2.$<=G[3FU&?W21I[?C?MB,7*',03&PQ8MF&CG;W8AQC( M`M7I9O'3A\5J"^X6M^N[[7+U$YBMKL%\O9KC3^]FV^5ZM0&?"IVQ^W-9I)%> M5-J$8<V2&R.C93KM'!"R(V/9K/FIPHGIDA0F;-`OH;AA4@7Y.?EBNDV8=N M`+D5DRYZNS\E$[*9&`.G=7W3P=7JF!4J+X9YK1A?E$%.7FR4N5VU:IA=ZJYK M2^`W0027*3QTWE/44.%TXVP5PUTZRXG-[EW@3Z>KYYHITR%S2PGX1*0!%7># M0FH`$?3^L@"**P&6MJ@JX'MSAIS70>*'*#D)+NM5U^!0DZEAF)D,'S9>`53V MJD-/GA6EHMPM7HK`(:"E)'IB5C*41:3D^CH/(@W.8RC[,P#&"U9?43'YJ<61M"0"+9)JJ+?Y*FZ MQ_&82@_C7)_2),6QQLUMDY+WO.!?]_E0JK4MZK+J".,`[3:I%Z?"C8VO`7!0^H_=AOC M7>DFS'G6Q@72]6FP5=:MFL;Y;7LRW^QV:+_T/68S9@_1[_:SW_ MKY_7-]>+N\WOP>*O'Y?;OX'O/D;>:1>D].YNEM+#$XJ1JJ#DT%:DSF2OW MYP*9YU[R^#Y$GQ,YA[FB7>HR1,TQMF/<$E%Y?A3YR597H^5\MOD9O+]9_[IQ MG8Q\4+`Y*`P>EWH=+0[C.-;')UI&_SDZ'%%$1FFL4\Y59-M48\N:XAK+NA6R M"1PIL8VK/\V>@.J1&V>)*\6:Q2!92#@48JDQ.<2W/SZ)F"_2,1^V:6+HM;B& M.2M$4'[)K:M0'S/FO(,6'KQ*MD16.N\DO$B@V\HF0ODFVC MF"UK"M0LZU8P+G"D!'FN?FW'M$LY7AAB%AUDD>"P@Z7&)`O?_OC<6>_+,Q1O M47;EGGQD(E7ICE`$*N9&*EPGED8L,G^*(Q>Q&=X(YFIV,UO-%V#S\V*Q=7[< M(H<,>_RB%%+N.(:KS1G/2+R-2%?D_[9,DA/<79_B('JXI5L M`G>DBH110G>.=\C;UT!)97T#@XFMZ]+&WNV^C1!SOY?1;)?!FWOR$/BUIV.S MO#>VD*EHMS.`KJUF/NC7DE'@;FYC>&_WYI%.MHT319!I@DP59+H30+4GH,Z& MNH7R?M?W*-[#(#W%HQ\L-")#>/NY1J#(J!O312TFS]9'>JG&X@N,_0`W7J<# M%>FK])]L?9OYA.71;)'/F#Z/)%-U&LUBOXI\G>UB>1/L%GE09O.?,S9'\($4@`H&Q#6@T("=(E#@4K<*E)_-TK<)/6I! MF5%^,>C0JSO]82:O#!4#KU0:"FPIU(;2EHR"?-O3*0KNS-)TUX.MEC-[TBE7*.-*Y7O"[ MS?:/U7QDCO`7-CNQ"[WNZ2)?Q$.'`RIZ&!!D\YKDHKIC#(]>L`.[((8^CD[R M>["'3@QVVC%C<^5"J=^XX,#[PG2NO["5Q2\T\_,%8R+[9055GMJ$474D'3$2 MZ(`%4Q4+2M7^69=,13[/MV:JT(K^M4^/5=.74O(/72!2C;Y.!=-WA4C>EG$8 M<*:ZW_0ZJMRL<"&U.+7@Q:^DGHDIO8I]6U09O7_E3/9E[=980&DJ**R@%`H6 MI[,S%V=>0VDX[3NK73/"7$5QK-=3PX3BA'8W:NH3VIFNZHQVW=-98'B6996F MN^$(5%E8V3B^MC<4B3W65OI"H?'N[3+RPQ,Y"^B6G%:)HEF:QL']*:67 MB:$5C@:*4AP9W)2'XJ8B[M9S&\;K/8U!XR;2@;'FV)D(,]T\::8QZW#*>@O? M@0QD'N'M;&4%5XS$9LQ/)PD:_@;.D=5L/V^\:>=EZL4WJAI&UDBZTZ@HO/L##/8S% MI&C*L!E1R)BE0V;5(A<:#C2(4--CL"![ZA8#6D'DP[_[FPNQGXD+@%^WYPKJ M$^Y-S#(Y-OH3@[&.\4"1D#Y M3&#_]D(V).R[:,5VG6$%;T>11(S#"7.[?#B&;3)"9].-2+7+!W<.G)2%5<`, MA:TM'`T1+UPY0+([H+E&!R_HO/8DD^./I0LY\Z/IS++E\73#B>:(NJ;+&U-G M(F[1@Q%=\;BZ&PCIR#I3D8RMZW:=H0CK\'N!"(<89@["9QBU20?50_%Y:HSQ M@Q,GY(O")T"^Y+1\AK0([RZX+*,]B@^>Z`!P/:V2$(I: M@SFBY,W-_3NHMD-N%YNYC?KS<>[17F/T7+U?GWW8;9= MKE=C\TT/,&A0--NL5#+0)*J&S]&XNX7^8X1"]/"\@?%3X,/D#N*\TCFR4"J7 M_UX"N8&,Y%HVR4&9$Q'KQ+K3#U[D/<`=6&Y!\IS0N5`OVH$DEQV76_+P(LU( M-/G#5:DS1F+7(8[,4=*Y`%PBQ>5'+F6<'=2N76[47>@QH]*+P@7V.]7T:[X"G8G;SPUR!]O(,A[=^2Q^"X18L( M?]=GYMQ`3^V"1[K:0_FEY\\H[WJY%O*QA\5I_3G!9B;AR%1$7S`A(Q%N\5G/ M4(/G?=K@#O\9>VF$,CPN&]E'P[1JE9>*>VCX>E/ZB'2&U4,G]L^(HR@BD7CO M#%-<2`@']LUL8^@EI_B9;HEC'D\BD"@@SY(8"OBN3:-PYYH7@IVC-2T>9!NU M)\!+@4\J06?.$Q$%$2G_ZBV\=X4;:.?9<@/KS)TP`@D6U@WM@F'8M(9UY1TP M/*T*Z]GQ)6[L?A$%CH=OVFFTB'55!U^`A6XSEW%T35HX.8KK M1!GAM?LU.,E\`B[>3MZ]_;?)VW_[4W%>%'[TGZ<(@G=O)X`$A0[RKZ&?@>7= M!?WT#PY1@WL7@CA,`F)T+CO@6;*"(V-'0O#-ZT/HHITDG;@B8P@..&\R]@'" MF&<5_.+%`5EB+-[@R(:?\FX?O9JR>%(2T:#?S& M>IEA3;"#?-Q;%!'^`_F6/P?LK"?I6O;"6E\-R9'-3W\JR?0(0&IU8B':P'.BG1) M>;W/OA-CX7:("5%ND9JPD50D3JUG$S7_VFE$Q2QOI$*P[L+2\B"X7CTVQ./"H`V.MFRK\*^A4G&+?.P4G3IA M8E"%]=.R:5!(LB#>M.($?)G[#?D"#`@;VC78-6D+QLI[_SA*;2@[L:M/$#(. MG&5[\[JR/$@[L<..78'><$[J4906COQNC)W;([%O?P37=J4_2FM:X,[Y.G2H MCRH$I",P9IQ41EDWK)-^E'R,QK)?8?#PB$=SLR<8>P]P=2)S1>M]M@%K?4J3 MU(O(07><%QG[JN>_IK[Z0&+J.C3)U)Z^1=3M97)Z!PF+\&@]NS\/[<&]EP0^ M`>TN"$_87K%AY41NF2+]Q",$T(LC;"H!1QAGSX'OA?XIVZ#MS+D5O1&)S*"D MF2=T+=431[]6.)])K@C6>J:1AJYF#LEUSY1`J#?C.R'Z>#>1/RI[TRQ5.+-3 MN1]R>G"]$]!^1+\J,NT`_^>&L+']#+T\&\4OO8^`1.!SK@F\3+7H\5"E]#6# MG+-#X7PH'W,_`J>QUUEMU&FS6E\FTQ;W9GQM.\F`Y^\,];#$=8]T(+0X+4I> MU]DN!9"<[RI152(\SY`"Y<5M.#^:M3HWZ;4A/1M@&-2XE\L?OXI^SC+R]?HZ M2]#OU]\]>0FBO=C;?WWWEO9AY)/_6:$HAOXI)C<;SW9_/R4I.8J'#/OCW0U\ M\,+W$";,W70]-/-?34NS)\UUOYQN;[5#_HD>6D1F-%K?KZ=O%K-[F9K>P3T> M'N8WAI2JP"MUR41.2#3!'JN"F)K"S-]EMX23.9SLGK$?QF5Y'XRA8<%O,EO# M"/FY^SD^(\0'C\_Z.C4%;MQ?-3!=J8!,!U`E0+0?(PQ!Z%. M/275%M94`FWS;.4Z.U-M)?.O25NQ.;4:"U$+X'-EXH646'+8B:FNA`45MG,- M21@O:<"9T6^S[)(Z-HE[0?F%X9XI@IJFTWV959!KE6)64&ZE)!-ZM%Z62;V; MQ'I6GF7"8`73SRA\PM79-Y#W+-RL@/P,!=P5BD[)S/?CDQ=J5&Y\-6')QE(S M3^.NES,5:5S'FLSEV%$KR^Z),O"(]HN9]!+`24Q@<:A5B-NU(&$LS^6Y<&RS MW.)[-()@08%%%4"NX72?8QBK6J64(;!:*9[8KJQ737RW1B#+J9.^6KAJ%46& MX'J&,FB+LEFT8G.Z1BDD5A660SQ5\^1D>SI3621TKLE2@2VU\B@HWMOPZ/O: M+VUY4((V,:7E*%!A-=N*A-DBU^>$N\WJ2>S5&-`%551:KKB4KR>YW#=9`K-6 M2648S59**[X[Z^65V+4Q3#=6"TOLH@A\@+L4^H\X>.2-U*\/RUKUEF$L&ZV[ MKDY)$,$DF:/#?1#1"H+X?8B"?\+=/GJX M7H]A^1ZF%P%(7Q_^?0+N\R]*=6-R3PZ6.7IQ^HS_G[8NF9#S:/DP+? M(]\V">@+F^00)ZKKA0D"B'P-X&??PYT3MQR)9J<[(BRR;ZTYH&H/J#)%+ MC[5<^JWR?:FYE#-'Y$@+7#^=Q4/KM$YZ<>O2<([B&,P`Z&P1,D`QQB`H7ET6$1B@]> M"'"BPC4-W:N7_R"3;`+JD/7*90-IE]QP7I_?(KD5?CE"GWR`D^P]Q)8C[#C_ MM^\ECY/,/VX'_.(_XJ"05^&#]!$W"$40/$,O)@]KC4-'&./(8%_^LQ_69L:R M1I!7YFFAD-WXA-NV!R'"=N-)-JL6\V?91EY0'S\_6JP=]%.-]6)!K4DVRP.= M'^7%=AW.SG[I?04W.PW;,URY?*TI5*4YK^7"=6'?DN>9IZU>4O9T;VI*O>UN M3T;I?0\WIBWZXP94_&RYN;$(U!!E./3L0,T8/\;O&^=O'PMA5\6>R M.:)3`IGI4E4\_\)R\2'PEUDWGD,5'7(IH:1?RZCWR(MW9"9S5TAG6_BH2OUS M\G>Y:V_D=*L,$=0CC$TBR31+/JFYL(U%,QE9U=,@%-*S77-L$&9.,<@%\Z\L$AS"%+Y=XX6!U!67'A+-Z>*+ M'YZ2X`GFA_7'Y*X(\!![$=F_=/],MQ`]H"<81\79!N03>NHLF4V@!W5D/F@U MGI9>B"C\<@Q1D)(YAR!Z(M,.Y(9'7+>#8XQ\LIR_S_Y%C_J@]H(#+CN.T`_V M0=:`T/L\0N_I%?8]&_M_??]+10[Y_M8&+3S1M^A^=WJO=O`W^[2 MT^3T.DC\$"6GF*Y=>-FN%;(7^DBE:B>4_%BYH?ZQS)009$:!]$7N0'N/1)L!%XH)G@NSW=J^T=CB&<@(\;LA0' M8R\,G\D;L)BI9%-AU:[;.,`FCG07>KYI$!VPDT<8T=*J;&RE,P'+]W>;[W^@ M26>?;_[.5VM@\>L4.]:S]I;W8S.;C$5Q%L&6#D'Z3'>7@X>RT5[1Z/J/639Z M[!WA`QB+S%"HM;]&WUBU,Z9O0T9(((;V+/=W;CIUY/?I4JK5=2G)/F;D*O7! MI\P"("8`M3%R5S\B$7@[:L_/A*&[6/MY-;G_M'\+3//A4H;LLSX]] MHZ7T)GB(@GW@>U%:E1W4:2"KH?NHYC^>GNH0INMX,EXN]W#.);>V+:4"&==] M(*DL=Z3(>S#Y_!VN+E%,GSBQ,:@7^M!`5#2YKV.E)+V^ZW/"WTRQU\>K,>#C M\JZFTAB`%8AVKJ8[*Y@Y5=Q9T#RP;M-U9[!@Z^/:&*8OI9C^BO#+J<3.@E^C MM==U7C_@HF]!N]0EG9G)"L'[)(T]/VVQ0$>EV#6MI#)H_Z""!X,[5C6\\;<0 M*AN9%J)T.)0)@YHT^%3(C[V34`<:J&_H6CL*%=2K787JO@SN+,0>=W"WA?%A MO=]X(4SN8'TR>/800SHWVMYBJ*M7[#54UQNT_T;5C?G=AYJ>^5MRM`S5]B.2 MP0C.R50;X$[[0$8H"3%`QBB-"8S"!+E)!)']!1YQ2C^!]`AUNG?`B?&,/N#0 M$"RT-OJHFJAV_.@Y/1O6#>UPU'5I!N5DSV,F#[8YKJD*:.J`4NFK@"QO.Z1= MS`[=(*GCR^1.25V_9I![62%7+2-_%$GLINC-=/NIZY_-0SU*J?@DSY]91/^GA#0Z#0)+2RB9+0FD[/!G4SY9.V M2S,@Q^53+O\BRJFC[\7LT9']=R70B.]&)J3#]X?Z?[ZC$C(W(">W[R>WZS8'$Z)=F]=/&6 MO!/H$T;@?QU0MM.)K@\4-P[&\`E&I]%WKPLBCI1BU#[SJRU;.^R+;<8\?$P= M"<>SK0D<<@C<`E1/''DSJW?DN<>]:8;>Z'+JXA^GX$CRP`8^D/\PTYM8*/\Z M/*$A.&7;-)[JA&ZXJ!5H3S6'.@.T;\G:S+!03$X=I$A'@VR^JKFP#7=K\V-ZB5[-`'L6 MPJWL;P5JZG-A_;%FM)>H[:2L#E\0]1/J"N6ZO%QAV(*/S+Z%E7A%EX(U'B4+ MM;5W_YQ]1W9@0)!D-]#YI]`CM^1E['V1_8H&:E$O7+47FF2ZM14F-3?V*6)J M!5_5UT!RT#7["K*U@W7L08^[/&\8>X,7Y%6<:*VX/,'X'@G7XE5=#L0@ M67W??BUXXRZJ&\:;T165FR""Z_T\AKL@?>_YY&J@YP_>E^!P.ERA.$:?<1\Y M]X[X2?I\!7'S(*Z^0L]G[4PT8BO_\0;:&D+(0:Z-UU(F6L-E\7#CTUPIH)2]Z+B]"PS%*X\`GCY*LJBH/ MC\T+K%.X(_?]9JZSBX8KH:0P%#X#[`N76A&]/+AJ5=&VD)%*9`9@O4C'VC%0LZ M3O)J8`T[V+_1\M9(:^SQZ[+B5ZM?G(`#OS>]S_@5?^.7&$%.\LOLZ0;5)3+T MM,OWWB$(V8>TJXAV[X!CB!JZ!:ECV7B]K.!,Y?HCMJ[\SK?L+M\]500'JCGV MW)X2!AB7(`ECQ;W_J*/%NON(8]HFR(Q?ZL;UTAM>[?-S9R99OD"^5=C"0Q!>]>>\43*=<'%-T=CNO(.Y?;1 M_+J7G1OO-@KBAI1^Z29RN[(E7GEFS(/`3*+CV]8,/TYJY8,)N67:D4S6._2< MK*4=>RO7`U][3\'N)H#8Q\&+A"6A2+15$K)%3?36+,O62D*!,VF?S=6=TB>@ M?`0^/R*0P)A^(E(_"$/\[>(*X?W_TGLC@+CF2*='[;)J4+#-G M=_^0D6"UAOR](Q6E$$+M*D`6:G81P-+J%`%\TS8Q:K:B%'GICJ$59/O_B"O)#*"(U;[PP4/7(Y8J:@=JL44,!U#1(93QRKZX.!]0G M8DWV2%5+"BDZL8X\,]V]LJMAF,,=OQ!JCN1I2Y#CU`&&,3>P(E#R8?!%>V5_ MPY!W*4">2^-_2]#C%`N&H6>T;%B=B-GUOJA5DO;D)N]Y,;?9?3YH5JMMSOS, M)L<#?V:+J3#-/FX.[(NKY,CN;R\:?7Z3&SJD\FNW9KC:HM4$%]N(<108FMKD MF=:+_T4)@/6^'`R,?%M`SWCSIC3U`CZP/V3:--C_<>WKA?V2R?L7&79.7Z49 M=J-]T1T,O13N;KTX?=[&7I1X=/_G;+<+R'^]<$TN/D\>@^.2'I.9M/<@]S>0 M_PA]#`R!O;X_X_UA[R9PF=/38FV@[)6BV5WW1)8JG-!\LRRM=,C;^!ZXS]V1>9K" MW\A5XS!,(E,0:5W"W,=<=0US_\:,0A,S1>0@]^8)@DO)0A?4E.M59$,=U/2_ M:D9P2LJ1*#&PL.SMU^`,W*`VF">&I+[,>I78"Q(L0`!)+PZ@%PB<[E&\([[P MDP3Z)Q+@"*7PJZ8+I]@V=AC?@MQFI]["?Y^P@WF7+G6[G*&G(F=EAVSUO:5\SQ) MMUBR%:?T8^#3S\LEIN;YZ]F[AE'Y6DW^IB&9`Z&S(70TM-\'84`[*2=>MI'C MHKTC4QA"]F[,CDIG*R;'J#7(F=TFSG71#VSU#>(9[#()1S;I&(*,9%]X3\P8 MVA'.M&VPZI;ZZ8>[OGM@Q>Q46C)\"'\YBW/D_9,=),CMFJ5QQ M=C5?;M`IOCRSQCMFF2?^Z;U"Q>D,D&])-W[`O$3+;T$A"]%>I94M2-.7MK*7 MP;#1^O.Q5ZCE2$`Z06L=YLM3J4[Q%1NU!C)#9T3+7/2#%SD5.D=*7<"1;&H( M,;SSGX=!QO")SX6O:(>'4P%Y]Y*93N6"Y0G/?,%A)X?R[!K/J%)7@H-"A9H] M:C)]#H:`8?""$C(YZ M%E]2&.W@+G>HNOSB6F:AE8OE7Y8L-H0//JO&T+''$)8)0 MKV`N+G/8JOT>D^W9_"67Y;-ZZSJW;,=G\_Y:^+MQ`XQ$3^ ML_0S,80Q?3P:3]4#&L'E6V^;M;W.]"7S_*:,(XP#M,-%]1%&"?[XT8L? MPNJ&>#+VK74;7M7*\OWWXRD^HH1V1K@?.OG956L^#)Z\^Y"$04VP]B$$'2CWEA\$^BA"D9XG[NN]HE(>3G M\--L&\T]+$[;@[NQ3\\;Q$5DB!O-7-?'6ID'^S=EC.1@IJL=XMUX6L!==*FJ MS=BOF`NWKUNB;@T,:89P4E]](,0P1#I#"["X97!7!*R^!Q!\I ME+)]M-&NOJ;(CA`[F( MURLKWP@SQTL>)X#ILP#+/IF?R2XMT.W'O8^.=' M&`'?"\D]PW36AI2^1"VOW-/L((R\S,?/R3LL3P$Y"0.0G>/9T=%!E&TE!@>8 M/J+=V#N0M)B%^@*_M4 MZ::[E`U,[0@UWZJSY0&ZZ]0X]R=D`/B-T?I`?(&4'KSKUFQSC,X7VVCX6V1:`I+@6]2;PZ%URN,WS;+-`*TMHZ^4_ MM(;>D/RE[,;X\$/7,S?QZ!FJ[?#(MW,DP$O(/^^]D&[)2!XA!N6.S(D'$=T! MLJ-9YN@]9[LG"!CS]Q+H]KZ$C-/I)HH8:^-O?,*@>J8#"/QW#">5'125&[%/ MY&#-^S!X*':.D$N)??RCD4EH/*IY(CNA@D,VWTYFN?/M)-$3"GS<:'J?8812 M\(Q;>P]AE._P(%ZPEVP#27;`Y`30/3"D&:,==G*AI"HF9"53919DM-IV=+$F9&)=HN MS:0'/)[(Y<&BS`[E3>$UG0G(M;X*S'(*?,N@'5B::_G2FV='J1=RJVYMOV:@ M>UE!%]:ABRAT:_GWJT`LIVZUC-B!A^)I^3)Z$)ZV9S.8??<-LZR(GA6S9H^P MR]^+V7BXRJRV':U0Y#-'1\KRQ9%V[KAPDHXZ0E"?(+8.G9*I5H=/J3FQ#D9#A]^INAH&0W(87O'B M'!6LO0,$*M%7"3C>$7EF$3?TR#P5'R:/SE/U-PQWES73'9%H>?+>#V5_?TSM"JNL1CEY`KPWQO6.`1];@ MN]GMCIW-D<)B3W+J?2G'#V.? MRZL)2]0;-(P-9E+]Y@XS17?GX8+!_;C*_@RPH-B1JPC.5XY-T;9<&^`TL3%7 MR9%:&?3G#)T171C9B??F*KLU`-++;R!EQ?),(+5RO?ROCR@,G\G]<+O-Z3X) M=H%'EM);*%>4;ET]SY4V<2$UQ[CQF MK_<@DZ-WU^Y`7?+5(8Q371B$V,!Z0L&#P?D416]#@'99`DV4WUX=T#@5@D&@ M&:T)JCF:)#\[J?L&CE"FJ)RER&T`Z,51<;<=D4OHG'<,C_CWR1K_1+9-Q3![*_ESD#Z"GQ;@ M9^B%Z:./BTEGSHEC(:1[]!@Z<%B`&=LQRA%^1H%YND9+3, MZ&I?`5"XG>T`I`SNZ8D>]$'.9(P8/>X_N]L$&D,/MB0<@I^R/Z[_/ M#?X+?UA\A/^/'!6"/_G_`5!+`P04````"`".80Y'M\JI6`L``00E#@`` M!#D!``#M?=UWXS:2[_L]Y_X/?;.OM]/I9#*[F3.Y>_S9ZUVW[6,[R=VG.;0$ MR9Q0A$)2=BM__0(42?$#!11`4`#4?DD[8J&`*OQ0*`"%PM___?="LCRF MZ<_??/SVNV_>D71&YW&Z_/F;3?X^RF=Q_,V__[___;_^_G_>O_]$4I)%!9F_ M>]J^NSC_='*_B!-&FK^[N[]E?Y)W/WS[X[????O=NS.ZWF;Q\KEX]_&GGWY\ M]_[=]]]]_/'=PV:UBHMWEW$:I;,X2M[=97%:,`;_]]WU]=FW[TZ2Y%U9*G^7 MD9QD+V3^[?OWO')6R^]_X_]YBG+RCC4ZS?_V)8]__N:Y*-9_^_#A]?7UV]UV3O^4_O/W[__H>/WW[)Y]]43>2?$974Y%\&])5,3(D_ M?2B_-J2,42QAW8C-M/?NW4Y_&4W(/5F\X__^4L.Q4=: M1(F==I;\AFT=5#.^T3>V5"MK\HU-+3,300Z@Y58UXQM]1[*8SB_2^?0-[U=E MJ_$/190=`"K#RL8+,'VK-9KZ$N5T1>;Q+$J^G='5COO#YBDG?VQ(6ER\L/_D MYZ2(XB17MYES>\]GM._^^L-W98M`5L:-NRPW6$[A..KS4;#MO'+$KS M:,;=A7':5K`T;NSI)H]3DN=,(T_,L>)<1[13QLVXB>?DJ1C1ID[Q$8U8D"PC M\WO"1NB&C&J/F)-QT]C@R]@8O/BR)FE..*!OBV>27ZF8.Y/9.64D7?^ M[S[.?Q_C6YE7-IV`4\ICP2>(\CB_7=SQ711FH3A77DO&S#VC:_EZ-(E'.F+& M59E/-MDR2N,_ZZKNDBB]7=RNR?B>P7*VZ:L]EM;.DJM6,[/E))DW#F`TH8MD MWE8\;QL.DGD[!4RF<(_,&XA@:LDY,F^CF,]$KM$H3"+XVG6,S%LK93>!6V3> M4C7/Z7P&\U:C61_,8Q@Q;1G6=##1ZG\/(=R^+FN[F#:V+R??MYQNPW*:G4K+ M6Y03[$W:W)2TZ^%:\FU'[C^:;CS:+9[,(;;O"MMV@JVYOY,XOG9=WBF=W4GS-GLL^YU_'`%+0;*;>+LRA_ODSH:_Y+&FWF,?MJYG`95#.=4`\%G?W^ M3),YR?*+/S9QL9U6.FE]TXFY1T@Y7%?KC#RS`O$+N4H9%\+-SK2":[;`KBI. MHX3'V3T\$^9G-+7<,>N:LLFJ'/C6A$;5=0CQ)I9HC,]-9QL."X:$"V9KB^U5 MNJ#9RG@A(N?7;N:Z9?6OV0^=RLB7@C#Q&\7QMHX0I*RVKCBALTY="8]NI9E* M,O[+/V2UG#SE;-Z=-3Y;PL.M?OY&IPC[S.7$%?F@+U6EP#)P+">S;Y?TY<.< MQ!^8H'_A?W")__+^NX]56.Z_L)_^L6O!/5G&O.*TN(E6I">BC*0224S2%:&- MB).L*TZ4S6J.[,\.'(;!O!7%AW4YTM_/GN.D0=(BHRO-3J$H"=NM_]L[3`7O M"OI.S)AF;%+Z^9OO>'PYX[M;TU[OE`U*78J,AE'(./`><*(!]]!\C9)N,ZOHQS9JS_FT3913H_9Q-9#R,J MLDJ%,%DP2$%*:@86F'F%E^]]Q\M.O-](DOQ72E_3!\(FW93,RRWL3&A8%+0= M`P/2!@,?'9G'&!RPA@I(/X0!I%]ILF$:R+:7<<)6>4(``30=X`QH`@.,7,8Q M0!EPK@#RES``4EG,9@>-+Y,W8IS(2;N.#$`:&&I0$H]R:X`**@S]&`:&2N2? ML6EV23.Q\RNDZ""F1Q$84&3RC<%'CV\%B[^&`8OJW(!O,I:'!_GMIN!W3/E= M8;&!013HFAEI@<`PI"']*),CK:9"V+_ZCK!:YKVG?\E^Z<];"JK>9M.`*A@` MX>0T0PW(NX+*OX4%E=W%5358!'1"N'3H`@4,+*L-R'2X5Z#Y*130/#*V`$[: MGWK0V'T*#@T"B<8!8,>PWJKS?C/WA+5Y7@(WB?H>BO!;I:3>MV#Z72:36D9@!Y-,(C`R#C.)/0XUP@9NR_[]P\#U5ZS'Z8[ M;=4YG!Z'X464/Y6B;_+WRRA:2PYJ]4I4N$!5V3D0#97PBZ>$Q!7_+$VZ[V/CD6H]HJDD@`T'8$&-,[DXM%5 M/`"'_(LRK(M6XZ6$9+]@S*=,O6I&:Z,,RLM[SMJ)G373`NK M*$_,<*Q=G\>/,(+/-"L>2;;B`A*0V`C^E3IK_O)7UA( M1$!"H,O!_"S>D^ZNK_.=T;P1M[\O(2&IMR6$)/["`"$2$@YB3N;'ZY[`XBXC MZRBN;U'6TVA'"SV4:)2H-(PJX2^&]`5&0@K%V/RDOAADM'6]XR#;:9#M,/B, M#@LX$/>XPQW/O^8Q.O M^=IXZ)9A2!N3*R/U$!L:LJD@(F=EOM_@A3VM+_'WH-'_N5+5_F/]:J%[K30C_:R9X7MQ?E_8Q;> M7CC)6J?C5'&\W-49AO5>DS9<:$^V,EJ9GYC7-TQ)`9QWZQ:KE(XOYH-"Y$?^ M:L*AT/X<_M=[]7?1EF_4RP_>Q$2]@8BI2M:R1@QNW3CS[#X$U$ ME3/N(4I(7N9(S/GK4)3W'G;D63.V8LA;7E_YM[I4I]\B4>V/>(\BJ MN9+8*(.;_5[LTFMO#0MUBMJUQU8EUO0Q!,*TI-H?TJDWK&':X;@4T;J3EZ9+ M?ANF;6#[8DI(:NF$)#Z,&$G'4)1HX``9)G- MH26M(]SPY*'05^DLV59@^!_CZGX\0>`H=3(VZ8?6!7VXZF<_+,.4HN8OB^55Z M%JWC(NK?=5)0U;%5$-41XA"GD:GA"+8B7$?HGA11G))Y_8[IR6RV66W*0[!S MLHAG<=^YP1>H.@53X`@1JZVGJ<&+:9#K!UM&Q3W7TI3;5DN%T\1E^& MX:TFI?=!KGJECQ#NXS0XN>'6;5VXL6V/6?E,]A9T:V&"JC-$!$>(6*4>I@:E MJ`$&X7,_[7"7DB6'MVL'UXZ:)ME0F60CY2B'QB3ZGGHXV6KTB'1$H9Y23+IA M:;[W;+M9@6=&4*D./K24DB-O^P8&:4WIK9R]`169^Y)>&!3=B_R&M\W-KOCC M*[-T".KSXPEW91\^DX)S>'M)P>F-_;>7%'Q]2>$D2>@K'SV7-#NGFZ=BL4F& MR9"!:]`F96L]Z)7U.!_D""5@\T7J56$Y!-:CW$%OJ22A7=YSPIK.K#Z7G?V= MD+*WTOG)BB\-_BQ_!_,DPMN_5M@.]X5'LO41G]/H3`EI:]5:CHKSV"-_2ZWU MEEKK+4(N]`@YMKJ[S-MH,; M%:XGUY5P][KZR:9XIEG\YWY[1(AIB%B(Y2'QT6-8H9_#8G?8F'!O(X@DN\KS M#0JO74()5FO"KP2G0KVXP&C=D'!C^412W6Z*O(A2KBL$2`74$J1VJ+\2N,(: M;8`!>"WQ%&XM@G((WJ_" MH<5KYH!@!5U9@V1WWH%4Z,\`R3LN&)((6@> MN\NJH9N#@U3DK!KDT?/DP*`3O;T34!9HWZ401=K7%$>(2K4F#AIK7[?`/'>? MZQ/`MR!?59!O@+$@;X&6_@5:-NK);Q>W:Y*5E>TRH0AOD#6QF,["+W=M:=H- M',`JJ"JH@%1N7XVH<]D1\'A93M5^)4)$9>^YE?V;,*V*!.XL2-/.632D<6>J M%`JF.+%ZIDC,M,E"-&06?-3)(YD]IS2AR^T#R5[B62-_WY54T=4.)4SG,U:P MXJ'Q(F$8[O%C6U[^1+#@(5T9B<#J[4E\1@="*#0PQ+S"/?+KB2J?!^7S7S@@ ML-3_8U]+]N%RELJ/&VH.M2H`V`HT>$0AH&V=H%QC#.5S#_2FC>7Z7T<4@]:/@2Z6Z MSA>?00&+@.[]#@MSH-%60A9P-$W8W44/3NZ`'K*3<0D/S# MO=MTSW3!.N.9R7;.%H()+6\T=P[]I=,D7O MGG[<,$'W<="G9$&S*OKY,?I"\HLO3&HF,9OELNT5TU>.RN]_@)HZ$3S M$#B%6)IHDU`3N#>XA^ MN=TWI`#W,(3?:F>I^\UG+,C$P$_572;F=_^\L`^85ZSN2!;3.?N=WWTDYV3W M+W3"9XUAO3MF@:&7ZKUD4U*\3'=9E6?;QRQ*<];:7>[9\O^2W;B9_W.3ER]G M`X_.35L)HAO&5.+N+,$>4.F!^J!WR,V%]VL6?X%BHN>J?G\(S%O4CN'7",<`K4I%52H?) MO!'P-,KCF4*Z#@T@6D7C;$PI>X3BY.J.$X@K'R@`MW`GRKY`YW&R*0:YOQ14 M`#P:JJ``(I;-'"(-OQ$3&/CBH%\3&-)"HJ`[F,UEQJX%NKJZ$XXOI=DPCYO[!&:MC'3H9[BTR@Q? MD/7T`:ZJ?8\\\2$D<.=C7[+JHWL1=DKENTTTY<@[^1+WSRI1M'T!Q;0^)#'^ M3+AI'VX\B[\/TQ77W]UGHY3V!U4+!>2;%+'MI0VNV86[U=)).RN$A(1"E"0X M'%BH!=,$AI!AN,&O)_-YF60U2NZB>'Z5GD7KN(@2(4A0M/6CLW):_X&C(ZPF MA!2LP\VM<4^**$[)O'9QA2B2$S5W3,5$_N,&)9XF8"">([)G^+#MT'I$&3H& M%-LAW7+#A[!5Y?S'F:D2=&T5OIIPWTKJ"7].5VRX]7>\933U?K:8QG\P8833 M!`[`TO(]!!?*[*YUJ=Z:$=!BR7/W#H&45[AKD$:P:S:3E3'ST,I[0-!?;K<( M7$;&=Z)1KM+A[LT]39)+FKU&6?]4V[#T/I)>KW3@K[OT&![ MR*^K8C(9A2_8X0L@T.C\?;N)X(AXS\XR'GOOU^GL0GD(R-W;I8/Q5A_1D_*I M+9+FI2Y%`#5BT`:L)H-@`3Q&478`K=D"\XTM3]*,`4+O!O`8A&,XR"$NYW!$ M&-=0U50@ES?!?&=N-,J!ET-V[;VAQ4X4)N#%:IW0+>$WZ.N7(+?"E1"V4&=Y MI"X4)!Y-%&)I(:6NU2!!1D#.`_]VNRZ3B%Q\(=DLS@<77(S+8UP'`E^"-('64*6:V44KI($Z>:,KFXZAHA'A\C_^/[MX-D MRP?)`Y7Z=I1L<@-K=Q9XD;I?K^J>)`\1?J1GR1/@#CY--HCNED/(123<]2!2 MBXZ-;0+BXYJ:JBR:>C58CIKS*^APV`F:D88M!N'>\]6[>DE!S4IU)^/=46G% MTQ+N_+NP>Q;ESY<)?;AWFLH0=DK#+=+\ZL,'U;E9J^^&"W5[46JW;JAM>P MH>99V>_;Y(_TGK`UQBQ.2$?&1XK4'#"8IZRBN=HY117..N6<,"3-XA)[[.^$ M5/MM)RN^-/Q3%`VA4Z12&JZ(,VLQ*6RHD<:Z)F6*!G(#@VN8N=V9*C:B%#-G MC6.+G'.Z>2H6F^1D-J,;?E4HY:$=JSC/.WO%_5EL#(NJC\Q8'"W*+6CT,*@W M:ZCYZG#2"*%!+!,?OED6I4LB@KU6F?:6E[K,T0+;1&>'03*R92,>%_/!<1SN M>#5JJ9)'`.Z@?D'PCB%=#*D$;B%[X;TS<#1F5!Y4C+>K0[KNQ] MX08N7C.J+7.H?O&VKK3>(WBIM"_O^8;P-\CN29EOX2[*RB5R&0V@'MB8PB!^ MY86#!["&;NPB6%ZQ@4/E.X2OTA@B+!0U&I![MH%%5G<+,O"$#R`"9]3$*EY+`?T"ND7)-W"P4/3H0NIEF%=RLT?]G:=30Q,/KJ^XG5 M6JV^HXA9R"#+R^VHK'SPH-73T`2V559WN/?TA(,UV^BA%RXB,ZV#(L%C5*D' MZV9U4)WYO3K_D'B74::/8EMOWCY&7T@]AR@QB2D,HE->.'B<:NC&+F+E%8=[ M`0W>N;@G+R0=)$=#TROWE1KZX$$IU\`T^TI-72.NMGF2H6QDE+8K=B3HNQQ2METGWI$2. MJLDU-M*10;OL*J2%3N1749NI,U6S-5\VV)[,_-G%&Z@VTNR1*BY-TSF^0KU?# MX$[]@O5]'(V"ODT2IF"A(_2%FA`T&U;>K]%H4/!QS`-A'YYI5CR2;+73G/#N MF4X9"-SB,L>,:X26#@9I<5N"#VEFJIH1,L]YV/9#E)#;!0;.6H7VER=1A8X) MT"9ZF@S1R,:8>^>>'"X,AN[I)H]3DN9@QGC0 MC.!#K;FF*N'F?(26?^>Q(!L#@K+J#BGE$:$4KY&I`"IM0;@/!0_&79T;\BK] M3QJGQ:_LXR;KQPMHEH+L*E3JB(!KIJF#65FH-<&':8_3F=7-(*N;0$2OXX7=)L M_YHD`R9=K>@N>R_@,ZD+]-PE60'?)@-34%`#_:`,OF:#VDZ2K"'!;W$SR2HQ M;Q?M<+X>:%5D55?`9$<$4*0NIH(E7/U1[5!+P*@B$^Q"'RT8D;J8S$:"U9OO M+8?M/%EUFJPZ2T>%>ZMZG6ITC&VD>93J,2P9QRTLK"P9M9L0KM6[6"S(C*GG MX@OS<],EN6<*NTW+W>YTSO_A@1TO42(X(S8I6O627E'OD3Q"$WIXU:O(W(ZX M1J58HKORO:!^O+_H\$RS:/LT#5W4>U2.T(0>*O4J,C\L@V*6/-R(JC1=_@K;BO"G^*E_+L M(M#@*&CMS6.+F_4Z*541);4JKM(%S5:[/@?>J=(K5>>HQY9R>%EX=WQ^%\7] M]^)%GYK+ONU/[@:09J=0J5"]`8/CO;N^V>89[C64W9W#*H.(``["K_OKW]VO M88%")MH(7/38'L53CM*IRLQ,ZDU5Z#K"S2'&;_@SR?;G_NF\V=`IGP6%#KIU MR]7;L_AR]AZ*:27"?LRB--_USR-MI31JKN1TWX)NK@9>\_58?D.&F?CMLVX, MG4W6[O:UM9%")U5K;R,;V[J=F;79*H?/BMEZ?)7.?K_*\PV9?^P[L8)/S>.J M[4]AP5(BU@A8=;F:3]UP3B`/YV_3"43SS`)?BZ7LBP=_KODV6T9I]58A$X_? M,;U=M$[(7%F'=KOV+TE7C6RIX'91]4B4[!^9!KP.JSPK0%GBZJ?+ M>ZX:2%#[9`("9_;#;A=3A/A=BV*E_M+T".JU.^4?W-2<1GF5E< M<+HJ4SBSK'=,:3.>*/)83.AKZX/Q[B91HO6(\P)W30 MZD?6ZZ?),.+6!JM*5>-8N2!+;EWOR9J_ MREPZ<2[_F43<].QRH[B";M.:O2V$_'L,:=7!"&1K?NP$U/:6^J5ZN=A1OLVP`%#\`4=2B`B,*9<6BU M1FT,<,1#.?T:[+(NHII"]H[UAYSY0%5Q-!^8PV`L%TM]_L;LQ93Z\;UWGZ5SV\1W+I!C'HD_ONIJ5/7:H5Q,H.DK*"#HG5D4L&V0\<`7 M4$GO@TG`=R4U$+UK`Y1U<4N`J2-P!_^ MOU(JH7!^C%1IGU"L9/TQ*>*Z&X@`M\!'7_V\PQE=/<5IR=798!2T!?+<,:1U MR*B4U%U\[;!9ZM&J5PA6@%]C&=69U%#Z[@"7557&PB*K"-K1KIZ*9QU2;,N[ MADQXIZ&NK;?K.PT"3^MQY,W1O8K<8?9?<=/4EL"@I$(=?MD$=!_3,;KH'];+ MZ]QE_]6H*W#?@,?*QKNWRG9A\3Q&F*1.;]](VJ3TXXW*UEF8],JZRTN%:2=D M5,P*ZVC(!]-B!@,Z4CU=4Z/5AC*SE6;=@9L>'@F5%LEV=W.]=0$IHRG[<^8X M2OB&O$)MXKU3I@3-K](V3Y%/LOB]>XVK$24&UK\ M-RE.YG1=[/'5[&V,X-'L?!CQ<)CIVQZ.J!T5]K-[CV[@;C_&J&&!F\6'S5-. M_M@PCAC`3:^:*5*D'71' MN0P48.MGRJ3FZI%C$4W?[!XKZ3U'G:[$.E!#\#9_H<93?#V0["6>\8=Y5JLX MS^-ADC"M,B#.A&6"PYI:\G%X$_(/^/V9=I:T7Z,LYO&0=:;R"Z:78KL;88.= M;,URS28VNISGT#/5@`[\-.H8\=B,#V;O+HMIMGM(APVV)&(CBWL496_/_[G) MRYWYUIY4/]#(Z?W-[W?@["TD3A[ M)O--PM:V0@,I29MH4+)>)>J4]-Q4F&M!:XVH4TO0P5_*A(>.S<+QISULH-9O M7.OYC]-M]5%M'(RX#`R%)A>_4R9:T8U&&D73^H(V)'!B1<<6Y.C3*^[Q]AN) ME\\%F9^\D"Q:DIO-ZHED#(:\H3M#KK8?!CP&UD.+A]9QLBOB%/)#9)BM=K8LOLV3#;-$EZS5F5M:;.BL^-J_H=!4,D&^O M@D"&Q40:-1DS]IIB\]#'CP2JCN?@KS.-:I4#)&W?TZ\Z97Z;WG.(9KLEUPU- ML_I_RWT;Z60]705]Q5JL()PLKU-IU3`UK,7FA!I0)4\DZ]BV'5\ZV=:46BF^ MS$U:9BEMOVJV;S7"\S+E-'2Q]#GYFF#6GGI0:69'51>J[>AFF75L*[Z>7+-[ MK#7M.V,S$]_PPAD,7+&!=5`5\ST?K:$"M'+3XNL(==!+$M0ZM@!O:6JQ=J-N ML=I4@)0#ZR"@#"_;+%[PD:EEI16%_Z1T(QUS?.*"7,\XXO7_(>3WTMJVV%LL3`-DA*^)H^65]< M5`YE%-N@C]'5B90=#^:O)YUR9[NDEVX7.=:Q!46;7(J"ON=)-E:"5FIDG5J" MM@N]S*^.C\++OFU8;R+] M#*O[>)Y2=5I]ZF6>MM\62!7-H,4IQ\]TUZHQ>\DCJ5D"U*D>R9NF> M74&7]A[DX_1AECX979?YEIO;:?8V6T9LB-:7[.Z2*+U=W*Y)=8?FG!11G#C< M@&LUKW-)E[>UI8ER>Y3'`$3)`_NE2L,&;-G9Y%EO\MGAZ; M;-)X%P!B8<(>4$6$QX=/I3HFAJ6H?F>YBX`<675;?WNF2;*]?4W)G&?_B^=Q MQ,.S`*`IJ'MH`ZF/#W(XQ4R,.[`1@2X;\;'L*CT9,;" M7:JU7J/$^;S.Z2J*^^FM3(K6"=>TBOJ%J.U=%J^B;'M*4L(D8([0]C/A7A(& M2\K",A1)"KM[5L4$!'2D=KH3NTX3^/RM6[7EU?X!.V>4.:.C1GBWBTP:4J8: MU&I`N!VE.R5#`TAOJNKENL&U`1Q!RKK#W343PX[YU>2*K0]03L206FKI6]3N M7(,H?^9>/OOGXH]-_!(EY4JH.(NR;,LD^$JG=$5X>DB^P=_HF_U,5_W6PA(D(FC MC8,>,_,T^K)+N`&N;\%5E-VE;+L:2[%J(6?:%IP&6,ZRO:LAU.A[97)MU\=A M1Y]=NPY3J&(QTV751BC8!*3KA9D(Z+S.@8V5#Y_E6L(QW`T&S=3=TC-4;0Z# M\U0-#NXT5D="U`%H-0P$AZ@HVEH+3=M9>$W+79&YX@:HHH-'G[0T$U-Q?F#@!#YU;%[#FE"5UN97#` M%VBRS:D+^`<);3$5H,#PLYL^Q@8Z^*'`FC=1A@@Y4:4>B,B_GD>)H^AMB(?E M[;A#J@LU$U/YE-;3FHQE:4B[K([A3%[?Q:-Z7A"T>X&NN%2\O,)PO?5.L&ZY M*R-P.N5$]4DS0.21:.)(.P49*)[S"+K!LE$X&2FHZFN#$)6[X#=5OU"L;+V( M-H`O'^8@OY`'>,8,'+->-_)%C9*N&0<@G==0PL""DHBWWD7,>6#8,\LW%F^<5S`B``)1=\%]"(Z0!<2:OG, MT"'D&ZY]%(9S"J,/G8=;ZB(`$4.)[?1>8&2`P6+RYYZJIRKZ,-`IT[VZJ2H3 M#H@,=&"(,5Q-EFXU.TSR69[^\+>,XSQG2NB!3D%5=)-V#JB"`19.3C,H@;S- M8]M<@Z>5FYS?]A?:*RE-[=2(:8*!#49&0\=&S+F"S(]'$`YI=K2@OQJT<\*` MJC?@XS)$A-7XP!]\[)517>'Z_7MQ+\H@W-_B.6DR-W^._DFSLTU>L`5.EI]N M&U74V^#R**W1'`=16R,XNLMVU&F@X!0-)JCS$PD(W$5]1BO6$9TF"8_/E'1U MU"=,9R\ZXQ/Y#Q(EQ?.,F2'A*0=,4#531.#,9JIU2Q$B=6TBR),;11&O<+?A M)0..XH';5=^09QG("_,*5WTV#3Q%F#_(C3*NOSLV'^SC__93G M5)D]KZ+L=W'$]4-RQO92[X#IH^-,=>K13[0&BTFZWHNID65%!N(JV/#%J6NE)IDEU&\)= M^@X4TU'+8%.GCN'6*U4'=6-+^3.3[A.K?E3-H@)2:`;MD#H;J;J=*!J-L-#= MD8BL2SC:.G78?&,O?.MH-@XG,9+HIGPMN[2V-OY,=FU'U&VI>_R["C^P*V]W MXP\]FXIVRN5$T`SJ>C_[;:_A:]MKJ"-2]I$HPNT&%5DO,FA(YM$*&=YT0$JI MO^\`,PYW1?RV]>!*T79W$\3LM38(CF-7_9'5B9OD^I3P_+:G]$=2WB;JRC0T%93V0<[XB"RN8,B+ MS"XX7I036LU>:';;;(](J9AI#+"T(V:P/<=P=[??PH[>PH[>PHY\,FYO84<3 MSPV:D43PE"`)#@KPRM=`SL'A".3;#P@AU_[:@P/,MYMMP#@9]J*5^VQP/?JW MV*R>:;X=FKL$EO$YN1Q/J*/Q,/.JZ*YX(*MLO."Y'IQ0V[I5ZMD)->K`#7_H M#+$+-:7Z192E3,2OSXKIEK%5E>X#S8A59'8P%DCF; M2'XC\?*Y(/.3%Y(QDU8G`"^;E]]NBKR(TCE\4&Y:O%*(?G'O%<4?SYX9:JE3 M5E-%55EG9M`8"72F#!'L,F$?5XAD&.`.N:'#\L;#0I\'?\`+6= MQ\F&_3K0'L[JJTK+[3Y<.DC?47ASKW[..&3M(CG'%_Q"WD@LTU6/HIU\666;-BBZ9)U$S.WZ\U. M@;>+O@+EF0]L,A\D0;##W-T^[;CFGV[%#`0GG`>HJ=X3GK(FSWJ*'RX)CUZQ MY%*=M2AH+/?;]>\T\3O>:CHZ@T'F,[=0X78WJ)X.;MSCJJ& M\NH,S#G<2:;RT[E(0$IUX'NS_S_X'@1,5'+IPT/`<8JUC'-]VIV3J+8MQO2, ME3:61X/*MH4;I#"1"PCVZ!3.#'1'TH9$5I1]4USU"GO"$"QUM#H9ZM3H+7G6`8.ZU]FQ:M3XN0>?-\ M#KP>1&P$&/J"V02==$L-OT5JNQF6.NW@$2*749S]&B4;\IE$^69W+I6[#@YI M&G4>Y[.$\G;E0)P$AK0"AYS4F=/2-&N7H?LDG5_'T5.F5^F]YS:&:[ M7!`W-,WJ_^6'Y\*LO=;Y]M4XGJ][G9]NFS__(R89,W'/VVOR0A+!YK->H;ZV M%(7X/&Y7M*P97UKU^KE(V">1EEWT4;@(B*/NRBRB=S=YFO4EU M!._.SUH5\DE;6E&X^P0BL;Y'0^Q[-,2^/RZ(B06?`&+?C]^I]A%B/Z`A]@,: M8C\<%\3$@D\`L1]Z$`LPH9RF>T3'N0]`'TCK[B@?5V>X&S3VW7]JZ`(#736V M79W>5+3G"'R#$>J"#A(FX6UQE>C#D<)9E#_S[(OLGXL_-O%+E'0,QGXKH1\1 MH%NNCA3`EPO:M`C/`$R59M_"=#;[-9KU-E^(YXL)+,PAIA4[S0YW0Q^UNVJI MG]7[^;+6V.JVP"]\RB_IN][7;[4&V,Z74#1OV`LHG*>HV+=*F9E"1@HF5/4B M#X6LE3CRC/Q/F&\*/%.EHV%V-&054_F0Q1^8H4G%@HD("L MPMVK.TD2^AJE,W))LW.Z>2H6FV0X%@`C8U*VMCIZ97T%UQ@5X.R27@4&.WH_ M[8"8DF545+0>S'%?>QHFY/1GGG]),0_B$B\9)'H97J`\N-]ZE;XP;C2+O?!3 MZ]9L]PL-P%]%4#8W\"64#C,75*VZCUX_,V.3Q5'">^!V<<_Z-WLAP\P$V`)] MN24%G`UI3/=1`Z&[XUI2RRX?@)I[N!O8C72_T>SWJ_0NHS.2XR"F+M''F*Q$ M,"!#BVV&,AG[<)WF1KS+.(WS9S+_1.D9=CD"%;0$)^Z`0$`8# M$9609H`1<*W@\Y?0=N6Y#7R-DZ1>P5TQUNDRYBLXUTN=5M/VK=J=GR@7/T9E MZS3X>F6=#?FZG?K!T*YQ(!8@!M=VB.9`JF8,.[1D?` MHWR.H"EKOL!:LP4;G3\445:XGI]J<1ZS*,V37=_,_[G)"U&.01QQ#P80L>_@ M0`FI!1F(H\$2RJ_MWL8RS_[8Q*SMYQM^.'Y7HAR:`"2D?7LO)/4=/@@!M<`C MYA?N@Q2*.>4?WP<[JPR:;C:O&*QX=O/*12HV"`XTI>?F48QG)%8FJJ*VFCL5 MF,_D+R1[HNZW%_97D_D>2D&NXQP(J&H[WZ(*$+$C5K4T>@15A'N`FJ78H9D#W11,#>6]-0`)1W%E]DG M(L64"1)T!NH8#T-$^PF7B.].Q3B6Z6_I-*&^!Z%8=[ITM@P6?O&\4RR$H MAYJJ=D6W#&L--]SI@6FGO%1^NLGCE.1Y]=R<:%V*HJV7Z'):=_+NFB%<60J_ MU?)TO]E;%?(;FFO.NJI!G.9=2E3G>`>(7#^(*,CFCA&G-WC;O,J\[0"/@*TC M:GA1.4Y[6I.Q+-,*=EE-L?3U?G[1,6MC9A1%/>'&,DJ$OX92.6@44>_<77N0 M>$'2O!M20-D@M0JI%=$IY*,J/F4TU\!"AUPM?D7NX^)#U)URWU8D.WJAT:I. MX0_2\WA\:=@H$8DR.`X,(K3SP2H!2L. M/IQ%KAZM^4-KWC@62*KBOZW`KQT<'NH+D%HNF%+GJ#<@,56J-3_9*Y`>*Q\5 M-(I5[R#:)]1#K+;IOUWT9>[92AQQ?;=;01P,<+2D-H.3JHIP3[E@#?R2D\4F MN8X7@RSV&D64\W*[2#"(,]"`[5FB7=&(*USA;FD9;*],=%9R/4@K%V"J8..( M4N,(QY&!ICKUAOH23'DSK5*"XTMIK:8`&WT2BJK'A13VCIG.JXY]B!*2\T=- MXSQG_7!#TYDXDQ>6OL[II:9W-GQERJ?ZHG;'IH!YF>=+S33P.$-ANCL03TAJ M64+!$+"D)R8*24J6X1X[?&J)`=H%*-C9*(*<. M0=G$UDLHG8W/.@GI/2D/4EI]($Z2B*:O`Y+4],[&,*;OJ+[(W7$MJ:0,85(S M#]]'Y*-=B2PEW=XOA.A\1Q)61"T$29@&[A4J(:.@:KL.(<(%)YX66$"6+CQ, M8)M"[1Y(#0B^7->@8,KYCAA3%9@8'$PE0;NI]?;-/7DAZ8:X]DG[S5%END+3 M]W;O)/3N7A[HMNTDRZ)TN8NCW3ZRRD69!;3*B'4`E?%0#[QU@NL:^`)*#>P+ M>"J^\#Z'3A&4"B:X_5%9I@>2O<0S/EE;[0\A*'B#M@X)L?S$?(`L& M%$A)S3`!,P_W;KV&0TF-O"\=5=44>I=>:<159]:\:'?BX>E MNP:N-&J44"XVKCVXT/B9OI1MN4I[[12D1ZQ4H%.DT@&NB"\PD'>YO'L=VA"M M?AF:$*F]P/`6F(LCR6#='\+S>X M_F=&EVG\)^F;6"RY&%$"\E"1I9+<"L($E03_/*;6E#9()WTTDYHB4?;8:2WD M!-HZGBPU\OJP2X[K]GT?7#U'L^0`7MB6$HD'J?LC;$U$H80TPA#$.?"+L#VQ ME+* ME]\K-(EOD*I=?(T068VE*==!D,^3\Z>[RS:HPWED1(W-%A-Y\"[(PS/-BD>2 MK7@;Y2^!P*2#MS]$I`YGX"?FF#*=;_CP$$;C0`2M_NL3>"(.^!:'BDPHVC2O M:WPFK:<<^*.A^+[^L_Q^I%>I*SM6^'T8U@:TH6JM,5L#'%&9HSX M))W7?^8/:[K)B7"NPI+7TZV2W)DQ,.TQJJV$KK70K+ MB@ZHISSM2HY_)L08M)@,CA"Q4SMGZ?\^;T MY1E^:6)T6U_4R*P]Y3U8\9KMY!M:]'<]L.3U744EN<<]KRDK%@YJMKZ%Y]]LN/-PNVA\BAXHP.^59@3? M/>YVE338?A;PF>*@Y="WW!N!3VF6T=@P,I&Q8C,+LI MZ@5B&6Y"6<6!'M4Z$1MN+*N2PHI8AGJ(6S^F=4973W%: MM_Y.?_.H5'YP&8XL[4Y2@ M@8)-?`55#PL#*J^DVRW#Q"?':'J)Q#UZBVLT4OQ&DQ<"'A[#!/4J34#@;+;! MZYHB1.M.-TK>Y>I-P-.CG`J?2/I*RNSJK*&O94.%O:ZDJS0DH0L#`UA!#:`@ M81UN[)[*:%-]>Z=6;75^@F!\#")8W4P!Q<3`HV M4;%`4:;4@`UXB2KQ[FQ,V/)'RN_?9O-Z>U4#6_*B4GQ!10/%&$H3-G`&5>3L MN$X+:[NV7Y-EE%P28!EH4%**-*!DH$##Z,$&SH!Z`G_N#^%0@YI'K"-A]K"B MO^Y5)'J%,WXA*:LJW$B]MXM1;Q>C/+FXI'X98\OWK M>@IR[Q&G*;$>RM3,S9<7+R1[HA-LSPA&1IWN,4J@,:(V:'@>L&7#\/`><#9T M,]K686HT]SM&0W.R&;FEHNKMQS.:#]Y`UB\HP2Q4,$B@HK0P'IU0-<=PG2#/ M-U'*G[H9X@[\WMZTZ'[W'D4JF?3`(N`V173_(4,A"%OPS>B*7`^],>&W?9QC M^YOW.)#)HH>!'J>J_W\,SS<76+Y]ON.K.=-(O(CYSD#U0/G.A9R?I.UG9]FW MS8H9R%T61/';Z/"T-DU]\&QHN[[CZ+LH?V8?+AC)2Y3P]<*4'0=6-D6O"2IS M;JFFA[_8>9JNR\3V^'LN'8=DQM MV]7M>#,@A^SHT&V+GNB!9R.?3'.EK@YEBCJ536UOJLK>C(KU+CLFRU')%WCF M$YOJN M+6G:'V8SGAKLAEJ8N;"WCYBEU+5_'^#I, M)X4S`ZD%JT;_OP9Z3W5$]-ZDP1ZC@_YLM\[O,'RU1EK8)Q7E=4O%SZMKE("5,2SADQW`]+,X/9="$\JQ+:D92-0U MK#'<.S8R\63AG=KE$,#T."S4`CQ'!9&.`*DXY-3%I9W)9YB+*$MY[OX[DCT\ ML^X]C?)XAI]CI,75LPQ0_#A@K*.C"="LJ/Y(SK81`I_'R:8`[ZSI,]"'=/?53MNNNW"]@8P9)7 M:%"3>_#P!]3(TVWGB_3U#P,>@R=`M'@XTQNNE8)$:?H%%2`2%?1"+<*4:C"! M0,SIGNP^CU[B^75,G@AS+E+I<]TRTMY3W6)29W.=1-=42[[N;#9DVWYH6\S. M?+Z:*C5)W=X[PKSRLRAG@DIA`-+U,""@\QP`*LET>E_`:XIK,(YTB+37%&'F M8*7**^'*%C$_ABQZ)MX#'3&C0JLDC7;TNT-5_U$=3+P]?*:F?WOX[.WA,[_L MK6J(OCUSY6HBPQE/2[,66%FX2%"(H*V&E ME,Y,%;*_J(ZD7;LDKX$;("GG8Y@%1E@.JCFDH#E!OPF\9U15'T/G&$[1%N<% M2_/XN!:%FP_^[462MQ=)/'DVX^U%DLE4^_8BR6'G-^-G231G+#]RW=PNKM)Y_!+/-U$BF(ZD-)5R`1I_Y.*OVI;]R;OV.5X_THN4M5U\U&M8 M&M*%JK3]H\$ZA\%EM(J3K?1T4$;:.R`4DSHS&::]1+6$[YH-S3K;!XSBNL*U MV'*S0,>.(H7>Z[E0NY)P%3YZBL08?X4UQ,E(/]U/XQ5'BLU()=' M2+7(?3I?O"/9C&-DR7KX5UK$Z;)^;+FYHJH^=-1@(KE9@&'B6P#&$`1`S+JV MAE"A&4WU4/PZIEK?$E,#LNX?^+E]35G%;#ZHA<$-6`0#^1"6,@@"F:,UHX]* MDRJ#OXWXU;Y1IP/&4>_48:"'?JON\#<$WUZJ'F$"73+=(=U5)N@>.A#04_&"E M-8*1A'F%II_"0],^NQ873QP5UW=PM,I4&D>6"0)H)O+K(PY92[T):?FV<$B' MC)HG7]/>9&S5:OF!9/>C09'\Q3RA!>Z"KS@+C%:MH::".:.K5;P;\B?I_(RF M_)",I#,V";G.!B-K6IS/$IIO,@*DAC$JVUP6T2IK;T_H(4I(?D\ZPW&9$5(& MYXGEU"E2WX1"%;$GU54:%W&4\-RR@?.@&:YQB%`EW,W,^ET&S7716]& M0M2Z<;,J_>36-JNJL;[H)F%X/(H<)"U!64BY M#IMT(Q"O<#-;_AIEY?.`]U$AFE^@SY7:AI^]$$0XE<`$`F&<3Q[7-)W3M/2/ MGZ+T]]L%PQ29\Z9=7YW>W@LG$ZTR=1`CKHRSX2WI-6HF<7>H#_F7`8XXON%: M37!<4\1`@358SS0B%N$J2S7%*(PD;FX9,@DX%V57QFO@AK.*3.S_MLCL'6!Q MIK>+,Z;@N+B,9OQ=W.WGZ$N\VJQ.:9;1USA=GD5K]J78GI(%S<@]62?13'2H M9857;9['\?)ER`R[EMK5DW2,77=BU\?5ZO`M!TN.A8;\(X`]`L='!-N#H#3D MF:*;"HL_H)D_,`FB^6W:GA`_BDZ'-(H),P/*BGF-0$/I\>C#5V`YA:9'3AW2 M.3':.+@>Q)2&KT!Q+*EZVUVJP&Z(J)#9Y!&@U1?^GZ`L``00E#@``!#D!``#M75]SXC@2?[^J^PZ^O-QLU1*2RR)6P!NC$6(]M)V$]_+1F#_V'9)IDA=7["6-URMWZM MEM1M61]_?5HZR@-F'J'NUK M=8-=S)"/;66Z5K3^C6K,B`.DGC(V1G")E8O3]Z=GIV=*CZ[6C,P7OG+>Z;Q7 M6LK;L_/WBADLE\17KHF+7(L@1QDSXOI0P8_*8-`[553'4027IS#L8?:`[=-6 MBS_\R;OTK`5>(L5';([](5IB;X4L?'6R\/W59;O]@#RZQ#:QD'-JT66;/_#L MPP57R,%+[/K7E"W[>(8"Q[\Z^1H@A\P(MD\4:`'7NWSRMC4]/CZ>/EZ<4C:' M2L[.VW_<#4SQ[(B6/ZK$1#QQ"W-C=7*^+.Z.8.W.-M>QGA8>"9 M(EK[DDMQ=>*1Y79UP>VE%1O+7BN%3D"\B8=3!!>#PXO:*=PTW ME&RP>W!4!6)6II:,-4`E=(693\#Z=L;4?C:U>&>HJ!:P6(%SU%K9>%95*V`A M+CEFI1PTK:H4L&#G9?7A]4Q``X5?W!OZ7G#X.E1U\8NU`\7'G6(S:<07>3P M<<9<8.Q[]RX*;.+SX9BC586A$#R`3H!G0OOB#7J]T;"O#4VMSZ_,T4#OJQ/X MTU4'ZK"G*>:MIDU,Y-;'-M`)/1L%`Q0*++ MZJ"*:661X9P?;CC*FX0"C2&5,J1MDWNCV6C%UQL@CP>.NT>7T"8+8"`/6(=5 MRA(/J%?*=]2OL]!*WI9W+^8$?NZT(5C(Z%H9C35#G>A`H*A#3GDW-K1;8-,_ M:8H^A/^:\F8P,LT?&D=TB/V8/K6^+*ACPPI7^QK`0%W56HIJ*+2-B[JV84Y& MO=]N1X.^9IC_5K3?[_7)GXT5'&(%/>0MKAWZ6-E5Y#`68OZN+N8]U;Q5K@>C MS\W$HPCI$9LCE_PM)`7G/88Y0]R?AZC*B`H1_!#-]HEG.=0+&(8_(^-&'>K_ M$0Y;^.LQC/A)-]Y`E8*JBSP"/6@X8^T7OJ0%%[O=']<*(/;Y0Q=-B>KC7XIO$U M\9P[.`.O*..(B+D4S.!=/]$9Y602!"^R")K:#7>&F(NC]3SV>T8,YCW+JEK+F!]$@)54"Y!Z%T6(4TUAH"+&X= M=#3S5C6T!IT4.M>(L$_("?`=1KP-Q?PC!":_2(+)^RPFUZIN*)_4P;VFW&FJ M>6^$LX\&BA04FT&&+PY'L')G!K8P>4!3!WM#[(>82&@DX'S(@K,9<<+5X&AR M"_W%T'J:_DGM#C3S1V6H31J@4D#I[@-H2!F)`9.Z)P'BIRP0^O`3](J1H3>M MGM_J-Y3:C\1Q(M/705UW3KCIAQ`4$4CP^#F+Q\UHU/^L#P:QCJ'#G&UXH_.. MT:"37B#Q%E<]#T>C1_R&I/4[.0L?T>"J:6K-0)$W4+``V]K3BL<0MF/!@*`I M<8B_7=.4H"M&YOPL=\`P[K6^HOTQYL&%^,`QT-6N/H"E3-,_LHE"/,.,8=O` M,$X$FZEO^J8$C9P`05^[U@P#X#`T&#[NF_EMMMVG?M384]FX?)ZS:N]KW68L MSL18`H^XV/-@L38E;BS;G5<@:?.<=7;WWM2'FFGRI5M7'XJ%=8-!"@,#.SQJ MO$+,7T\8TLE:.2LJ0UMP`/'K;%J3/Y4)H8Z--5>$^O(3PCPUPS% M0CF,-_'($W9W8<8B`@DR.2MK'MG0)V$L?Q.)XE$I;=@$#G,[#(_^.6O=\V!6 M%`OI,NK"I16/?92DE4"6L][FB^OA9/"GHILFGT;%([[&:`C7O28\DA_W#:8> M_AJ`EMK##JC,70DD.2MO\[YK:K_?\\`NGT0U37]P2N6PU$INBB7]VDV]9(KD MW9N?GB]MH[R)U&B2J8>:TP3M@CPU>;^Y*?W\G*84*M$84N548-QRRA(7F4J9 M!*#4,&HF%ALSJ)YAC.,OI2H"7I97E()>(U?9`%XI:1G'NHB@".8]J4HINN6S MG@VH]=*?<71+41;!7"+I*86\7BZU@;]<4C4.=VY)$;SI5*H4RQ+IV`:X&GG9 M.(IRLB)(B[.Q4H`KYW<;N$LD>N/P9F\7P1E/[TK!DZ2'&ZCJYXE3HVHY:LG( M6B([+(.\?MZY,8:2">@X\OE%13"GT\Y20$NDKAOH*F1;$R&QO<6%4:^<'*L4 MQI*YV@;*FOM(^MA'Q"FWG22B+1QGY?M'))AW:FY+4=YLY&MLX-#P=\(HZC)_ M\P!XY^SMV=OG"H`WME0W`IXPGM+4+QP#[]2/@3>64-<2$O\,XGVI9AI[V;^! MK63\2)EZ?U02(BM4TE&@++WGRFKTI%G51JT:J=5TB-L2?(73ZQT#DFL-/90+K.2 M`']/V3/F5CKE@4;!%.034O-BOC&0"DV>S84-GA4278E`^#[RY\YW=4I MG^YJT*RX23$!J8RH"-?]FQ.EZ%;:ZMA@7&?38P+F$G1%2!=N=I2"777W9(/W M@?LH4SV\"DMQ?R^Y?U)J$8=LSFRLH_0VS626:4]A80XIO3U3BFR9/9[_%PA^ M;*<.#@EO)(\7X8>+D"5/^RENYFR;^)$Q'9W$4"A.T?$IA>*D>?A%:\=<3X"M707UQ/"(55F(B(=?U!$@?91+)QPG7#Q'XGO8>V1(L#F,);A:O)[6 M^=O6^8?#Y?`KR^#7>7ZR4?T5JXY$Q"2NG@.+^*E;9=I`L/!_K8B/M\0%;XD# MI'C79OPHGY(""&K^6'`*/[?.SZH!D#E!K.13(P;^X/?U-,T_(ZS,\^.6LFB3UQ2@^AJ[^I$+45<=39SW#YCPI$-7R6_AIY2`7^92MK^%_>6\1 MKT7;55+09IL#`X6,?,'L^:.96#9[_)A$+_'Q.#[[_FL_27@*ESAT[W))P6

@'_76*V6CV>4$=9SUZ=+'-5T'$)HAM/Y$B-)52QG4FKH_GF+VDRJ&++U!- MO/;E#:D?+NNO*=.6*X>N,9Z@IRB_M8YI6);AU8`;I7=,Y&!O9ZE#ZH:SU[@A MEZ#]UGIO$:[69>49S5Y&^PH\Q](*,O!C+]*(J'4([X2.PV,&U_S$OZ\!68G3 M_WR?D6G@<]$F=+.)PYT/,/)B'Y$6+?6\U;Z:KB1\0Q?D%B=C@9%$>QM4!JTP MCW^<;>=+Y/1'H[^D3P&Z#X3[`W"*?1I,_5G@Q-[-V_D+U?YOX/GIUJC'_EH: M9R?^9@K@W6$^5N9.$](DH9+AX;V7-ETBXCZ#CN'_(A7W*:,]^=BU81S`[(%8 MF.=!>)59E62$QZ:8[FXD!8,#ST7X>^(9I8J(CDVA2-*80\GH4T!S;.KT"<,6 M#"QC[&/60Y[OX(PZ!33'ID[.BP"J;8LX.7+XN6K$WFR5C`VC,55K\A^-SY0- MJ)NL^CB55=_IR%<8S%N0E0YK"9B7QRF_4]'WT0.P!P2#D M$KE[_5$^V;$I!3/NS]2!YL\#*:_PV!2(FCM:GEVC)7'6>U'))SLVI0;@YD>S MGG"7U\@2,88[]$26P;)+&:./,`7IH164^.LNGE&&#;QR4/A20DSK`^MY/RV1Z:,YV3$Q^;/8@`#$`3R^3O4T].>FS*;4,#^U3:1W!LBMS@6XP< M?V'!,C^C1%[AL2F08SOJG&%!HF[J+S:U'/*X$X%[X'&^\Y(/IH/(F<"H/)H5 M:9!P&:5YXMI&PGS?69FZ%$OR2@I7X#D^A?O4"H0)NK;FPL/7,8^?8\7ER(_, MBDTR=\F,6#!:[OD:_7J"G_RN0ZTO\1Y;B2WAGOSH_O<%-_]C,O<>3',T$`9@ M*]*_%O_;NS1!M5B"4,H@['&WN0-0\K8YPNBQ6FB MO#C^]ZUD.)8N)4F[O$`+Q0LVZ:DQ6HLZDDV5.A[&@6!N@_ M$W]A,_0(=E52YP+.UZ%Z:*,#F-0XUSAGF*S$]3U5%ILUPG<-X=__`%!+`0(> M`Q0````(`(YA#D`Q0` M```(`(YA#D?V__YBN!$``%OW```5`!@```````$```"D@:O,``!V87-O+3(P M,34P-C,P7V-A;"YX;6Q55`4``VL3SE5U>`L``00E#@``!#D!``!02P$"'@,4 M````"`".80Y'^B\;5A(C``#H,`(`%0`8```````!````I(&RW@``=F%S;RTR M,#$U,#8S,%]D968N>&UL550%``-K$\Y5=7@+``$$)0X```0Y`0``4$L!`AX# M%`````@`CF$.1W51+F`?BP``<<<'`!4`&````````0```*2!$P(!`'9A M`Q0````(`(YA#D>WRJE9SD,``$B:!``5`!@```````$```"D@8&-`0!V87-O M+3(P,34P-C,P7W!R92YX;6Q55`4``VL3SE5U>`L``00E#@``!#D!``!02P$" M'@,4````"`".80Y'JG,S!*@.```QF0``$0`8```````!````I(&>T0$`=F%S M;RTR,#$U,#8S,"YX`L``00E#@``!#D!``!02P4&```` /``8`!@`:`@``D>`!```` ` end XML 22 R52.htm IDEA: XBRL DOCUMENT v3.2.0.727

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details)
6 Months Ended

Jun. 30, 2015

USD ($)

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS [Abstract]

Debt issuance costs $ 60,000

Interest expense $ 1,250

X

- Definition
Amount of debt issuance costs (for example, but not limited to, legal, accounting, broker, and regulatory fees).
+ References
No definition available.
+ Details

Name: us-gaap_DebtIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Interest and debt related expenses associated with nonoperating financing activities of the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

+ Details

Name: us-gaap_InterestAndDebtExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 23 R47.htm IDEA: XBRL DOCUMENT v3.2.0.727

DEFERRED REVENUE (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Dec. 31, 2014

Changes in deferred revenue [Roll Forward]

Deferred revenue at beginning of period $ 21,453 $ 17,004 $ 22,532 $ 18,019

Deferred revenue at end of period 19,614 17,712 19,614 17,712

Less: current portion 11,560 9,183 11,560 9,183 $ 9,882

Long-term deferred revenue at end of period 8,054 8,529 8,054 8,529 $ 12,650

Extended Service Contracts [Member]

Changes in deferred revenue [Roll Forward]

Additions: 94 309 305 546

Recognized as revenue: (214) (220) (445) (448)

In-Service and Training [Member]

Changes in deferred revenue [Roll Forward]

Additions: 3 13 5 15

Recognized as revenue: (3) (8) (10) (15)

Service Arrangements [Member]

Changes in deferred revenue [Roll Forward]

Additions: 5 25 15 30

Recognized as revenue: (20) (23) (43) (46)

Commission Revenues [Member]

Changes in deferred revenue [Roll Forward]

Additions: 1,481 3,614 3,330 5,384

Recognized as revenue: $ (3,185) $ (3,002) $ (6,075) $ (5,773)

X

- Definition
Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueAdditions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueRevenueRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_MovementInDeferredRevenueRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_DeferredRevenueArrangementTypeAxis=vaso_ExtendedServiceContractsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DeferredRevenueArrangementTypeAxis=vaso_InServiceAndTrainingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DeferredRevenueArrangementTypeAxis=vaso_ServiceArrangementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DeferredRevenueArrangementTypeAxis=vaso_CommissionRevenuesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 24 R9.htm IDEA: XBRL DOCUMENT v3.2.0.727

SEGMENT REPORTING AND CONCENTRATIONS
6 Months Ended

Jun. 30, 2015

SEGMENT REPORTING AND CONCENTRATIONS [Abstract]

SEGMENT REPORTING AND CONCENTRATIONS
NOTE C – SEGMENT REPORTING AND CONCENTRATIONS

The Company views its business in three segments – the Sales Representation segment, the Equipment segment, and the IT segment. The Sales Representation segment operates through the Vaso Diagnostics subsidiary and is currently engaged solely in the fulfillment of the Company’s responsibilities under our agreement with GEHC. The IT segment includes the operations of NetWolves and VasoHealthcare IT Corp. Operations in the IT segment began in the third quarter of 2014. The Equipment segment is engaged in designing, manufacturing, marketing and supporting EECP^® enhanced external counterpulsation systems both domestically and internationally, as well as the development, production, marketing and supporting of other medical devices.

The chief operating decision maker is the Company’s Chief Executive Officer, who in conjunction with upper management, evaluates segment performance based on operating income. Administrative functions such as finance, human resources, and information technology are centralized and related expenses allocated to each segment. Other costs not directly attributable to operating segments, such as audit, legal, director fees, investor relations, and others, as well as certain assets – primarily cash balances – are reported in the Corporate entity below. There are no intersegment revenues. Summary financial information for the segments is set forth below:

(in thousands)

As of or for the three months ended June 30, 2015 (unaudited)

Sales

Representation

Equipment

Segment

IT Segment

Segment

Corporate

Consolidated

Revenues from external customers

$
7,036

$
2,811

996

$
-

$
10,843

Operating income (loss)

$
1,794

$
(366
)

(676
)

$
(546
)

$
206

Total assets

$
10,421

$
25,205

9,385

$
1,309

$
46,320

Accounts and other receivables, net

$
4,421

$
1,399

500

$
-

$
6,320

Deferred commission expense

$
2,388

$
19

-

$
-

$
2,407

Other assets

$
3,098

$
51

675

$
113

$
3,937

As of or for the three months ended June 30, 2014 (unaudited)

Sales

Representation

Equipment

Segment

IT Segment

Segment

Corporate

Consolidated

Revenues from external customers

$
6,684

$
-

1,180

$
-

$
7,864

Operating income (loss)

$
1,021

$
-

(875
)

$
(352
)

$
(206
)
Total assets

$
13,144

$
-

8,052

$
10,036

$
31,232

Accounts and other receivables, net

$
6,585

$
-

941

$
-

$
7,526

Deferred commission expense

$
2,297

$
-

-

$
-

$
2,297

Other assets

$
4,066

$
-

1,164

$
13

$
5,243

As of or for the six months ended June 30, 2015 (unaudited)

Sales

Representation

Equipment

Segment

IT Segment

Segment

Corporate

Consolidated

Revenues from external customers

$
13,427

$
2,811

2,059

$
-

$
18,297

Operating income (loss)

$
2,880

$
(721
)

(1,311
)

$
(928
)

$
(80
)
Total assets

$
10,421

$
25,205

9,385

$
1,309

$
46,320

Accounts and other receivables, net

$
4,421

$
1,399

500

$
-

$
6,320

Deferred commission expense

$
2,388

$
19

-

$
-

$
2,407

Other assets

$
3,098

$
51

675

$
113

$
3,937

As of or for the six months ended June 30, 2014 (unaudited)

Sales

Representation

Equipment

Segment

IT Segment

Segment

Corporate

Consolidated

Revenues from external customers

$
12,926

$
-

2,030

$
-

$
14,956

Operating income (loss)

$
1,544

$
-

(1,955
)

$
(883
)

$
(1,294
)
Total assets

$
13,144

$
-

8,052

$
10,036

$
31,232

Accounts and other receivables, net

$
6,585

$
-

941

$
-

$
7,526

Deferred commission expense

$
2,297

$
-

-

$
-

$
2,297

Other assets

$
4,066

$
-

1,164

$
13

$
5,243

For the three months ended June 30, 2015 and 2014, GE Healthcare accounted for 65% and 85% of revenue, respectively. For the six months ended June 30, 2015 and 2014, GE Healthcare accounted for 73% and 86% of revenue, respectively, and $4.3 million or 68%, and $14.2 million or 93%, of accounts and other receivables at June 30, 2015 and December 31, 2014, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 34

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 41

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 33

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 32

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 35

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 40

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 42

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 29

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 31

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8906-108599

+ Details

Name: us-gaap_SegmentReportingDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 25 R43.htm IDEA: XBRL DOCUMENT v3.2.0.727

INVENTORIES, NET (Details) - USD ($)

Jun. 30, 2015

Dec. 31, 2014

INVENTORIES, NET [Abstract]

Raw materials $ 588,000 $ 583,000

Work in process 688,000 679,000

Finished goods 892,000 636,000

Inventories, net 2,168,000 1,898,000

Reserves for excess and obsolete inventory $ 791,000 $ 815,000

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.BB)

-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section BB

+ Details

Name: us-gaap_InventoryFinishedGoodsNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51655945&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.BB)

-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(4))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section BB

+ Details

Name: us-gaap_InventoryRawMaterialsNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of valuation reserve for inventory.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.BB)

-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SX 210.12-09)

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51655945&loc=d3e3927-108312

+ Details

Name: us-gaap_InventoryValuationReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.BB)

-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section BB

+ Details

Name: us-gaap_InventoryWorkInProcessNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 26 R29.htm IDEA: XBRL DOCUMENT v3.2.0.727

ACCOUNTS AND OTHER RECEIVABLES, NET (Tables)
6 Months Ended

Jun. 30, 2015

ACCOUNTS AND OTHER RECEIVABLES, NET [Abstract]

Accounts and Other Receivables
The following table presents information regarding the Company’s accounts and other receivables as of June 30, 2015 and December 31, 2014:

(in thousands)

June 30, 2015

December 31, 2014

(unaudited)

Trade receivables

$
10,374

$
19,734

Due from employees

124

110

Allowance for doubtful accounts and

commission adjustments

(4,178
)

(4,571
)
Accounts and other receivables, net

$
6,320

$
15,273

X

- References
No definition available.
+ Details

Name: us-gaap_ReceivablesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3,4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 27 R28.htm IDEA: XBRL DOCUMENT v3.2.0.727

FAIR VALUE MEASUREMENTS (Tables)
6 Months Ended

Jun. 30, 2015

FAIR VALUE MEASUREMENTS [Abstract]

Assets Measured at Fair Value
The following tables present information about the Company’s assets measured at fair value as of June 30, 2015 and December 31, 2014:

(in thousands)

Quoted Prices

Significant

in Active

Other

Significant

Balance

Markets for

Observable

Unobservable

as of

Identical Assets

Inputs

Inputs

June 30,

(Level 1)

(Level 2)

(Level 3)

2015

Assets

(unaudited)

Cash equivalents invested in money market funds

(included in cash and cash equivalents)

$
2

$
-

$
-

$
2

Quoted Prices

Significant

in Active

Other

Significant

Balance

Markets for

Observable

Unobservable

as of

Identical Assets

Inputs

Inputs

December 31,

(Level 1)

(Level 2)

(Level 3)

2014

Assets

Cash equivalents invested in money market funds

(included in cash and cash equivalents)

$
8,149

$
-

$
-

$
8,149

X

- Definition
Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19279-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a,b,bb)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2C

-URI http://asc.fasb.org/extlink&oid=36462937&loc=SL7498348-110258

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19190-110258

+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 28 R44.htm IDEA: XBRL DOCUMENT v3.2.0.727

GOODWILL AND OTHER INTANGIBLES (Details) - USD ($)
3 Months Ended 6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Dec. 31, 2014

Change in carrying amount of goodwill [Roll Forward]

Goodwill, Beginning Balance $ 3,288,000

Foreign currency translation 27,000

Acquisition of Netwolves 19,303,000

Goodwill, Ending Balance $ 22,618,000 22,618,000

Other intangible assets, net [Abstract]

Intangible assets, net 2,561,000 $ 2,826,000

Goodwill 22,618,000 3,288,000 3,288,000

Amortization expense 164,000 $ 50,000 335,000 $ 96,000

Equipment Segment [Member]

Change in carrying amount of goodwill [Roll Forward]

Goodwill, Ending Balance 3,315,000 3,315,000

Other intangible assets, net [Abstract]

Goodwill 3,315,000 $ 3,315,000

Patents and Technology [Member]

Other intangible assets, net [Abstract]

Costs 2,467,000 2,489,000

Accumulated amortization (678,000) (549,000)

Intangible assets, net 1,789,000 1,940,000

Patents [Member]

Other intangible assets, net [Abstract]

Useful life of intangible assets 10 years

Customer Lists [Member]

Other intangible assets, net [Abstract]

Costs 800,000 800,000

Accumulated amortization (438,000) (381,000)

Intangible assets, net 362,000 419,000

Useful life of intangible assets 7 years

Software [Member]

Other intangible assets, net [Abstract]

Costs 1,054,000 962,000

Accumulated amortization (644,000) (495,000)

Intangible assets, net $ 410,000 $ 467,000

Useful life of intangible assets 5 years

X

- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(2)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNetAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

+ Details

Name: us-gaap_GoodwillAcquiredDuringPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_GoodwillRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) from foreign currency translation adjustments of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (f)

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

+ Details

Name: us-gaap_GoodwillTranslationAdjustments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=vaso_EquipmentSegmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vaso_PatentsAndTechnologyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerListsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 29 R30.htm IDEA: XBRL DOCUMENT v3.2.0.727

INVENTORIES, NET (Tables)
6 Months Ended

Jun. 30, 2015

INVENTORIES, NET [Abstract]

Inventories, Net of Reserves
Inventories, net of reserves, consist of the following:

             (in thousands)

June 30, 2015

December 31, 2014

(unaudited)

Raw materials

$
588

$
583

Work in process

688

679

Finished goods

892

636

$
2,168

$
1,898

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 2

-Paragraph 6

-Subparagraph a,b,c

-Article 5

+ Details

Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R31.htm IDEA: XBRL DOCUMENT v3.2.0.727

GOODWILL AND OTHER INTANGIBLES (Tables)
6 Months Ended

Jun. 30, 2015

GOODWILL AND OTHER INTANGIBLES [Abstract]

Schedule of Changes in Carrying Amount of Goodwill
The components of the change in goodwill are as follows:

(in thousands)

Carrying

Amount

Balance at December 31, 2014

$
3,288

Foreign currency translation

27

Acquisition of Netwolves

19,303

Balance at June 30, 2015 (unaudited)

$
22,618

Schedule of Other Intangible Assets
The Company’s other intangible assets consist of capitalized patent costs, customer lists and software costs, as follows:
(in thousands)

June 30, 2015

December 31, 2014

(unaudited)

Patents and Technology

Costs

$
2,467

$
2,489

Accumulated amortization

(678
)

(549
)

1,789

1,940

Customer lists

Costs

800

800

Accumulated amortization

(438
)

(381
)

362

419

Software

Costs

1,054

962

Accumulated amortization

(644
)

(495
)

410

467

$
2,561

$
2,826

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275

+ Details

Name: us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13854-109267

+ Details

Name: us-gaap_ScheduleOfGoodwillTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R8.htm IDEA: XBRL DOCUMENT v3.2.0.727

BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES
6 Months Ended

Jun. 30, 2015

BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES [Abstract]

BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES
NOTE B - BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES

Basis of Presentation and Use of Estimates

The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and pursuant to the accounting and disclosure rules and regulations of the Securities and Exchange Commission (the "SEC"). Certain information and disclosures normally included in the unaudited condensed consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in connection with:

1)
The audited consolidated financial statements and related notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2014, as filed with the SEC on March 30, 2015.

2)
The audited consolidated financial statements of NetWolves, LLC and related notes thereto included in the Form 8-K/A filed with the SEC on August 12, 2015. The operating results of NetWolves from May 29, 2015 to June 30, 2015 are included in the accompanying condensed consolidated statements of operations and comprehensive income (loss) for the three and six month periods ended June 30, 2015.

These unaudited condensed consolidated financial statements include the accounts of the companies over which we exercise control. In the opinion of management, the accompanying condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of interim results for the Company. The results of operations for any interim period are not necessarily indicative of results to be expected for any other interim period or the full year.

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the condensed consolidated financial statements, the disclosure of contingent assets and liabilities in the unaudited condensed consolidated financial statements and the accompanying notes, and the reported amounts of revenues, expenses and cash flows during the periods presented. Actual amounts and results could differ from those estimates. The estimates and assumptions the Company makes are based on historical factors, current circumstances and the experience and judgment of the Company's management. The Company evaluates its estimates and assumptions on an ongoing basis.

Significant Accounting Policies

Note B of the Notes to Consolidated Financial Statements, included in the Annual Report on Form 10-K for the year ended December 31, 2014, and Note B of the Notes to Consolidated Financial Statements for the year ended December 31, 2014, included on Form 8-K/A, include a summary of the significant accounting policies used in the preparation of the condensed consolidated financial statements.


Revenue Recognition

The Company recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred or service has been rendered, the price is fixed or determinable and collectability is reasonably assured.

Revenue and Expense Recognition for the Sales Representation Segment

The Company recognizes commission revenue in its Sales Representation segment (see Note C) when persuasive evidence of an arrangement exists, service has been rendered, the price is fixed or determinable and collectability is reasonably assured. These conditions are deemed to be met when the underlying equipment has been accepted at the customer site in accordance with the specific terms of the sales agreement. Consequently, amounts billable under the agreement with GE Healthcare in advance of the customer acceptance of the equipment are recorded as accounts receivable and deferred revenue in the condensed consolidated balance sheets. Similarly, commissions payable to our sales force related to such billings are recorded as deferred commission expense when the associated deferred revenue is recorded. Commission expense is recognized when the corresponding commission revenue is recognized.

Variable Interest Entities

The Company follows the guidance of accounting for variable interest entities, which requires certain variable interest entities to be consolidated by the primary beneficiary of the entities. Biox is a Variable Interest Entity (VIE).

Liabilities recognized as a result of consolidating this VIE do not represent additional claims on the Company’s general assets. The financial information of Biox, which was included in the accompanying condensed consolidated financial statements, is presented as follows:

(in thousands)

As of June 30,
2015 (unaudited)

As of December 31, 2014

Cash and cash equivalents

$
157

$
159

Total assets

$
1,014

$
1,047

Total liabilities

$
1,065

$
878

(in thousands)

Three months ended June 30,

Six months ended June 30,

2015

2014

2015

2014

(unaudited)

(unaudited)

(unaudited)

(unaudited)

Total net revenue

$
454

$
429

$
825

$
758

Net (loss) income

$
(87
)

$
(82
)
$
(223
)

$
(230
)

Reclassifications

Certain reclassifications have been made to prior period amounts to conform with the current period presentation.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.
+ References
No definition available.
+ Details

Name: us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R32.htm IDEA: XBRL DOCUMENT v3.2.0.727

OTHER ASSETS (Tables)
6 Months Ended

Jun. 30, 2015

OTHER ASSETS [Abstract]

Schedule of Other Assets
Other assets consist of the following at June 30, 2015 and December 31, 2014:

(in thousands)

June 30, 2015

December 31, 2014

(unaudited)

Deferred commission expense - noncurrent

$
2,121

$
2,988

Trade receivables - noncurrent

1,186

2,171

Other

630

458

$
3,937

$
5,617

X

- References
No definition available.
+ Details

Name: us-gaap_OtherAssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfOtherAssetsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R40.htm IDEA: XBRL DOCUMENT v3.2.0.727

EARNINGS (LOSS) PER COMMON SHARE (Details) - shares
shares in Thousands
3 Months Ended 6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Reconciliation of basic to diluted shares used in the earnings per share calculation [Abstract]

Basic weighted average shares outstanding (in shares) 156,258 155,320 156,102 155,386

Dilutive effect of share-based compensation 308 0 0 0

Diluted weighted average shares outstanding (in shares) 156,566 155,320 156,102 155,386

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive securities excluded from computation of diluted earnings per share (in shares) 460 2,529 3,808 2,529

Stock Options [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive securities excluded from computation of diluted earnings per share (in shares) 335 1,754 935 1,754

Common Stock Grants [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive securities excluded from computation of diluted earnings per share (in shares) 125 775 2,873 775

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 28A

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1500-109256

+ Details

Name: us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Weighted-Average Number of Common Shares Outstanding

-URI http://asc.fasb.org/extlink&oid=6528421

+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 34 R53.htm IDEA: XBRL DOCUMENT v3.2.0.727

SUBSEQUENT EVENTS (Details) - Jul. 31, 2015 - Subsequent Event [Member] - USD ($)
$ in Millions

Total

Subsequent Event [Line Items]

Line of credit facility, maximum borrowing capacity before replacement $ 2.0

Line of credit facility, maximum borrowing capacity amount $ 3.0

LIBOR [Member]

Subsequent Event [Line Items]

Interest rate percentage (in hundredths) 2.25%

X

- Definition
Percentage points added to the reference rate to compute the variable rate on the debt instrument.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(b),22(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.
+ References
No definition available.
+ Details

Name: us-gaap_SubsequentEventLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.
+ References
No definition available.
+ Details

Name: vaso_LineOfCreditFacilityMaximumBorrowingCapacityBeforeReplacement

Namespace Prefix: vaso_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 35 R2.htm IDEA: XBRL DOCUMENT v3.2.0.727

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
$ in Thousands

Jun. 30, 2015

Dec. 31, 2014

CURRENT ASSETS

Cash and cash equivalents $ 2,931 $ 9,128

Short-term investments 109 111

Accounts and other receivables, net of an allowance for doubtful accounts and commission adjustments of $4,178 at June 30, 2015 and $4,571 at December 31, 2014 6,320 15,273

Receivables due from related parties 20 21

Inventories, net 2,168 1,898

Deferred commission expense 2,407 2,200

Prepaid expenses and other current assets 581 363

Total current assets 14,536 28,994

PROPERTY AND EQUIPMENT, net of accumulated depreciation of $3,123 at June 30, 2015 and $1,397 at December 31, 2014 2,668 266

GOODWILL 22,618 3,288

INTANGIBLES, net 2,561 2,826

OTHER ASSETS 3,937 5,617

Total Assets 46,320 40,991

CURRENT LIABILITIES

Accounts payable 3,571 462

Accrued commissions 1,202 2,247

Accrued expenses and other liabilities 5,156 5,627

Sales tax payable 626 247

Deferred revenue - current portion 11,560 9,882

Notes payable - current portion 1,523 163

Deferred tax liability, net 112 112

Notes payable due to related party 1,070 1,039

Total current liabilities 24,820 19,779

LONG-TERM LIABILITIES

Notes payable 4,817 0

Deferred revenue 8,054 12,650

Other long-term liabilities 649 811

Total long-term liabilities $ 13,520 $ 13,461

COMMITMENTS AND CONTINGENCIES (NOTE O)

STOCKHOLDERS' EQUITY

Preferred stock, $.01 par value; 1,000,000 shares authorized; nil shares issued and outstanding at June 30, 2015, and December 31, 2014 $ 0 $ 0

Common stock, $.001 par value; 250,000,000 shares authorized; 168,710,370 and 166,435,370 shares issued at June 30, 2015 and December 31, 2014, respectively; 158,402,283 and 156,127,283 shares outstanding at June 30, 2015 and December 31, 2014, respectively 169 166

Additional paid-in capital 62,181 61,924

Accumulated deficit (52,495) (52,433)

Accumulated other comprehensive income 125 94

Treasury stock, at cost, 10,308,087 shares at June 30, 2015 and December 31, 2014 (2,000) (2,000)

Total stockholders' equity 7,980 7,751

Total liabilities and stockholders' equity $ 46,320 $ 40,991

X

- Definition
Amount due from customers, clients, or other third-parties, or arising from transactions not separately disclosed, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.
+ References
No definition available.
+ Details

Name: us-gaap_AccountsAndOtherReceivablesNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
For an unclassified balance sheet, amount of receivables arising from transactions with related parties.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),3)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a

-Article 5

+ Details

Name: us-gaap_AccountsReceivableRelatedParties

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

+ Details

Name: us-gaap_AccruedSalesCommissionCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e681-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14A

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669686-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),19)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.17)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.8)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DeferredCostsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, netted by jurisdiction and classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32621-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31958-109318

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31917-109318

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31931-109318

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32632-109319

+ Details

Name: us-gaap_DeferredTaxLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51655945&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of obligation due after one year or beyond the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22, 23, 24, 25, 26, 27

-Article 5

+ Details

Name: us-gaap_LiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LongTermNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_NotesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a)(5))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_NotesPayableRelatedPartiesClassifiedCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

+ Details

Name: us-gaap_SalesAndExciseTaxPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Investments which are intended to be sold in the short term (usually less than one year or the normal operating cycle, whichever is longer) including trading securities, available-for-sale securities, held-to-maturity securities, and other short-term investments not otherwise listed in the existing taxonomy.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.2)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Subparagraph g

-Article 7

+ Details

Name: us-gaap_ShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4I

-URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4590271-111686

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=51664549&loc=SL4568740-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=51664549&loc=SL4568447-111683

+ Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656

+ Details

Name: us-gaap_TreasuryStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of expenses as of balance sheet date incurred and payable, pertaining to costs that are statutory in nature, incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include, but not limited to, taxes, interest, rent and utilities. Also includes the aggregate carrying amount of liabilities not separately disclosed.
+ References
No definition available.
+ Details

Name: vaso_AccruedExpensesAndOtherLiabilitiesCurrent

Namespace Prefix: vaso_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 36 R45.htm IDEA: XBRL DOCUMENT v3.2.0.727

OTHER ASSETS (Details) - USD ($)
$ in Thousands

Jun. 30, 2015

Dec. 31, 2014

Jun. 30, 2014

OTHER ASSETS [Abstract]

Deferred commission expense - noncurrent $ 2,121 $ 2,988

Trade receivables - noncurrent 1,186 2,171

Other 630 458

Total $ 3,937 $ 5,617 $ 5,243

X

- Definition
Amount due from customers or clients, more than one year from the balance sheet date, for goods or services that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Article 5

+ Details

Name: us-gaap_AccountsReceivableNetNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The aggregate carrying amounts, as of the balance sheet date, of assets not separately disclosed in the balance sheet.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 10

-Article 7

+ Details

Name: us-gaap_OtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_OtherAssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Noncurrent carrying amount of advanced commission payments.
+ References
No definition available.
+ Details

Name: vaso_DeferredSalesCommissionNoncurrent

Namespace Prefix: vaso_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 37 R6.htm IDEA: XBRL DOCUMENT v3.2.0.727

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
$ in Thousands
6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Cash flows from operating activities

Net loss $ (62) $ (1,220)

Adjustments to reconcile net loss to net cash provided by operating activities

Depreciation and amortization 483 199

Provision for doubtful accounts and commission adjustments 61 4

Share-based compensation and arrangements 260 244

Changes in operating assets and liabilities:

Accounts and other receivables 10,429 6,030

Receivables due from related parties 1 0

Inventories, net (354) (297)

Deferred commission expense (207) 15

Other current assets (115) (119)

Other assets 1,859 (1,276)

Accounts payable (43) (117)

Accrued commissions (1,092) 137

Accrued expenses and other liabilities (1,268) (966)

Sales tax payable (32) (51)

Deferred revenue (2,918) (307)

Notes payable due to related party 31 0

Other long-term liabilities (199) 162

Net cash provided by operating activities 6,834 2,438

Cash flows from investing activities

Purchases of equipment and software (188) (205)

Purchases of short-term investments (38) (40)

Redemption of short-term investments 40 40

Acquisition of Netwolves (18,000) 0

Cash acquired through purchase of Netwolves 733 0

Investment in VSK (100) 0

Net cash used in investing activities (17,553) (205)

Cash flows from financing activities

Repurchase of common stock 0 (207)

Repayment of notes payable (21) 0

Proceeds from note payable 4,550 0

Net cash provided by (used in) financing activities 4,529 (207)

Effect of exchange rate differences on cash and cash equivalents (7) (1)

NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS (6,197) 2,025

Cash and cash equivalents - beginning of period 9,128 7,961

Cash and cash equivalents - end of period 2,931 9,986

SUPPLEMENTAL DISCLOSURE OF CASH INFORMATION

Interest paid 15 0

Income taxes paid 66 19

SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES

Inventories transferred to property and equipment, attributable to operating leases, net 3 5

Common shares issued for prepaid directors' fees $ 0 $ 175

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3179-108585

+ Details

Name: us-gaap_CashAcquiredFromAcquisition

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906

+ Details

Name: us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (f)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_IncomeTaxesPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableTrade

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the value of expenditures made during the current reporting period for benefits that will be received over a period of years. Deferred charges differ from prepaid expenses in that they usually extend over a long period of time and may or may not be regularly recurring costs of operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDeferredCharges

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate increase (decrease) during the reporting period in the amount due from the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amount owed by the reporting entry in the form of loans and obligations (generally evidenced by promissory notes) made by the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInNotesPayableRelatedParties

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in other current operating assets not separately disclosed in the statement of cash flows.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOtherCurrentAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Change in carrying value during the period of obligations incurred through and payable within one year (or in the operating cycle if longer) for employer-related costs not otherwise specified in the taxonomy.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInOtherEmployeeRelatedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in other noncurrent operating assets not separately disclosed in the statement of cash flows.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOtherNoncurrentAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in other noncurrent operating liabilities not separately disclosed in the statement of cash flows.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the period in the amount of cash payments due to taxing authorities for non-income-related taxes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of cash paid for interest during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NoncashInvestingAndFinancingItemsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash outflow to reacquire common stock during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_PaymentsForRepurchaseOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquireBusinessesGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the investment in or advances to an entity in which the reporting entity shares control of the entity with another party or group.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquireInterestInJointVenture

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquireShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from a borrowing supported by a written promise to pay an obligation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3179-108585

+ Details

Name: us-gaap_ProceedsFromSaleOfShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow for a borrowing supported by a written promise to pay an obligation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585

+ Details

Name: us-gaap_RepaymentsOfNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The fair value of stock issued in noncash financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

+ Details

Name: us-gaap_StockIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The value of inventories transferred to property and equipment, attributable to operating leases in noncash financing and investing activities.
+ References
No definition available.
+ Details

Name: vaso_InventoriesTransferredToPropertyAndEquipmentAttributableToOperatingLeasesNet

Namespace Prefix: vaso_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of the current period expense charged against operations, the offset which is generally to the allowance for doubtful accounts and commission adjustments for the purpose of reducing receivables, including notes receivable, to an amount that approximates their net realizable value (the amount expected to be collected).
+ References
No definition available.
+ Details

Name: vaso_ProvisionForDoubtfulAccountsAndCommissionAdjustments

Namespace Prefix: vaso_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate amount of noncash, equity-based Employee and Non Employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
No definition available.
+ Details

Name: vaso_ShareBasedCompensationAndArrangements

Namespace Prefix: vaso_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 38 R35.htm IDEA: XBRL DOCUMENT v3.2.0.727

BUSINESS COMBINATION (Tables)
6 Months Ended

Jun. 30, 2015

BUSINESS COMBINATION [Abstract]

Estimated Fair Values of the Net Assets Acquired
The following table summarizes the preliminary allocation of the assets acquired and liabilities assumed based on their preliminary estimated fair values as follows:

(in thousands)
Cash and cash equivalents

$
733

Accounts receivable and other current assets

1,638

Other assets

50

Property and equipment

2,359

Accounts payable and other current liabilities

(4,382
)
Long term debt

(1,701
)
Goodwill and other intangibles 19,303
Total

$
18,000

Business Acquisition Proforma Information
The following unaudited supplemental pro forma information presents the financial results as if the acquisitions of Genwell and NetWolves had occurred January 1, 2013, and January 1, 2014, respectively.

(in thousands)

Three months ended

Six months ended

June 30, 2015

June 30, 2014

June 30, 2015

June 30, 2014

Revenue

$
16,088

$
15,070

$
31,449

$
29,431

Net income (loss)
$
580
$
(160
)
$
517
$
(1061
)
Basic earnings (loss) per share

$
0.00

$
(0.00
)

$
0.00

$
(0.01
)
Diluted earnings (loss) per share

$
0.00

$
(0.00
)

$
0.00

$
(0.01
)

X

- Definition
Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(2)-(3)

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

+ Details

Name: us-gaap_BusinessAcquisitionProFormaInformationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

+ Details

Name: us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 39 R22.htm IDEA: XBRL DOCUMENT v3.2.0.727

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
6 Months Ended

Jun. 30, 2015

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS [Abstract]

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
NOTE P - RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

In May 2014, the FASB issued ASU 2014-09 “Revenue from contracts with customers”, a comprehensive new revenue recognition standard which will supersede previous existing revenue recognition guidance. The standard creates a five-step model for revenue recognition that requires companies to exercise judgment when considering contract terms and relevant facts and circumstances. The five-step model includes (1) identifying the contract, (2) identifying the separate performance obligations in the contract, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations and (5) recognizing revenue when each performance obligation has been satisfied. The standard also requires expanded disclosures surrounding revenue recognition. The standard is effective for fiscal periods beginning after December 15, 2017 and allows for either full retrospective or modified retrospective adoption, with early adoption permitted as of January 1, 2017. The Company is currently evaluating the impact of the adoption of this standard on its Consolidated Financial Statements.

In April 2015, the FASB issued ASU 2015-03 “Simplifying the Presentation of Debt Issuance Costs”, which changes the presentation of debt issuance costs in financial statements. An entity presents such costs in the balance sheet as a direct deduction from the related debt liability rather than as an asset. Amortization of the costs is reported as interest expense. The standard is effective for fiscal periods beginning after December 31, 2015 and allows for early adoption. The Company has early adopted this statement for the six months ended June 30, 2015, resulting in $60,000 in debt issue costs initially deducted from the MedTech debt and $1,250 amortized to interest expense.

X

- Definition
The entire disclosure for a new accounting pronouncement that has been issued but not yet adopted.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section S99

-Paragraph 5

-Subparagraph (SAB TOPIC 11.M)

-URI http://asc.fasb.org/extlink&oid=26874127&loc=d3e31137-122693

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 11

-Section M

+ Details

Name: us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 40 R36.htm IDEA: XBRL DOCUMENT v3.2.0.727

ORGANIZATION AND PLAN OF OPERATIONS (Details) - Jun. 30, 2015

State

Company

Subsidiary

ORGANIZATION AND PLAN OF OPERATIONS [Abstract]

Number of contiguous states in which VasoHealthcare has been appointed exclusive representative for GE Healthcare Diagnostic Imaging products | State 48

Number of Chinese operating companies acquired | Company 2

Number of wholly-owned subsidiaries 3

Noncontrolling interest (in hundredths) 49.90%

X

- Definition
The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.
+ References
No definition available.
+ Details

Name: us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of businesses acquired by the entity during the period.
+ References
No definition available.
+ Details

Name: us-gaap_NumberOfBusinessesAcquired

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of states the entity operates in as of the balance sheet date.
+ References
No definition available.
+ Details

Name: us-gaap_NumberOfStatesInWhichEntityOperates

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of wholly-owned subsidiaries owned by the entity.
+ References
No definition available.
+ Details

Name: vaso_NumberOfWhollyOwnedSubsidiaries

Namespace Prefix: vaso_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

XML 41 R24.htm IDEA: XBRL DOCUMENT v3.2.0.727

BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES (Policies)
6 Months Ended

Jun. 30, 2015

BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES [Abstract]

Basis of Presentation and Use of Estimates
Basis of Presentation and Use of Estimates

The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and pursuant to the accounting and disclosure rules and regulations of the Securities and Exchange Commission (the "SEC"). Certain information and disclosures normally included in the unaudited condensed consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in connection with:

1)
The audited consolidated financial statements and related notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2014, as filed with the SEC on March 30, 2015.

2)
The audited consolidated financial statements of NetWolves, LLC and related notes thereto included in the Form 8-K/A filed with the SEC on August 12, 2015. The operating results of NetWolves from May 29, 2015 to June 30, 2015 are included in the accompanying condensed consolidated statements of operations and comprehensive income (loss) for the three and six month periods ended June 30, 2015.

These unaudited condensed consolidated financial statements include the accounts of the companies over which we exercise control. In the opinion of management, the accompanying condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of interim results for the Company. The results of operations for any interim period are not necessarily indicative of results to be expected for any other interim period or the full year.

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the condensed consolidated financial statements, the disclosure of contingent assets and liabilities in the unaudited condensed consolidated financial statements and the accompanying notes, and the reported amounts of revenues, expenses and cash flows during the periods presented. Actual amounts and results could differ from those estimates. The estimates and assumptions the Company makes are based on historical factors, current circumstances and the experience and judgment of the Company's management. The Company evaluates its estimates and assumptions on an ongoing basis.

Significant Accounting Policies
Significant Accounting Policies

Note B of the Notes to Consolidated Financial Statements, included in the Annual Report on Form 10-K for the year ended December 31, 2014, and Note B of the Notes to Consolidated Financial Statements for the year ended December 31, 2014, included on Form 8-K/A, include a summary of the significant accounting policies used in the preparation of the condensed consolidated financial statements.

Revenue Recognition
Revenue Recognition

The Company recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred or service has been rendered, the price is fixed or determinable and collectability is reasonably assured.

Revenue and Expense Recognition for the Sales Representation Segment
Revenue and Expense Recognition for the Sales Representation Segment

The Company recognizes commission revenue in its Sales Representation segment (see Note C) when persuasive evidence of an arrangement exists, service has been rendered, the price is fixed or determinable and collectability is reasonably assured. These conditions are deemed to be met when the underlying equipment has been accepted at the customer site in accordance with the specific terms of the sales agreement. Consequently, amounts billable under the agreement with GE Healthcare in advance of the customer acceptance of the equipment are recorded as accounts receivable and deferred revenue in the condensed consolidated balance sheets. Similarly, commissions payable to our sales force related to such billings are recorded as deferred commission expense when the associated deferred revenue is recorded. Commission expense is recognized when the corresponding commission revenue is recognized.

Variable Interest Entity
Variable Interest Entities

The Company follows the guidance of accounting for variable interest entities, which requires certain variable interest entities to be consolidated by the primary beneficiary of the entities. Biox is a Variable Interest Entity (VIE).

Liabilities recognized as a result of consolidating this VIE do not represent additional claims on the Company’s general assets. The financial information of Biox, which was included in the accompanying condensed consolidated financial statements, is presented as follows:

(in thousands)

As of June 30,
2015 (unaudited)

As of December 31, 2014

Cash and cash equivalents

$
157

$
159

Total assets

$
1,014

$
1,047

Total liabilities

$
1,065

$
878

(in thousands)

Three months ended June 30,

Six months ended June 30,

2015

2014

2015

2014

(unaudited)

(unaudited)

(unaudited)

(unaudited)

Total net revenue

$
454

$
429

$
825

$
758

Net (loss) income

$
(87
)

$
(82
)
$
(223
)

$
(230
)

Reclassifications
Reclassifications

Certain reclassifications have been made to prior period amounts to conform with the current period presentation.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 5A

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=52262685&loc=SL6759159-111685

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 4

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=52262685&loc=d3e5728-111685

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 2AA

-Subparagraph a

-URI http://asc.fasb.org/extlink&oid=52262685&loc=SL6759068-111685

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 2A

-URI http://asc.fasb.org/extlink&oid=52262685&loc=SL6225816-111685

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

+ Details

Name: us-gaap_ConsolidationVariableInterestEntityPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

+ Details

Name: us-gaap_PriorPeriodReclassificationAdjustmentDescription

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18823-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18726-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.B.Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section B

-Paragraph Question 1

+ Details

Name: us-gaap_RevenueRecognitionPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for revenue recognition for commission revenue.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.B.Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 20

-Section 25

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=51667699&loc=d3e48393-111629

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

-Paragraph a

-Subparagraph Question 2

-Subsection 4

+ Details

Name: us-gaap_RevenueRecognitionServicesCommissions

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). and for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
No definition available.
+ Details

Name: vaso_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock

Namespace Prefix: vaso_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for all significant accounting policies of the reporting entity.
+ References
No definition available.
+ Details

Name: vaso_SignificantAccountingPoliciesPolicyTextBlock

Namespace Prefix: vaso_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 42 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 43 R7.htm IDEA: XBRL DOCUMENT v3.2.0.727

ORGANIZATION AND PLAN OF OPERATIONS
6 Months Ended

Jun. 30, 2015

ORGANIZATION AND PLAN OF OPERATIONS [Abstract]

ORGANIZATION AND PLAN OF OPERATIONS
NOTE A - ORGANIZATION AND PLAN OF OPERATIONS

Vasomedical, Inc. was incorporated in Delaware in July 1987. Unless the context requires otherwise, all references to “we”, “our”, “us”, “Company”, “registrant”, “Vasomedical” or “management” refer to Vasomedical, Inc. and its subsidiaries. Until 2010, we were primarily engaged in designing, manufacturing, marketing and supporting Enhanced External Counterpulsation (EECP^®) systems, based on our proprietary technology, to physicians and hospitals throughout the United States and in select international markets. Beginning in July 2010 the Company, through its wholly-owned subsidiary Vaso Diagnostics, Inc. (Vaso Diagnostics), began its sales representation business via its agreement (the “GEHC Agreement”) with GE Healthcare (“GEHC”), the healthcare business unit of General Electric Company (NYSE: GE), to be GEHC’s exclusive sales representative for the sale of select GEHC diagnostic imaging products in specific market segments in the 48 contiguous states of the United States and the District of Columbia. In June 2012, the GEHC Agreement was amended and extended through June 30, 2015 and again, in December 2014, the GEHC Agreement was further amended and extended through December 31, 2018, subject to earlier termination under certain circumstances and termination without cause on or after July 1, 2017.

In September 2011, the Company acquired Fast Growth Enterprises Limited (FGE), a British Virgin Islands company, which owns or controls two Chinese operating companies - Life Enhancement Technology Ltd. and Biox Instruments Co. Ltd. (Biox), respectively - to expand its technical and manufacturing capabilities and to enhance its distribution network, technology, and product portfolio. Also in September 2011, the Company restructured to further align its business management structure and long-term growth strategy, and started to operate through three wholly-owned subsidiaries. Vaso Diagnostics continues as the operating subsidiary for the sales representation of GE diagnostic imaging products; Vasomedical Global Corp. operates the Company’s Chinese companies; and Vasomedical Solutions, Inc. was formed to manage and coordinate our EECP^® therapy business as well as other medical equipment operations.

In April 2014, the Company entered into an agreement with Chongqing PSK-Health Sci-Tech Development Co., Ltd. (PSK) of Chongqing, China, the leading manufacturer of ECP therapy systems in China, to form a joint venture company, VSK Medical Limited (VSK), for the global marketing, sale and advancement of ECP therapy technology. The Company owns 49.9% of the joint venture, which began operations in January 2015.

In June 2014, the Company entered into a Value Added Reseller Agreement (VAR Agreement) with GEHC to become a national value added reseller of GE Healthcare IT's Radiology PACS (Picture Archiving and Communication System) software solutions and related services, including implementation, management and support. This multiyear VAR Agreement focuses primarily on existing customer segments currently served by Vaso Diagnostics on behalf of GEHC. A new wholly owned subsidiary, VasoHealthcare IT Corp., was formed to conduct the healthcare IT business.

In August 2014, the Company, through its wholly owned subsidiary Wuxi Gentone Instruments Co. Ltd. (Gentone), acquired all of the outstanding shares of Genwell Instruments Co. Ltd. (Genwell), located in Wuxi, China. Genwell was formed in China in 2010 with the assistance of a government grant to develop the MobiCare^TM wireless multi-parameter patient monitoring system and holds the patents and intellectual property rights for this system.

In May 2015, the Company entered into an agreement for, and completed its purchase of, all of the assets of NetWolves, LLC and its affiliates, including the membership interests in NetWolves Network Services LLC (collectively, “NetWolves”). The purchase of NetWolves was accomplished pursuant to an Asset Purchase Agreement. As a result, the Company effectively purchased all rights, titles and ownership of all assets held by NetWolves. NetWolves designs and delivers efficient and cost-effective multi-network and multi-technology solutions as a managed network provider, and provides a complete single-source solution that includes design, network redundancy, application device management, real-time network monitoring, reporting and support systems as a comprehensive solution. The Company believes there are significant operational synergies between NetWolves’ capabilities and VasoHealthcare IT’s requirements under its VAR Agreement with GEHC, as well as the opportunity to expand NetWolves’ existing services to the healthcare IT market.

We report the operations of Vasomedical Global Corp. and Vasomedical Solutions, Inc. under our Equipment segment. Vaso Diagnostics activities are included under our Sales Representation segment. VasoHealthcare IT and NetWolves operations report under the IT segment.

X

- Definition
The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6003-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 2A

-URI http://asc.fasb.org/extlink&oid=51801978&loc=SL51803626-108592

+ Details

Name: us-gaap_NatureOfOperations

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 44 R3.htm IDEA: XBRL DOCUMENT v3.2.0.727

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($)
$ in Thousands

Jun. 30, 2015

Dec. 31, 2014

CURRENT ASSETS

Accounts and other receivables, allowance for doubtful accounts and commission adjustments $ 4,178 $ 4,571

PROPERTY AND EQUIPMENT, accumulated depreciation $ 3,123 $ 1,397

STOCKHOLDERS' EQUITY

Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01

Preferred stock, shares authorized (in shares) 1,000,000 1,000,000

Preferred stock, shares issued (in shares) 0 0

Preferred stock, shares outstanding (in shares) 0 0

Common stock, par value (in dollars per share) $ 0.001 $ 0.001

Common stock, shares authorized (in shares) 250,000,000 250,000,000

Common stock, shares issued (in shares) 168,710,370 166,435,370

Common stock, shares outstanding (in shares) 158,402,283 156,127,283

Treasury stock, at cost (in shares) 10,308,087 10,308,087

X

- Definition
Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=49124121&loc=d3e5074-111524

+ Details

Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_TreasuryStockShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 45 R17.htm IDEA: XBRL DOCUMENT v3.2.0.727

DEFERRED REVENUE
6 Months Ended

Jun. 30, 2015

DEFERRED REVENUE [Abstract]

DEFERRED REVENUE
NOTE K- DEFERRED REVENUE

The changes in the Company’s deferred revenues are as follows:

(in thousands)

For the three months ended

For the six months ended

June 30, 2015

June 30, 2014

June 30, 2015

June 30, 2014

(unaudited)

(unaudited)

(unaudited)

(unaudited)

Deferred revenue at beginning of period

$
21,453

$
17,004

$
22,532

$
18,019

Additions:

Deferred extended service contracts

94

309

305

546

Deferred in-service and training

3

13

5

15

Deferred service arrangements

5

25

15

30

Deferred commission revenues

1,481

3,614

3,330

5,384

Recognized as revenue:

Deferred extended service contracts

(214
)

(220
)

(445
)

(448
)
Deferred in-service and training

(3
)

(8
)

(10
)

(15
)
Deferred service arrangements

(20
)

(23
)

(43
)

(46
)
Deferred commission revenues

(3,185
)

(3,002
)

(6,075
)

(5,773
)
Deferred revenue at end of period

19,614

17,712

19,614

17,712

Less: current portion

11,560

9,183

11,560

9,183

Long-term deferred revenue at end of period

$
8,054

$
8,529

$
8,054

$
8,529

X

- References
No definition available.
+ Details

Name: us-gaap_DeferredRevenueDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for deferred revenues at the end of the reporting period, and description and amounts of significant changes that occurred during the reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.3(b).Q1(c),(b).Q2,(c).Q3)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 46 R1.htm IDEA: XBRL DOCUMENT v3.2.0.727

Document and Entity Information - shares
6 Months Ended

Jun. 30, 2015

Aug. 08, 2015

Document and Entity Information [Abstract]

Entity Registrant Name VASOMEDICAL, INC

Entity Central Index Key 0000839087

Current Fiscal Year End Date --12-31

Entity Well-known Seasoned Issuer No

Entity Voluntary Filers No

Entity Current Reporting Status Yes

Entity Filer Category Smaller Reporting Company

Entity Common Stock, Shares Outstanding 158,412,283

Document Fiscal Year Focus 2015

Document Fiscal Period Focus Q2

Document Type 10-Q

Amendment Flag false

Document Period End Date Jun. 30, 2015

X

- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
+ References
No definition available.
+ Details

Name: dei_EntityVoluntaryFilers

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.
+ References
No definition available.
+ Details

Name: dei_EntityWellKnownSeasonedIssuer

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: vaso_DocumentAndEntityInformationAbstract

Namespace Prefix: vaso_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 47 R18.htm IDEA: XBRL DOCUMENT v3.2.0.727

DEBT
6 Months Ended

Jun. 30, 2015

DEBT [Abstract]

DEBT
NOTE L – DEBT

On May 29, 2015, the Company entered into a Note Purchase Agreement with MedTechnology Investments, LLC (“MedTech”) pursuant to which it issued MedTech a secured subordinated promissory note (“Note”) for $3,800,000 for the purchase of NetWolves . MedTech was formed to acquire the Note, and $1,950,000 of the aggregate funds used to acquire the Note was provided by six of our directors. In June 2015, a second Note for $750,000 was issued to MedTech for working capital purposes, $250,000 of which was provided by a director and a director’s spouse. Subsequent to June 30, 2015, an additional $250,000 was borrowed under the Note Purchase Agreement.

The Notes bear interest at an annual rate of 9%, matures on May 29, 2019, may be prepaid without penalty, and is subordinated to any current or future Senior Debt as defined in the Subordinated Security Agreement. The Subordinated Security Agreement secures payment and performance of the Company’s obligations under the Note and as a result, MedTech was granted a subordinated security interest in the Company’s assets.

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20,22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 48 R4.htm IDEA: XBRL DOCUMENT v3.2.0.727

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Revenues

Professional sales services $ 7,036 $ 6,684 $ 13,427 $ 12,926

Managed IT systems and services 2,811 0 2,811 0

Equipment sales and services 996 1,180 2,059 2,030

Total revenues 10,843 7,864 18,297 14,956

Cost of revenues

Cost of professional sales services 1,524 1,852 3,047 3,454

Cost of managed IT systems and services 1,613 0 1,613 0

Cost of equipment sales and services 378 530 741 854

Total cost of revenues 3,515 2,382 5,401 4,308

Gross profit 7,328 5,482 12,896 10,648

Operating expenses

Selling, general and administrative 6,985 5,482 12,704 11,523

Research and development 137 206 272 419

Total operating expenses 7,122 5,688 12,976 11,942

Operating income (loss) 206 (206) (80) (1,294)

Other income (expense)

Interest and financing costs (89) (2) (117) (3)

Interest and other income, net 80 46 147 101

Total other income (expense), net (9) 44 30 98

Income (loss) before income taxes 197 (162) (50) (1,196)

Income tax expense (6) (14) (12) (24)

Net income (loss) 191 (176) (62) (1,220)

Other comprehensive income

Foreign currency translation gain (loss) 24 10 31 (30)

Comprehensive income (loss) $ 215 $ (166) $ (31) $ (1,250)

Income (loss) per common share

basic (in dollars per share) $ 0 $ 0 $ 0 $ (0.01)

diluted (in dollars per share) $ 0 $ 0 $ 0 $ (0.02)

Weighted average common shares outstanding

basic (in shares) 156,258 155,320 156,102 155,386

diluted (in shares) 156,566 155,320 156,102 155,386

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831223

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e557-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(a),(d))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_CostOfGoodsAndServicesSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CostOfGoodsAndServicesSoldAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Total costs related to goods produced and sold during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(a))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_CostOfGoodsSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.23)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
This element represents interest incurred for borrowed money which was used to produce goods or render services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_FinancingInterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1,2)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 940

-SubTopic 20

-Section 25

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51673353&loc=d3e41242-110953

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 10

-Article 5

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).
+ References
No definition available.
+ Details

Name: us-gaap_InterestAndOtherIncome

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 45

-Paragraph 20

-Subparagraph (b,c)

-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32211-110900

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(a))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_SalesRevenueGoodsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_SalesRevenueNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SalesRevenueNetAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 30

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=51677171&loc=d3e3636-108311

+ Details

Name: us-gaap_SellingGeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Costs incurred in providing technology services. The services may include training, installation, engineering or consulting. Consulting services often include implementation support, software design or development, or the customization or modification of the licensed software.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(d))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 605

-Section 25

-Paragraph 76

-URI http://asc.fasb.org/extlink&oid=51674016&loc=d3e132428-111767

+ Details

Name: us-gaap_TechnologyServicesCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Revenue from providing technology services. The services may include training, installation, engineering or consulting. Consulting services often include implementation support, software design or development, or the customization or modification of the licensed software.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(d))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 605

-Section 25

-Paragraph 76

-URI http://asc.fasb.org/extlink&oid=51674016&loc=d3e132428-111767

+ Details

Name: us-gaap_TechnologyServicesRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Weighted-Average Number of Common Shares Outstanding

-URI http://asc.fasb.org/extlink&oid=6528421

+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate revenue during the period from commissions earned from the sales representative agreement with GE Healthcare.
+ References
No definition available.
+ Details

Name: vaso_CommissionsRevenueNet

Namespace Prefix: vaso_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total costs related to commissions earned under the sales representative agreement with GE Healthcare.
+ References
No definition available.
+ Details

Name: vaso_CostOfCommissionsRevenue

Namespace Prefix: vaso_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 49 R12.htm IDEA: XBRL DOCUMENT v3.2.0.727

ACCOUNTS AND OTHER RECEIVABLES, NET
6 Months Ended

Jun. 30, 2015

ACCOUNTS AND OTHER RECEIVABLES, NET [Abstract]

ACCOUNTS AND OTHER RECEIVABLES, NET
NOTE F – ACCOUNTS AND OTHER RECEIVABLES, NET

The following table presents information regarding the Company’s accounts and other receivables as of June 30, 2015 and December 31, 2014:

(in thousands)

June 30, 2015

December 31, 2014

(unaudited)

Trade receivables

$
10,374

$
19,734

Due from employees

124

110

Allowance for doubtful accounts and

commission adjustments

(4,178
)

(4,571
)
Accounts and other receivables, net

$
6,320

$
15,273

Trade receivables include amounts due for shipped products and services rendered. Amounts currently due under the GEHC Agreement are subject to adjustment in subsequent periods should the underlying sales order amount, upon which the receivable is based, change.

Allowance for doubtful accounts and commission adjustments include estimated losses resulting from the inability of our customers to make required payments, and adjustments arising from subsequent changes in sales order amounts that may reduce the amount the Company will ultimately receive under the GEHC Agreement. Due from employees is primarily commission advances made to sales personnel.

X

- Definition
The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=49124121&loc=d3e5066-111524

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3,4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=49124121&loc=d3e5162-111524

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=49124121&loc=d3e5074-111524

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 7

-Article 9

+ Details

Name: us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ReceivablesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 50 R11.htm IDEA: XBRL DOCUMENT v3.2.0.727

FAIR VALUE MEASUREMENTS
6 Months Ended

Jun. 30, 2015

FAIR VALUE MEASUREMENTS [Abstract]

FAIR VALUE MEASUREMENTS
NOTE E – FAIR VALUE MEASUREMENTS

The Company complies with the provisions of ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”). Under ASC 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date.

The following tables present information about the Company’s assets measured at fair value as of June 30, 2015 and December 31, 2014:

(in thousands)

Quoted Prices

Significant

in Active

Other

Significant

Balance

Markets for

Observable

Unobservable

as of

Identical Assets

Inputs

Inputs

June 30,

(Level 1)

(Level 2)

(Level 3)

2015

Assets

(unaudited)

Cash equivalents invested in money market funds

(included in cash and cash equivalents)

$
2

$
-

$
-

$
2

Quoted Prices

Significant

in Active

Other

Significant

Balance

Markets for

Observable

Unobservable

as of

Identical Assets

Inputs

Inputs

December 31,

(Level 1)

(Level 2)

(Level 3)

2014

Assets

Cash equivalents invested in money market funds

(included in cash and cash equivalents)

$
8,149

$
-

$
-

$
8,149

The fair values of the Company’s cash equivalents invested in money market funds are determined through market, observable and corroborated sources.

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13537-108611

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13504-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13433-108611

+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 51 R23.htm IDEA: XBRL DOCUMENT v3.2.0.727

SUBSEQUENT EVENTS
6 Months Ended

Jun. 30, 2015

SUBSEQUENT EVENTS [Abstract]

SUBSEQUENT EVENTS
NOTE Q – SUBSEQUENT EVENTS

In July 2015, the lending institution extended the Company’s NetWolves subsidiary’s $2.0 million line of credit and increased the maximum borrowings to $3.0 million. Advances under the line, which expires on August 26, 2016, bear interest at a rate of LIBOR plus 2.25% and are secured by substantially all of the assets of NetWolves Network Services, LLC and the guaranty of Vasomedical, Inc.

X

- References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 52 R19.htm IDEA: XBRL DOCUMENT v3.2.0.727

BUSINESS COMBINATION
6 Months Ended

Jun. 30, 2015

BUSINESS COMBINATION [Abstract]

BUSINESS COMBINATION
NOTE M – BUSINESS COMBINATION

On May 29, 2015, the Company entered into an agreement for, and completed its purchase of, all of the assets of NetWolves, LLC and its affiliates, including the membership interests in NetWolves Network Services LLC (collectively, “NetWolves”) for $18,000,000 (the “Purchase Price”). The purchase of NetWolves was accomplished pursuant to an Asset Purchase Agreement (the "Purchase Agreement"). As a result, the Company effectively purchased all rights, titles and ownership of all assets held by NetWolves. The Purchase Price was paid using $14,200,000 in cash on hand and $3,800,000 raised through the issuance of the Note to MedTech. The Company believes there are significant operational synergies between NetWolves’ capabilities and VasoHealthcare IT’s requirements under its VAR contract with GEHC, as well as the opportunity to expand NetWolves’ existing services to the healthcare IT market.

The operating results of NetWolves from May 29, 2015 to June 30, 2015 are included in the accompanying condensed consolidated statements of operations and comprehensive income (loss) for the three and six month periods ended June 30, 2015. The accompanying condensed consolidated balance sheet at June 30, 2015 reflects the acquisition of NetWolves effective May 29, 2015.

In accordance with Accounting Standards Codification 805, Business Combinations, the total purchase consideration is allocated to the net tangible and intangible assets acquired and liabilities assumed based on their estimated fair values at May 29, 2015 (the acquisition date). The purchase price was allocated based on the information currently available, and may be adjusted after obtaining more information regarding, among other things, asset valuations, liabilities assumed, and revisions of preliminary estimates. The following table summarizes the preliminary allocation of the assets acquired and liabilities assumed based on their preliminary estimated fair values as follows:

(in thousands)
Cash and cash equivalents

$
733

Accounts receivable and other current assets

1,638

Other assets

50

Property and equipment

2,359

Accounts payable and other current liabilities

(4,382
)
Long term debt

(1,701
)
Goodwill and other intangibles 19,303
Total

$
18,000

During the three months ended June 30, 2015, the Company expensed $100,000 of acquisition-related legal costs and incurred $60,000 in debt issue costs. The legal costs are included in the line item Selling, General & Administrative costs in the accompanying condensed consolidated statements of operations and comprehensive income (loss). The debt issue costs are recorded as a reduction to long term notes payable in the accompanying condensed consolidated balance sheet at June 30, 2015. The amounts of revenue and net income of NetWolves included in the Company’s condensed consolidated statements of operations and comprehensive income (loss) for both the three and six months ended June 30, 2015 was $2,763,000 and $150,000, respectively. The goodwill is expected to be deductible for tax purposes.

The following unaudited supplemental pro forma information presents the financial results as if the acquisitions of Genwell and NetWolves had occurred January 1, 2013, and January 1, 2014, respectively.

(in thousands)

Three months ended

Six months ended

June 30, 2015

June 30, 2014

June 30, 2015

June 30, 2014

Revenue

$
16,088

$
15,070

$
31,449

$
29,431

Net income (loss)
$
580
$
(160
)
$
517
$
(1061
)
Basic earnings (loss) per share

$
0.00

$
(0.00
)

$
0.00

$
(0.01
)
Diluted earnings (loss) per share

$
0.00

$
(0.00
)

$
0.00

$
(0.01
)

X

- Definition
The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

Name: us-gaap_BusinessCombinationDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 53 R15.htm IDEA: XBRL DOCUMENT v3.2.0.727

OTHER ASSETS
6 Months Ended

Jun. 30, 2015

OTHER ASSETS [Abstract]

OTHER ASSETS
NOTE I – OTHER ASSETS

Other assets consist of the following at June 30, 2015 and December 31, 2014:

(in thousands)

June 30, 2015

December 31, 2014

(unaudited)

Deferred commission expense - noncurrent

$
2,121

$
2,988

Trade receivables - noncurrent

1,186

2,171

Other

630

458

$
3,937

$
5,617

X

- References
No definition available.
+ Details

Name: us-gaap_OtherAssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.
+ References
No definition available.
+ Details

Name: us-gaap_OtherAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 54 R13.htm IDEA: XBRL DOCUMENT v3.2.0.727

INVENTORIES, NET
6 Months Ended

Jun. 30, 2015

INVENTORIES, NET [Abstract]

INVENTORIES, NET
NOTE G – INVENTORIES, NET
Inventories, net of reserves, consist of the following:

             (in thousands)

June 30, 2015

December 31, 2014

(unaudited)

Raw materials

$
588

$
583

Work in process

688

679

Finished goods

892

636

$
2,168

$
1,898

At June 30, 2015 and December 31, 2014, the Company maintained reserves for excess and obsolete inventory of $791,000 and $815,000, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a, b, c

-Article 5

+ Details

Name: us-gaap_InventoryDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 55 R14.htm IDEA: XBRL DOCUMENT v3.2.0.727

GOODWILL AND OTHER INTANGIBLES
6 Months Ended

Jun. 30, 2015

GOODWILL AND OTHER INTANGIBLES [Abstract]

GOODWILL AND OTHER INTANGIBLES
NOTE H – GOODWILL AND OTHER INTANGIBLES

Goodwill aggregating $22,618,000 and $3,288,000 was recorded on the Company’s condensed consolidated balance sheets at June 30, 2015 and December 31, 2014, respectively, of which $19,303,000, allocated to the IT segment, resulted from the acquisition of NetWolves in May 2015. The remaining $3,315,000 of goodwill is allocated to the Company’s Equipment segment. The components of the change in goodwill are as follows:

(in thousands)

Carrying

Amount

Balance at December 31, 2014

$
3,288

Foreign currency translation

27

Acquisition of Netwolves

19,303

Balance at June 30, 2015 (unaudited)

$
22,618

The Company’s other intangible assets consist of capitalized patent costs, customer lists and software costs, as follows:
(in thousands)

June 30, 2015

December 31, 2014

(unaudited)

Patents and Technology

Costs

$
2,467

$
2,489

Accumulated amortization

(678
)

(549
)

1,789

1,940

Customer lists

Costs

800

800

Accumulated amortization

(438
)

(381
)

362

419

Software

Costs

1,054

962

Accumulated amortization

(644
)

(495
)

410

467

$
2,561

$
2,826

Patents, customer lists, and software are included in other assets in the accompanying condensed consolidated balance sheets and are amortized on a straight line basis over their estimated useful lives of ten, seven, and five years, respectively. Amortization expense amounted to $164,000 and $335,000 for the three and six months ended June 30, 2015, respectively, and $50,000 and $96,000 for the three and six months ended June 30, 2014, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16373-109275

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13854-109267

+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 56 R16.htm IDEA: XBRL DOCUMENT v3.2.0.727

ACCRUED EXPENSES AND OTHER LIABILITIES
6 Months Ended

Jun. 30, 2015

ACCRUED EXPENSES AND OTHER LIABILITIES [Abstract]

ACCRUED EXPENSES AND OTHER LIABILITIES
NOTE J – ACCRUED EXPENSES AND OTHER LIABILITIES

Accrued expenses and other liabilities consist of the following at June 30, 2015 and December 31, 2014:

(in thousands)

June 30, 2015

December 31, 2014

(unaudited)

Accrued compensation

$
1,536

$
2,917

Accrued expenses - other

1,313

1,098

Other liabilities

2,307

1,612

$
5,156

$
5,627

X

- Definition
The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a),20,24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 57 R34.htm IDEA: XBRL DOCUMENT v3.2.0.727

DEFERRED REVENUE (Tables)
6 Months Ended

Jun. 30, 2015

DEFERRED REVENUE [Abstract]

Changes in Deferred Revenues
The changes in the Company’s deferred revenues are as follows:

(in thousands)

For the three months ended

For the six months ended

June 30, 2015

June 30, 2014

June 30, 2015

June 30, 2014

(unaudited)

(unaudited)

(unaudited)

(unaudited)

Deferred revenue at beginning of period

$
21,453

$
17,004

$
22,532

$
18,019

Additions:

Deferred extended service contracts

94

309

305

546

Deferred in-service and training

3

13

5

15

Deferred service arrangements

5

25

15

30

Deferred commission revenues

1,481

3,614

3,330

5,384

Recognized as revenue:

Deferred extended service contracts

(214
)

(220
)

(445
)

(448
)
Deferred in-service and training

(3
)

(8
)

(10
)

(15
)
Deferred service arrangements

(20
)

(23
)

(43
)

(46
)
Deferred commission revenues

(3,185
)

(3,002
)

(6,075
)

(5,773
)
Deferred revenue at end of period

19,614

17,712

19,614

17,712

Less: current portion

11,560

9,183

11,560

9,183

Long-term deferred revenue at end of period

$
8,054

$
8,529

$
8,054

$
8,529

X

- Definition
Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueByArrangementDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DeferredRevenueDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 58 R51.htm IDEA: XBRL DOCUMENT v3.2.0.727

COMMITMENTS AND CONTINGENCIES (Details)
6 Months Ended

Jun. 30, 2015

Sales Representation Agreement [Abstract]

Initial term of sales representation agreement 3 years

Amended term of sales representation agreement 5 years

X

- Definition
Refers to the extended term of sales representation agreement into an amendment entered by entity.
+ References
No definition available.
+ Details

Name: vaso_AmendedTermOfSalesRepresentationAgreement

Namespace Prefix: vaso_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Refers to the initial term of sales representation agreement into an amendment entered by entity.
+ References
No definition available.
+ Details

Name: vaso_InitialTermOfSalesRepresentationAgreement

Namespace Prefix: vaso_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: vaso_SalesRepresentationAgreementAbstract

Namespace Prefix: vaso_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 59 R21.htm IDEA: XBRL DOCUMENT v3.2.0.727

COMMITMENTS AND CONTINGENCIES
6 Months Ended

Jun. 30, 2015

COMMITMENTS AND CONTINGENCIES [Abstract]

COMMITMENTS AND CONTINGENCIES
NOTE O – COMMITMENTS AND CONTINGENCIES

Sales representation agreement

In June 2012, the Company concluded an amendment of the GEHC Agreement with GEHC, originally signed on May 19, 2010. The amendment, effective July 1, 2012, extended the initial term of three years commencing July 1, 2010 to five years through June 30, 2015. In December 2014, the Company concluded an additional amendment, effective January 1, 2015, extending the term through December 31, 2018, subject to earlier termination under certain circumstances and termination without cause on or after July 1, 2017. These circumstances include not materially achieving certain sales goals, not maintaining a minimum number of sales representatives, and various legal and GEHC policy requirements. Under the terms of the agreement, the Company is required to lease dedicated computer equipment from GEHC for connectivity to their network.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=51674963&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 60 R26.htm IDEA: XBRL DOCUMENT v3.2.0.727

SEGMENT REPORTING AND CONCENTRATIONS (Tables)
6 Months Ended

Jun. 30, 2015

SEGMENT REPORTING AND CONCENTRATIONS [Abstract]

Summary Financial Information for Segments
Summary financial information for the segments is set forth below:

(in thousands)

As of or for the three months ended June 30, 2015 (unaudited)

Sales

Representation

Equipment

Segment

IT Segment

Segment

Corporate

Consolidated

Revenues from external customers

$
7,036

$
2,811

996

$
-

$
10,843

Operating income (loss)

$
1,794

$
(366
)

(676
)

$
(546
)

$
206

Total assets

$
10,421

$
25,205

9,385

$
1,309

$
46,320

Accounts and other receivables, net

$
4,421

$
1,399

500

$
-

$
6,320

Deferred commission expense

$
2,388

$
19

-

$
-

$
2,407

Other assets

$
3,098

$
51

675

$
113

$
3,937

As of or for the three months ended June 30, 2014 (unaudited)

Sales

Representation

Equipment

Segment

IT Segment

Segment

Corporate

Consolidated

Revenues from external customers

$
6,684

$
-

1,180

$
-

$
7,864

Operating income (loss)

$
1,021

$
-

(875
)

$
(352
)

$
(206
)
Total assets

$
13,144

$
-

8,052

$
10,036

$
31,232

Accounts and other receivables, net

$
6,585

$
-

941

$
-

$
7,526

Deferred commission expense

$
2,297

$
-

-

$
-

$
2,297

Other assets

$
4,066

$
-

1,164

$
13

$
5,243

As of or for the six months ended June 30, 2015 (unaudited)

Sales

Representation

Equipment

Segment

IT Segment

Segment

Corporate

Consolidated

Revenues from external customers

$
13,427

$
2,811

2,059

$
-

$
18,297

Operating income (loss)

$
2,880

$
(721
)

(1,311
)

$
(928
)

$
(80
)
Total assets

$
10,421

$
25,205

9,385

$
1,309

$
46,320

Accounts and other receivables, net

$
4,421

$
1,399

500

$
-

$
6,320

Deferred commission expense

$
2,388

$
19

-

$
-

$
2,407

Other assets

$
3,098

$
51

675

$
113

$
3,937

As of or for the six months ended June 30, 2014 (unaudited)

Sales

Representation

Equipment

Segment

IT Segment

Segment

Corporate

Consolidated

Revenues from external customers

$
12,926

$
-

2,030

$
-

$
14,956

Operating income (loss)

$
1,544

$
-

(1,955
)

$
(883
)

$
(1,294
)
Total assets

$
13,144

$
-

8,052

$
10,036

$
31,232

Accounts and other receivables, net

$
6,585

$
-

941

$
-

$
7,526

Deferred commission expense

$
2,297

$
-

-

$
-

$
2,297

Other assets

$
4,066

$
-

1,164

$
13

$
5,243

X

- Definition
Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8813-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 21

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 22

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8736-108599

+ Details

Name: us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 61 R49.htm IDEA: XBRL DOCUMENT v3.2.0.727

BUSINESS COMBINATION (Details) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended

May. 29, 2015

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Dec. 31, 2014

Business Acquisition [Line Items]

Business combination, cash paid $ 18,000,000 $ 0

Debt issuance costs 60,000

Net income (loss) $ 191,000 $ (176,000) (62,000) (1,220,000) $ 1,128,000

Estimated fair values of the net assets acquired [Abstract]

Goodwill and other intangibles 22,618,000 22,618,000 $ 3,288,000

NetWolves, LLC [Member]

Business Acquisition [Line Items]

Consideration for acquisition $ 18,000,000

Business combination, cash paid 14,200,000 14,200,000

Acquisition-related legal costs 100,000

Debt issuance costs 60,000

Net income (loss) 2,763,000 150,000

Estimated fair values of the net assets acquired [Abstract]

Cash and cash equivalents 733,000

Accounts receivable and other current assets 1,638,000

Other assets 50,000

Property and equipment 2,359,000

Accounts payable and other current liabilities (4,382,000)

Long term debt (1,701,000)

Goodwill and other intangibles 19,303,000

Total 18,000,000

NetWolves, LLC [Member] | MedTechnology Investments LLC [Member]

Business Acquisition [Line Items]

Business combination, issue of notes $ 3,800,000 3,800,000

Genwell and Netwolves [Member]

Business acquisition proforma information [Abstract]

Revenue 16,088,000 15,070,000 31,449,000 29,431,000

Net income (loss) $ 580,000 $ (160,000) $ 517,000 $ (1,061,000)

Basic earnings (loss) per share (in dollars per share) $ 0 $ 0 $ 0 $ (0.01)

Diluted earnings (loss) per share (in dollars per share) $ 0 $ 0 $ 0 $ (0.01)

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_BusinessAcquisitionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(2)-(3)

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

+ Details

Name: us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(2)-(3)

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

+ Details

Name: us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessAcquisitionProFormaInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(2)-(3)

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

+ Details

Name: us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(2)-(3)

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

+ Details

Name: us-gaap_BusinessAcquisitionsProFormaRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 25

-Paragraph 23

-URI http://asc.fasb.org/extlink&oid=34752592&loc=d3e1043-128460

+ Details

Name: us-gaap_BusinessCombinationAcquisitionRelatedCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 30

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6578-128477

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 30

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6911251&loc=d3e6613-128477

+ Details

Name: us-gaap_BusinessCombinationConsiderationTransferred1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The amount of property, plant, and equipment recognized as of the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 55

-Paragraph 37

-URI http://asc.fasb.org/extlink&oid=35744172&loc=d3e2207-128464

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of debt issuance costs (for example, but not limited to, legal, accounting, broker, and regulatory fees).
+ References
No definition available.
+ Details

Name: us-gaap_DebtIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquireBusinessesGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of additional consideration transferred in a business combination.
+ References
No definition available.
+ Details

Name: vaso_BusinessCombinationAdditionalConsiderationTransferred

Namespace Prefix: vaso_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle and also includes other assets, if longer, acquired at the acquisition date.
+ References
No definition available.
+ Details

Name: vaso_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivablesAndOtherCurrentAssets

Namespace Prefix: vaso_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date and also other current liabilities
+ References
No definition available.
+ Details

Name: vaso_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndOtherCurrentLiabilities

Namespace Prefix: vaso_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=vaso_NetWolvesLLCMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=vaso_MedTechnologyInvestmentsLLCMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=vaso_GenwellAndNetwolvesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 62 R41.htm IDEA: XBRL DOCUMENT v3.2.0.727

FAIR VALUE MEASUREMENTS (Details) - USD ($)
$ in Thousands

Jun. 30, 2015

Dec. 31, 2014

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Cash equivalents invested in money market funds (included in cash and cash equivalents) $ 2 $ 8,149

Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Cash equivalents invested in money market funds (included in cash and cash equivalents) 2 8,149

Significant Other Observable Inputs (Level 2) [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Cash equivalents invested in money market funds (included in cash and cash equivalents) 0 0

Significant Unobservable Inputs (Level 3) [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Cash equivalents invested in money market funds (included in cash and cash equivalents) $ 0 $ 0

X

- Definition
Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

+ Details

Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 63 R5.htm IDEA: XBRL DOCUMENT v3.2.0.727

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($)
shares in Thousands, $ in Thousands

Common Stock [Member]

Treasury Stock [Member]

Additional Paid-in Capital [Member]

Accumulated Deficit [Member]

Accumulated Other Comprehensive Income [Member]

Total

Balance at Dec. 31, 2013 $ 165 $ (1,755) $ 61,508 $ (53,561) $ 108 $ 6,465

Balance (in shares) at Dec. 31, 2013 164,705 (9,481)

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Repurchase of shares $ 0 $ (245) 0 0 0 (245)

Repurchase of shares (in shares) 0 (827)

Share-based compensation $ 1 389 0 0 390

Share-based compensation (in shares) 1,280

Shares not issued for employee tax liability $ 0 (9) 0 0 (9)

Exercise of stock options $ 0 36 0 0 36

Exercise of stock options (in shares) 450

Foreign currency translation gain (loss) $ 0 0 0 (14) (14)

Net income (loss) 0 0 1,128 0 1,128

Balance at Dec. 31, 2014 $ 166 $ (2,000) 61,924 (52,433) 94 7,751

Balance (in shares) at Dec. 31, 2014 166,435 (10,308)

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Share-based compensation $ 3 257 0 0 260

Share-based compensation (in shares) 2,275

Foreign currency translation gain (loss) $ 0 0 0 31 31

Net income (loss) 0 0 (62) 0 (62)

Balance at Jun. 30, 2015 $ 169 $ (2,000) $ 62,181 $ (52,495) $ 125 $ 7,980

Balance (in shares) at Jun. 30, 2015 168,710 (10,308)

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 45

-Paragraph 20

-Subparagraph (b,c)

-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32211-110900

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares issued which are neither cancelled nor held in the treasury.
+ References
No definition available.
+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (d)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock issued as a result of the exercise of stock options.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockRepurchasedDuringPeriodShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_StockRepurchasedDuringPeriodValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4I

-URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4590271-111686

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=51664549&loc=SL4568740-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=51664549&loc=SL4568447-111683

+ Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Refers to amount of increase (decrease) in additional paid in capital (APIC) resulting from common stock that is not issued for employee tax liability.
+ References
No definition available.
+ Details

Name: vaso_SharesNotIssuedForEmployeeTaxLiability

Namespace Prefix: vaso_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 64 R10.htm IDEA: XBRL DOCUMENT v3.2.0.727

EARNINGS (LOSS) PER COMMON SHARE
6 Months Ended

Jun. 30, 2015

EARNINGS (LOSS) PER COMMON SHARE [Abstract]

EARNINGS (LOSS) PER COMMON SHARE
NOTE D – EARNINGS (LOSS) PER COMMON SHARE

Basic earnings (loss) per common share is computed as earnings applicable to common stockholders divided by the weighted-average number of common shares outstanding for the period. Diluted earnings (loss) per common share reflects the potential dilution that could occur if securities or other contracts to issue common shares were exercised or converted to common stock.

Diluted earnings (loss) per share were computed based on the weighted average number of shares outstanding plus all potentially dilutive common shares. A reconciliation of basic to diluted shares used in the earnings per share calculation is as follows:

(in thousands)

Three months ended June 30,

Six months ended June 30,

2015

2014

2015

2014
Basic weighted average shares outstanding
                       156,258

                    155,320

                    156,102

                       155,386
Dilutive effect of share-based compensation
                              308

                             -

                             -

                                   -
Diluted weighted average shares outstanding
                       156,566

                    155,320

                    156,102

                       155,386

The following table represents common stock equivalents that were excluded from the computation of diluted earnings per share for the three and six months ended June 30, 2015 and 2014, because the effect of their inclusion would be anti-dilutive.

(in thousands)

For the three months ended

For the six months ended

June 30, 2015

June 30, 2014

June 30, 2015

June 30, 2014

(unaudited)

(unaudited)

(unaudited)

(unaudited)

Stock options

335

1,754

935

1,754

Common stock grants

125

775

2,873

775

460

2,529

3,808

2,529

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for earnings per share.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 65 R27.htm IDEA: XBRL DOCUMENT v3.2.0.727

EARNINGS (LOSS) PER COMMON SHARE (Tables)
6 Months Ended

Jun. 30, 2015

EARNINGS (LOSS) PER COMMON SHARE [Abstract]

Reconciliation of Basic to Diluted Shares Used in Earnings Per Share Calculation
A reconciliation of basic to diluted shares used in the earnings per share calculation is as follows:

(in thousands)

Three months ended June 30,

Six months ended June 30,

2015

2014

2015

2014
Basic weighted average shares outstanding
                       156,258

                    155,320

                    156,102

                       155,386
Dilutive effect of share-based compensation
                              308

                             -

                             -

                                   -
Diluted weighted average shares outstanding
                       156,566

                    155,320

                    156,102

                       155,386

Antidilutive Common Stock Equivalents Excluded from Computation of Diluted Earnings Per Share
The following table represents common stock equivalents that were excluded from the computation of diluted earnings per share for the three and six months ended June 30, 2015 and 2014, because the effect of their inclusion would be anti-dilutive.

(in thousands)

For the three months ended

For the six months ended

June 30, 2015

June 30, 2014

June 30, 2015

June 30, 2014

(unaudited)

(unaudited)

(unaudited)

(unaudited)

Stock options

335

1,754

935

1,754

Common stock grants

125

775

2,873

775

460

2,529

3,808

2,529

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 66 FilingSummary.xml IDEA: XBRL DOCUMENT 3.2.0.727 html 144 231 1 false 38 0 false 9 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://vasomedical.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 010000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Sheet http://vasomedical.com/role/CondensedConsolidatedBalanceSheetsUnaudited CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Statements 2 false false R3.htm 010100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Sheet http://vasomedical.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Statements 3 false false R4.htm 020000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Unaudited) Sheet http://vasomedical.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Unaudited) Statements 4 false false R5.htm 030000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) Sheet http://vasomedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) Statements 5 false false R6.htm 040000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://vasomedical.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Statements 6 false false R7.htm 060100 - Disclosure - ORGANIZATION AND PLAN OF OPERATIONS Sheet http://vasomedical.com/role/OrganizationAndPlanOfOperations ORGANIZATION AND PLAN OF OPERATIONS Notes 7 false false R8.htm 060200 - Disclosure - BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES Sheet http://vasomedical.com/role/BasisOfPresentationAndCriticalAccountingPolicies BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES Notes 8 false false R9.htm 060300 - Disclosure - SEGMENT REPORTING AND CONCENTRATIONS Sheet http://vasomedical.com/role/SegmentReportingAndConcentrations SEGMENT REPORTING AND CONCENTRATIONS Notes 9 false false R10.htm 060400 - Disclosure - EARNINGS (LOSS) PER COMMON SHARE Sheet http://vasomedical.com/role/EarningsLossPerCommonShare EARNINGS (LOSS) PER COMMON SHARE Notes 10 false false R11.htm 060500 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://vasomedical.com/role/FairValueMeasurements FAIR VALUE MEASUREMENTS Notes 11 false false R12.htm 060600 - Disclosure - ACCOUNTS AND OTHER RECEIVABLES, NET Sheet http://vasomedical.com/role/AccountsAndOtherReceivablesNet ACCOUNTS AND OTHER RECEIVABLES, NET Notes 12 false false R13.htm 060700 - Disclosure - INVENTORIES, NET Sheet http://vasomedical.com/role/InventoriesNet INVENTORIES, NET Notes 13 false false R14.htm 060800 - Disclosure - GOODWILL AND OTHER INTANGIBLES Sheet http://vasomedical.com/role/GoodwillAndOtherIntangibles GOODWILL AND OTHER INTANGIBLES Notes 14 false false R15.htm 060900 - Disclosure - OTHER ASSETS Sheet http://vasomedical.com/role/OtherAssets OTHER ASSETS Notes 15 false false R16.htm 061000 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES Sheet http://vasomedical.com/role/AccruedExpensesAndOtherLiabilities ACCRUED EXPENSES AND OTHER LIABILITIES Notes 16 false false R17.htm 061100 - Disclosure - DEFERRED REVENUE Sheet http://vasomedical.com/role/DeferredRevenue DEFERRED REVENUE Notes 17 false false R18.htm 061200 - Disclosure - DEBT Sheet http://vasomedical.com/role/Debt DEBT Notes 18 false false R19.htm 061300 - Disclosure - BUSINESS COMBINATION Sheet http://vasomedical.com/role/BusinessCombination BUSINESS COMBINATION Notes 19 false false R20.htm 061400 - Disclosure - RELATED-PARTY TRANSACTIONS Sheet http://vasomedical.com/role/RelatedpartyTransactions RELATED-PARTY TRANSACTIONS Notes 20 false false R21.htm 061500 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://vasomedical.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 21 false false R22.htm 061600 - Disclosure - RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS Sheet http://vasomedical.com/role/RecentlyIssuedAccountingPronouncements RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS Notes 22 false false R23.htm 061700 - Disclosure - SUBSEQUENT EVENTS Sheet http://vasomedical.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 23 false false R24.htm 070200 - Disclosure - BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES (Policies) Sheet http://vasomedical.com/role/BasisOfPresentationAndCriticalAccountingPoliciesPolicies BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES (Policies) Policies 24 false false R25.htm 080200 - Disclosure - BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES (Tables) Sheet http://vasomedical.com/role/BasisOfPresentationAndCriticalAccountingPoliciesTables BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES (Tables) Tables http://vasomedical.com/role/BasisOfPresentationAndCriticalAccountingPolicies 25 false false R26.htm 080300 - Disclosure - SEGMENT REPORTING AND CONCENTRATIONS (Tables) Sheet http://vasomedical.com/role/SegmentReportingAndConcentrationsTables SEGMENT REPORTING AND CONCENTRATIONS (Tables) Tables http://vasomedical.com/role/SegmentReportingAndConcentrations 26 false false R27.htm 080400 - Disclosure - EARNINGS (LOSS) PER COMMON SHARE (Tables) Sheet http://vasomedical.com/role/EarningsLossPerCommonShareTables EARNINGS (LOSS) PER COMMON SHARE (Tables) Tables http://vasomedical.com/role/EarningsLossPerCommonShare 27 false false R28.htm 080500 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet http://vasomedical.com/role/FairValueMeasurementsTables FAIR VALUE MEASUREMENTS (Tables) Tables http://vasomedical.com/role/FairValueMeasurements 28 false false R29.htm 080600 - Disclosure - ACCOUNTS AND OTHER RECEIVABLES, NET (Tables) Sheet http://vasomedical.com/role/AccountsAndOtherReceivablesNetTables ACCOUNTS AND OTHER RECEIVABLES, NET (Tables) Tables http://vasomedical.com/role/AccountsAndOtherReceivablesNet 29 false false R30.htm 080700 - Disclosure - INVENTORIES, NET (Tables) Sheet http://vasomedical.com/role/InventoriesNetTables INVENTORIES, NET (Tables) Tables http://vasomedical.com/role/InventoriesNet 30 false false R31.htm 080800 - Disclosure - GOODWILL AND OTHER INTANGIBLES (Tables) Sheet http://vasomedical.com/role/GoodwillAndOtherIntangiblesTables GOODWILL AND OTHER INTANGIBLES (Tables) Tables http://vasomedical.com/role/GoodwillAndOtherIntangibles 31 false false R32.htm 080900 - Disclosure - OTHER ASSETS (Tables) Sheet http://vasomedical.com/role/OtherAssetsTables OTHER ASSETS (Tables) Tables http://vasomedical.com/role/OtherAssets 32 false false R33.htm 081000 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES (Tables) Sheet http://vasomedical.com/role/AccruedExpensesAndOtherLiabilitiesTables ACCRUED EXPENSES AND OTHER LIABILITIES (Tables) Tables http://vasomedical.com/role/AccruedExpensesAndOtherLiabilities 33 false false R34.htm 081100 - Disclosure - DEFERRED REVENUE (Tables) Sheet http://vasomedical.com/role/DeferredRevenueTables DEFERRED REVENUE (Tables) Tables http://vasomedical.com/role/DeferredRevenue 34 false false R35.htm 081300 - Disclosure - BUSINESS COMBINATION (Tables) Sheet http://vasomedical.com/role/BusinessCombinationTables BUSINESS COMBINATION (Tables) Tables http://vasomedical.com/role/BusinessCombination 35 false false R36.htm 090100 - Disclosure - ORGANIZATION AND PLAN OF OPERATIONS (Details) Sheet http://vasomedical.com/role/OrganizationAndPlanOfOperationsDetails ORGANIZATION AND PLAN OF OPERATIONS (Details) Details http://vasomedical.com/role/OrganizationAndPlanOfOperations 36 false false R37.htm 090202 - Disclosure - BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES (Details) Sheet http://vasomedical.com/role/BasisOfPresentationAndCriticalAccountingPoliciesDetails BASIS OF PRESENTATION AND CRITICAL ACCOUNTING POLICIES (Details) Details http://vasomedical.com/role/BasisOfPresentationAndCriticalAccountingPoliciesTables 37 false false R38.htm 090300 - Disclosure - SEGMENT REPORTING AND CONCENTRATIONS (Details) Sheet http://vasomedical.com/role/SegmentReportingAndConcentrationsDetails SEGMENT REPORTING AND CONCENTRATIONS (Details) Details http://vasomedical.com/role/SegmentReportingAndConcentrationsTables 38 false false R39.htm 090302 - Disclosure - SEGMENT REPORTING AND CONCENTRATIONS, Concentration Risk (Details) Sheet http://vasomedical.com/role/SegmentReportingAndConcentrationsConcentrationRiskDetails SEGMENT REPORTING AND CONCENTRATIONS, Concentration Risk (Details) Details 39 false false R40.htm 090400 - Disclosure - EARNINGS (LOSS) PER COMMON SHARE (Details) Sheet http://vasomedical.com/role/EarningsLossPerCommonShareDetails EARNINGS (LOSS) PER COMMON SHARE (Details) Details http://vasomedical.com/role/EarningsLossPerCommonShareTables 40 false false R41.htm 090500 - Disclosure - FAIR VALUE MEASUREMENTS (Details) Sheet http://vasomedical.com/role/FairValueMeasurementsDetails FAIR VALUE MEASUREMENTS (Details) Details http://vasomedical.com/role/FairValueMeasurementsTables 41 false false R42.htm 090600 - Disclosure - ACCOUNTS AND OTHER RECEIVABLES, NET (Details) Sheet http://vasomedical.com/role/AccountsAndOtherReceivablesNetDetails ACCOUNTS AND OTHER RECEIVABLES, NET (Details) Details http://vasomedical.com/role/AccountsAndOtherReceivablesNetTables 42 false false R43.htm 090700 - Disclosure - INVENTORIES, NET (Details) Sheet http://vasomedical.com/role/InventoriesNetDetails INVENTORIES, NET (Details) Details http://vasomedical.com/role/InventoriesNetTables 43 false false R44.htm 090800 - Disclosure - GOODWILL AND OTHER INTANGIBLES (Details) Sheet http://vasomedical.com/role/GoodwillAndOtherIntangiblesDetails GOODWILL AND OTHER INTANGIBLES (Details) Details http://vasomedical.com/role/GoodwillAndOtherIntangiblesTables 44 false false R45.htm 090900 - Disclosure - OTHER ASSETS (Details) Sheet http://vasomedical.com/role/OtherAssetsDetails OTHER ASSETS (Details) Details http://vasomedical.com/role/OtherAssetsTables 45 false false R46.htm 091000 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES (Details) Sheet http://vasomedical.com/role/AccruedExpensesAndOtherLiabilitiesDetails ACCRUED EXPENSES AND OTHER LIABILITIES (Details) Details http://vasomedical.com/role/AccruedExpensesAndOtherLiabilitiesTables 46 false false R47.htm 091100 - Disclosure - DEFERRED REVENUE (Details) Sheet http://vasomedical.com/role/DeferredRevenueDetails DEFERRED REVENUE (Details) Details http://vasomedical.com/role/DeferredRevenueTables 47 false false R48.htm 091200 - Disclosure - DEBT (Details) Sheet http://vasomedical.com/role/DebtDetails DEBT (Details) Details http://vasomedical.com/role/Debt 48 false false R49.htm 091300 - Disclosure - BUSINESS COMBINATION (Details) Sheet http://vasomedical.com/role/BusinessCombinationDetails BUSINESS COMBINATION (Details) Details http://vasomedical.com/role/BusinessCombinationTables 49 false false R50.htm 091400 - Disclosure - RELATED-PARTY TRANSACTIONS (Details) Sheet http://vasomedical.com/role/RelatedpartyTransactionsDetails RELATED-PARTY TRANSACTIONS (Details) Details http://vasomedical.com/role/RelatedpartyTransactions 50 false false R51.htm 091500 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://vasomedical.com/role/CommitmentsAndContingenciesDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://vasomedical.com/role/CommitmentsAndContingencies 51 false false R52.htm 091600 - Disclosure - RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details) Sheet http://vasomedical.com/role/RecentlyIssuedAccountingPronouncementsDetails RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details) Details http://vasomedical.com/role/RecentlyIssuedAccountingPronouncements 52 false false R53.htm 091700 - Disclosure - SUBSEQUENT EVENTS (Details) Sheet http://vasomedical.com/role/SubsequentEventsDetails SUBSEQUENT EVENTS (Details) Details http://vasomedical.com/role/SubsequentEvents 53 false false All Reports Book All Reports In ''CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)'', column(s) 3, 4 are contained in other reports, so were removed by flow through suppression. In ''CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Unaudited)'', column(s) 13 are contained in other reports, so were removed by flow through suppression. In ''CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)'', column(s) 1, 2, 5 are contained in other reports, so were removed by flow through suppression. vaso-20150630.xml vaso-20150630_cal.xml vaso-20150630_def.xml vaso-20150630_lab.xml vaso-20150630_pre.xml vaso-20150630.xsd true true XML 67 R38.htm IDEA: XBRL DOCUMENT v3.2.0.727

SEGMENT REPORTING AND CONCENTRATIONS (Details)
$ in Thousands
3 Months Ended 6 Months Ended

Jun. 30, 2015

USD ($)

Jun. 30, 2014

USD ($)

Jun. 30, 2015

USD ($)

Segment

Jun. 30, 2014

USD ($)

Dec. 31, 2014

USD ($)

SEGMENT REPORTING AND CONCENTRATIONS [Abstract]

Number of segments | Segment 3

Segment Reporting Information [Line Items]

Revenues from external customers $ 10,843 $ 7,864 $ 18,297 $ 14,956

Operating income (loss) 206 (206) (80) (1,294)

Total assets 46,320 31,232 46,320 31,232 $ 40,991

Accounts and other receivables, net 6,320 7,526 6,320 7,526 15,273

Deferred commission expense 2,407 2,297 2,407 2,297

Other assets 3,937 5,243 3,937 5,243 $ 5,617

Corporate [Member]

Segment Reporting Information [Line Items]

Revenues from external customers 0 0 0 0

Operating income (loss) (546) (352) (928) (883)

Total assets 1,309 10,036 1,309 10,036

Accounts and other receivables, net 0 0 0 0

Deferred commission expense 0 0 0 0

Other assets 113 13 113 13

Sales Representation Segment [Member] | Operating Segments [Member]

Segment Reporting Information [Line Items]

Revenues from external customers 7,036 6,684 13,427 12,926

Operating income (loss) 1,794 1,021 2,880 1,544

Total assets 10,421 13,144 10,421 13,144

Accounts and other receivables, net 4,421 6,585 4,421 6,585

Deferred commission expense 2,388 2,297 2,388 2,297

Other assets 3,098 4,066 3,098 4,066

IT Segment [Member] | Operating Segments [Member]

Segment Reporting Information [Line Items]

Revenues from external customers 2,811 0 2,811 0

Operating income (loss) (366) 0 (721) 0

Total assets 25,205 0 25,205 0

Accounts and other receivables, net 1,399 0 1,399 0

Deferred commission expense 19 0 19 0

Other assets 51 0 51 0

Equipment Segment [Member] | Operating Segments [Member]

Segment Reporting Information [Line Items]

Revenues from external customers 996 1,180 2,059 2,030

Operating income (loss) (676) (875) (1,311) (1,955)

Total assets 9,385 8,052 9,385 8,052

Accounts and other receivables, net 500 941 500 941

Deferred commission expense 0 0 0 0

Other assets $ 675 $ 1,164 $ 675 $ 1,164

GE Healthcare [Member] | Sales Revenue, Net [Member]

Revenue, Major Customer [Line Items]

Percentage of revenue (in hundredths) 65.00% 85.00% 73.00% 86.00%

X

- Definition
Amount due from customers, clients, or other third-parties, or arising from transactions not separately disclosed, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.
+ References
No definition available.
+ Details

Name: us-gaap_AccountsAndOtherReceivablesNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6351-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13531-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6404-108592

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13537-108611

+ Details

Name: us-gaap_ConcentrationRiskPercentage1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying amount of advanced commission payments.
+ References
No definition available.
+ Details

Name: us-gaap_DeferredSalesCommission

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_EntityWideRevenueMajorCustomerLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.
+ References
No definition available.
+ Details

Name: us-gaap_NumberOfOperatingSegments

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_SegmentReportingInformationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=vaso_SalesRepresentationSegmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=vaso_InformationTechnologySegmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=vaso_EquipmentSegmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MajorCustomersAxis=vaso_GeHealthcareMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 68 R20.htm IDEA: XBRL DOCUMENT v3.2.0.727

RELATED-PARTY TRANSACTIONS
6 Months Ended

Jun. 30, 2015

RELATED-PARTY TRANSACTIONS [Abstract]

RELATED-PARTY TRANSACTIONS
NOTE N – RELATED-PARTY TRANSACTIONS

One of the Company’s directors, Peter Castle, was the Chief Executive Officer and President of NetWolves, LLC. Another of the Company’s directors, David Lieberman, was a director of NetWolves Network Services, LLC. Mr. Castle and Mr. Lieberman owned of record approximately 10.4% and 5.7%, respectively of the membership interests of NetWolves LLC. Mr. Lieberman may also be deemed to have owned beneficially up to an additional 13.5% of such membership interests. The Company’s board of directors negotiated the Purchase Price on an arm’s length basis, and both Mr. Castle and Mr. Lieberman abstained from the vote approving the Purchase Agreement.

The Company obtained an opinion regarding the fairness of the Purchase Price for the NetWolves entities from a reputable, independent third-party investment banking firm. $14,200,000 of the Purchase Price was paid for by cash on hand, and the remaining $3,800,000 was raised from the sale of a Subordinated Secured Note sold to MedTech. Of the $4,550,000 borrowed from MedTech at June 30, 2015, $2,200,000 was provided by six of our directors, or members of their families.

David Lieberman, the Vice Chairman of the Company’s Board of Directors, is a practicing attorney in the State of New York and a senior partner at the law firm of Beckman, Lieberman & Barandes, LLP, which performs certain legal services for the Company. Fees of approximately $60,000 and $120,000 were billed by the firm through the three and six month periods ended June 30, 2015, respectively, at which date $20,000 was outstanding. Fees of approximately $60,000 and $120,000 were billed by the firm through the three and six month periods ended June 30, 2014, respectively, at which date no amounts were outstanding.

In January 2015, operations began under the VSK joint venture. The Company accounts for its investment in VSK using the equity method. At June 30, 2015, the Company had contributed $100,000 to VSK, and no amounts were due from VSK for equipment the Company sold to it. VSK earned approximately $50,000 and $46,000 for the three and six months ended June 30, 2015, respectively. Under the terms of the agreement, the Company’s accrues no interest in VSK’s income in the years ending December 31, 2015, 2016 and 2017 unless certain performance targets are achieved. For the six months ended June 30, 2015 such targets had not been achieved.

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph b

-Article 3A

+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details)	6 Months Ended
RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details)	Jun. 30, 2015 USD ($)
RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS [Abstract]
Debt issuance costs	$ 60,000
Interest expense	$ 1,250

DEFERRED REVENUE (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
DEFERRED REVENUE (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Changes in deferred revenue [Roll Forward]
Deferred revenue at beginning of period	$ 21,453	$ 17,004	$ 22,532	$ 18,019
Deferred revenue at end of period	19,614	17,712	19,614	17,712
Less: current portion	11,560	9,183	11,560	9,183	$ 9,882
Long-term deferred revenue at end of period	8,054	8,529	8,054	8,529	$ 12,650
Extended Service Contracts [Member]
Changes in deferred revenue [Roll Forward]
Additions:	94	309	305	546
Recognized as revenue:	(214)	(220)	(445)	(448)
In-Service and Training [Member]
Changes in deferred revenue [Roll Forward]
Additions:	3	13	5	15
Recognized as revenue:	(3)	(8)	(10)	(15)
Service Arrangements [Member]
Changes in deferred revenue [Roll Forward]
Additions:	5	25	15	30
Recognized as revenue:	(20)	(23)	(43)	(46)
Commission Revenues [Member]
Changes in deferred revenue [Roll Forward]
Additions:	1,481	3,614	3,330	5,384
Recognized as revenue:	$ (3,185)	$ (3,002)	$ (6,075)	$ (5,773)

INVENTORIES, NET (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
INVENTORIES, NET [Abstract]
Raw materials	$ 588,000	$ 583,000
Work in process	688,000	679,000
Finished goods	892,000	636,000
Inventories, net	2,168,000	1,898,000
Reserves for excess and obsolete inventory	$ 791,000	$ 815,000

GOODWILL AND OTHER INTANGIBLES (Details) - USD ($)	3 Months Ended		6 Months Ended
GOODWILL AND OTHER INTANGIBLES (Details) - USD ($)	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Change in carrying amount of goodwill [Roll Forward]
Goodwill, Beginning Balance			$ 3,288,000
Foreign currency translation			27,000
Acquisition of Netwolves			19,303,000
Goodwill, Ending Balance	$ 22,618,000		22,618,000
Other intangible assets, net [Abstract]
Intangible assets, net	2,561,000				$ 2,826,000
Goodwill	22,618,000		3,288,000		3,288,000
Amortization expense	164,000	$ 50,000	335,000	$ 96,000
Equipment Segment [Member]
Change in carrying amount of goodwill [Roll Forward]
Goodwill, Ending Balance	3,315,000		3,315,000
Other intangible assets, net [Abstract]
Goodwill	3,315,000		$ 3,315,000
Patents and Technology [Member]
Other intangible assets, net [Abstract]
Costs	2,467,000				2,489,000
Accumulated amortization	(678,000)				(549,000)
Intangible assets, net	1,789,000				1,940,000
Patents [Member]
Other intangible assets, net [Abstract]
Useful life of intangible assets			10 years
Customer Lists [Member]
Other intangible assets, net [Abstract]
Costs	800,000				800,000
Accumulated amortization	(438,000)				(381,000)
Intangible assets, net	362,000				419,000
Useful life of intangible assets			7 years
Software [Member]
Other intangible assets, net [Abstract]
Costs	1,054,000				962,000
Accumulated amortization	(644,000)				(495,000)
Intangible assets, net	$ 410,000				$ 467,000
Useful life of intangible assets			5 years

SUBSEQUENT EVENTS (Details) - Jul. 31, 2015 - Subsequent Event [Member] - USD ($) $ in Millions	Total
Subsequent Event [Line Items]
Line of credit facility, maximum borrowing capacity before replacement	$ 2.0
Line of credit facility, maximum borrowing capacity amount	$ 3.0
LIBOR [Member]
Subsequent Event [Line Items]
Interest rate percentage (in hundredths)	2.25%

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
CURRENT ASSETS
Cash and cash equivalents	$ 2,931	$ 9,128
Short-term investments	109	111
Accounts and other receivables, net of an allowance for doubtful accounts and commission adjustments of $4,178 at June 30, 2015 and $4,571 at December 31, 2014	6,320	15,273
Receivables due from related parties	20	21
Inventories, net	2,168	1,898
Deferred commission expense	2,407	2,200
Prepaid expenses and other current assets	581	363
Total current assets	14,536	28,994
PROPERTY AND EQUIPMENT, net of accumulated depreciation of $3,123 at June 30, 2015 and $1,397 at December 31, 2014	2,668	266
GOODWILL	22,618	3,288
INTANGIBLES, net	2,561	2,826
OTHER ASSETS	3,937	5,617
Total Assets	46,320	40,991
CURRENT LIABILITIES
Accounts payable	3,571	462
Accrued commissions	1,202	2,247
Accrued expenses and other liabilities	5,156	5,627
Sales tax payable	626	247
Deferred revenue - current portion	11,560	9,882
Notes payable - current portion	1,523	163
Deferred tax liability, net	112	112
Notes payable due to related party	1,070	1,039
Total current liabilities	24,820	19,779
LONG-TERM LIABILITIES
Notes payable	4,817	0
Deferred revenue	8,054	12,650
Other long-term liabilities	649	811
Total long-term liabilities	$ 13,520	$ 13,461
COMMITMENTS AND CONTINGENCIES (NOTE O)
STOCKHOLDERS' EQUITY
Preferred stock, $.01 par value; 1,000,000 shares authorized; nil shares issued and outstanding at June 30, 2015, and December 31, 2014	$ 0	$ 0
Common stock, $.001 par value; 250,000,000 shares authorized; 168,710,370 and 166,435,370 shares issued at June 30, 2015 and December 31, 2014, respectively; 158,402,283 and 156,127,283 shares outstanding at June 30, 2015 and December 31, 2014, respectively	169	166
Additional paid-in capital	62,181	61,924
Accumulated deficit	(52,495)	(52,433)
Accumulated other comprehensive income	125	94
Treasury stock, at cost, 10,308,087 shares at June 30, 2015 and December 31, 2014	(2,000)	(2,000)
Total stockholders' equity	7,980	7,751
Total liabilities and stockholders' equity	$ 46,320	$ 40,991

OTHER ASSETS (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014	Jun. 30, 2014
OTHER ASSETS [Abstract]
Deferred commission expense - noncurrent	$ 2,121	$ 2,988
Trade receivables - noncurrent	1,186	2,171
Other	630	458
Total	$ 3,937	$ 5,617	$ 5,243

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Cash flows from operating activities
Net loss	$ (62)	$ (1,220)
Adjustments to reconcile net loss to net cash provided by operating activities
Depreciation and amortization	483	199
Provision for doubtful accounts and commission adjustments	61	4
Share-based compensation and arrangements	260	244
Changes in operating assets and liabilities:
Accounts and other receivables	10,429	6,030
Receivables due from related parties	1	0
Inventories, net	(354)	(297)
Deferred commission expense	(207)	15
Other current assets	(115)	(119)
Other assets	1,859	(1,276)
Accounts payable	(43)	(117)
Accrued commissions	(1,092)	137
Accrued expenses and other liabilities	(1,268)	(966)
Sales tax payable	(32)	(51)
Deferred revenue	(2,918)	(307)
Notes payable due to related party	31	0
Other long-term liabilities	(199)	162
Net cash provided by operating activities	6,834	2,438
Cash flows from investing activities
Purchases of equipment and software	(188)	(205)
Purchases of short-term investments	(38)	(40)
Redemption of short-term investments	40	40
Acquisition of Netwolves	(18,000)	0
Cash acquired through purchase of Netwolves	733	0
Investment in VSK	(100)	0
Net cash used in investing activities	(17,553)	(205)
Cash flows from financing activities
Repurchase of common stock	0	(207)
Repayment of notes payable	(21)	0
Proceeds from note payable	4,550	0
Net cash provided by (used in) financing activities	4,529	(207)
Effect of exchange rate differences on cash and cash equivalents	(7)	(1)
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(6,197)	2,025
Cash and cash equivalents - beginning of period	9,128	7,961
Cash and cash equivalents - end of period	2,931	9,986
SUPPLEMENTAL DISCLOSURE OF CASH INFORMATION
Interest paid	15	0
Income taxes paid	66	19
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES
Inventories transferred to property and equipment, attributable to operating leases, net	3	5
Common shares issued for prepaid directors' fees	$ 0	$ 175

ORGANIZATION AND PLAN OF OPERATIONS (Details) - Jun. 30, 2015	State Company Subsidiary
ORGANIZATION AND PLAN OF OPERATIONS [Abstract]
Number of contiguous states in which VasoHealthcare has been appointed exclusive representative for GE Healthcare Diagnostic Imaging products \| State	48
Number of Chinese operating companies acquired \| Company	2
Number of wholly-owned subsidiaries	3
Noncontrolling interest (in hundredths)	49.90%

ORGANIZATION AND PLAN OF OPERATIONS	6 Months Ended
ORGANIZATION AND PLAN OF OPERATIONS	Jun. 30, 2015
ORGANIZATION AND PLAN OF OPERATIONS [Abstract]
ORGANIZATION AND PLAN OF OPERATIONS	NOTE A - ORGANIZATION AND PLAN OF OPERATIONS Vasomedical, Inc. was incorporated in Delaware in July 1987. Unless the context requires otherwise, all references to “we”, “our”, “us”, “Company”, “registrant”, “Vasomedical” or “management” refer to Vasomedical, Inc. and its subsidiaries. Until 2010, we were primarily engaged in designing, manufacturing, marketing and supporting Enhanced External Counterpulsation (EECP^®) systems, based on our proprietary technology, to physicians and hospitals throughout the United States and in select international markets. Beginning in July 2010 the Company, through its wholly-owned subsidiary Vaso Diagnostics, Inc. (Vaso Diagnostics), began its sales representation business via its agreement (the “GEHC Agreement”) with GE Healthcare (“GEHC”), the healthcare business unit of General Electric Company (NYSE: GE), to be GEHC’s exclusive sales representative for the sale of select GEHC diagnostic imaging products in specific market segments in the 48 contiguous states of the United States and the District of Columbia. In June 2012, the GEHC Agreement was amended and extended through June 30, 2015 and again, in December 2014, the GEHC Agreement was further amended and extended through December 31, 2018, subject to earlier termination under certain circumstances and termination without cause on or after July 1, 2017. In September 2011, the Company acquired Fast Growth Enterprises Limited (FGE), a British Virgin Islands company, which owns or controls two Chinese operating companies - Life Enhancement Technology Ltd. and Biox Instruments Co. Ltd. (Biox), respectively - to expand its technical and manufacturing capabilities and to enhance its distribution network, technology, and product portfolio. Also in September 2011, the Company restructured to further align its business management structure and long-term growth strategy, and started to operate through three wholly-owned subsidiaries. Vaso Diagnostics continues as the operating subsidiary for the sales representation of GE diagnostic imaging products; Vasomedical Global Corp. operates the Company’s Chinese companies; and Vasomedical Solutions, Inc. was formed to manage and coordinate our EECP^® therapy business as well as other medical equipment operations. In April 2014, the Company entered into an agreement with Chongqing PSK-Health Sci-Tech Development Co., Ltd. (PSK) of Chongqing, China, the leading manufacturer of ECP therapy systems in China, to form a joint venture company, VSK Medical Limited (VSK), for the global marketing, sale and advancement of ECP therapy technology. The Company owns 49.9% of the joint venture, which began operations in January 2015. In June 2014, the Company entered into a Value Added Reseller Agreement (VAR Agreement) with GEHC to become a national value added reseller of GE Healthcare IT's Radiology PACS (Picture Archiving and Communication System) software solutions and related services, including implementation, management and support. This multiyear VAR Agreement focuses primarily on existing customer segments currently served by Vaso Diagnostics on behalf of GEHC. A new wholly owned subsidiary, VasoHealthcare IT Corp., was formed to conduct the healthcare IT business. In August 2014, the Company, through its wholly owned subsidiary Wuxi Gentone Instruments Co. Ltd. (Gentone), acquired all of the outstanding shares of Genwell Instruments Co. Ltd. (Genwell), located in Wuxi, China. Genwell was formed in China in 2010 with the assistance of a government grant to develop the MobiCare^TM wireless multi-parameter patient monitoring system and holds the patents and intellectual property rights for this system. In May 2015, the Company entered into an agreement for, and completed its purchase of, all of the assets of NetWolves, LLC and its affiliates, including the membership interests in NetWolves Network Services LLC (collectively, “NetWolves”). The purchase of NetWolves was accomplished pursuant to an Asset Purchase Agreement. As a result, the Company effectively purchased all rights, titles and ownership of all assets held by NetWolves. NetWolves designs and delivers efficient and cost-effective multi-network and multi-technology solutions as a managed network provider, and provides a complete single-source solution that includes design, network redundancy, application device management, real-time network monitoring, reporting and support systems as a comprehensive solution. The Company believes there are significant operational synergies between NetWolves’ capabilities and VasoHealthcare IT’s requirements under its VAR Agreement with GEHC, as well as the opportunity to expand NetWolves’ existing services to the healthcare IT market. We report the operations of Vasomedical Global Corp. and Vasomedical Solutions, Inc. under our Equipment segment. Vaso Diagnostics activities are included under our Sales Representation segment. VasoHealthcare IT and NetWolves operations report under the IT segment.

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
CURRENT ASSETS
Accounts and other receivables, allowance for doubtful accounts and commission adjustments	$ 4,178	$ 4,571
PROPERTY AND EQUIPMENT, accumulated depreciation	$ 3,123	$ 1,397
STOCKHOLDERS' EQUITY
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	250,000,000	250,000,000
Common stock, shares issued (in shares)	168,710,370	166,435,370
Common stock, shares outstanding (in shares)	158,402,283	156,127,283
Treasury stock, at cost (in shares)	10,308,087	10,308,087

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2015	Aug. 08, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	VASOMEDICAL, INC
Entity Central Index Key	0000839087
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		158,412,283
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q2
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2015

DEBT	6 Months Ended
DEBT	Jun. 30, 2015
DEBT [Abstract]
DEBT	NOTE L – DEBT On May 29, 2015, the Company entered into a Note Purchase Agreement with MedTechnology Investments, LLC (“MedTech”) pursuant to which it issued MedTech a secured subordinated promissory note (“Note”) for $3,800,000 for the purchase of NetWolves . MedTech was formed to acquire the Note, and $1,950,000 of the aggregate funds used to acquire the Note was provided by six of our directors. In June 2015, a second Note for $750,000 was issued to MedTech for working capital purposes, $250,000 of which was provided by a director and a director’s spouse. Subsequent to June 30, 2015, an additional $250,000 was borrowed under the Note Purchase Agreement. The Notes bear interest at an annual rate of 9%, matures on May 29, 2019, may be prepaid without penalty, and is subordinated to any current or future Senior Debt as defined in the Subordinated Security Agreement. The Subordinated Security Agreement secures payment and performance of the Company’s obligations under the Note and as a result, MedTech was granted a subordinated security interest in the Company’s assets.

SUBSEQUENT EVENTS	6 Months Ended
SUBSEQUENT EVENTS	Jun. 30, 2015
SUBSEQUENT EVENTS [Abstract]
SUBSEQUENT EVENTS	NOTE Q – SUBSEQUENT EVENTS In July 2015, the lending institution extended the Company’s NetWolves subsidiary’s $2.0 million line of credit and increased the maximum borrowings to $3.0 million. Advances under the line, which expires on August 26, 2016, bear interest at a rate of LIBOR plus 2.25% and are secured by substantially all of the assets of NetWolves Network Services, LLC and the guaranty of Vasomedical, Inc.

COMMITMENTS AND CONTINGENCIES (Details)	6 Months Ended
COMMITMENTS AND CONTINGENCIES (Details)	Jun. 30, 2015
Sales Representation Agreement [Abstract]
Initial term of sales representation agreement	3 years
Amended term of sales representation agreement	5 years

COMMITMENTS AND CONTINGENCIES	6 Months Ended
COMMITMENTS AND CONTINGENCIES	Jun. 30, 2015
COMMITMENTS AND CONTINGENCIES [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE O – COMMITMENTS AND CONTINGENCIES Sales representation agreement In June 2012, the Company concluded an amendment of the GEHC Agreement with GEHC, originally signed on May 19, 2010. The amendment, effective July 1, 2012, extended the initial term of three years commencing July 1, 2010 to five years through June 30, 2015. In December 2014, the Company concluded an additional amendment, effective January 1, 2015, extending the term through December 31, 2018, subject to earlier termination under certain circumstances and termination without cause on or after July 1, 2017. These circumstances include not materially achieving certain sales goals, not maintaining a minimum number of sales representatives, and various legal and GEHC policy requirements. Under the terms of the agreement, the Company is required to lease dedicated computer equipment from GEHC for connectivity to their network.

BUSINESS COMBINATION (Details) - USD ($)		3 Months Ended		6 Months Ended		12 Months Ended
BUSINESS COMBINATION (Details) - USD ($)	May. 29, 2015	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Business Acquisition [Line Items]
Business combination, cash paid				$ 18,000,000	$ 0
Debt issuance costs				60,000
Net income (loss)		$ 191,000	$ (176,000)	(62,000)	(1,220,000)	$ 1,128,000
Estimated fair values of the net assets acquired [Abstract]
Goodwill and other intangibles		22,618,000		22,618,000		$ 3,288,000
NetWolves, LLC [Member]
Business Acquisition [Line Items]
Consideration for acquisition	$ 18,000,000
Business combination, cash paid	14,200,000			14,200,000
Acquisition-related legal costs		100,000
Debt issuance costs		60,000
Net income (loss)		2,763,000		150,000
Estimated fair values of the net assets acquired [Abstract]
Cash and cash equivalents	733,000
Accounts receivable and other current assets	1,638,000
Other assets	50,000
Property and equipment	2,359,000
Accounts payable and other current liabilities	(4,382,000)
Long term debt	(1,701,000)
Goodwill and other intangibles	19,303,000
Total	18,000,000
NetWolves, LLC [Member] \| MedTechnology Investments LLC [Member]
Business Acquisition [Line Items]
Business combination, issue of notes	$ 3,800,000			3,800,000
Genwell and Netwolves [Member]
Business acquisition proforma information [Abstract]
Revenue		16,088,000	15,070,000	31,449,000	29,431,000
Net income (loss)		$ 580,000	$ (160,000)	$ 517,000	$ (1,061,000)
Basic earnings (loss) per share (in dollars per share)		$ 0	$ 0	$ 0	$ (0.01)
Diluted earnings (loss) per share (in dollars per share)		$ 0	$ 0	$ 0	$ (0.01)

FAIR VALUE MEASUREMENTS (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents invested in money market funds (included in cash and cash equivalents)	$ 2	$ 8,149
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents invested in money market funds (included in cash and cash equivalents)	2	8,149
Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents invested in money market funds (included in cash and cash equivalents)	0	0
Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents invested in money market funds (included in cash and cash equivalents)	$ 0	$ 0

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Common Stock [Member]	Treasury Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income [Member]	Total
Balance at Dec. 31, 2013	$ 165	$ (1,755)	$ 61,508	$ (53,561)	$ 108	$ 6,465
Balance (in shares) at Dec. 31, 2013	164,705	(9,481)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Repurchase of shares	$ 0	$ (245)	0	0	0	(245)
Repurchase of shares (in shares)	0	(827)
Share-based compensation	$ 1		389	0	0	390
Share-based compensation (in shares)	1,280
Shares not issued for employee tax liability	$ 0		(9)	0	0	(9)
Exercise of stock options	$ 0		36	0	0	36
Exercise of stock options (in shares)	450
Foreign currency translation gain (loss)	$ 0		0	0	(14)	(14)
Net income (loss)	0		0	1,128	0	1,128
Balance at Dec. 31, 2014	$ 166	$ (2,000)	61,924	(52,433)	94	7,751
Balance (in shares) at Dec. 31, 2014	166,435	(10,308)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation	$ 3		257	0	0	260
Share-based compensation (in shares)	2,275
Foreign currency translation gain (loss)	$ 0		0	0	31	31
Net income (loss)	0		0	(62)	0	(62)
Balance at Jun. 30, 2015	$ 169	$ (2,000)	$ 62,181	$ (52,495)	$ 125	$ 7,980
Balance (in shares) at Jun. 30, 2015	168,710	(10,308)

SEGMENT REPORTING AND CONCENTRATIONS (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015 USD ($)	Jun. 30, 2014 USD ($)	Jun. 30, 2015 USD ($) Segment	Jun. 30, 2014 USD ($)	Dec. 31, 2014 USD ($)
SEGMENT REPORTING AND CONCENTRATIONS [Abstract]
Number of segments \| Segment			3
Segment Reporting Information [Line Items]
Revenues from external customers	$ 10,843	$ 7,864	$ 18,297	$ 14,956
Operating income (loss)	206	(206)	(80)	(1,294)
Total assets	46,320	31,232	46,320	31,232	$ 40,991
Accounts and other receivables, net	6,320	7,526	6,320	7,526	15,273
Deferred commission expense	2,407	2,297	2,407	2,297
Other assets	3,937	5,243	3,937	5,243	$ 5,617
Corporate [Member]
Segment Reporting Information [Line Items]
Revenues from external customers	0	0	0	0
Operating income (loss)	(546)	(352)	(928)	(883)
Total assets	1,309	10,036	1,309	10,036
Accounts and other receivables, net	0	0	0	0
Deferred commission expense	0	0	0	0
Other assets	113	13	113	13
Sales Representation Segment [Member] \| Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues from external customers	7,036	6,684	13,427	12,926
Operating income (loss)	1,794	1,021	2,880	1,544
Total assets	10,421	13,144	10,421	13,144
Accounts and other receivables, net	4,421	6,585	4,421	6,585
Deferred commission expense	2,388	2,297	2,388	2,297
Other assets	3,098	4,066	3,098	4,066
IT Segment [Member] \| Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues from external customers	2,811	0	2,811	0
Operating income (loss)	(366)	0	(721)	0
Total assets	25,205	0	25,205	0
Accounts and other receivables, net	1,399	0	1,399	0
Deferred commission expense	19	0	19	0
Other assets	51	0	51	0
Equipment Segment [Member] \| Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues from external customers	996	1,180	2,059	2,030
Operating income (loss)	(676)	(875)	(1,311)	(1,955)
Total assets	9,385	8,052	9,385	8,052
Accounts and other receivables, net	500	941	500	941
Deferred commission expense	0	0	0	0
Other assets	$ 675	$ 1,164	$ 675	$ 1,164
GE Healthcare [Member] \| Sales Revenue, Net [Member]
Revenue, Major Customer [Line Items]
Percentage of revenue (in hundredths)	65.00%	85.00%	73.00%	86.00%

RELATED-PARTY TRANSACTIONS	6 Months Ended
RELATED-PARTY TRANSACTIONS	Jun. 30, 2015
RELATED-PARTY TRANSACTIONS [Abstract]
RELATED-PARTY TRANSACTIONS	NOTE N – RELATED-PARTY TRANSACTIONS One of the Company’s directors, Peter Castle, was the Chief Executive Officer and President of NetWolves, LLC. Another of the Company’s directors, David Lieberman, was a director of NetWolves Network Services, LLC. Mr. Castle and Mr. Lieberman owned of record approximately 10.4% and 5.7%, respectively of the membership interests of NetWolves LLC. Mr. Lieberman may also be deemed to have owned beneficially up to an additional 13.5% of such membership interests. The Company’s board of directors negotiated the Purchase Price on an arm’s length basis, and both Mr. Castle and Mr. Lieberman abstained from the vote approving the Purchase Agreement. The Company obtained an opinion regarding the fairness of the Purchase Price for the NetWolves entities from a reputable, independent third-party investment banking firm. $14,200,000 of the Purchase Price was paid for by cash on hand, and the remaining $3,800,000 was raised from the sale of a Subordinated Secured Note sold to MedTech. Of the $4,550,000 borrowed from MedTech at June 30, 2015, $2,200,000 was provided by six of our directors, or members of their families. David Lieberman, the Vice Chairman of the Company’s Board of Directors, is a practicing attorney in the State of New York and a senior partner at the law firm of Beckman, Lieberman & Barandes, LLP, which performs certain legal services for the Company. Fees of approximately $60,000 and $120,000 were billed by the firm through the three and six month periods ended June 30, 2015, respectively, at which date $20,000 was outstanding. Fees of approximately $60,000 and $120,000 were billed by the firm through the three and six month periods ended June 30, 2014, respectively, at which date no amounts were outstanding. In January 2015, operations began under the VSK joint venture. The Company accounts for its investment in VSK using the equity method. At June 30, 2015, the Company had contributed $100,000 to VSK, and no amounts were due from VSK for equipment the Company sold to it. VSK earned approximately $50,000 and $46,000 for the three and six months ended June 30, 2015, respectively. Under the terms of the agreement, the Company’s accrues no interest in VSK’s income in the years ending December 31, 2015, 2016 and 2017 unless certain performance targets are achieved. For the six months ended June 30, 2015 such targets had not been achieved.